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A Prologue to a thesis is perhaps a break from tradition but it is felt that due to the involvement of 
several people in this project it will serve to delin ate each participant’s contribution. This project was 
initially conceptualised in 2000 and was to be submitted for a M.Sc. degree. The idea of investigating 
southern African psychoactive plant use came initially from discussions with my then B.Sc. Honours (4th 
year) colleague Michael Gardner and Honours Supervisor Dr. Anna K. Jäger. Discussions revolved 
around the observation that African traditional healing shows similar characteristics to shamanistic 
practices, in particular the practice of ancestor ‘c mmunication’. Unlike other shamanistic cultures, such 
as those found in South America, very few psychoactive plant species were recognised in southern Africa.  
 
The release of ‘People’s Plants’ (VAN WYK and GERICKE, 2000) that contained a chapter 
dedicated to plants that affect the ‘mind and mood’, stimulated further interest in this topic. After some 
preliminary research it was clear that this area was in need of further research and that perhaps this top c 
was too large for an M.Sc. For the next two years while I completed a Masters on the ‘Effect of storage 
on medicinal plants’ I continued to gather literatue on African psychotropic plants. As I was nearing the 
completion of my M.Sc. and at last about to tackle ‘Southern African plants used to treat central nervous 
system related disorders’ for my Doctorate, J.F. Sobiecki published ‘A preliminary inventory of plants 
used for psychotropic purposes in southern African healing traditions’ (SOBIECKI, 2002). This detailed 
literature review, accompanied by new data from interviewing traditional healers, superseded the work I 
had done to this point. Although initially this was  large disappointment, it turned out to be for the best, 
as it forced me to alter my research emphasis.  
 
Both my initial research and Sobiecki’s paper showed that despite the numerous references to 
potential psychotropic plants in the literature on African traditional medicine, relative little validation and 
further investigations have occurred. This inspired the continued documentation and extensive screening 
of these plants in several in vitro bioassays. 
 
Professor Anna Jäger, now co-supervisor for my Ph.D. ad moved from Research Centre for 
Plant Growth and Development, Pietermaritzburg to take up a Pharmacognosy Professorship at the 
Department of Medicinal Chemistry, University of Copenhagen (Denmark). In 2003 I had the pleasure of 
working with two M.Sc. (Pharmacy) students under hesupervision, Nicolaj D. Nielsen and Mikkel 
Sandager, on the development of the serotonin transporter assay. This radiochemical bioassay was set up 
at the Research Centre and was used to conduct the first screening of plant extracts for selective serotonin 
re-uptake inhibition (SSRI) activity. At the same time another two M.Sc. students, Jofrid Risa and Anlaug 




were screened for compounds with an affinity for γ-aminobutyric acid (subtype-A)-benzodiazepine 
(GABAA-benzodiazepine) receptor, and for AChE activity. A year later Ann B. Svenningsen and Katrine 
Damkjær Madsen came to South Africa to follow through on some of the active plants with an affinity for 
GABAA-benzodiazepine receptor. Their work lead to the isolation of flavonoid compounds with affinity 
for the GABAA-benzodiazepine receptor from Rhus (Searsia) species. 
 
In July 2005 I had the pleasure of travelling to Copenhagen for six weeks to work in Professor 
Anna Jäger’s laboratories. I had brought with me several Amaryllidaceae alkaloids isolated by Dr E. 
Elgorashi from South African species and successfully tested them in the serotonin transporter assay and 
for affinity for the GABAA-benzodiazepine receptor. This research resulted in a publication; this research 
however did not form part of this thesis. I had also brought an additional 46 extracts which were screened 
in the GABAA-benzodiazepine receptor assay leading to a second publication. 
 
Another two pharmacy M.Sc. students from Professor Anna Jäger’s laboratory, J. Peter Almqvist 
and Stefan A.K. Vangsøe came to South Africa to follow through on some of the active plants that I had
discovered while in Copenhagen. This collaboration led to the isolation and identification of active 
compounds from Mentha aquatica in the GABAA-benzodiazepine receptor assay. 
 
That same year I worked closely with Pernille D. Pedersen on the development of a photometric 
peroxidase linked assay to determine the inhibition of the oxidative deamination of tyramine by 
monoamine oxidase (MAO) isolated from rat liver. This enabled us to screen twenty plants, used in Zulu
traditional medicine to treat several CNS-related ailments, for MAO inhibition and specific MAO-B 
inhibition activity. Additional researched conducted with Helle T. Olsen on Mentha aquatica lead to the 
isolation and identification of a non-selective MAO inhibitor. 
 
Mikael E. Pedersen, who worked in the Research Centre during his Masters project, is finalizing 
his Ph.D. at the University of Copenhagen on anti-epileptic and anti-depressive activity of South African 
plants that were identified through earlier work in this project.  
 
An ambitious project such as this would not have ben possible without the co-operation of all 
those involved. I am extremely grateful to have hadthe opportunity to have worked with such talented 
researchers. I am a botanist by training, having had little formal organic chemistry education, I am 
therefore extremely grateful to the chemists at the University of Copenhagen for providing the NMR data 
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The majority of the population in South Africa use traditional health care to treat various mental 
conditions. This thesis has two main objectives; to bring together a comprehensive and detailed record of 
psychotropic plants used in southern Africa by indigenous peoples for medicinal or cultural purposes. 
Secondly, this research attempts to investigate the validity and rationale of the use of these plants by 
screening them in various biological assays for psychotropic activity. Plants were selected, based on their
traditional use and availability, and were screened i  four assays, which detect biological activity of a 
useful nature. A number of in vitro enzymatic and neuronal signal transduction assays were employed in 
this thesis, the inhibition of the serotonin reuptake transporter protein (SERT); inhibition of catabolic 
enzymes (e.g. acetylcholinesterase, monoamine oxidase); GABAA- benzodiazepine receptor binding. 
 
The influence of legislation, past and present, on the state of traditional medicine is highlighted. 
Aspects of the philosophies and practises of the various practitioners of South African traditional 
medicine will be discussed. An annotated list compiled from available ethnobotanical literature of plants 
traditionally used for central nervous system-related purposes is provided. It contains more than 330 
species, from 94 families, which are currently used or have been used for cultural, medicinal and 
recreational purposes related to the central nervous system (CNS). Where available, information 
pertaining to plant part used, preparation method, d sage, route of administration, known and potentially 
active constituents are included. 
 
Seventy five extracts from 34 indigenous plant species used in South African traditional medicine or 
taxonomically related to these were investigated for their affinity to the serotonin reuptake transport 
protein, making use of an in vitro [3H]-citalopram serotonin reuptake transport protein bi ding assay. 
Aqueous and 70% ethanolic extracts of various plant p rts were screened and 45 extracts derived from 15 
plant species showed affinity. The affinity of 12 extracts from four plants was characterized as high (more 
than 50% inhibition at 5, 1, and 0.5 mg/ml). Plant species with high affinity to the serotonin reuptake 
transport protein included Agapanthus campanulatus, Boophone disticha, Datura ferox and Xysmalobium 
undulatum. Agapanthus campanulatus yielded high activity in aqueous extracts from leaves and flowers. 
B. disticha showed high activity both in aqueous and ethanolic extracts of leaves and bulbs. D ferox 
showed high activity in aqueous extracts from the se d  and X. undulatum showed high activity in the 





Two compounds, buphanadrine and buphanamine, were isolated by bioassay-guided fractionation on 
vacuum-liquid-chromatography (VLC) and preparative thin-layer-chromatography (TLC) from B. 
disticha. The structures of the compounds were determined by 1H and 13C NMR. Fractions were tested for 
affinity to the serotonin transporter in a binding assay using [3H]-citalopram as a ligand. The IC50 values 
of buphanidrine and buphanamine were 274 µM (Ki = 132 µM) and 1799 µM (Ki = 868 µM), respectively. 
The two alkaloids were also tested for affinity to the 5HT1A receptor, but only showed slight affinity.  
 
Aqueous and ethanol extracts of 43 plants that are tr ditionally used to treat against epilepsy and 
convulsions were initially tested in the GABAA-benzodiazepine receptor binding assay, where the binding 
of 3H-Ro 15-1788 (flumazenil) to the benzodiazepine sit is measured. The GABAA-benzodiazepine 
receptor complex is involved in epilepsy and convulsions. Out of the 118 extracts tested, one aqueous and 
18 ethanol extracts showed activity. The most active extracts were the ethanolic leaf extracts of  Searsia 
tridentata, Searsia rehmanniana nd Hoslundia opposita and the ethanolic corm extract of Hypoxis 
colchicifolia, which all showed good dose-dependent activity. A further forty-six ethanol extracts from 
another 35 species, both indigenous and exotic that are traditionally used predominantly as sedatives or to 
treat various CNS-related ailments were tested in the GABAA-benzodiazepine receptor-binding assay. 
Out of the 46 extracts tested, seven showed good activity and 10 showed moderate activity. The most 
active extracts were the ethanolic leaf extracts of Arctopus echinatus, Artemisa afra, four Helichrysum 
species and Mentha aquatica which all showed good dose-dependent activity. 
 
Two biflavonoids with activity in the 3H-Ro 15-1788 (flumazenil) binding assay were isolated by high 
pressure liquid chromatography (HPLC) fractionation of the ethanol extract of the leaves from Searsia 
pyroides. The structures of the two biflavonoids were elucidated by nuclear magnetic resonance 
spectroscopy (NMR) to be agathisflavone and amentoflav ne. Agathisflavone and amentoflavone 
competitively inhibited the binding of 3H-Ro 15-1788 with a Ki of 28 and 37 nM, respectively. Extracts of 
Searsia dentata nd Searsia pentheri were not as active as the extract from Searsia pyroides; both were 
found to contain apigenin and agathisflavone. The monomer apigenin, agathisflavone and amentoflavone 
were fitted into a pharmacophore model for ligands binding to the GABAA receptor benzodiazepine site. 
This reflected the affinities of the compounds in the [3H]-flumazenil binding assay. 
 
Mentha aquatica, a mint that is found in Europe and Africa, is used in Zulu traditional medicine for 
spiritual purposes. The ethanolic leaf extract showed a strong affinity to the GABA-benzodiazepine 




bioassay-guided fractionation using binding to the GABA-benzodiazepine site. Viridiflorol had an IC50 of 
0.19 M and (S)-naringenin of 0.0026 M. 
 
Twenty plants used in Zulu traditional medicine forseveral CNS-related ailments were screened for 
MAO inhibition and specific MAO-B inhibition activity. MAO-B inhibitors are currently employed in the 
treatment of neurodegenerative related illnesses such as Parkinson's and Alzheimer's diseases. A 
photometric peroxidase linked assay was used to determine the inhibition of the oxidative deamination of 
tyramine by MAO isolated from rat liver. Ruta graveolens exhibited the best MAO inhibitory activity 
(ethyl acetate leaf extract = IC50 5 ± 1 µg/ml, petroleum ether extract = 3 ± 1 µg/ml) and specific MAO-B 
inhibition (ethyl acetate leaf extract = IC50 7 ± 6 µg/ml petroleum ether extract = 3 ± 1 µg/ml). Schotia 
brachypetala, Mentha aquatica and Gasteria croucheri also exhibited good MAO-B inhibition activity.  
 
Six extracts of varying polarity of Mentha aquatica were tested in a photometric peroxidase linked 
MAO bioassay. The 70% ethanol extract had highest inhib tory activity. (S)-Naringenin was isolated from 
the extract by bioassay guided fractionation on VLC and preparative TLC. The structure of the compound 
was determined by 1H, 13C and 13C-DEPT NMR and optical rotation. The IC50 values for MAO inhibition 
by naringenin were 342 ± 33 µM for the rat liver mitochondrial fraction, 955 ± 129 µM for MAO-A and 
288 ± 18 µM for MAO-B respectively.  
 
South African traditional medicine clearly utilizes many botanical species with CNS-related activity. 
Only a small number of the more than 330 southern Af ican plant species reported to treat or alter the 
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Plants and the central nervous system 
 
1.1.  Introduction  
 
This Chapter will introduce the reader to the intriguing variety of plants that have an effect on the central 
nervous system (CNS). The basic principles of brain anatomy and function are briefly outlined to provide 
a framework within which to discuss the effect of plants on the CNS.  
 
Botanically derived preparations, other than for nutritional value, have been used for a variety of spiritual, 
therapeutic and recreational reasons for thousands of years. Their use is not unique to any one 
civilization, culture or historical era. Archaeological evidence and pollen analysis from a Neanderthal 
burial site in modern day Iraq date the use of medicinal plants to 50,000 B.C. (SOLECKI, 1975). 
 
Among the plants used by humans, those able to alter the consciousness and the senses have drawn 
particular consideration. Often surrounded by mystic uperstitions, magical thoughts and religious rituals, 
they have often been revered (Figure 1.1). In the early stages of 
development, humans needed to explain all natural phenomena, 
and without an adequate understanding of biological systems, 
these plants were considered the ‘residences of divinities or 
other spiritual forces’, some were even deemed gods 
(SCHULTES and HOFMANN, 1992).  
 
Plants with an effect on the central nervous system, r ferred to 
as psychotropic plants, are still used by modern societies, 
although most, such as coffee, tea, chocolate and various 
alcoholic beverages are generally not considered to be 
psychotropic drugs. The indigenous ethnic groups of sub-
Saharan Africa have also used various psychotropic agents, such 
as alcoholic beverages, psycho-stimulants, and hallucinogens, 
since earliest pre-historic times. Some of these agents have been 
used on a global scale (Datura sp.), whereas others are more 
typical or even unique to Africa (SCHULTES, 1981; DE 
SMET, 1996).  
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Most research on psychotropic plants has focus on the New World (SCHULTES, 1967; DE SMET, 
1996). A large majority of researchers in the field agree that there is insufficient documentation and
scientific investigation of African psychotropic plant use (SMITH, CROUCH, GERICKE and HIRST, 
1996; VAN WYK and GERICKE, 2000; SOBIECKI, 2002). Psychoactive plants, in particular 
hallucinogens (psychodysleptics), have been avoided or have been assigned as low priority by researchers 
due to the stigma attached to substance use and abuse (CARLINI, 2003; WINKELMANN and DOBKIN 
DE RIOS, 1989). This has excluded the possibility that these plants could also have beneficial properties 
to treat mental disease and some psychic ailments.  
 
Early literature and documentation of psychotropic plant use is littered with bias and scepticism. In this
respect, it is pertinent to quote a sentence from the first description (1651) of a Mexican hallucinogenic 
plant (ololiuqui): “A thousand visions and satanic hallucinations appeared to them” (cited in 
HOFMANN, 1982). CARLINI (2003) also adds that “most psychoactive plants were first used by the so-
called primitive cultures; their occasional use by the European occidental culture was relegated to a 
second plan, being considered as sorcerer’s therapeutics and often viewed in a negative light”.  
 
However, investigation of psychoactive plants and their mechanisms of action have provided valuable 
insight into the neurochemistry of many CNS diseases (LEWIN, 1924; NICHOLS, 2004). The 
observation that serotonin and lysergic acid diethylamide (LSD) share structural and pharmacological 
properties led to the suggestion that biogenic amines, like serotonin, are involved in mental disorders such 
as schizophrenia (GADDUM and HAMEED, 1954; WOOLEY and SHAW, 1954). Lysergic acid 
diethylamide is the analogue of ergot alkaloids produced by Claviceps purpurea  fungus associated with 
incorrectly stored grains. Additionally, the active ingredient in Rauwolfia serpentina (resperine) has been 
shown to deplete biogenic amines and induce depression, therefore suggesting that a lack of serotonin 
and/or noradrenalin may be the cause of this pathology (VERTULANI and SULSER, 1975). Current 
basic understanding of mental illness as neurochemical d seases, as well as science’s ability to treat hese 
disorders has been greatly enhanced through the study of psychoactive plants. 
 
The ethnobotanical approach to selecting plants for screening programmes has on numerous occasions 
been shown to be successful (BALICK, 1990; FOURIE, SWART and SNYCKERS, 1992; COX and 
BALICK, 1994, BALICK and COX, 1996). This thesis hopes to achieve two main objectives: to 
consolidate literature on the traditional use of psychotropic plants and to screen a large proportion of 
these plants in relevant assays to validate their traditional use. It is hoped that this will serve to fill the gap 
in literature with respect to African psychotropic lant use and further validate traditional medicine, thus 
narrowing the gap between western and traditional therapies. The specific aims and objectives are dealt 
with in detail at the end of this Chapter (Page 39).
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1.2. The central nervous system 
 
This section reviews basic principles of brain anatomy and function to provide a framework within whic 
to discuss the effect of plants on the CNS. The nervous system is the body’s major communication 
system, and is divided into central and peripheral regions. The central nervous system consists of the 
brain and spinal cord, and the peripheral nervous system consists of all other nerves. Although thought 
processes and reason are most commonly associated with the CNS, it should also be noted that almost 
every aspect of physiological function is affected by CNS activity. ‘Brain death’ is widely accepted as the 
definition of the end of human life (HOUGHTON, 2005).  
 
The spinal cord controls reflex actions, and relays sensory and motor information between the body and 
the brain, so that the organism can respond appropriately to its environment. The region of the brain 
where it meets the spinal cord is called the hindbrain (rhombencephalon), and is composed of the medulla 
(myelencephalon) and metencephalon (pons and cerebellum) (Figure 1.2.1). The medulla is vital to 
sustaining life, and controls processes such as breathing, heartbeat and blood flow. The medulla also 
contains receptors for the opioid drugs, such as heroin and morphine, which is why these drugs can 
cause respiratory depression and death (WORLD HEALTH ORGANIZATION, 2004). The pons is a 
relay station for signals being carried from the cortex to the cerebellum, which is involved in body 



























Figure 1.2.1. Anatomy of the human brain. 
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Above the hindbrain is the midbrain (mesencephalon), which contains two areas that are important with 
respect to psychotropic plant use, in particular substance dependence. The ventral tegmental area (VTA) 
is rich in dopamine cell bodies, and projects to the limbic system and forebrain regions. The VTA is 
involved in signalling the importance of stimuli tha  are critical to survival such as those associated with 
feeding and reproduction. However, many psychoactive drugs also have powerful effects on the VTA, 
which contributes to the development of dependence by signalling to the brain that psychoactive 
substances are very important from a motivational pers ective (WORLD HEALTH ORGANIZATION, 
2004). The dopaminergic projection from the VTA to the nucleus accumbens (discussed below, Figure 
1.2.3) is known as the mesolimbic dopamine system, and is the neurotransmitter system that is most 
strongly implicated in the dependence-producing potential of psychoactive drugs (WISE, 1998).  
 
Another important midbrain structure is the substantia igra, which also has dopaminergic projections to 
the forebrain, but these pathways are involved in coordinating and executing movements of the body. 
Degeneration of neurons in the substantia nigra leads to the characteristic symptoms of Parkinson 
disease. 
 
Lastly, there is the forebrain (prosencephalon), which is composed of the diencephalon and the 
telencephalon (cerebral hemispheres) (Figure 1.2.1). Important areas of the diencephalon (Figure 1.2.2) 
are the thalamus, the hypothalamus, and the posterir lobe of the pituitary gland. The hypothalamus is 
critical for regulating hormonal signals and basic bodily functions concerning, for example, water 
balance, body temperature and reproductive hormones as well as responding to changes in these 
functions. The hypothalamus also secretes hormones that travel to the nearby posterior lobe of the 
pituitary gland. The thalamus functions as a relay st tion for sensory and motor information going to and 










Figure 1.2.2. Structure of the inner human brain, including the limbic system. 
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The telencephalon of the forebrain is the most highly developed area of the brain, and is composed of 
two cerebral hemispheres separated by the longitudinal fissure. The outermost layer of the brain is the 
cortex, which is made up of layers of nerve cells or neurons, and has a highly folded organization that 
increases its surface area and the number of neurons that it contains. Beneath the cortex run millions f 
axons that interconnect the neurons and allow the diff rent areas of the brain to communicate and to 
coordinate behaviour. Each hemisphere of the brain is divided into four lobes: frontal, parietal, temporal, 
and occipital (Figure 1.2.1). Different areas of the cortex are specialized for different functions. The 
motor association cortex, for example, is involved in coordinating movements of the body, and the 
primary motor cortex is involved in executing this function. Similarly, there is a primary sensory cortex 
that receives information from each of these sense organs (COOPER, BLOOM and ROTH, 1982). 
 
Information from the primary sensory areas goes to sensory association areas of the cortex, which are 
involved in perception and memory connected with the sense organs. Here information from several sense 
organs can be combined to form complex perceptions. The cortex is involved in many aspects of 
psychotropic plant use, from the primary effects of psychoactive drugs on sensations and perceptions, to 
the complex behaviours and thoughts involved in drug craving and uncontrolled use (WORLD 
HEALTH ORGANIZATION, 2004).  
 
 
Beneath the cortex are several other important structu es. The basal ganglia (Figure 1.2.2) are structures 



















Figure 1.2.3. The ‘pleasure circuit’, main regions targeted by addictive plant substances. Cocaine and 
amphetamines target the ventral tegmental area, the neurons of which connect to the ‘pleasure circuit’ 
(mesolimbic dopamine system). Opiates also target this region as well as regions activated by the brain’s 
natural opiates, like beta-endorphins. Alcohol also targets the ventral tegmental area and ‘pleasure circuit’, 
but goes further. It also affects the cortex (thought), cerebellum (movement), amygdala (emotion) and 
binding to the GABAA receptor (sedative) (after GROPPETTI, CERESOLI, MANDELLI and PARENTI, 
1990). 
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amygdala. The caudate and putamen together are known as the striatum. Just below the striatum is a key 
area for substance dependence and motivation, known as the nucleus accumbens, which is made up of 
core and shell regions (Figure 1.2.3). The nucleus accumbens is a very important brain area involved in 
motivation and learning, and signalling the motivational value of stimuli (DURLACH-MISTELI and 
VAN REE, 1992; ROBBINS and EVERITT, 1996; CARDINAL, PARKINSON, HALL and EVERITT, 
2002). Psychoactive substances increase the production of dopamine in the nucleus accumbens, which 
is thought to be an important event in drug reinforcement (Figure 1.2.3).  
 
The limbic system (Figure 1.2.2) is an interconnected series of structures that are important in relation to 
emotion, motivation and learning. The limbic system plays a vital role in the development of 
dependence, and interacts with the cortex and nucleus accumbens. Important structures of the limbic 
system are the hippocampus, which is associated with memory, and the amygdala, which is critical in 
emotional regulation. All of these areas receive sensory information from other brain areas to help 
coordinate the appropriate emotional and behavioural response to external stimuli (WORLD HEALTH 
ORGANIZATION, 2004).  
 
Neurons 
Communication in the brain takes place between nerve cells or neurons. Psychoactive substances alter 
many aspects of communication between neurons, as will be discussed below. The terms ‘neuron’ and 
‘synapse’ as components of an integrated nervous system were first described by Sir Charles Sherringto 
while studying the acetylcholine receptor (nicotinic, nACh-R). Sherrington shared the Nobel Prize for 
Medicine (1932) with Lord Edgar Adrian for his work on electrical potential differential-based 
neurotransmission.  
 
Neurons are highly specialized cells that exist in many shapes, sizes and varieties. However, they share 
the following basic structural regions: cell body or s ma, dendrites, axon, and terminal buttons (Figure 
1.2.4) (CARLSON, 1988). The cell body, or soma, is the mtabolic centre of the neuron, and contains the 
nucleus and other structures that sustain the neuro (Figure 1.2.4). 
 
The nucleus plays a role in mature neurons, where it is used to synthesize proteins in response to a wide
variety of stimuli. Psychoactive substances can affect the expression of DNA, resulting in short-term or 
long-term changes in neuronal function, and ultimately, behaviour. Dendrites are highly branched 
processes extending from the cell body of the neuron, which receive chemical messages from other 
neurons (Figure 1.2.5). This branching, and the presence of dendritic spnes (small swellings on the 
surface of a dendrite with which a terminal button from another neuron forms a synapse), allows many 
different neurons to converge on a single nerve cell, facilitating the coordination and integration of many 
complex messages. 
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The number of dendritic spines can increase or decrease following exposure to psychoactive substances 
(SKLAIR-TAVRON, XING SHI, LANE, HARRIS, BUNNEY and NESTLER, 1996; ROBINSON and 
KOLB, 1999; EISCH, BARROT, SCHAD, SELF and NESTLER, 2000), thus altering communication 
between neurons, and most likely contributing to the behavioural and neurological effects of the 
substances. The axon is a long slender process extending from the cell body, which carries information 
from the cell body to the terminal buttons. Certain chemicals such as neurotransmitters are transported 
along the axon, and it also propagates nerve impulses. The area where the axon leaves the cell body is 
known as the axon hillock. 
 
The synapse 
The overall architecture of a synapse is illustrated in Figure 1.2.5. The presynaptic terminal contains 
vesicles, which are filled with neurotransmitters. Presynapse and postsynapse are separated by a narrow 
synaptic cleft into which the neurotransmitters are rel ased from the vesicles via exocytosis. Transmitters 
diffuse across the synaptic cleft and, after a lag period of about 0.5 ms, bind to a receptor on the 
postsynaptic cell. The ion permeability of the postsynaptic membrane is changed in the next step causing 
a sudden change in the corresponding membrane potential. I  neurons within the brain, this electric 
disturbance can induce an action potential, which will result in a change of mental state. Many nerves are 































Figure 1.2.4. Structure of a neuron (after PINEL, 1990). 
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the opening of K+ and Cl- ion channels that hyperpolarise the membrane and thus blocks the generation of 
an action potential. Neuroreceptors are found at the post- and presynaptic membrane. Activation of 
presynaptic receptors usually leads to an inhibition of neurotransmitter release, whereas their inhibition 
results in an enhanced release of neurotransmitters. Thus the neurotransmitters and neuroreceptors are the 
basic elements for signal transduction in the synapses of the central nervous system. These will be 
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Figure 1.2.5. The monoamine neuron and the site of action of plant compounds screened for in this thesis. 
Monoamines are synthesized in the presynaptic nerve t minal, stored in the storage vesicles by vesicular 
monoamine transporter and released by Ca2+ -dependent exocytosis. After release, they act on postsynaptic or 
presynaptic receptors. Most of the monoamine receptors are linked to G proteins, the activation of which will 
open ion channels or either activate or inactivate membrane enzymes. The inactivation of the monoamine is 
done by active reuptake into the nerve terminal and/or glial cells using a specific Na+/Cl--dependent 
transporter. After reuptake into the nerve terminal, the monoamine is taken up again by the storage vesicles 
using the vesicular transporter or exposed to oxidation by MAO. The acute effect of antidepressants on the 
monoamine system is [1] inhibition of neuronal MAO; [2] inhibition of the reuptake of the monoamines; [3] 
GABAA- benzodiazepine receptor binding; and [4] the inhibition of membrane enzymes, in this case 
acetylcholinesterase (AchE). Adapted from STAHL (1998) and ELHWUEGI (2004). 
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Ligand-gated ion channels 
Two classes of membrane residing neuroreceptors can be distinguished. The fast ligand-gated channels 
and the slower G-protein coupled receptor (GPCR). These are structurally remarkably similar across a 
wide range of animals. The ligand-gated channel belongs to the ion-channel complex (Figure 1.2.6). 
When a neurotransmitter binds, a conformational change induces the opening of an ion channel. 
Depending on the geometry and polarity of the ‘gate’,  selective permeability of the channel is achieved 
for Na+, K+, Ca2+ and Cl- ions. The driving force is provided via the ion con entration in the cells and the 
extracellular space. The ligand-gated ion channels include the excitory nicotinic acetylcholine, 
glutamate/aspartate, ATPP2z, and the 5-HT3 (serotonin) receptor and the inhibitory glycine and GABAA 
receptor (Table 1.3.1) (WINK, 2000). 
 
 
The G-protein coupled receptors (Figure 1.2.6 [C]) are much more numerous and complex than the 
ligand-gated ion channels (MYSLIVECEK and TROJAN, 2000). They include muscarinic acetylcholine, 
adenosine, adrenergic, serotonergic (except 5-HT3), GABAB, glutamate, histamine, and opiate receptors. 
They share a common architecture, having seven transmembrane domains and three internal and three 
Figure 1.2.6. Schematic illustration of ligand-gated ion channels ([A]: nAchR; [B] GABAA receptor) and 
[C] G-protein coupled neuroreceptors (After WINK, 2000). 
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external loops each. When the corresponding neurotransmitter binds, the receptor changes its three-
dimensional structure, inducing a conformational change in an adjacent G-protein molecule, consisting of 
three subunits α, β and γ. G-proteins function as an ‘on-off switch’, which is off when the α-subunit binds 
GDP. Binding of a ligand to the receptor causes the G-protein to release its bound GDP and bind to GTP, 
converting the α-subunit to the ‘on’ state. The α-subunit dissociates and either interacts with an ion 
channel, or activates/inhibits the enzymes of a second messenger (Figure 1.2.6), such as adenyl cyclase 
(making cAMP, an allosteric regulator of protein kinases and other such proteins), or phospholipase C 
(splitting phosphatidylinositol-4-5-diphosphate (PIP2) into inositol-1,4,5-triphosphate (IP3) which 
activates Ca2+ release channels in the endoplasmic reticulum setting free the second messenger Ca2+) nd 
diacylglycerol (DAG which activates proteinkinase C). Whereas the hydrolysis of GTP (bound to the α-
subunit) switches the G-protein back to the inactive state, the second messenger can regulate various ion 




Sir Hendry Dale (UK) and Otto Loewi (Germany) were awarded the Nobel Prize for Medicine (1936) for 
their contribution to our understanding of chemical neurotransmission. Their work described the 
neurotransmitter acetylcholine. 
 
A neurotransmitter can be defined as a chemical substance that is released via the synapse from one 
neuron and that affects another cell in a specific manner (KANDEL and SCHWARTZ, 1985). A 
neurotransmitter must also meet the following criteria: 
− be synthesized in the neuron; 
− be present in the presynaptic neuron; 
− be released in sufficient quantity to have a postsynaptic effect; 
− have the same effect whether released by natural mens (endogenously) or whether applied as a 
drug (exogenously); and 
− it must have a specific mechanism for its removal from the synaptic cleft.  
Many types of neurotransmitters have been discovered so far, but in general there are three categories: 
amino acid neurotransmitters, amino acid-derived neurotransmitters, and peptides (chains of amino acids) 
(Table 1.3.1). The amino acid transmitters include glutamate, GABA, glycine and aspartate. The 
monoamines, noradrenalin and dopamine (catecholamines) and serotonin (indoleamine) are derived from 
amino acids. Large molecule peptide neurotransmitters are generally synthesized in the cell body, and 
transported along the axons to the synapse. Small molecule neurotransmitters can be synthesized in the 
terminals. 
 
There are distinct regions of the brain where cell bodies for a specific neurotransmitter exist, and other 
regions or “projection areas” where the axons from those cell bodies project to, and where the 
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neurotransmitter is ultimately released. Thus, not every neurotransmitter is released in every area of the 
brain. This allows certain areas of the brain to perform specific functions. Some of the more important 
neurotransmitters relevant to this work are discussed below, in particular the monoamine 
neurotransmitters (DAHLSTRÖM and FUXE, 1962), GABA and acetylcholine.  
 
Table 1.3.1. Simplistic characterisation of major neurotransmitters and receptors (After WINK, 2000). 
Receptor Transmitter Receptor Subtype Mechanism 
 
Cholinergic 






nicotinic muscle type 
nicotinic neuronal type 
muscarine M1, M3 
muscarine M2, M4 
 
cation channel (Na+>K+) 
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The monoamines  
The monoamines will be discussed in some detail as they feature prominently in the research presented i  
this thesis. The monoamines as neurotransmitters share certain properties but differ in their brain 
distribution, the type of receptors upon which they act and the mechanisms of their actions. In the 
following sections, the common properties that the monoamines share will be discussed, followed by a 
brief description about each monoamine in terms of its distribution, the types of receptors they interact 
with and the mechanisms of the actions.  
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Noradrenalin (NA), adrenaline (Ad) and dopamine (DA) are also known as catecholamines (CA). These 
monoamines share a common pathway in their synthesis, where they are synthesized from the same 
precursor (tyrosine) which is converted inside the nerve terminal by tyrosine hydroxylase (the rate-
limiting step enzyme) to 3,4-dihydroxyphenylalanine (DOPA). DOPA is then converted to DA, which is 
converted to NA by dopamine-β-hydroxylase (IVERSON, 1991; BOOIJ, VAN DER DOES,  
BENKELFAT, BREMNER, JCOWEN, FAVA, GILLIN, LEYTON, MOORE, SMITH and VAN DER 
Noradrenalin (NA) pathways – most of the 
noradrenalin-containing neurons in the CNS are 
located in the locus ceruleus in the pons and 
midbrain. These neurons project through the medial 
forebrain bundle to the limbic system, cerebral 
cortices, the thalamus, and the hypothalamus. A 
second group of neurons in the ventral tegmental 
area have projections to the hypothalamus and 
amygala 
Dopamine (DA) pathways – these tracts include the 
nigrostriatal tract, the mesolimbic/mesocorticsal tr c , 
and the tuberoinfundular tract 
Serotonin or 5-hydroxytryptamine  
(5-HT) pathways – 5-HT-containing neurons are 
found in the median and dorsal raphe nuclei, the 













cingulate gyrus to hippocampus 
hippocampus caudal raphe nuclei 
rostral raphe nuclei 





Figure 1.2.8. Neurotransmitter pathways and receptor distribution (adapted from RANG, DALE and 
RITTER, 1996). 
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KLOOT, 2002). The other monoamine serotonin is also known as 5-hydroxytryptamine (5-HT). 
Serotonin is synthesized from tryptophan, which is converted inside the nerve terminal to 5-
hydroxytryptophan by tryptophan hydroxylase (the rate-limiting step) then to 5-HT (FULLER, 1980; 
1995; RIEDEL, KLAASSEN and SCHMITT, 2002). 
 
All monoamines after their synthesis are concentrated in vesicles at the nerve terminal by a specific 
vesicular monoamine transporter (VMAT) (NJUS, KELLEY, and HARDABEK, 1986). Using a 
homology cloning strategy, VMAT-1 and VMAT-2 were successfully isolated in humans. VMAT-1 is 
primarily present in endocrine and paracrine cells of peripheral organs. On the other hand, VMAT-2 is the 
predominant monoamine vesicular transporter in the central nervous system (MASSON, SAGNE, 
HAMON and EL MESTIKAWY, 1999; ELHWUEGI, 2004). The accumulation of intraneuronal 
monoamines into storage vesicles acts as an amplification step for the overall process of Na+-dependent 
uptake of these molecules from the extracellular space. Consequently, it controls their concentration 
gradient across the plasma membrane. Vesicular accumulation also protects these molecules from leakage 
and/or intraneuronal metabolism (MASSON, SAGNE, HAMON and EL MESTIKAWY, 1999). Three 
distinct pools of synaptic vesicles have been identfi d. The first pool of vesicles, known as ‘ready 
releasable pools’, are those that are ready for immediate release upon elevation of intracellular calcium. 
The second pool is in close proximity to the site of release is known as ‘proximal pool’ and the third pool, 
which resides at some distance from the site of release, is known as ‘a reserve pool’. It is thought that
vesicles are recruited from the reserve pool to the proximal and subsequently to the readily releasable 
pool (BOEHM and KUBISTA, 2002). 
 
When the action potential reaches the monoamine nerve terminals, it causes the opening of voltage-
activated calcium channels. Calcium entry activates calcium sensors, which in turn cause the release 
machinery to cause vesicle fusion with the presynaptic membrane and the release of the monoamine into 
the synaptic cleft via exocytosis (Figure 1.2.5). The extra cellular calcium concentration-dependent 
release of the monoamines has a high requirement for energy. This is limited by tetrodotoxin (i.e. action 
potential-dependent) and subjected to presynaptic modulation through activation of different presynaptic 
receptors (LLINAS, 1977; VIZI, 2000; ELHWUEGI, 2004).  
 
The released monoamine will act on specific receptors l cated either on post- synaptic or presynaptic 
membranes (Figure 1.2.5). Stimulation of the postsynaptic receptors results in changes in the properties 
of the postsynaptic membrane with either a shift in membrane potential when the receptors are coupled to 
ion channels (known as ionotropic receptors), or bichemical changes in intracellular cyclic nucleotides, 
protein kinase activity, and related substrate proteins when the receptors are coupled to G-proteins 
(known as metabotropic receptors, vide infra) (STARKE, TAUBE and BOROWSKI, 1977; KALSNER, 
S., 2000). This stimulation of the presynaptic receptors located on the nerve terminal will regulate th
monoamine release triggered by action potential, such as vesicular release, thereby providing a feedback 
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mechanism that controls the concentration of the transmitter in the synaptic cleft (LANGER, 1980; 
BOEHM and KUBISTA, 2002). If the regulatory receptors are present on the same neuron releasing the 
neurotransmitter, then they are called autoreceptors. However, if the regulatory receptors are present on 
another neuron releasing different neurotransmitters, they are then called heteroreceptors (Figure 1.2.5) 
(ELHWUEGI, 2004). The regulatory receptors may be either ionotropic or metabotropic receptors 
(BOSKER, KLOMPMAKERS and WESTENBERG, 1997; BOEHM and KUBISTA, 2002). 
 
The non-synaptic transmission is a more recent concept of transmission inside the CNS, where there are 
functional interactions between neurons without morph logical ‘synaptic’ contacts. This type of 
neurotransmission is known as ‘wireless’ interaction between neurons (ELHWUEGI, 2004). In this case, 
the transmitter released from the axon terminal withou  a synaptic contact with another neuron will 
diffuse far away from the release site and activates remote receptors of high affinity on another axon 
terminal (VIZI, 2000).  
 
The actions of all monoamines are terminated by active reuptake of the monoamines into the presynaptic 
neuron (known as uptake 1) and/or glial cells. The uptake 1 mechanisms utilize Na+/Cl- dependent 
transporters (LESTER, CAO and MAGER, 1996). These transporters are members of a large family of 
Na+/Cl--containing putative transmembrane domains that conrol the concentration of the transmitter 
released into the intrasynaptic and extrasynaptic saces via rapid reuptake into the nerve terminals, thus
maintaining a low concentration of the neurotransmitter at these sites (NELSON, 1998; MASSON, 
SAGNE, HAMON and EL MESTIKAWY, 1999). Several drugs, including some antidepressants, inhibit 
these transporters specifically, thus increasing the amount of the monoamines at the synapse. It has been 
shown that the transporter velocity is increased by hyperpolarization of the membrane and is decreased by 
depolarization, i.e. the function of the reuptake system is voltage-dependent (SONDERS, ZHU, 
ZAHNISER, KAVANAUGH and AMARA, 1997). In such a case, it is expected that autoreceptors or 
heteroreceptors would affect the activity of the reuptake system by changing the membrane potential. 
This was found to be true where stimulation of dopamine receptors, type 2 (D2), that causes activation of 
K+ currents, i.e. hyperpolarization, increased the activity of dopamine transporter and therefore decreased 
its availability at the synapse (GINGRICH and CARON, 1993; VIZI, 2000). 
 
The two enzymes that are important in the initial step  of metabolism of the catecholamines, are 
monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT) (KOPIN, 1985). Both MAO and 
COMT are widely distributed throughout the body, including the brain; the highest concentrations of each 
are in the liver and the kidney. However, little or no COMT is found in the monoaminergic neurons 
(KOPIN, 1985). Two isoforms of MAO (MAO-A and MAO-B) were differentiated on the basis of 
substrate and inhibitor specificities. MAO-A preferentially metabolizes 5-HT and NA; clorgyline is a 
specific inhibitor of this enzyme. MAO-B prefers h-p enylethylamine and benzylamine as substrates; 
selegiline is a selective inhibitor. Dopamine and tryptamine are metabolized equally by both isoforms. 
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Neurons contain both isoforms of MAO, localized primarily in the outer membrane of mitochondria 
(SHIH, 1994). Inhibitors of MAO cause an increase in the amount of these amines stored and released 
from the nerve terminals, thus increasing the monoaminergic activity (See Chapter 5). 
 
Noradrenalin - Central noradrenergic pathways 
The existence of noradrenalin in the brain was establi hed biochemically in the 1950s. When noradrenalin 
is applied by microionophoresis to individual cells in the brain, the effect most often is inhibitory, and in 
most cases it is produced by activation of β-adrenoceptors. Activation of adenylate cyclase with a 
resultant build-up of cAMP has been unequivocally demonstrated as the mechanism of action in several 
types of CNS neurons (RANG and DALE, 1987). In some situations, however, noradrenalin has an 
excitatory effect, which is mediated by either α- or β-adrenoceptors. 
 
There is still much to be learned, as mentioned earlier, about the actual behavioural and physiological 
responses of these fairly well characterized neuronal mechanisms. Reward studies conducted on animals 
have shown that drugs that prevent noradrenergic transmission disrupt the ‘reward’ system. Studies of this 
kind (ASHTON, 1992) have led to the suggestion thate noradrenergic pathways constitute a ‘reward’ 
system, though the relationship of this psychological construct to subjective feelings in man is uncertain. 
The catecholamine (monoamine) hypothesis of affectiv  disorders, originally formulated by 
SCHILDKRAUT (1965) suggests that depression results from a functional deficiency of noradrenalin in 
certain parts of the brain, while mania results from an excess. Various lines of evidence suggest that 
activation of noradrenergic pathways can produce behavioural arousal. One is that amphetamine-like 
drugs, which are known to act by releasing catecholamines in the brain, increase wakefulness, alertness 
and exploratory activity. There is a close relationship between mood and state of arousal. Depressed 
patients are usually lethargic and unresponsive to x ernal stimuli. This association of symptoms may 
reflect the dual role of noradrenergic neurons in co trolling both mood and arousal (RANG and DALE, 
1987).  
 
The understanding that central, as well as peripheral, noradrenergic synapses are involved in blood 
pressure regulation, derived from investigation of the mechanisms of action of hypotensive drugs such as 
clonidine and methyldopa, both of which were shown to decrease the discharge of sympathetic nerves 
emerging from the central nervous system (RANG and DALE, 1987). It was then revealed that they cause 
obvious hypotension when injected locally into the vasomotor centres. Noradrenalin, injected locally into
the region of the vasomotor centres has similar effects. Agonist and antagonists show that these responses 
are due to activation of α2-adrenoceptors, which, on the basis of lesion studies, appear to be located post-
synaptically (in contrast to most peripheral α2 –receptors, which are pre-synaptic) (RANG and DALE, 
1987). Noradrenergic synapses in the medulla probably form part of the baroreceptor reflex pathway. 
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Dopamine 
Recognition of the role of dopamine in the brain, as a transmitter in its own right and not merely as a 
precursor of noradrenalin, came in the mid-1960s (RANG and DALE, 1987). The synthesis of dopamine 
follows the same route as that of noradrenalin, namely the conversion of tyrosine to dopa (the rate-limited 
step, catalysed by tyrosine hydroxylase) followed by decarboxylation (catalysed by dopa decarboxylase).  
 
Dopamine produces inhibitory postsynaptic potentials. It is involved in movement, learning and 
motivation. Dopamine plays a key role in the neurobiol gy of dependence. Dopamine receptor genes 
have also been highly implicated in substance dependence in general, as well as in nicotine and alcohol 
dependence. There are two major dopamine projections in the brain. One, the mesolimbic pathway, 
projects from the VTA to the nucleus accumbens. This pathway appears to be directly or indirectly 
activated by most known psychoactive substances. Closely associated with this is the mesocortical 
dopamine pathway, which projects from the VTA to regions of the cortex. The second major dopamine 
pathway projects from the substantia nigra to the sriatum, which is known as the nigrostriatal pathway 
(UNGERSTEDT, 1971). In Parkinson disease, this pathw y undergoes degeneration leading to the 
characteristic movement disorders. Excessive dopamine function in the mesolimbic and mesocortical 
dopamine systems is thought to underlie the delusions and hallucinations of schizophrenia. It is 
interesting to note here that certain substances such as cocaine and amphetamine can, in high doses, 
mimic some of the features of schizophrenia and bipolar disorders through the same basic actions on the 
dopamine system (RANG and DALE, 1987). 
 
The functions of dopaminergic pathways are better understood than those of pathways involving other 
transmitters (RANG and DALE, 1987). This is partly due to the availability of selective agonists and 
antagonist for dopamine receptors, and to the fact that dopaminergic neurons can be selectively destroyed 
by local injections of 6-hydroxydopamine into small areas of the brain. 
 
Parkinson’s disease is a progressive motor disturbance that occurs mainly in elderly patients, whose main 
symptoms are rigidity and tremors, together with extreme slowness in initiating voluntary movements 
(hypokinesia). It is known to be associated with a deficiency of dopamine in the nigro-striatal pathway. 
Huntington’s chorea, an inherited disease that results in severe involuntary movements, may be the 
pathological opposite of Parkinsonism, in which symptoms are associated with an excess, rather than a 
deficit, of dopamine (RANG and DALE, 1987). 
 
The tuberoinfundibular dopaminergic pathway is involved in the control of prolactin secretion. The 
hypothalamus secretes various mediators, which control the secretion of different hormones from the 
pituitary gland. One of these, which have an inhibitory effect on prolactin release, is dopamine. This 
system is of considerable clinical importance. It was observed many years ago that ergot derivatives tend 
to suppress lactation, whereas anti-psychotic drugs have the opposite effect, even to the point of causing 
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breast development and lactation in males. Studies on i olated pituitary glands confirmed that dopamine 
and related agonists strongly inhibit prolactin secretion, an effect that is abolished by many anti-psychotic 
drugs, which block dopamine receptors. Anti-psychotic drugs are used in South Africa to increase milk-
production in breast-feeding mothers. This often results in a dependency on these drugs by the mothers 
after breast-feeding which is a negative aspect of dopamine antagonists (RANG and DALE, 1987). 
 
The secretion of growth hormone is similarly regulated by dopamine. In normal subjects dopamine 
receptor activation increases growth hormone secretion, but paradoxically inhibits the excessive secretion 
responsible for acromegaly, a condition in which bromocriptine (high potency D2 agonist  and partial D1 
agonist) has a useful therapeutic application, provided that it is given before excessive growth has taken 
place (RANG and DALE, 1987). 
 
Serotonin (5-Hydroxytryptamine) 
Interest in serotonin as a possible CNS transmitter dates from 1953 (RANG and DALE, 1987), when 
lysergic acid diethylamide (LSD), a powerful hallucinogen, acted as a serotonin antagonist in peripheral 
tissues, and suggested that its central effects might also be related to this action. Its presence in the brain 
was demonstrated a few years later. It is involved in regulation of mood, arousal, impulsivity, aggression, 
appetite and anxiety. Serotonin-synthesizing cell bodies are found in the midbrain in a region called the 
raphe nuclei. These neurons project into many areas of the brain such as the cortex, hypothalamus and 
limbic system. There are many subtypes of serotonin receptor. In the body, serotonin is found in the 
gastrointestinal tract, platelets and spinal cord. Most antidepressant drugs work by increasing the action of 
serotonin in the brain. Serotonin is also involved in the primary actions of some psychoactive compounds 
such as LSD and ecstasy, and is also implicated in the effects of cocaine, amphetamine, alcohol and 
nicotine. Serotonin will be discussed in greater detail in Chapter 3. 
 
Amino-acid neurotransmitters 
γ-aminobutyric acid (GABA) 
GABA is particularly abundant in brain tissue and not in other mammalian tissues, where it is found in 
trace amounts. GABA is thought to act as an inhibitory ransmitter in many different CNS pathways. The 
most detailed studies have been carried out on the cerebellum, cerebral cortex, hippocampus and striatum. 
GABA mediates inhibitory action throughout the CNS by activating three classes of receptors, GABAA, 
GABAB and GABAC receptors that are classified structurally and pharmacologically (Table 4.1; Chapter 
4). GABAA receptors are ligand-gated chloride ion channels and resemble, but not identically, the 
inhibitory GABA receptor of invertebrates.  
 
It was thought that a GABA-like substance may prove to be effective in controlling epilepsy and other 
convulsive states, and since GABA itself fails to penetrate the blood-barrier, the search for more 
lipophilic GABA analogues continues. One such substance is the p-chlorophenyl derivative of GABA 
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(baclofen), which was introduced in 1972 (RANG and DALE, 1987). GABAA receptors contain 
modulator binding sites for benzodiazepine (BZD), barbiturates, neurosteroids and ethanol, are activated 
by GABA, muscimol and inhibited by bicuculline and picrotoxin. 
 
In contrast, GABAB receptors are members of the ‘seven transmembrane’ ec ptor family, which are 
coupled to either K+ or Ca 2+ channels via G-proteins and are regulated by intracellular secondary 
messenger systems. GABAB receptors are selectively activated by GABA and (-)baclofen and are 
inhibited by phaclofen. Although similar to GABAA receptors directly associated with a Cl
- ion channel, 
GABAC receptors differ markedly from GABAA and GABAB receptors in their pharmacological 
properties. They are insensitive to both bicuculline and baclofen as well as to GABAAR modulatory drugs 
like BZDs, barbiturates or neurosteroids, but stimulated by GABA and certain analogues of GABA, such 
as cis-4-aminocrotonic acid (CACA). 
 
A remarkable relationship exists between GABAA receptors and the actions of the benzodiazepine group 
of drugs, which have powerful sedative, anxiolytic and antiepileptic effects. These drugs selectively 
potentiate the effects of GABA on GABAA receptors in such a way that the binding of GABA is 




Acetylcholine is a central and a peripheral neurotransmitter. The symptoms of Parkinson’s disease result 
from a defect in the balance between acetylcholine a d dopamine in the basal ganglia. Thus 
anticholinergic medication is used to treat the parkinsonian adverse effects of antipsychotic medications 
(e.g. procyclidine and orphenadrine which block theD2 receptors in the basal ganglia) and idiopathic 
Parkinson’s disease (RANG and DALE, 1987).  
 
An important approach to treat Alzheimer’s disease (AD) is directed towards the inhibition of 
acetylcholinesterase (AChE). Nicotinic (receptor-operated Cl- ion channels) and muscarinic (which are G-
protein-coupled of which there are many sub-types) agonists or drugs that enhance endogenous 
acetylcholine function appear to be beneficial in the reatment of Alzheimer’s disease. Based on the 
cholinergic hypothesis, a defect in the cholinergic system is involved in AD. The cholinergic system will
be discussed in greater detail in Chapter 5. 
 
BOX 1. 
The classification of psychotropic drugs (RANG, DALE and RITTER, 1996). 
Psychotropic drugs are defined as those that affect mood and behaviour. Due to the fact that these are 
extremely complex functions, arriving at an adequate classification of drug effects is far from 
straightforward, and no single basis for classification has been found to be satisfactory. Thus 
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classification is on a chemical basis, which produces ategories such as benzodiazepines, butyrophenones 
etc., but does not give much guide to pharmacological effects. A pharmacological or biochemical 
classification, on the other hand, is appealing for th se drugs whose mechanism of action is reasonably 
well understood (e.g. monoamine oxidase inhibitors, catecholamine uptake blockers), but there are still 
many instances (e.g. hallucinogens) where the mechanism of action is too poorly understood to form the
basis of a reliable classification. Another possibility is to adopt an empirical classification based on 
clinical use, and divide drugs into categories such as ‘antidepressants’, ‘antipsychotic agents’ and so on, 
but this has an weakness that some important psychotropic drugs have no clinical use, or their use may 
have changed or been superseded according to clinical fashion. Amphetamine, for example, a drug with 
well-characterized effects on mood and behaviour, has ad an extremely chequered clinical career and 
would have been dismissed, revived and reclassified many times if a purely clinical classification had 
been adopted. Because no single basis for classifying psychotropic drugs is feasible, different authori ies 
tend to offer a variety of hybrid, and often-incompatible schemes. This currents arrangement is not ideal
and is often confusing. 
 
The following classification (TYRER, 1982; TREASE and EVANS, 1983) is based on suggestions by the 
World Health Organization (WHO) in 1976. Although it is not completely indisputable it provides a 
useful basis for the material discussed in this project. 
 
a. Anxiolytic sedatives 
Synonyms: Hypnotics, sedatives, minor tranquillizers 
Definition: Drugs that cause sleep and reduce anxiety. Some may be used as anticonvulsants 
Examples: Barbiturates, benzodiazepines, ethanol 
 
b. Neuroleptics 
Synonyms: Antipsychotic drugs, antischizophrenic drugs, major tranquillisers 
Definition: Drugs that are effective in relieving the symptoms of schizophrenic illness 
Examples: Phenothiazines, butyrophenones 
 
c. Antidepressant drugs 
Synonyms: Thymoleptics 
Definition: Drugs that alleviate the symptoms of depressive illn ss 
Examples: Monoamine oxidase A inhibitors (MAOI) e.g. , Serotonin reuptake inhibitors (SSRI), noradrenalin 
reuptake inhibitors, tricyclic antidepressants (TA) 
 
d. Psychomotor stimulants 
Synonyms: Psychostimulants 
Definition: Drugs that cause wakefulness and euphoria 
Examples: Amphetamine, cocaine, caffeine 
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e. Psychodysleptics 
Synonyms: Hallucinogens, psychotomimetic agents 
Definition: Drugs that cause disturbances of perception and behaviour in ways that cannot be simply characterized 
as sedative or stimulant effects, but resemble the symptoms of schizophrenia 
Examples: Lysergic acid diethylamide (LSD), mescaline, phencyclidine. 
 
1.4. Plants and the central nervous system 
 
Allopathic medicines, and the strongly associated disciplines of pharmacology and medicinal chemistry, 
have their historical roots in an earlier era in which the compounding of herbal remedies for specific 
illnesses were conducted as largely empirical activities. This was usually with no scientific basis and 
often, when a therapeutic rationale was provided at all, it was within a theoretical framework that 
resembled magic or superstition (KRIEG, 1964). Centuries of trial-and-error experimentation by 
shamans, herbalists, witches, alchemists, and other practitioners, inevitably lead to the discovery of the 
‘bioactive’ properties of certain plants, and of these, it was plants affecting the nervous system and mental 
functions that often had the most profound and dramatic effects. For instance, the juice of certain poppies 
(Papaver somniferum) had the power to block pain and induce a dream-like sleep; chewing the leaves of 
other plants (Catha edulis or Erythroxylum cocoa) could induce a state of wakefulness and mental clarity; 
consumption of certain mushrooms (Amanita muscaria) or seeds (Ipomoea violaceae) could plunge the 
eater into a bizarre alternate reality, complete with visions, voices, and confrontations with gods (or 
demons). Hemlock (Conium maculatum) is known for its potent depression of the nervous sy tem and 
more so for its most famous victim; Socrates in 399 B.C. The major psychoactive botanicals, active 
components and their principal molecular targets are given in Table 1.4.1. 
 
Due to the unmistakable and occasionally terrifying effects of psychoactive plants, whether consumed 
accidentally or deliberately, it is little wonder that our predecessors developed a healthy respect early on 
for the power of plants to heal, as well as to derange and even destroy. Knowledgeable practitioners 
adapted the use of psychoactive and other biodynamic plants to their own purposes, incorporating them 
into quasi-medical practices as well as ceremonial and magical activities. Gradually, people became more 
sophisticated in the phytotherapy, sharing and transferring their knowledge between cultures and 
generations. New methods of preparing sophisticated, multicomponent 'recipes' were discovered, as were 
new technologies for extracting the 'essences' or 'pirit  of the plants (McKENNA, 1996).  
 
The discovery of steam distillation in the Middle Ages (STOLL, 1967) was one such turning point, as it 
marked the appearance of one of the initial pharmaceutical technologies that went beyond the preparation 
of simple aqueous decoctions. It was not until the nineteenth century, however, that this natural desire to 
literally isolate the 'spirit' of plants in an ever more purified, concentrated, and potent form, stimulated the 
discoveries that eventually would form the foundations of modern organic chemistry, pharmacology, and 
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Figure 1.4.1. Louis Lewin M.D. 
(1850-1929), author of more than 
200 publications on the subject of 
pharmacology and the first 
researcher to study peyote and 
kava. (Photo: Clendening Library 
Portrait Collection) 
pharmacotherapeutic medicine. Once again, psychoactive plants assumed center stage as the focus of the 
new phytochemical technologies. Morphine, from the opium poppy (Papaver somniferum), isolated by 
the German pharmacist Sërtuner in 1803 (JAFFE and MARTIN, 1975), was the first alkaloid to be 
purified from a plant. This event marked the first scientific application of phytochemical technology that 
would lead to the isolation of the presumed 'active principles' from many of the important medicinal 
plants of the era, including cocaine from coca leaves by Squibb in 1885 (KENNEDY, 1985), and 
mescaline from the dried tops of the peyote cactus by Arthur Heffter in 1896 (HEFFTER, 1896). It was a 
fortunate accident of nature that these and other highly bioactive plant constituents were alkaloids, and 
thus amenable to purification using relatively crude isolation methods.  
 
Several other early scientific investigators can be cr dited with 
beginning interdisciplinary research on psychoactive plants and plant 
substances. As early as 1855, Ernst Freiherr von Bibra published Die 
narkotischen Genussmittel und der Mensch, a study of 17 plants. The 
non-technical article, The Seven Sisters of Sleep (1860) by the British 
mycologist Mordecai Cooke, was a noteworthy work on narcotic 
plants. Inspired by von Bibra’s work, Karl Hartwich over half a 
century later published Die Menschlichen Genussmittel (1911), a 
thorough work on about thirty psychoactive plants.  
 
However, the publication of Louis Lewin’s Phantastica in 1924 
began a new era of ethnobotany. Until Lewin, texts on the use of 
psychotropic plants were purely anthropological, largely concerned 
with how these plants were used rather than their mode of action. As 
a world renowned pharmacologist and toxicologist, he was fascinated 
by both. Lewin travelled extensively and acquired an astounding 
variety of knowledge on psychotropic plant use. He provided detailed 
information on all major psychotropic plants of the time, including opium, cocaine, heroin, cannabis, 
peyote, kava, coffee, tea, cocoa and tobacco. This knowledge forms the foundations of most work in this 
field.  
 
The isolation of active compounds (e.g. plant alkaloids) contributed to the development and eventual 
understanding that physiological processes occurring in living organisms were fundamentally not 
different from physicochemical processes which could be studied and manipulated in a variety of 
systems, both living and non-living. Chemists found that they could modify the structural characteristics 
of an isolated natural product using relatively simple methods, and that the pharmacological properties of 
the modified compound would often be altered as a result, sometimes in unexpected ways. These 
discoveries further eroded the notion that bioactive plants were the dwelling place of some kind of 
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mystical ‘healing spirit or god’ as mentioned earlier. These ideas gained general acceptance and became 
firmly entrenched in Western views of nature, and have lead to modern medicine, pharmaceutical 
technology, and medicinal chemistry. Natural products, which provided the foundation of the field in the 
first place, continue to make their contributions felt in significant ways. Specifically, natural products, 
whether isolated from plant, animal, or microbial sources, have provided and still provide medicinal 
chemists and pharmacologists with: (1) pharmacological research tools; (2) novel structural templates; 
and (3) leads to new pharmacologic mechanisms (McKENNA, 1996).  
 
Natural products provide pharmacologists with useful research tools for elucidating basic 
pharmacological mechanisms. Many examples could be cited here, but a CNS-related one that should be 
quite familiar to most neuroscientists is reserpine, th  major alkaloid of Rauwolfia serpentine or Indian 
Snake Root. It has been used clinically as an antipsychotic tranquilizer and hypotensive medication 
(NICKERSON and COLLIER, 1975). While its clinical use has been all but superseded by newer and 
more sophisticated medications, its ability to deplete neuronal vesicles of their stores of serotonin a d
catecholamines rendered it a useful tool for pharmacologists studying processes related to 
neurotransmitter storage, synthesis, and release.  
 
Seventy-five percent of prescription drugs sold in the United States are synthetic, while many of the 
remaining 25% are semisynthetic derivatives of natural products (FARNSWORTH and MORRIS, 1976; 
FARNSWORTH, AKERELE, BINGEL, SOEJARTO and GUO, 1985). Natural products also provide 
medicinal chemists with ideas for novel structural templates; these are new molecular entities, whether 
synthetic or semi-synthetic, which bear a clear correlation to the natural product which provided the 
inspiration for their manufacture, but which may have unique pharmacological properties that are not 
shared by the parent compound. 
 
The last important area where natural products have significant impact on pharmacology lies in their 
usefulness in identifying new mechanisms of action, and/or novel or previously uncharacterized receptor 
populations mediating those mechanisms (McKENNA, 1996). Often, a structurally novel class of 
neuropharmacological agents can lead investigators to the discovery of a new class of receptors with 
which the compounds interact.  
 
The discovery of cardiovascular activity from the roots of the Indian plant Rauwolfia serpentine led to the 
isolation of reserpine over five decades ago. Reserpin , was brought to the attention of the Western world 
in 1949 by Vakil who described its use in hypertensio ; in rapid succession between 1952 and 1958, 
reserpine was isolated from Rauwolfia, its structure determined and its total synthesis achieved 
(DOHADWALLA, 1985). The indiscriminate use of reserpine as an antihypertensive agent and 
tranquilizer led to reports of depression and Parkinsonism effects. These findings stimulated further 
investigation and evidence was found that reserpine depleted not only brain serotonin but also nor-
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epinephrine and dopamine (CURZON, 1990). This was a major stimulus for continued research on 
transmitter amine defects in depression and Parkinson’s disease. This in part laid the foundation for the
development of many of the modern psychoactive drugs and stimulated a significant interaction between 
researchers and drug industry. 
 
As the adverse effects of reserpine continued to be rev aled through clinical research, interest in the 
product gradually diminished, particularly when safer antihypertensive drugs were made available, 
though reserpine is still used in clinical medicine, particularly in low-income population. In deed, there is 
a revival of interest in its use based on some recent linical trials, which showed that lower doses of 
reserpine (0.05–0.1 mg) combined with low doses of thiazide diuretic and hydralazine provides highly 
effective blood pressure lowering regimen along with renal protective effect; relatively free from 
conventional side-effects and is perhaps the most c-effective antihypertensive treatment available 
today (MILNE and PINKNEY-ATKINSON, 2004).  
 
This development of reserpine clearly illustrates the scientific principle that drugs, in addition to being 
therapeutic agents, become tools for further understanding of disease and hence design of new drugs. 
Other compounds, which have been considered invaluable pharmacological “tools” for evaluating the 
mode of action of other drugs or investigation of basic physiological function, include muscarine and 
nicotine (pioneer selective agonists for muscarinic and nicotinic receptors respectively), cocaine 
(catecholamine uptake inhibitor), yohimbine (selective α2 blocker) and himbacine, a prototype of cardio-
selective antimuscarinic agents (GILANI, 1998). 
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Table 1.4.1. Main psychoactive botanicals and their principal mo ecular targets (adapted from ROTH, LOPEZ, BEISCHEL, WESTKAEMPER and EVANS, 2004)  






Principal molecular target(s)  Class of target  




Amanita muscaria  
AMANITACEAE 
Siberia, Asia and northern Europe 
Muscimol, ibotenic 
acid  
Muscarinic and metabotropic 
glutamate receptors 
(NICOLETTI et al., 1986) 
GPCR  Fly agaric, Ibo Tengatake 





constituents in the nut 
include arecaidin, 
arecaine and choline  
Muscarinic cholinergic receptors  GPCR  Betel nut 
Artemisia absinthium  
COMPOSITAE 
Europe 
Thujone  GABAA receptors and 
likely other targets 
Ion channels  Absinthe 
Atropa belladonna  
SOLANACEAE 
Europe 
Atropine  Muscarinic receptors  GPCR  Belladonna, night shade 
Cannabis sativa  
CANNABACEAE 
China and Middle East 
Tetrahydro-cannabinol  CB-1 cannabinoid receptors 
(HOWLETT et al., 1990, 
MAKRIYANNIS and RAPAKA, 
1990) 
GPCR  Marijuana, dagga. 
Catha edulis  
CELASTRACEAE 
East Africa and the Middle East 
Cathinone  Noradrenalin transporter 
(ROTHMAN et al., 2003) 




Ergot alkaloids  5-HT receptors (many)  GPCR  Ergot, St Anthony's Fire 
Coffee arabica  
RUBIACEAE 
Arabia 
Caffeine  Adenosine receptors 
(SNYDER et al., 1981) 






Nicotinic cholinergic (nACh) 
receptors agonist 
(POLYA, 2003) 





Yohimbine  a2-Adrenergic antagonist  GPCR  Yohimbine 
                                                
* Not a plant, but a fungus that can grow on incorrectly stored grains 
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Principal molecular target(s)  Class of target  




Datura sp.  
SOLANACEAE 
South America and Europe 
Scopolamine  Muscarinic receptors  GPCR  Jimson weed 






(ROTHMAN et al., 2003) 
Transporters  Ephedra 
Erythroxylum cocoa  
ERYTHROXYLACEAE 
South America 
Cocaine  Multiple biogenic amine 
transporters 
Transporters  Cocaine, Huanuco 
Heimia salicifolia  
LYTHRACEAE 
Mexico 
Cryogenine  Unknown (? prostaglandin 
synthetase inhibition) 
(LEMA et al., 1986) 
Enzyme/GPCR indirectly  Sinicuichi 
Hyoscyamus niger  
SOLANACEAE 
Europe, Middle East 
Hyoscamine and other 
tropanes  
Muscarinic receptors  GPCR  Henbane 








Many GPCR, transporters, 
kinases, and ion channels 
(SIMMEN et al., 1999, 2001; 
BUTTERWECK et al., 2002) 
GPCR, ion channels, 
transporters 
 
St. John’s wort 
Ipomoea violaceae  
CONVOLVULACEAE 
Mexico 
Lysergic acid amide  5-HT2A serotonin receptors 
(GLENNON et al., 1984; 
NICHOLS, 2004) 





Lobeline Nicotinic cholinergic (nACh) 
receptors agonist 
(POLYA, 2003) 
Ion channels Indian tobacco 
Lophophora williamsii  
CACTACEAE 
Mexico 
Mescaline  5-HT2A serotonin receptors 
(GLENNON et al., 1984; 
NICHOLS, 2004) 
GPCR  Peyote 
Myristica fragrens  
MYRISTICACEAE 
New Guinea, East Indies 
Myristicin  Unknown  Unknown  Nutmeg 




Nicotine  Nicotinic cholinergic (nACh) 
receptors 
Ion channel  Tobacco 
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Principal molecular target(s)  Class of target  




Papaver somniferum  
PAPAVERACEAE 
Persia, Asia 
Morphine and many 
related alkaloids 
α-opioid receptor 
(PERT and SNYDER, 1973) 
GPCR  Opium 
Paulinia cupana 
SAPINDACEAE 
Used interchangeably with Ilex 
paraguariensis, and others 
Brazil, South America 
Caffeine Adenosine receptors 
(SNYDER et al., 1981) 
GPCR  Guarana, Yerbe mate 
Piper methysticum  
PIPERACEAE 
Pacific Islands 
Kava lactones  Multiple ion channels 
(SINGH and SINGH, 2002) 
Ion channels  Kava kava 
Psilocybe mexicana  
STROPHARIACEAE 
Mexico 
Psilocybin  5-HT2A serotonin receptors 
(GLENNON et al., 1984; 
NICHOLS, 2004) 




Used with Mimosa tenuiflora, 
Peganum harmala nd 
Virola sp. 
Amazon Basin 
N,N-DMT (and related 
tryptamines) 
5-HT2A serotonin receptor 
(GLENNON et al., 1984; 
NICHOLS, 2004) 
GPCR  Chacruna, 
ayahuasca 
Salvia divinorum  
LAMIACEAE 
Mexico 
Salvinorin-A  Kappa opioid receptor (KOR) 
(ROTH et al., 2002; YAN and 
ROTH, 2004) 
(see Table 1.4.1.) 
GPCR  Salvia,  
Ska Pastora 
Tabernanthe iboga  
APOCYNACAE 
Congo, Gabon 
Ibogaine  Unknown  
(see Table 1.4.2.) 
Unknown  
(see Table 1.4.2.) 
Eboga, Ibogaine 
Vocanga africana  
APOCYNACEAE 
Congo, Gabon 
Voacangine  Unknown—related to ibogaine  Unknown  None 
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The following section will highlight in more detail a few of the highly researched and better documented 
psychotropic plants already mentioned in Table 1.4.1.  
 
Cannabis sativa (Cannabaceae) 
Cannabis has had a long history of use (over 5000 years) starting in Central and 
Northeast Asia with current use spreading worldwide as a recreational drug or as 
a medicine; albeit unauthorized. A number of countries, notably Canada, have 
eased restrictions on the use of cannabis for medicinal purposes. Several historic 
reviews have been written on Cannabis use as a therpeutic drug, the most recent 
of which are those by RUSSO (2001, 2002) and ELSOHLY (2002). Cannabis is extremely complex in its 
chemistry due to the enormous number of its constituents and their possible interaction with one another. 
These compounds represent almost all of the chemical classes, e.g., mono- and sesquiterpenes, steroids, 
flavonoids, nitrogenous compounds and amino acids, sugars, hydrocarbons, among others. The best-
known and the most specific class of Cannabis constituents is the C21 terpenophenolic cannabinoids, with 
(-)-∆9-trans-(6aR, 10aR)-tetrahydrocannabinol (∆9-THC) being the most psychologically active 
constituent (MECHOULAM and GAONI, 1967). The total number of natural compounds identified in 
C.sativa L. in the 1980s was approximately 420 (TURNER, ELSOHLY and BOEREN, 1980; 
ELSOHLY, BOEREN, TURNER and ELSOHLY, 1984) and 495 in a more recent paper (ELSOHLY and 
SLADE, 2005).  
 
Atropa and Datura species (Solanaceae)  
Atropine and scopolamine are found in jimson weed (Datura stramonium), 
nightshade (Atropa belladonna) and mandrake (Mandragora officionarum), and 
scopolamine alone is found in henbane (Hyoscyamus niger) (BROWN and 
TAYLOR, 2001), all of which are popularly grown as ornamental flowers. D. 
stramonium, a weed that is probably indigenous to tropical America is now 
widely distributed throughout the world including southern Africa. The seeds are 
the most potent part of the plants, followed by theroots, stems, leaves, and 
flowers, and as few as ten seeds are sufficient for psychoactivity. Dissociative 
rather than entirely hallucinogenic, both chemicals act as CNS depressants and 
competitively antagonize muscarinic cholinergic receptors. They have 
considerable application in ophthalmology to dilate pupils (atropine), anaesthesia to decrease secretions 
and treat bradycardia, toxicology to treat organophos ate and nerve gas poisoning, and in emergency 
medicine for cardiac arrest. Scopolamine is also used as a treatment for motion sickness. In excess, the e 
plants can cause a toxic delirium that may lasts hours to days, marked by amnesia, confusion, 
dissociation, hallucinations, delusions, euphoria, and sometimes episodes of bizarre self-injury 
(GRINSPOON and BAKALAR, 1997). This is evident by the Afrikaans name, malpitte which translates 
as ‘mad seeds’ (VAN WYK and GERICKE, 2000) and its Zulu name iloyi which is derived from –loya 
Datura 
stramonium 
Seed capsule  
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which means to bewitch, or cast a spell on. In tropical West Africa, Datura spp. are used in native beer or 
in palm wine to add a stupefying or narcotic effect. A drink made from the seeds of D. metel (D. fastuosa 
var. alba) is given as an intoxicant to Fulani youth to incite them in the ‘Sharo contest’ or ordeal of 
manhood (OLIVER-BEVER, 1986). In Tanzania, the leaves of D. fastuosa are added to native beer to 
further its intoxicating effect (BALLY, 1938). 
 
Hypericum perforatum (Hypericaceae) 
St. John’s Wort, Hypericum perforatum, is a perennial herbaceous plant 
traditionally used in the treatment of ulcers, burns, abdominal pains and 
bacterial diseases (MILLS and BONE, 2000). Currently it is a popular 
botanical used for mild to moderate depression. A total sales figure of 
about US$ 6 billion for 1998 in Europe alone attests to the popularity of 
this herb for treating depression (HARRISON, 1998). 
 
The antidepressant actions are believed to be mediated through multiple 
modes. These include inhibition of monoamine oxidase, catechol-o-
methyltransferase and dopamine-β-hydroxylase (THIEDE and WALPER, 1994; KLEBER, OBRY, 
HIPPELI, SCHNEIDER and ELSTNER, 1999; RON, WILLIS, BONE and MORGAN, 2000), by 
blocking synaptic reuptake of 5-HT, noradrenalin, dopamine, GABA and L-glutamate (MULLER, 2003), 
inhibiting nitric oxide synthase (LUO, SUN, MAO, LU and TAN, 2004) and through calcium channel 
and PDE blockade (GILANI, SHAH, GHAYUR, and MAJEED, 2005). Reports show that H. perforatum 
extracts have a significant antidepressant effect when administered to humans. Numerous clinical trials 
and meta-analyses assessing the efficacy of H. perforatum for the alleviation of mild to moderate 
depression report that extracts are significantly superior to placebo, similarly effective as standard 
antidepressant drugs (such as imiprimine and diazepam), and apparently produce significantly fewer side-
effects than the synthetic preparations (ERNST, 1995; LINDE, RAMIREZ, MULROW, PAULS, 
WEIDENHAMMER and MELCHART, 1996; VOLZ, 1997; SCHRADER, MEIER and BRATTSTROM, 
1998; PHILLIP, KOHNEN and HILLER, 1999; KIM, STRELTZER and GOEBERT, 1999; SCHULZ, 
2002; LINDE and MULROW, 2003). 
 
Of the known constituents of H. perforatum, amentoflavone had highest affinity for any tested molecular 
target, with high affinity for the GABA-benzodiazepine receptor complex (Ki = 6 nM) and moderate 
affinity for δ-opioid receptors (Ki = 37 nM). Several other compounds have shown affinities in the low 
nanomolar to micromolar range for several cloned receptors, including various serotonin receptors for 
amentoflavone (5- HT1B, 5-HT1D, 5-HT2C) and dopamine receptors for hypericin (D3 and D4). Another 
study using fewer receptors (SIMMEN, BURKARD, BERGER, SCHAFFNER and LUNDSTROM, 
1999) disclosed low micromolar affinities for various opioid and 5-HT receptor subtypes. Other studies 
by the same group found that hypericin was a low affinity CRF-1 antagonist (SIMMEN, HIGELIN, 
Hypericum perforatum 
Flower  
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BERGER-BUTER, SCHAFFNER and LUNDSTROM, 2001, SIMMEN, BOBIRNAC, ULLMER, 
LUBBERT, BERGER BUTER, SCHAFFNER and SCHOEFFTER, 2003). Finally, GOBBI, MOIA, 
PIRONA, MORIZZONI and MENNINI, (2001) found that hypericin and other constitutents had low 
micromolar affinities for various peptide (NPY-1, NPY-2), serotonin, and δ-opioid receptors. Taken 
together, these results indicate that certain purified substances obtained from H. perforatum can interact 
with a variety of biogenic amine and peptide receptors with low affinities, generally in the micromolar 
range. With the exception of amentoflavone, which has igh affinity for the GABA/benzodiazepine 
receptor complex and δ-opioid receptors (BUTTERWECK, NAHRSTEDT, EVANS, HUFEISEN, 
RAUSER, SAVAGE, POPADAK, ERNSBERGER and ROTH, 2002), and hypericin, which has 
moderate affinity for CRF-1 receptors, the evidence is not yet persuasive that the main molecular targets  
responsible for the antidepressant actions of these compounds have been discovered. It is most likely that 
the putative antidepressant actions are mediated by a mixture of compounds, each of which has a complex 
pharmacological profile (BUTTERWECK, WALL, LIEFLANDER-WULF, WINTERHOFF and 
NAHRSTEDT, 1997; BUTTERWECK, PETEREIT, WINTERHOFF and NAHRSTEDT, 1998; 
BUTTERWECK, NAHRSTEDT, EVANS, HUFEISEN, RAUSER, SAVGE, POPADAK, 
ERNSBERGER and ROTH, 2002; BUTTERWECK, 2003). 
 
Salvia divinorum (Lamiaceae) 
Salvia divinorum is a hallucinogenic plant that has been used by curanderos in Mexico and other Central 
American countries for centuries for divination and shamanism. The plant was named S. divinorum after 
its use in divination by the Mazatec Indians and was first described by a western observer in 1962 
(WASSON, 1962; 1963; OTT, 1996). Other native uses for the plant include the treatment of diarrhoea, 
headache, and rheumatism. In addition, the plant is used to treat a semi-magical disease known as panzo´n 
de barrego, or swollen belly, which is caused by a curse from an evil sorcerer (VALDES, DIAZ and 
PAUL, 1983). For many years after its discovery there was considerable controversy regarding the 
psychoactive potential of S. divinorum largely because the active ingredient is less active when taken 
orally. Additionally, S. divinorum’s actions are relatively short-lived and subtle (SIEBERT, 1994; 
VALDES, 1994). Traditionally it is consumed by chewing fresh leaves or by drinking the juice of the 
leaves for absorption of the active principle through the oral mucosa (VALDES, DIAZ and PAUL, 1983). 
These plants are now grown and sold throughout the world for ingestion and for smoking by people who 
obviously do not have a historical ceremonial connection to this plant. Although the Drug Enforcement 
Administration (DEA) has not scheduled S. divinorum, they are closely monitoring it as a possibly 
emerging drug of abuse (NATIONAL DRUG INTELLIGENCE CENTER, 2003). 
 
The presumed active ingredient, salvinorin-A (Figure 1.4.2.) was independently isolated by two groups in 
the early 1980s (ORTEGA, BLOUNT and MANCHAND, 1982; VALDES, BUTLER, HATFIELD, 
PAUL and KOREEDA, 1984) and shown by SIEBERT (1994) to be the main active ingredient more than 
a decade later. Salvinorin-A defines a novel structural family of hallucinogens in that it is a non-
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nitrogenous neoclerodane diterpene of known absolute stereochemistry. Its structure gives no clue 
regarding its site of action. Subsequently, a large number of other constituents including salvinorin-B, -C, 
-D, -E, and -F (MUNRO and RIZZACASA, 2003), along with divinaturin-A, -B, and -C (BIGHAM, 
MUNRO, RIZZACASA and ROBINS-BROWNE, 2003), have been described. All of these are 
neoclerodane diterpenoids in structure. None of the known diterpenoids, with the exception of salvinor-
A, has any known psychoactive actions and, thus, attention has focused on discovering the mechanism of 





















Figure 1.4.2. Non-nitrogenous neoclerodane diterpenes from S. divinorum. 
 
There are 59 Salvia species in Africa, S. chamelaeagnea Berg. and S. runcinata L. f. are used traditionally 
in South Africa by both the Xhosa and Zulu people. An infusion of S. chamelaeagnea leaves are used as a 
remedy for convulsions (WATT and BREYER-BRANDWIJK, 1962). Table 1.4.2. shows the 
psychotropic activity of compounds from Salvia species. 
 
Table 1.4.2. Biological activity of compounds from Salvia species (excluding neoclerodane diterpenoids salvinorin 




Species Biological activity 
Cryptotanshinone 
(diterpine quinine) 
S. miltiorrhiza Central Benzodiazepine/GABAA receptor partial 





S. miltiorrhiza Central Benzodiazepine/GABAA receptor partial 
agonist (Flunitrazepam competition, IC50 = 1 
µM), 
Tranquillizer 





Species Biological activity 
(-)-1,2-Dihydrotanshinone I 
(diterpine quinine) 
S. miltiorrhiza Central Benzodiazepine/GABAA receptor partial 





S. miltiorrhiza Central Benzodiazepine/GABAA receptor partial 





S. miltiorrhiza Central Benzodiazepine/GABAA receptor partial 





S. miltiorrhiza Central Benzodiazepine/GABAA receptor partial 





S. miltiorrhiza Central Benzodiazepine/GABAA receptor partial 





S. miltiorrhiza Central Benzodiazepine/GABAA receptor partial 





S. miltiorrhiza Central Benzodiazepine/GABAA receptor partial 





S. miltiorrhiza Central Benzodiazepine/GABAA receptor partial 





(tutinolide sesquiterpene lactone) 
S. deserta GABAA receptor non-competitive antagonist 
(Glycine receptor), 
CNS stimulant, barbiturate antidote, insecticide 
Salvanolic acid A  
(stilbene, phenylpropanoid) 
S. miltiorrhiza H+, K+-ATPase 
Anti-peptic ulcer, inhibits gastric H+ secretion 












S. miltiorrhiza A1 Adenosine receptor ligand ((Ki = 17 nM) 
Oleanolic acid 
(triterpene) 
Salvia spp. Muscarinic acetylcholine receptor agonist, 
Uterine smooth muscle contraction 
α- and  β-Thujone 
(=α- and  β-Thujan-3-one) 
(monoterpene) 
 
S. officinalis and 
S. triloba 
Cannabinoid receptors  
CB1-receptor ligand (rat, , IC50 > 10 µM), CB2-
receptor ligand (rat, , IC50 > 10 µM), 





Salvia spp. Acetylcholinesterase (IC50 = 630 µM), 
Ataxic, delirium-inducing, dermatitic, irritant, 
perfume 
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1.4.1. African psychotropic plants 
 
“There is always something new out of Africa” Gaius Plinius Secundus, (circa AD 23 - 
79) better known as Pliny the Elder, Roman Natural Historian 
 
In the following sections several well documented African psychotropics will be reviewed. The relatively 
unknown southern African psychoactives, the main topic f this thesis will be reviewed in Chapter 2.  
 
 
Figure 1.4.3. Distribution of documented African psychotropic plant use, also showing southern African regions 
(adapted from SCHULTES and HOFMANN, 1992). 
 
Catha edulis (Celastraceae) 
The psychotropic properties and use of ‘Khat,’ has been known for centuries in East Africa, the Middle 
East, including Ethiopia, Tanzania and North Yemen (CARLINI, 2003). The usual method of ingestion is 
chewing of the young leaves (NENCINI, AHMED and ELMI, 1986). Recently, this habit has reached 
other parts of the world (AL-MOTARREB, BAKER and BROADLEY, 2002). Khat induces a clear 
anorectic effect (ZELGER and CARLINI, 1980), togethr with euphoria, excitation and cheerful 
sensation (NENCINI, AHMED and ELMI, 1986). These effects are produced mostly by 
phenylpropanolamines present in the leaves: cathinone (S-α-aminopropiophenone), cathine [(-)-1S,2S-
norpseudoephedrine] and (-)-IR,2S-norephedrine (CARLINI, 2003). These substances have 
pharmacological properties similar to those of D-amphetamine (ZELGER, SCHORNO and CARLINI, 
1980), as they provoke the release and inhibit the uptake of dopamine in CNS (ZELGER and CARLINI, 
1981).  
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Cola species (Sterculiaceae)  
Caffeine is the most widely used psychoactive substance in the world (GILBERT, 1976; BARONE and 
ROBERTS, 1996). Caffeine is valued because of its st mulant-like behavioural activity on mood and 
performance. It occurs in several plants which are widely known and employed throughout the world. 
Wherever these ‘caffeine containing plants’ were found, indigenous groups have recorded their mildly 
stimulant effects and have grown habituated to their use. The most well-known sources in contemporary 
western society are coffee, tea, caffeinated soft drinks, cocoa, chocolate and certain medications. 
 
More tradional sources include Ilex and Paullinia species valued by South American Indians, whereas 
Cola spp. are an important social drug for West African peoples (Table 1.4.3.) (DE SMET, 1990). Kola 
nuts have also played an important role in Western Af ica as a commodity. Whole caravan trains were 
assembled to purchase them (MADAUS, 1979).The Yoruba farmers of Western Nigeria recognize at least 
four kinds of kola nuts, which probably belong to three different Cola species (C. acuminata, C. nitida 
and C. verticillata) (DE SMET, 1996). 
 
Table 1.4.3. Botanical sources rich in caffeine other than coffee, tea and cacao (DE SMET, 1990). 
FAMILY  
Species 















0.3 – 2 











2.5 – 5 
2.7 
STERCULIACEAE 






1.5 – 3.5 
a Several other Ilex spp. contain caffeine as well and are used as substitute  for Mate´ (e.g. I. amara, I. conocarpa, I. 
theezans). 
b Cola nuts may also be obtained from other caffeine-containing Cola spp. (e.g. C. acuminata and C. ballayi ). 
 
The notable behavioral effects of caffeine occur after low to moderate doses (50–300 mg) and are 
increased alertness, energy and ability to concentrate. Moderate caffeine consumption leads very rarely to 
health risks (BARONE and ROBERTS, 1996). Higher doses of caffeine induce negative effects such as 
anxiety, restlessness, insomnia and tachychardia. These effects are only evident primarily in a small 
portion of caffeine-sensitive individuals (BARONE and ROBERTS, 1996). 
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Left Figure 1.4.4: West African wooden kola nut dish. This 
specimen probably originates from an Igbo group in Southeast 
Nigeria. The Igbo call such platters okwa oji (dish kola) and use 
them for serving kola nuts and other foods to their guests 




The effect of caffeine on the release of intracellular calcium and as an inhibitor of cyclic nucleotide 
phosphodiesterases has been mainly shown in vitro at 500 µM - 500 mM concentrations. Doses higher 
than those usually achieved by human consumption (NEHLIG and DEBRY, 1994) and cannot therefore 
account for most of the physiological effects of caffeine. One exception is the respiratory stimulant effect 
of caffeine that appears to be prominently mediated by the inhibition of type-IV phosphodiesterase 
(HOWELL, 1993). In fact, it is now widely accepted that the main mechanism of action of caffeine 
occurring at circulating concentrations achieved after the consumption of one or two cups of coffee, is the 
antagonism at the level of adenosine receptors (NEHLIG and DEBRY, 1994, FREDHOLM, 1995). 
Indeed, in animals, most pharmacological effects of adenosine in the brain can be suppressed by relatively 
low concentrations of circulating caffeine, i.e. less than 100 mM, which are attained after the 
consumption of one to three cups of coffee. Adenosine decreases the firing rate of neurones and exerts an 
inhibitory effect on synaptic transmission and on the release of most neurotransmitters, while caffeine 
increases the turnover of many neurotransmitters, including monoamines and acetylcholine (NEHLIG and 
DEBRY, 1994).  
 
The A1 and A2a adenosine receptors are the subtypes that are primarily involved in the effects of caffeine, 
while the A2b and A3 receptors play only a minor role. The A1 receptors are negatively linked to adenyl 
cyclase, while the A2a receptors are positively linked to the enzyme. Adenosine A1 receptors are widely 
distributed throughout the brain with high levels in the hippocampus, cerebral and cerebellar cortex, and 
thalamus (DAVAL, WERCK, NEHLIG and PEREIRA DE VASCONCELOS, 1991). Conversely, A2a 
receptors are almost exclusively located in the striatum, nucleus accumbens and olfactory tubercle 
(ONGINI and FREDHOLM, 1996). In the latter regions, A2a receptors are coexpressed with enkephalin 
and dopamine D2 receptors in the same kind of striatal  neuronal cells (ONGINI and FREDHOLM, 1996). 
There is direct evidence for a central functional interaction between adenosine A2a and dopamine D2 
receptors. Indeed, the administration of adenosine A2a receptor agonists decreases the affinity of 
dopamine binding to D2 receptors in striatal membranes (FERRÉ, VON EULER, JOHANSSON, 
FREDHOLM and FUXE, 1991). The interaction between adenosine A2a receptors and dopamine D2 
receptors in the striatum might underlie some of the behavioral effects of methylxanthines. By 
antagonizing the negative modulatory effects of adenosine receptors on dopamine receptors, caffeine 
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leads to the inhibition and blockage of adenosine A2 receptors, leading to a potentiation of dopaminergic 
neurotransmission (GARRETT and GRIFFITHS, 1997). The latter interaction is very interesting since it 
could explain the adenosine receptor antagonists-induced increase in behaviors related to dopamine 
(DALY, 1993), such as, e.g. caffeine-induced rotatinal behavior (GARRETT and HOLTZMAN, 1995). 
 
Piper betle (Piperaceae) 
Betel is a preparation of several natural substances ch wed for its mild psycho-stimulating effects. Betel 
is composed of the fruit or nut of the areca palm (Areca catechu, Arecaceae), the leaf of the betel pepper 
(Piper betle), and lime (calcium hydroxide). Approximately 200 million persons chew betel regularly 
mainly throughout the western Pacific basin and south Asia. However, it is reportedly used by the Swahili 
of Zanzibar (NORTON, 1998) and plants can be found through-out Africa. According to EICHHORN 
(1911), the Kenyan Shambala (Waschambaa) considered the chewing of betel as a means to preserve the 
teeth and as a way to soften toothache. In South Africa, the habit is primarily confined to people of Indian 
or South East Asian origin (SEEDAT and VAN WYK, 1988). Betel chewing is also associated with oral 
leukoplakia, submucous fibrosis, and squamous cell carcinoma. The active ingredient of the areca nut is 
arecoline, an alkaloid with properties that mimic aetylcholine. The hydrolyzing action of lime on 
arecoline produces arecaidine a central nervous system timulant, which in combination with the betel 
pepper produces mild euphoria. Along with the mild euphoria, chewers experience cholinergic effects 
such as diaphoresis, lacrimation, pupillary constriction, and occasionally diarrhoea (MUJUMDAR, 
KAPADI and PENDSE, 1979). Arecoline can cause bronch constriction and may trigger asthma attacks 
(TAYLOR, AL-JARAD, CONROY and BARNES, 1992). Betel appears to be psychologically and 
physiologically addictive (PICKWELL, SCHIMELPFENIG and PALINKAS, 1994). 
 
Tabernanthe iboga (Apocynaceae) 
The Iboga people living in Gabon and other nearby West African countries chew the roots of this plant t 
the religious cult of Bwiti (Bouiti) in order to communicate with their ancestors. In large doses the roots 
of T. iboga produce altered states of consciousness and even hallucinations (EMBODEN, 1972). Apart 
from this religious use, according to European explorers in the 19th century, eating the roots had also 
stimulant and aphrodisiac effects and greatly increased endurance (POPIK, LAYER and SKOLNICK, 
1995). Not unexpectedly, Ibogaine, the main active constituent has been used as a performance enhancing 
agent by athletes (DE SIO, 1970). Ibogaine was isolated and identified in the beginning of the 20th 
century (POPIK, LAYER and SKOLNICK, 1995); at least 12 more indole alkaloids have been isolated 
from the plant (SCHULTES and HOFMANN, 1992; POLYA, 2003). Ibogaine mimics most of the effects 
of crude T. iboga extracts; however, there seem to be some pharmacologi a  differences between both 
(for a review, see POPIK, LAYER and SKOLNICK, 1995 and Table 1.4.4.). 
 











In the mid-1980s, a new era of interest arose for ib gaine, with the filing of a patent for ibogaine 
treatment of opiate dependence (SANCHEZ-RAMOS and MASH, 1994). Three other patent filings 
followed in rapid succession for treatment of cocaine, amphetamine, alcohol and nicotine/ tobacco 
dependence syndromes. 
 
Ibogaine is currently the only representative of a class of complex indole alkaloids that are particularly 
abundant in the Apocynaceae family, and it is likely that other naturally occurring alkaloids with relat d 
structures will also exhibit interesting CNS activity. Potential candidates worthy of investigation are 
Acokanthera oppositifolia which is administered to treat fits, Tabernaemontana species and Strophanthus 
species which are used to treat hysteria (HUTCHINGS, SCOTT, LEWIS and CUNNINGHAM, 1996). 
 
Table 1.4.4. The diverse biological activity of Tabernanthe alkaloids (adapted from POLYA, 2003). 
Compound 
 
Biological activity  
Tabernanthine 
(= 13-Methoxyibogamine) 
Benzodiazepine receptor agonist 
(flunitrazepam displacement (IC50 = 150 µM), NMDA-Glutamate-
receptor antagonist (Ki = 11 µM),  
σ1-receptor ligand (IC50 = ~1 µM) and σ2-receptor ligand (IC50 = 0.2 
µM) 
Opiate (κO)-receptor ligand (Ki = 0.2 µM), µO-receptor (IC50 >100 µM 
;), δO-receptor (Ki = 3 µM), 
(±)-Coronaridine  
(= Carbomethoxyibogamine) 
NMDA-Glutamate-receptor antagonist (Ki = 6 µM), 
Opiate (µO)-receptor (Ki = 3 µM), δO-receptor ligand (Ki = 8 µM), κO-
receptor ligand (Ki = 4 µM), 
Voltage-gated Na+ channel antagonist (Ki = 16 µM) 
cytotoxic, diuretic and oestrogenic 




Biological activity  
Ibogaine  
(=12-Methoxyibogamine) 
5HT3-receptor ligand (IC50 = 4 µM),  
Dopamine and 5HT re-uptake transporter inhibitor (IC50 = 4 and 0.6 
µM respectively) 
Dopamine receptor (D1) ligand (IC50 > 10 µM), 
Dopamine receptor (D2) ligand (IC50 > 10 µM), 
NMDA-Glutamate-receptor antagonist (Ki = 1 µM),  
σ1-receptor ligand (IC50 = 9 µM) and σ2 receptor ligand (IC50 = 0.2 
µM), 
Opiate (κO)-receptor ligand (IC50 = 25 µM ; Ki = 2 µM), µO-receptor 
(Ki = 4 µM), δO-receptor (Ki > 100 µM), 
Adenosine-receptor (subtype A1) ligand,  
Muscarinic acetylcholine-receptor ligand, 
α1-Adrenergic-receptor (IC50 = 7 µM) 
Voltage-gated Na+ channel antagonist (Ki = 9 µM) 
Anticonvulsant, hallucinogen, inhibits morphine dependence, anti-
addictive, increases synaptic 5HT) 
Noribogaine  
(=12-Hydroxyibogamine) 
Metabolite of Ibogaine 
Dopamine receptor (D1) ligand (IC50 > 10 µM), 
Dopamine receptor (D2) ligand (IC50 > 10 µM), 
Opiate (κO)-receptor ligand (Ki = 4 µM), µO-receptor (Ki = 0.2 µM),  
Ibogamine NMDA-Glutamate-receptor antagonist (Ki = 6 µM),  
σ1-receptor ligand (IC50 = ~1 µM) and σ2 receptor ligand (IC50 = 0.1 
µM), 
Opiate (κO)-receptor ligand (Ki = 3 µM), µO-receptor (Ki > 100 µM), 
δO-receptor (Ki > 100 µM), 
Voltage-gated Na+ channel antagonist (Ki = 8 µM) 
Brachycardiac activity, cytotoxic and hypotensive 
Tubotaiwine Adenosine-receptor (subtype A1) ligand. 
Opiate-receptor ligand (Ki = 2 µM) 
Analgesic (mouse abdominal relaxant) 
 
Plants and alcoholic beverages 
One of the most common traditional psychotropic agents throughout Africa is ethyl alcohol (ethanol). It is 
known that the imbibing of this reversible general CNS depressant can lead to inebriation. All that is 
needed to prepare an alcoholic beverage is a ‘sugar-providing’ plant and the right yeast to transform the 
sugar in the presence of water into ethyl alcohol and carbon dioxide. Thus the psychotropic effects that
these alcoholic preparations produce are not a direct effect of a plant secondary metabolite. This 
fermentation process is so simple that it is believd that man already knew it before he learnt how to 
record his own history (LEWIS and ELVIN-LEWIS, 1977). What are of more pertinence to this project 
are the plants which are added to these beverages to ‘fortify’ them.  
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Various additives to alcoholic beverages have been described (DE SMET, 1996, 1998; VAN WYK and 
GERICKE, 2000) but little is known about their chemical constituents. Examples are; Anacampseros 
rhodesica (Portulacaceae) which according to GELFAND, MAVI, DRUMMOND and NDEMERA 
(1985), is used in Zimbabwe to initiate hallucinations and to serve as a narcotic additive to beer. WATT 
and BREYER-BRANDWIJK (1962) also mention that it is thought to be narcotic. They state that it is 
used as an adulterant in African beer making. In Tazania, the fruit of Kigelia aethiopica (Bignoniaceae) 
is added to beer to increase its strength. However, this potentiation may be due to the fermentation 
process rather than to specific Kigelia constituents. The drinking of the beer may result in a severe 
headache, perhaps due to the formation of amyl alcoho  (BALLY, 1938; WATT and BREYER-
BRANDWIJK, 1962). The Turkana in Kenya use the fruit of the related Kigelia africana together with 
sorghum or sugar to make beer (MORGAN, 1981). Lachnopylis platyphylla (Loganiaceae) leaves are 
used in Tanzania to ferment sugar-cane beer or to increase its intoxicating effects (WATT and BREYER-
BRANDWIJK, 1962). In Tanzania, the Chaga of the Kilimanjaro region frequently add the bark of 
Rauwolfia caffra (Apocynaceae) (msesewe) to a traditional beer called mbege, to give the beer a ‘kick’ 
and to conveniently intoxicate a drinker after imbibing only a moderate amount. Different parts of R. 
inebrians and R. obliquinervis have also been used for this purpose (BRAUN, 1912; 19 5; BALLY, 
1938; MADATI, KAYANI, PAZI and NYAMGENDA, 1977). Of the people who habitually drink mbege 
which has been adulterated like this, annual averages of 45 die (MADATI, KAYANI, PAZI and 
NYAMGENDA, 1977). In Kenya, the stem of R. caffra is used for making beer (OMINO and 
KOKWARO, 1993). African Rauwolfia species are known to be rich in indole alkaloids (COURT, 1983). 
The stem bark of R. caffra yields 0.25 mg/g of total alkaloids, which largely consist of ajmaline, 
norajmaline, ajmalicine and ajmalicinine (NASSER and COURT, 1984). 
 
1.5.  Aims of this study 
This project has two main objectives. Firstly, to bring together a comprehensive and detailed record of 
psychotropic plants used in southern Africa by indigenous peoples for medicinal or cultural purposes. 
Secondly, this research attempts to investigate the validity and rationale of the use of these plants by 
screening them in various biological assays for psychotropic activity. Obviously, not all the plants ued 
can be screened in all available bioassays and thus plants were selected, based on their traditional use and 
availability, and were screened in four assays, which detect biological activity of a useful nature. A 
number of in vitro neuronal signal transduction assays were employed in this thesis, the inhibition of the 
serotonin reuptake transporter protein (SERT); inhibition of catabolic enzymes (e.g. acetylcholinesteras , 
monoamine oxidase); GABAA- benzodiazepine receptor binding (Figure 1.5.1.). Activity in these assays 
indicates that the plants may have potentially useful psychotropic activity. 
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Figure 1.5.1. Schematic illustration of important elements of neuronal signal transduction (Adapted from 
WINK, 2000). Numbers indicate targets of assays employed in this thesis: [1] the inhibition of the 
serotonin reuptake transporter protein (SERT; see Chapter 3); [2] inhibition of catabolic enzyme (e.g. 
acetylcholinesterase and monoamine oxidase; see Chapter 5); [3] GABAA- benzodiazepine receptor 




Ethnobotanical literature survey: 
South African medicinal plants with central nervous system related activity and use 
 
2.1.  Introduction  
 
This Chapter examines the history and current statu of African traditional medicine is South Africa. Aspects 
of the philosophies and methodologies of the various practioners of South African traditional medicine will 
be discussed. The materia medica of southern African traditional medicine, known locally as muthi, will be 
outlined as well as the importance of the indigenous botanical knowledge, including Zulu botanical names. 
These topics, where appropriate, will be discussed in relation to the use of plants for central nervous system-
related purposes. Lastly, an annotated list compiled from available ethnobotanical literature of plants 
traditionally used for central nervous system-related purposes is provided (Table 2.2a). An alphabetical 
reference list is also supplied (Table 2.2b). The advancement of South African traditional medicine is about 
to get a much needed boost with the recent development of National Policy on African Traditional Medicine 
and expected establishment of a National Institute of African Traditional Medicine (DRAFT NATIONAL 
POLICY on ATMSA, 2008). The influence of legislation, past and present, on the state of traditional 
medicine will be highlighted.  
 
2.1.1. Southern African traditional healing: history and current status  
 
The WHO acknowledges that it is difficult to assign o e definition to the broad range of characteristics and 
elements of traditional medicine, but that a working definition is essential. It thus concluded that a traditional 
medicine includes:  
“diverse health practices, approaches, knowledge and beliefs incorporating plant, animal and/or 
mineral based medicines, spiritual therapies, manual techniques and exercises applied singularly 
or in combination to maintain well-being, as well as to treat, diagnose or prevent illness” 
(WORLD HEALTH ORGANIZATION, 2002). 
The terms, ‘indigenous’, ‘traditional’ and ‘western’ medicines and practitioners are frequently used. With the 
use of these terms, it is acknowledged that they ar somewhat inappropriate, politically-loaded and rather 
unhelpful in describing the principles, philosophies and practices they represent. It is problematic to assign 
sensitive and precise definitions to these terms and no suitable synonyms are readily available. The WHO 
draws a distinction between ‘traditional medicines’ and ‘complementary and alternative medicines’. 
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Complementary and alternative medicines relate to practices such as acupuncture, homeopathy and 
chiropractic systems. These are considered a ‘broad set of health care practices that are not part of a 
country’s own tradition, or not integrated into its dominant health care systems’ and thus fall outside the 
scope of this Thesis. 
 
Traditional medicine is part of African culture and is intricately linked with the African world view. One of 
the definitions given for ‘African Traditional Medicine’ by the WHO Centre for Health Development is the
following:  
“ the sum total of all knowledge and practices, whether explicable or not, used in diagnosis, 
prevention and elimination of physical, mental, or s cietal imbalance, and relying exclusively on 
practical experience and observation handed down from generation to generation, whether 
verbally or in writing” (WORLD HEALTH ORGANIZATION, 1976). 
 
The Draft National Policy on African Traditional Medicine in South Africa (DRAFT NATIONAL POLICY 
on ATMSA, 2008) defines African traditional medicine as follows: 
“African Traditional Medicine is a body of knowledge that has been developed and accumulated by 
Africans over tens of thousands of years, which is as ociated with the examination, diagnosis, 
therapy, treatment, prevention of, or promotion and rehabilitation of the physical, mental, spiritual 
or social wellbeing of humans and animals”. 
 
The Third World, in particular Africa, is faced with a lack of medical personnel in general but especially in 
rural areas. In 1982 it was estimated that there was in the region of one western medical practitioner for every 
17 500 people (SAVAGE, 1985). More recently, for Sub-Saharan Africa, the estimated ratio of traditional 
healers to the population is approximately 1:500, while medical doctors have a 1:40 000 ratio to the rest of 
the population (ABDOOL KARIM, ZIQUBU-PAGE and ARENDSE, 1994). It is unlikely that this situation 
has improved since 1994 when one considers that population growth far exceeds the current training of 
medical practitioners. This relative lack of medical personnel is likely to remain in the foreseeable future, and 
one question that often arises is how the health services for the entire population can be improved? Whatever 
is done in terms of the allocation of personnel andmoney is likely to fall far short of what is necessary, and 
drastic measures are called for. There are a number of these, but one possibility is the utilisation of the 
services of traditional healers who are indeed numerous and situated where they are required in under 
developed rural areas.  
 
In 1998 the National Council of Provinces (NCOP) Select Committee on Social Services estimated that there 
are about 350 000 traditional practitioners in South Africa, providing their services to 60-80% of the 
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population, yet there was only about 250 000 allopathic (modern) medical personnel in South Africa. This 
raises another much asked question; can modern medicin  and traditional indigenous medicine find common 
ground in the form of much needed primary health care? 
 
Traditional healing in virtually all its forms has been illegal for more than a century in South Africa. Under 
the provisions of the SUPPRESSION OF WITCHCRAFT ACT (1957) (first introduced in 1895, last 
amended in 1970), all forms of divination are outlawed. Divination is the heart of healing in Africa; therefore, 
all healing is outlawed. One of the main hindrances for the improvement of traditional medicine, especially 
the medicinal plant aspect, in South Africa has been Clause 36 of the MEDICAL, DENTAL AND 
SUPPLEMENTARY HEALTH SERVICES PROFESSION ACT (1974). This clause forbade any registered 
practitioner to practise in collaboration with a non-registered person, and for non-registered persons t  
perform acts pertaining to the medical or dental professions. The outcome of this legislation was the division 
of the traditional healers as a group in hundreds of ecretive sub-groups. The trust between healers and 
allopathic practitioners and westerners in general is tenuous, making collaboration near impossible. 
Compounded by the over-sensationalism created by the media surrounding ‘muthi’ murders which has 
created the perception of traditional healers as being vil, we are left with lack of trust and unity among 
traditional healers which has proved to be one of the major stumbling blocks in the formation of a unified 
traditional healers’ body. Until this happens traditional healers will not gain recognition from the Dpartment 
of Health. Some progress has been made, in 1989, nine years after attempts were made by traditional helers 
to gain recognition; the KwaZulu-Natal legislature changed their laws to allow ‘black medicine-men’, 
herbalists and midwives to practise, subject to certain provisions. This change in legislation led to the 
establishment of a register of traditional healers aided by the longest standing non-governmental organisation 
in Zululand, the Inyangas’ National Association (INA).  
 
Despite these advancements no form of quality control exists amongst those who are registered and it had no 
recognisable code of ethics. In 1995 the KWAZULU-NATAL HEALTH ACT (1995) proposed further 
investigations and found that the public called for more legal control. Again all efforts put in place to resolve 
the situation were hindered by the lack of unity between various healer groups. The University of Zululand, 
under the guidance of Mrs. A. Hutchings undertook the task of explaining to a large number of traditional 
healers in KwaZulu-Natal the benefits of a unified traditional healers’ council. Their success resulted in the 
formation of the KZN Traditional Healers’ Council. More recently, the South African Medicines and Medical 
Devices Regulatory Authority Act of 1998 requires all medicines, including traditional medicines, to be
registered with the Medicines Control Council. Despite these laws, traditional healers have only rarely b en 
prosecuted simply for plying their trade (ASHFORTH, 2005).  
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Following recommendations of the WHO (1978), and, like its neighbours Ghana, Tanzania, Zambia and 
Zimbabwe, South Africa has attempted the ‘professional zation’ route to traditional healers (LAST and 
CHAVUNDUKA, 1986; PILLSBURY, 1982). The TRADITIONAL HEALTH PRACTITIONERS ACT 
(THPA) was gazetted in parliament in May 2005, and is esigned to formalize the structure and organization 
of traditional health practice through the Traditional Health Practitioners Council of South Africa (the 
THP Council) (THPA, 2004). The THP Council is expected to comprise a maximum of 25 members 
consisting of registered traditional health practitioners, a representative from the Department of Health, 
someone from a legal background, a medical practitioner of the Health Professions Council of South Africa 
(HPCSA), and others. The Council will have to meet at least twice a year (THPA, 2004). 
 
The THPA, which is intended  
“ to establish the Interim Traditional Health Practitioners Council of South Africa; to provide for 
a regulatory framework to ensure the efficacy, safety and quality of traditional health care 
services; to provide for the management and control over the registration, training and conduct 
of practitioners, students and specified categories in the traditional health practitioners 
profession; and to provide formatters connected therewith” ,  
has raised concerns amongst western medicinal practitioners and researchers.  
 
To mention two concerns expressed by BERGER (2006); firstly, the regulations governing membership of 
the THP Council of South Africa calls for 10 traditional health practitioners, one to serve as chair, in addition 
to a representative from each of the traditional healer categories. In contrast to this overwhelming 
representation from the traditional sector, the Act provides for the appointment of only one orthodox medical 
practitioner. Secondly, while the document is almost entirely made up of rules and procedures regarding its 
constitution it lacks substantive statements that set out standards of skill, knowledge and training, or that 
address the safety and efficacy specifications requi d of materials and methods used in the practice of 
traditional medicine. It leaves it to the Minister of Health to prescribe the necessary qualifications  
recommendation of the Council. BURGER (2006) suggests that, given the composition of the council and the 
absence of mandated academic, scientific expertise, i  will be unlikely if the regulations that ultimately 
emerge will meet the scientific and ethical concerns of medical science and modern standards of patient care. 
It should be noted that section 19(1) provides that“No person shall be entitled to practise as a traditional 
health practitioner within the Republic unless he or she is registered in terms of this Act” (THPA, 2004). 
Thus traditional health practitioners not registered with the Council will not be able to recover remuneration 
“ in respect of any act specially pertaining to the occupation of a traditional health practitioner” (THPA, 
2004). It also states that a person who “diagnoses, treats or offers to treat, or prescribes tr atment or any 
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cure for cancer, HIV/AIDS or such other terminal diseases as may be described” shall be guilty of an offence 
(THPA, 2004). 
 
WREFORD (2005) points out that despite calls, from utside and within government, for collaborative 
relationships between health systems in South Africa, it is useful to note that the Act includes only passing 
references to liaison between biomedical and traditional practitioners, and offers no practical suggestion  for 
implementation. The effects the legislation is intend d to have on the medical status quo are therefor 
unclear. WREFORD (2005) predicts that, as in Zimbabwe, despite longstanding experience of similar 
legislative frameworks, the two systems (traditional and western medicine) continue to operate in parallel 
rather than in partnership (CHAVUNDUKA, 2004). 
 
Perhaps in response to the concerns mentioned above, and many others, a Draft National Policy on African 
Traditional Medicine in South Africa (the Policy) was recently gazetted (NATIONAL POLICY on ATMSA, 
2008) for public comment. The Policy “is designed to provide a framework for the institutionalisation of 
African Traditional Medicine in the South African healthcare system.” This document is the result of The 
Presidential Task Team on African Traditional Medicine which was appointed in 2006 to make 
recommendations with regard to a national policy and  appropriate regulatory and legal framework for the 
institutionalisation of African traditional medicine in South Africa.  
 
To achieve the institutionalization African traditional medicine the Policy recommended that legislation on 
African traditional medicine be enacted to provide “an enabling environment for African Traditional 
Medicine in its entirety and scope, covering but not limited to: 
- the regulation of African traditional medicine in South Africa; 
- registration and regulation of African traditional medicines and medicinal products in South Africa; 
- protection of African traditional medicine knowledge and intellectual property rights; and 
- the protection of the rights of persons involved in the discipline of African traditional medicine in
South Africa” (NATIONAL POLICY on ATMSA, 2008). 
 
It is recommended that a National Institute of African Traditional Medicine should be established, which 
would devise strategies, coordinate, undertake and provide leadership in the research of African traditional 
medicine and collaborate with other institutions on a eeds basis. Research priority areas should be ientif ed 
and developed and addressed through well developed, scientifically rigorous and ethical research protoc ls. It 
is suggested that a national pharmacopoeia of African traditional medicine in South Africa be developed. 
Conservation issues are also addressed and it is stated that the development of commercial medicinal plants 
should be limited to cultivated raw materials with wild harvesting only allowed under exceptional 
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circumstances. A National Ethics Committee for African Traditional Medicine research should be formed, 
consisting of both orthodox phytochemists and clinial trial specialists with experience in African traditional 
medicine research, as well as traditional health practitioners (NATIONAL POLICY on ATMSA, 2008). The 
recommendations contained within the Policy are largely in line with those made by FENNELL, LINDSEY, 
McGAW, SPARG, STAFFORD, ELGORASHI, GRACE and VAN STADEN (2004) and FENNELL, 
LIGHT, SPARG, STAFFORD, VAN STADEN, (2004) amongst others. 
 
2.2.  African traditional views of illness and treatment 
 
Culture is the lens and guide we use in constructing, defining, and interpreting the world around us. Thus 
people from different cultural contexts and traditions define and experience events (i.e. illness) in different 
ways. This is particularly true of views about mental disorders and subsequently their diagnosis and treatment 
since these cannot be separated from cultural experi nc s. In order to determine which plants used in African 
traditional medicine may act on the CNS, an understanding of indigenous or traditional African views of 
illness and treatments are required. A brief interpr tation follows, however, more thorough treatments on 
African culture as a whole and of specific regions are available (GLUCKMAN, 1956; BERGLUND, 1976; 
NGUBANE, 1977; LAMBO, 1982; GUMEDE, 1990; INGSTAD, 1989; 1990; GREEN, 1994; PATEL, 
MUSARA, MARAMBA and BUTAU, 1995; TSEY, 1997; YAMBA, 1997; JACOBSSON, 2002; LIDDELL, 
BARRETT and BYDAWELL, 2005). 
 
In many traditional cultures, illness is believed to be caused by psychological conflicts or disturbed social 
relationships that upset an equilibrium which is expressed in the form of physical or mental problems 
(KLEINMAN, EISENBERG, GOOD, 1978). Although Africa has a diverse culture, there is a common 
thread, particularly with cultures south of the Sahar , that follows that the disruption of this equilibr um, what 
the west calls illness, may be caused by external psychological or spiritual factors, or both, that relate to 
African cosmology and "threaten the intactness of the person" (HEWSON, 1998). In these traditional cultures 
healing involves restoring this equilibrium. The DRAFT NATIONAL POLICY on ATMSA (2008) states that 
the philosophy underpinning African traditional medicine is ubuntu. 
“Umuntu ngumuntu ngabantu/motho ke motho ka batho/a human being is a human being 
through other human beings” .  
Thus an important causal factor considered in African traditional medicine is the status of relations existing 
between the ‘unwell’ individual and other human beings, both the living, and the deceased. Thus, philosophy, 
religion, psychiatry, physiology and biology, are all essential elements within the practice of African 
traditional medicine. 
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OKPAKO (1999) proposes that ‘ancestor spirit anger’ can be understood as a metaphorical reference to 
emotional stress, similar views are expressed by HORT N (1976). OKPAKO (1999) argues that when 
divination reveals that an illness is underpinned by ancestor spirit anger, it also invariably points to the 
probable existence of a hidden guilt. Therefore, treatment usually includes exposing the cause of the guilt and 
offering of propitiatory sacrifices to the offended ancestral spirits. This is often done through a ritual which is 
attended by members of the afflicted person’s family and community. The immoral conduct by the afflicted 
person is recognized as a condition for the occurrence of grave illness and ancestor spirits are not considered 
to be unpredictable agents inflicting illness on their victims at random.  
 
OKPAKO (1999) suggests that in a group that is conditioned to believe that some types of immorality can 
enrage the ancestors or gods, a hidden sin of this type can give rise to emotional stress that, by “gnawing at 




guilt   fear 
anxiety  stress 







Figure 2.1. African traditional medicine holds that ancestor spi it anger is the cause of serious illness in 
individuals who have sinned. (+), positive impact; (-), negative impact (From OKPAKO, 1999). 
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In general, many African cultures group illnesses into three categories (LIDDELL, BARRETT and 
BYDAWELL, 2005). Illnesses which have no discernible moral or social cause; these tend to be minor 
ailments such as rashes and colds. This is the only class of illness that occurs by chance, and for which causes 
are not sought (YAMBA, 1997). In this situation peole aquire herbal treatments without recourse to spiritual 
evocations (OKPAKO, 1999), similarly as one might trea  such ailments in Western medicine without a 
doctor’s prescription. 
 
Some illnesses are considered ‘modern diseases’ which can be contracted by people anywhere in the world, 
and which are believed to have been first introduce into Africa by European settlers (GREEN, 1994). Lastly, 
there is the belief that there are diseases which only African people can contract, and to which all African 
people are vulnerable (NGUBANE, 1977). A large majority of mental disorders fall under this last category. 
The ‘epidemic’ of indiki  spirit possession in Zululand, South Africa from the 1890s to 1914 is an interesting 
example (PARLE, 2003). Indiki was first reported among the Zulu of South Africa around 1910 (JUNOD, 






















Figure 2.2. Plant remedies in traditional African medicine (TAM). (+), positive impact (From OKPAKO, 1999). 
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OKPAKO (1999) suggests that chronic debilitating illnesses in which the cause is not apparent to the healer 
and the patient is not responding to common therapis, then ‘ritual treatment of hidden guilt’ becomes a 
major therapeutic consideration. When a plant remedy is used as part of the treatment regime, its physical 
characteristics (e.g. aroma, texture, shape, taste, colour and nutrient value) and the rituals attending ts 
preparation and administration (e.g. incantation or s ng) are more important than its pharmacological 
constituents (Figure 2.2). 
 
Perhaps a better explaination follows that, African cultures define two types of causes for illnesses 
(GLUCKMAN, 1956; LIDDELL, BARRETT and BYDAWELL, 2005). Firstly, a proximate cause, which 
accounts for how a disease is contracted (YAMBA, 1997). Infection and contagion from pollutants are 
examples of proximate causes (INGSTAD, 1990). Secondly, an ultimate cause, which accounts for why a 
disease is contracted by a particular person. A simple explanation by GREEN (1994) clarifies, ‘a mother may 
recognize that her infant has diarrhoea because flies settled on and contaminated its food (proximate cause), 
but she will also want to establish who sent the flies to harm her child (ultimate cause)’. The material types 
of treatment (i.e. herbal remedies) are often considered of secondary importance and only complementary. 
The primary concern of African traditional healing is to discover who, or what has caused the imbalance or 
illness (i.e. the ultimate cause). 
 
As mentioned, three main types of ultimate cause are often raised in explaining illness, contact with 
pollutants (literal and/or spiritual), sorcery and ancestral punishment. Pollutants are considered to often 
originate in other people’s bodies, and include semen, menstrual discharge, vaginal secretions, and blood 
(INGSTAD, 1990). Death is also believed to be a pollutant (NGUBANE, 1977). Since contact with pollutants 
cannot always be avoided, people fortify themselves from contamination by maintaining strict moral codes 
and observing protective rituals (GREEN, 1994). Illness is often suspected to be inflicted by people who have 
been offended by a victim’s behaviour. Failure to honour filial obligations, violence, or other forms of
uncooperative behaviour risk creating a level of offence which elicits kin or neighbours to seek redress 
through ‘witchcraft’ (DOUGLAS, 1987). The ‘survival’ of ancestors in the spirit world depends on them 
being accorded regular attention from living offspring (e.g. respect paid to mizimu in Uganda and amadlozi 
in South Africa). This attention is manifest in rituals, sacrifices, avoidance of taboos, and high standards of 
social behavior. Where these requirements are not met, illnesses can be sent as a warning or punishment 
(NGUBANE, 1977).  
 
To return to indiki and ufufunyane mentioned earlier, these are considered examples of illness representation 
theories that incorporate new diseases. LIDDELL, BARRETT and BYDAWELL (2005) point out that both 
these ‘epidemics’ coincided with periods in Zulu history when migrant labour was becoming extremely 
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disruptive to family life. Migrant labourers were engaged in high-risk occupations such as construction w rk 
and underground mining. Men who were killed whilst working away from home were buried near their place 
of work. It was believed that their spirits were too far away to benefit from sacrifices, and they were unable to 
monitor the daily activities of their successors. Consequently, these spirits were unable to attain ancestral 
status. As a last resort, the spirits possessed Zulu men in an attempt to return home with them and assume an 
ancestral role with a new family. This provided an ‘ultimate’ explanation for indiki and ufufunyane. 
Simultaneously, ‘proximate’ causes could be located in the sexual infidelities, violations of taboos, lack of 
ritual observances, and general breakdown in traditional family life that accompanied the prolonged absence 
of a head of household. The means to avoid spirit possession lay in observing stricter social and moral codes. 
Branches of Zizphus mucronata, known as umlahlankosi (from -lahla (v) meaning to bury; -nkosi (i-, ama-) 
(n) meaning king or chief) are used in Zulu culture to return a departed relative’s spirit to his or he ome.  
 
Both proximate and ultimate causes require treatment if a disease is to be cured. Diseases manifest 
themselves not only in physical symptoms, such as fever or pain, but in mystical disturbances of the blood 
commonly described in terms of ‘impurities’ or ‘heat’ (INGSTAD, 1990). To treat proximate causes and 
physical symptoms, people may consult medical personnel and/or traditional healers for appropriate 
remedies. However, treatment for ultimate causes mut also be sought, and since these lie within the mystical 
or spiritual domain, it is believed that only traditional healers or diviners are capable of useful insights and 
therapies (BUHRMANN, 1984). 
 
These cultural beliefs make it difficult for outsiders to understand and determine the use, in western terms, of 
many African medicinal plants. It is difficult for ethnobotanists to separate plants with a so-called ‘magical’ 
or ‘spiritual’ use (i.e. to treat ultimate cause of disease) from those that are medicinal (i.e. to treat proximate 
cause of disease). Literature on African medicinal pl nts is replete with references to plants used to 
counteract curses and appease the ancestors. For exampl , the plant Asparagus virgatus (Syn. = 
Protasparagus virgatus) is known by the Zulu people of South Africa as ‘iphinganhloya’  which means ‘what 
suppresses the ill-omen or curse’ (POOLEY, 2005). Many of these plants are not ingested but are usually 
carried about on the person in the form of a protectiv  amulet or charm (referred to as ‘imfingo’ in Zulu 
culture) or administered by sprinkling onto the person or around the homestead (referred to collectively as 
‘ intelezi’ in Zulu). These are assumed to have no physiological effect on the patient, however, some remedies 
such as those referred to as ‘makhubalo’ which are plant materials which are ingested, for protection from 
‘evil’ may have a physiological effect on the user. It is therefore not only important to know the symptoms, 
including the proximate and ultimate causes, but also the methods of administration of the plant materi l, 
many of which are often neglected in ethnobotanical l terature. 
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2.2.1. South African traditional health practitioners 
 
The misunderstanding and negative stigma that is associated with traditional medicine in South Africa is 
largely due to the grouping of all traditional practitioners under the now taboo name of ‘witch-doctors’. 
Traditionally the press has portrayed ‘witch-doctors’ as a group of evil, money-hungry, con-artists who are 
responsible for the numerous ‘muthi-killings’ (the use of human remains). This is unfortunate as these 
exploits are most likely the work of umthakathi whose intention is not to heal. The more socially cceptable 
term of ‘sintu healer’ has also been used as an umbrella name. This refers to a person who treats patients with 
the intention to heal, based on his or her tradition and customs. Terms such as traditional healer, traditional 
medical practitioners and traditional herbalist arenglicised translations that are not entirely correct. The 
situation is a lot more complicated in Sintu culture with many specialized practitioners each with their own 
name. The terms ‘izinyanga’ and ‘izangoma’ (plural) are often used to refer exclusively to the herbalist and 
diviner respectively. However today the distinction has become blurred in some cases, more often the 
diviners (izangoma) practice both arts (VAN WYK, VAN OUDSTHOORN and GERICKE, 1997). 
 
Izinyanga 
In western terms the inyanga would be the medicine man or herbalist, of which in South Africa the majority 
are male. The izinyanga’s (plural) craft is passed from father to son as opposed to that of isangoma who are 
chosen by ancestral spirits (amadlozi). One may also merely choose to be an inyanga as a profession then be 
trained by a qualified inyanga or several different izinyanga’s.  
 
An inyanga trains for several years as an apprentice and focuses mainly on diagnosis of illnesses and the 
identification and use of plants in healing physical illness. Generally the training of an i yanga is more 
academic and much longer than that of an isangoma (KOOPMAN pers. comm.). An inyanga is often a very 
skilled botanist with a vast knowledge of the local flora. At the end of their training izinyanga’s can obtain a 
certificate from the Inyangas’ National Association (INA). The izinyanga specializes in different illness and 
it is not uncommon for this speciality for curing one particular illness or a group of illnesses to have run in 
the family for many generations. 
 
Their mode of treatment generally starts with an interview where the patient is asked where they think they 
acquired the illness or symptoms in question. By combining this information with the observable symptoms, 
the inyanga will prescribe umuthi. The umuthi usually consists of plant material, but may also contain 
animal parts, soils, and water from rivers, dams and seas. Coloured powders, which consist of soils, burnt 
animal hair and plant ash is sometimes added to the wat r (isiwasho). Umuthi will be discussed in greater 
detail in the sections to follow. Izinyanga also supply protective and good-luck charms that are used mostly 
CHAPTER TWO South African Psychoactive Plants  52  
 
for good intentions. An inyanga ebhulayo is similar to an isangoma and practice divination and is considered 




Plate 2.1. Taken from BRYANT (1966) Zulu Medicine and Medicine Men, an example of Western perceptions of 
African Traditional medicine. 
 
Isangoma  
Amagqirha (isiXhosa singular ugqirha) and izangoma (isiZulu singular isangoma) were previously referred 
to as ‘witch-doctors’ but this term is no longer used due to its derogatory nature. Izangoma are traditionally 
considered to be diviners who consult with ancestral pirits (amadlozi).  
 
BOX 2.  
Important spiritual components to traditional Zulu belief systems (DENT and NYEMBEZI, 1999, 
BURGLUND, 1976): 
amadlozi – (n) spirit of departed person; guardian spirit; snake supposed to be the spirit of departed.  
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umhlabathi – (n) spirit(s) of departed, used when related to pains in the chest and shoulders (uhlabo) which 
are caused by ancestral sprits when they require a person to become a diviner.  
amathongo – (n) spirit of departed person seen in dreams (isithongo – (n) deep sleep) 
uNkulunkulu  – (n) Deity, God; the ancestral spirit of all mankind (DENT and NYEMBEZI, 1999), also 
referred to as umhlabathi (-hlabathi – ground, soil or earth). ‘Earth’ (umhlabathi) is believed to be the 
mother of ancestral spirit of all mankind and the ‘reed’ (uhlanga) the father. 
 
The role of the isangoma has changed in recent years as many have similar ‘herbalist’ skills to those of the 
inyanga. The majority of the izangoma in South Africa are female although the gender inequality is not as 
definite as it is in the izinyanga. Like izinyanga, izangoma show specialization in various areas, for example 
an isangoma that specializes in ‘smelling-out’ bad elements is referred to as an isanusi. According to the way 
in which izangoma divine, can be divided into several types. For example, that of isangoma sekhanda who 
practices a form of divination that involves communication with the amadlozi or ithongo (spirit) through a 
‘telepathic trance’. These trances are often induce through the inhalation of smoke from burning plant 
material, in particular impepho (Helichrysum species). The second type is the isangoma samathambo. These 
izangoma throw bones (ukubhula) and various other objects (e.g. shells, dice and seed pods) and according 
to the position and arrangement of the objects various predictions can be made with the guidance of the 
amadlozi. Some plants are used in these rituals for example the divining dice of the Lobedu, a Northern 
Sotho group, were reportedly left overnight in an infusion made from Lonchocarpus capassa (raintree) so 
that divination could occur (KRIGE, 1940). The isangoma sabalozi apparently asks questions and the 
amadlozi will answer in audible whistling which both patient and isangoma can hear, these are then 
interpreted by the isangoma who then informs the patient.  
 
SWIFT and ASUNI (1975) suggest that healers, because of their knowledge of the ways of their people and
the power conferred upon them by their people, can often provide peace of mind to the distressed and thus
provide a feeling of protection to the threatened. LAING (1965) and others have initiated a school of th ught, 
much unliked by medical spheres, that indigenous medicine is in many respects better, more holistic, than its 
modern western counterpart, that it is conducive with ‘indigenous world-views’ and therefore more effective 
for ‘indigenous patients’ than the biomedical approach (HAMMOND-TOOKE, 1989). They argue that 
traditional healers do not only know their patients as people, but also understand the social matrix in which 
they move and live and therefore are bound to be more effective. 
 
Umthakathi 
These persons, male or female, could be referred to as sorcerers. Umthakathi (abathakathi plural; 
ubuthakathi – (n) witchcraft) tend to go against social norms and the community does often not know their 
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identity. If they are discovered they will be hunted and killed by the community, similar to that of ‘witch-
hunts’ in medieval Europe. Umthakathi are believed to know which umuthi ingredients to mix in order to 
make umuthi wakuthakatha (witchcraft medicine) or umuthi omnyama (‘black’ muthi). This is used for 
negative purposes such as to kill, cause disorder and stop childbirth. Another example is an umbhulelo, which 
is any poisonous or injurious concoction, which may or may not contain plant material, placed onto a path by 
an umthakathi in order to harm passers-by. 
 
Several herbal remedies, which may or may not be ing sted, are employed by healers and the general public 
as protection or to counteract the work of umthakathi. These include imfingo, any medicine used to protect 
against evil, usually carried about on the person in the form of a protective amulet or charm. Amakhubalo, 
however, are any ‘medicines’ such as roots or barks, but not leaves, bulbs or animal powders, which are used 
for self-fortification and protection from evil. These are nibbled or chewed and are often carried around the 
neck or on ones person for this purpose. A very comm n preparation, an i telezi is any protective medicine 
or charm against evil, usually administered by “sprinkling” (ukuchela) onto the person or around the 
homestead. This consists of a mixture of plant parts like bulbs (commonly Clivia and Agapanthus species), 
leaves and bark that is placed in a container with cold water for use later when it is sprinkled around the 
homestead or on the person. It can also be boiled and used when bathing (NGWENYA, KOOPMAN and 
WILLIAMS, 2003). An imbozisa (-bozisa (v) cause to rot) is any strong-smelling herbal counter-remedy. A 
number of strongly scented plants (e.g. Plectranthus species) are known generally by this term. 
 
Umthakathi are reported to use specific human body parts to use in umuthi wakuthakatha, these are 
generally taken from young children (SCHOLTZ, PHILLPS and KNOBEL, 1997). It should be stressed that 
these umthakathi are not traditional healers and ‘true traditional healers’ (izangoma and izinyanga) should 
not be painted with the same brush.  
 
When a healer sets out to cure a person afflicted by the work of umthakathi, he or she will typically promise 
that their muthi will return the evil forces deployed by the umthakathi to their source, thereby killing the 
umthakathi. Such violence, however, is considered by the community to be legitimate, for it is executed in the 
name of defense. Umthakathi, by definition, are engaged in illegitimate uses of the powers of muthi 
(ASHFORTH, 2005). 
 
Umuthi – preparation and administration of African traditional medicine 
When traditional healers, both inyanga and izangoma, administer aid to patients in distress, they almost 
always dispense substances known generically as muthi. The term muthi (spelled muti in Xhosa 
transliterations) derives from the Nguni root -thi, signifying ‘tree’. Usually translated into English as either 
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‘medicine’ or ‘poison,’ with the anodyne ‘herbs’ used occasionally (ASHFORTH, 2005), muthi refers to 
substances fabricated by an experienced or trained han , substances designed by persons possessing secret 
knowledge to achieve either positive ends of healing, volving cleansing, strengthening, and protecting 
persons from evil forces, or negative ends of ‘witchcraft’ (ubuthakathi), bringing illness, misfortune, and 
death to others or illicit wealth and power to the witch (ASHFORTH, 2005). 
 
 
Figure 2.3. An example of flyer advertising a ‘traditional heal rs’ abilities and claims. 
 
To clarify whether the muthi is medicine or poison, the valence of the term can be specified, as in several 
cultures, by reference to the colours black and white. For example in Zulu, umuthi omnyama (black muthi) 
is the harmful poison, and umuthi omhlope (white muthi) is the healing medicine. According to NGUBANE 
(1977), colour plays an important role in the symbolism associated with the treatment in Zulu people. The 
important colours are black, red (-bomvu), and white. Black and red are equivocal; and they stand for good 
and bad, while white represents what is good. Whenev r red or black objects or plant materials are used, they 
generally are always followed by white; however, white is often used alone. Red and black are used to xpel 
bad things from the body, and to strengthen the body against future attacks. White is used to regain good 
health. 
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Plant material and mixtures are administered in several forms and by several routes. Several traditional Zulu 
preparations, umbhulelo, imfingo, amakhubalo, intelezi and imbozisa, have been discussed. Another 
important preparation are amakhambi (plural) which are any green, vegetable medicines, l aves or roots 
which are used as common house-hold remedies. These ar  well-known to most Zulu mothers, as are imbiza 
which include a large number of herbs which are boiled nto decoctions for scrofula, chest complaints and 
blood purifying. 
 
Oral ingestion, of preparations made by cold infusion  (isichonco, -chonco (isi- izi-) (n) mixture taken in 
small doses), hot infusions (imfudumezelo, from –fudumeza (v) make warm) or boiled and simmered 
decoctions (impheko, from -pheka (v) cook) are common. These would normally be swallowed, but 
sometimes would be held in the mouth by the patient and blown out in a fine spray over the affected boy 
part. Emetics (umuthi wokuphalaza or umhlanziso from –phalaza (v) vomit) are an extremely common 
particularly when administering charms of all kinds (i.e. protective charms, lucky charms and love charms). 
VAN WYK, VAN OUDTSHOORN and GERICKE (1997) mention that among Zulus and other cultural 
groups, a common health practise is to drink a large volume (up to two litres) of weak, luke-warm herbal 
infusions (ukuphalaza or ukugabha) and then induce vomiting to cleanse and tone the system. Sea water is 
also commonly used for this purpose.  
 
The Zulu administer hot stem infusions of Stapelia gigantea (ililo elikhulu  or uzililo) or cold water infusions 
of Psoralea pinnata (umhlongani) (BRYANT, 1966) and infusions or decoctions of Crassula alba (isidwe) 
(GERSTNER, 1939) as emetics to treat hysteria (umhayizo). Umhayizo is an illness associated with Zulu 
teenage girls and is commonly explained as an affliction that is the direct result of witchcraft (ubuthakathi). 
It is believed to be caused by the actions of a jealous or bitter man who performs, usually at a distance from 
the girl in question, a particular ritual act involing umuthi. This results in screaming and wailing with a 
possession-like experience of having relinquished control over one's body. These symptoms are a visible 
manifestation of ‘bewitchment’, and it is this that calls for treatment. Zulu men and adolescent boys use 
decoctions of unspecified parts of Bulbine latifolia (ibhucu), as emetics, in purification rites aimed at the 
prevention of antisocial behaviour (HUTCHINGS, SCOTT, LEWIS and CUNNINGHAM, 1996). Zulu 
izangoma (diviners) use root infusions of Adenopodia spicata (ibobo) as emetics to increase their divining 
power (HUTCHINGS, SCOTT, LEWIS and CUNNINGHAM, 1996). 
 
Another common oral method, which appears to be particularly prevalent in Zimbabwe, is the administration 
of plant material in traditional porridge, for example Crabbea hirsuta, Tulbaghia leucantha, Steganotaenia 
araliacea, the exotic Bauhinia candicans, Bauhinia thonningii, Vigna unguiculata, Pycnostachys urticifolia, 
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Securidaca longepedunculata, Fadogia ancylantha and Gnidia kraussiana (Table 2.2.). Most of these are 
used in the treatment of epilepsy or madness (SHONE and DRUMMOND, 1965; GELFAND, MAVI, 
DRUMMOND and NDEMERA, 1985).  
 
Decoctions, and in some cases infusions, are commonly administered as enemas (uchatho, isitho, upotsho). 
Today this is most commonly done using enema syringes or tubes. However in some rural areas, as in the 
past, a lubricated, truncated cow’s horn is used (VAN WYK, VAN OUDTSHOORN and GERICKE, 1997). 
Ground bulbs of Scilla nervosa (ingcino or ingcolo) are administered in the form of milk enemas to reliev  
nervous conditions in children in the northern Transvaal (WATT and BREYER-BRANDWIJK, 1962). Some 
other plants used in this manner to treat mental illness are Tulbaghia alliacea, Blumea alata, Cissampelos 
torulosa, Oxygonum species and Aptosimum decumbens (Table 2.2.). 
 
Plant materials may be applied directly to the skin, where it is assumed that the active principles ar absorbed 
into the underlying tissues. A common administration method in African traditional medicine is where plant 
or other material which has been dried, roasted or burnt, may be ground to a fine powder, which is then 
rubbed into incisions in the skin (umgcaba from gabela (v) to cut slits). It is claimed that the San in 
Botswana induce visual hallucinations by rubbing the bulb of Pancratium tenuifolium into incisions on the 
head (DOBKIN DE RIOS, 1986). Asparagus roots of an unidentified species are burned, powdered and 
placed in incisions for febrile convulsions in Zimbabwe (CHINEMANA, DRUMMOND, MAVI and DE 
ZOYSA, 1985). Launaea nana, Canthium inerme and Lopholaena coriifolia roots are used as a body wash 
and are applied into incisions made on the forehead or body to treat convulsions in Zimbabwe (GELFAND, 
MAVI, DRUMMOND and NDEMERA, 1985). Swartzia madagascariensis (mukosho in Shona) roots and 
pods are taken orally as an infusion or applied to incisions made on the forehead for convulsions in 
Zimbabwe (GELFAND, MAVI, DRUMMOND and NDEMERA, 1985). 
 
A large variety of plants are taken as fine dried powders, referred to as snuff (ugwayi or umakhalisa). Some 
are taken to induce sneezing ((n) ukuthimula), which is believed to aid the expulsion of disease or evil 
spirits. Traditional healers induce sneezing through the use of snuff frequently. Snuffs are also used for the 
treatment of respiratory ailments and headaches. The nasal route is an extremely effective route for 
introducing soluble phytochemicals directly into the cerebral circulation and is often a method used in taking 
narcotics and stimulants (refer to Table 2.1. and Table 2.3.). 
 
WATT and BREYER-BRANDWIJK (1962) mention other botanical snuff sources utilized in southern 
Africa, these include: Agave americana, Aloe aristata, Aloe marlothii Aloe saponaria var. ficksburgensis, 
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Aloe sp., Amaranthus caudatus, Amaranthus spinosus, Artemisia afra, Cussiona spicata, Rhus erosa, Salvia 
sp., Senecio coronatus, Senecio longiflorus, Tagetes minuta and Zea mays. 
 
Table 2.1. Snuffs used in southern African traditional medicine for sedative, narcotic and divination proposes 
or in the treatment of mental illness (authorities are given in Table 2.2 page 68).  
Species Traditional use 
Alepidea amatymbica The dry rhizome and roots are smoked, or powdered and taken as a snuff by 
unspecified diviners and healers in South Africa to ssist in divination and 
communication with the ancestors (VAN WYK and GERICKE, 2000). 
*Centella asiatica Unspecified groups use the dry powdered leaf as a snuff, which produces a 
calming, sedative effect (VAN WYK and GERICKE, 2000). 
Chenopodium ambrosiodes South African traditional healers use the plant as an intoxicating snuff to 
communicate with the ancestors (SOBIECKI, 2002) 
*Datura stramonium Powdered roots and leaves are inhaled as snuff to aid he lers in divining in 
South Africa (HUTCHINGS, SCOTT, LEWIS and CUNNINGHAM, 1996). 
Entandrophragma spicatum The pods are burned and the ashes are mixed with tobacco to make a narcotic 
snuff (RODIN, 1985). 
Erythrophleum lasianthum The Zulu administer a snuff for hysteria (HUTCHINGS, SCOTT, LEWIS and 
CUNNINGHAM, 1996). 
Gomphocarpus pecies Unspecified groups use a snuff of the powdered l aves as a sedative (VAN 
WYK and GERICKE, 2000). 
Lannea schweinfurthii Unspecified groups in South Africa use the root as a sedative snuff (VAN WYK 
and GERICKE, 2000) 
*Nicotiana tabacum Taken as a snuff by southern African diviners at the start of divination, and is 
also made as a traditional offering to the ancestors (VAN WYK and GERICKE, 
2000). 
Ocimum canum The Ndebele use the whole plant mixed with the seed of Ricinus communis 
L.(exotic) and Chenopodium ambrosidoides L. as a snuff for madness 
(GELFAND, MAVI, DRUMMOND and NDEMERA, 1985). 
Pachycarpus asperifolius A powdered snuff is used for hysteria in South Africa (HUTCHINGS, SCOTT, 
LEWIS and CUNNINGHAM, 1996).  
Phytolacca octandra The shoots are used as a stimulant snuff in Venda (MABOGO, 1990). 
Pleiospilos bolusii Unspecified groups dry and powder it to be used as a snuff (VAN WYK and 
GERICKE, 2000). 
Ptaeroxylon obliquum The Xhosa use powdered bark traditionally as a snuff for recreational purposes 
(WATT and BREYER-BRANDWIJK, 1962). 
Rabiea albinota The pulverised plant is reported to be a hallucinogenic additive to tobacco to be 
smoked or taken as snuff (VAN WYK and GERICKE, 2000). 
Rhamnus prinoides Unspecified groups use ground bark that is administered as snuff for mental 
disorders in the Transkei (HUTCHINGS, SCOTT, LEWIS and 
CUNNINGHAM, 1996). 
Sceletium tortuosum The traditionally prepared dried plant material is chewed, smoked, or powdered 
and inhaled as a snuff. It is used as a sedative, and elevates mood and decreases 
anxiety, stress and tension (VAN WYK and GERICKE, 2000). 
Tephrosia capensis Dried powdered roots are also used as a snuff for headaches (HUTCHINGS, 
SCOTT, LEWIS and CUNNINGHAM, 1996). 
Turbina oblongata The Sotho use the leaves as a snuff mixed with tobacco in Lesotho (JACOT 
GUILLARMOD, 1971). 
Xysmalobium undulatum Powdered tubers are administered as snuff to treat hysteria in Transkei 
(HUTCHINGS, 1989). 
* exotic species 
 
CHAPTER TWO South African Psychoactive Plants  59  
 
The inhalation of smoke and vapours from burning or heated plant material is a common practise in many 
cultures. In a recent review on ‘medicinal smokes’ used throughout the world, 19 species were reported to be 
used in treating mood disorders, 70 species were reported to have neurological action 
(MOHAGHEGHZADEH, FARIDI, SHAMS-ARDAKANI and GHASEMI, 2006). These were divided into 8 
categories: analgesic (38 spp.), anticonvulsive (9 spp.), stimulant (9 spp.), narcotic (7 spp.), sedative (7 spp.), 
hallucinogen (3 spp.), strengthener (2 spp.) and as a remedy for vertigo (2 spp.). In seven cases of its use as 
an analgesic, the smoke is directed at specific organs; in all other cases, it is inhaled. Important families 
within this group are Asteraceae (11 spp.), Solanaceae (10 spp.), Apiaceae (9 spp.), Fabaceae (7 spp.) and 
Ranunculaceae (4 spp.) (MOHAGHEGHZADEH, FARIDI, SHAMS-ARDAKANI and GHASEMI, 2006).  
 
A few treatments are administered by steaming them in hot water or by heating over a fire or hot plate nd the 
vapours inhaled. The tubers of Trichodesma physaloides are boiled and the steam inhaled for madness in 
Zimbabwe (GELFAND, MAVI, DRUMMOND and NDEMERA, 1985). In South Africa, leaves and bark of 
Maerua angolensis are heated over a fire without water and the steam is inhaled to treat children with 
convulsions (MABOGO, 1990; VENTER, 1996). Unspecified parts of Buxus macowanii (umgalagala in 
isiXhosa) are used in a vapour bath to treat mental illness in southern Africa (SIMON and LAMLA, 1991), 
members of this genus are known to contain alkaloids that inhibit acetylcholinesterase (Chapter 5). 
 
Southern African plants that are burnt and the smoke inhaled to treat mental illness, for narcotic or 
































Herbal mixtures may also be added to bath water to relieve certain conditions. The Zulu use the leaves of 
Uvaria lucida (umavumba) for bathing patients with mental disease in South Africa (HUTCHINGS, SCOTT, 
LEWIS and CUNNINGHAM, 1996). A bath taken in water in which the bark of Balanites maughamii has 
been infused is reported to be both stimulating andexhilarating (COATES PALGRAVE, 2002). Cold 
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infusions of Commelina africana are used to bathe restless sleepers (WATT and BREYE-BRANDWIJK, 
1962). Desmodium gangeticum is used in Liberia to bathe children with convulsions (OLIVER-BEVER, 
1986). Leaf decoctions of Clerodendrum myricoides are used for bathing patients with convulsions in 
Zimbabwe (GELFAND, MAVI, DRUMMOND and NDEMERA, 1985). 
 
Zulu botanical names 
Zulu plant names are extremely descriptive and can often provide insight into the plants cultural and 
medicinal use. Zulu plants names often provide more than a means of identifying the plant; they also often 
show a link between Zulu culture and their environme t (NGWENYA, KOOPMAN and WILLIAMS, 2003). 
Much can be learnt about the medicinal use, administration, location and morphology from these names. This
is only true where Zulu plant name exhibits a relationship between the plant itself (the ‘denotatum’ of the 
name) and the underlying meaning of the name (the ‘designatum’) (Figure 2.4). The Zulu Botanical 
Knowledge Project, involving the Natal Herbarium, National Botanical Institute and the University of 
KwaZulu-Natal, was established to capture this botanical and cultural knowledge. A pilot project, focusing on 
tree regions within KwaZulu-Natal, Bulwer/eLotheni, oNgoye/eNkandla and eNtimbankulu resulted in a 
small publication which has inspired and assisted in the inclusion of the meanings of some of the Zulu names 
in Table 2.2. Additional assistance was given by Prof Adrian Koopman, a lexicography specialist, in the 
School of Language, Culture and Communication at the University of KwaZulu-Natal. 
 
A single plant name is often used for a variety of dif erent species in different genuses because of some 
perceived similarity. When further qualified, however, the new phrasal name will normally only refer to one 
species, similar to the Latin binomial system. For example the name ishongwe is used for the following 
taxonomically related (members of Asclepiadaceae) plants; Asclepias cucullata, Xysmalobium undulatum, 
Pachycarpus coronarius, Pachycarpus dealbatus and Pachycarpus concolor. When further qualified, only 
one species is referred to, for example ishongwe elibomvu (meaning the red ishongwe) for Pachycarpus 
asperifolius; ishongwe elibomvu elikhulu (meaning the big red ishongwe) for Pachycarpus natalensis; and 
ishongwe elincane elibomvu (meaning the small red ishongwe) for Schizoglossum atropurpureum. However 
another Asclepiad Gomphocarpus physocarpus, has five names, umangwazane, umbababa, 
umqumbuqumbu, uphuphuma nd usingalwesalukazi, and does not follow the system above. 
 
Another example of a single name that is used for variety of different species because of some perceived 
similarity is impepho. This time however, the similarity lies in the plants use. Impepho refers to any species 
of small everlasting plants with a sweet smell, used for burning as an offering to the amadlozi (ancestral 
spirits). This term is used especially for various species of Helichrysum again suggesting a taxonomic 
relationship however taxonomically unrelated species ( .g. Psammotropha myriantha) are also used as 
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impepho. When further qualified, again only one species is referred to, for example; impepho-emhlophe 
(white impepho) Helichrysum aureonitens, impepho-tshani (grass impepho) Psammotropha myriantha, 
impepho- yamakhosi (royal or chief’s impepho) Helichrysum herbaceum).  
 
 
An example of a plant which shows a relationship betwe n its Zulu name and its medicinal use is Dioscorea 
dregeana. The tuber, used in traditional medicine to treat insanity and fits (HUTCHINGS, SCOTT, LEWIS 
and CUNNINGHAM, 1996), has three Zulu names which refer to the conditions treated and the effect (see 
plant name 
denotatum 
 morphology habitat use 
designatum 
appearance 
e.g. Gerbera ambigua - 
ulimilwenkomo (meaning cow’s 
tongue) 
colour 
e.g. Gerbera kraussii - 
uhlamvuhloshane (meaning white 
leaf) 
size 
e.g. Ocimum gratissimum - 
uqabikhulu (meaning large leaf) 
habit/behaviour 
e.g. Bidens pilosa - umhlabangubo 
(meaning what stabs the clothing) 
smell 
e.g. Brunsvigia natalensis - 
umbhola (from bola meaning to 
rot) 
taste 
e.g. Epilobium hirsutum - 
itswayilentaba (meaning salt of the 
mountain) 
locality 
e.g. Argemone mexicana - 
ugudlathukela (meaning 
what grows along the 
Tugela River) 
proximity/habitat 
e.g. Rhipsalis baccifera - 
ugibeleweni  
(meaning mounted on a 
rock) 
medicinal - disease 
e.g. Vernonia anisochaetoides - 
ikhambi-lesimungumungwane 
(meaning herb of measles) 
medicinal – body part 
e.g. Ursinia tenuiloba - umuthi 
wezifuba ( meaning chest 
medicine) 
medicinal – symptom 
e.g. Tephrosia macropoda - ilozane 
(meaning restlessness in sleep) 
medicinal – effect 
e.g. Dioscorea dregeana - 
undiyaza ( meaning be stunned, 
confused, giddy); 
e.g. Pentanisia prunelloides - 
icishamlilo (meaning put out the 
fire) 
practical use 
e.g. Gomphocarpus physocarpus - 
usingalwesalukazi ( meaning 
thread of the old lady) 
magical/spiritual 
e.g. Asparagus virgatus - 
iphinganhloya (meaning what 
suppresses the ill-omen) 
e.g. Ipomoea obscura - 
usiboniseleni ( meaning what has 
been shown to us) 
love charms 
e.g. Cyanotis speciosa - 
umakotigoyile (meaning the 
hypnotised maiden) 
Figure 2.4. Diagram shown examples of the relationship between Zulu botanical names (denotatum) and 
features of the plant such as habitat, appearance and use (designatum). After KOOPMAN pers. comm. 
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Figure 2.4). Ilabatheka refers to any medicine for causing/treating madness or excitement, undiyaza means 
to be stunned or confused and u akwa is to be drunk or inebriated. Where possible the meanings of the Zulu 
names of plants have been incorporated in Table 2.2. 
 
Not all Zulu plant names have a clear relationship between underlying meaning and the plant itself. There are 
a vast number of plant names where designatum and de otatum overlap (e.g. ihlukwe refers to any plant that 
‘western taxonomy’ refers to as Zantedeschia aethiopica and has no other meaning). These are mainly single-
stemmed words where the ‘underlying meaning’ and the ‘surface meaning’ are the same. In some instances 
several underlying meanings are perfectly clear but there are no apparent reasons to link the meaning to any 
attribute of the plant (eg. Callilepsis laureola is known in isiZulu as amafuthomhlaba, meaning fat of the 
earth which has no obvious relation to the plant). Occasionally there are ambiguous meanings where plant
names where the underlying meaning could be taken in two ways, either of which relates sensibly to aspects 
of the plant. 
 
2.3. Southern African psychoactive plants 
 
A closer look at plants used in African traditional medicine reveals a large number of plants with potential 
psychoactive properties. One study in South Africa list 306 plants from 94 families with reported 
psychoactive uses in southern Africa (SOBIECKI, 2002). Thirty plants belonging to 21 families and 
traditionally used in southern Nigeria by herbalists for the management of mental disorders (including 
amnesia, insomnia and senile dementia) have been reported (NWOSU, 1999). NEUWINGER (2000) cites 
more than 1 750 potential psychoactive traditional African medicinal applications (Figure 2.5); the majority 
(more than 600) of treatments were aphrodisiacs and sexual stimulants. What is also of interest is the large 
number of treatments with potential CNS suppressant effects, for example 300 plants for treating epilepsy 
and convulsions alone, possibly indicating the high prevalence of this disease in Africa. In addition t  these 
there are plants to calm the insane, to treat insomia, hysteria and tranquilizers (NEUWINGER, 2000), which 
could work on a similar physiological system (i.e. CNS suppressant). 
 
Mental health problems constitute a serious problem in southern Africa. Not surprisingly, a large number of 
plants, over 320 species from 94 familiess, are used by traditional healers in their treatment of these ailments 
(Table 2.2 at the end of this Chapter). Nearly 150 plant species from 63 families are used for the indications 
epilepsy and convulsions, possibly reflecting the severity of this problem in the population. The families most 
often represented are Fabaceae (15 species), Asteracea  (13 species) and Lamiaceae (9 species). Over 40 
plant species are used for ailments that could loosely be described as depression. These plants come fr  26 
families. The number of plants used for dementia and ge-related mental problems is lower with only 15 
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species from 7 families recorded, which could be duto a previous demographic situation, where traditional 













































































































Figure 2.5. Number of African traditional plant treatments with potential psychoactive properties based on their 
traditional uses reported in NEUWINGER (2000). 
 
Plants used to induce dreams, visions, trances and hallucinations 
Psychoactive plants have often featured in the religious and medicinal practices of numerous cultures a ound 
the world. In shamanic societies, hallucinogenic plants, and the altered mental state they induce, are often 
employed by the community spiritual practitioner, o shaman, in various religious and healing rituals. 
Shamanism simplistically involves practitioners who voluntarily or with the aid of psychoactive substances, 
dance and/or music; enter an altered mental state. In this state they experience themselves or their spirits 
travelling to other realms where they reportedly interact with other entities in order to acquire knowledge and 
power to heal people in their communities (ELIADE, 1987; WALSH, 1990). African traditional medicinal 
and cultural practices are considered to fall under shamanistic practices (LAMBRECHT, 1998).  
 
Possibly the most culturally important hallucinogenic plant in southern Africa is Boophone disticha (incotho) 
(DE SMET, 1996). LAYDEVANT (1932) described its use in initiation ceremonies of the South African 
Basotho. The boys were given food mixed with the bulb and are instructed it would imbue them with the 
qualities of their ancestors and that it would tend to make men of them. The signs of intoxication were 
regarded as a token that the spirit of manhood had entered their bodies. Traditional healers and patients in 
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South Africa drink Boophone disticha bulb infusions to induce hallucinations for divinatory purposes, and 
also as a medicine to treat mental diseases. However, many injuries result from the toxic use of this plant 
(SOBIECKI, 2002). Other Amaryllidaceae species, Crinum species and Pancratium tenuofolium are used in a 
similar way to B. disticha (SOBIECKI, 2002). A plant resembling Tulbaghia capensis is reported to be used 
in South Africa with B. disticha to induce visions (isibonakalo mental vision) (SOBIECKI, 2002). Dioscorea 
dregeana is often mixed with Boophane disticha reportedly to synergize the visionary experience and is a 
popular psychoactive plant sold on the muthi markets in Johannesburg (SOBIECKI, 2002). These and other 
species that may induce an altered mental state and are used in African traditional medicine will be discussed 
in detail in the rest of this section. 
 
Several species have been identified as being used to in uce or enhance dreams. The Zulu use unidentified 
species of Agapanthus for inducing visions and dreams (iphupho) in South Africa (SOBIECKI, 2002). 
Smoking the roots of Alepidea amatymbica is reported to result in mild sedation and vivid dreams (VAN 
WYK and GERICKE, 2000). An unidentified plant corresponding to the name umhlambamasi, possibly 
Rauvolfia caffra, is used by the Zulu to enable one to hear one’s ancestors in one’s dreams (MANANA, 
1968). The root of Silene capensis are used by Xhosa diviners for spiritual purposes and inducing dreams 
(HIRST, 1997b). Pleurostylia capensis is used to encourage sleep to bring good dreams in the cape of South 
Africa (DE JAGER, 1963). 
 
Unspecified groups in South Africa crush two to four seeds of Ipomoea alba in water and the resulting liquid 
is taken orally at night to induce vivid dreams, while the seeds of an unknown Convolvulaceae are usedto 
induce dreams and communication with the ancestors (VAN WYK and GERICKE, 2000). The roots of 
Albizia adianthifolia are used for improving memory, and inducing dreams bout medicinal plants in Venda 
(MABOGO, 1990). Tobacco smoked in a pipe made from the large Entada rheedii (umbhone or intindili  in 
isiZulu) seeds have been reported to cause vivid dreaming in South Africa (VAN WYK and GERICKE, 
2000), and are also reported by MANANA (1968) to be us d to remember dreams. A plant called umnono 
identified as Strychnos henningsii by SOBIECKI (2002) is used to induce visionary dreams associated with 
the ancestors. An unidentified plant with the name ubuvimbha, possibly Withania somnifera, is taken to 
induce clear dreams (MANANA, 1968). 
 
The bark of Brackenridgea zanguebarica is reported to be smoked to induce visions and is also used as a 
protection against evil and bad omens in South Africa (SOBIECKI, 2002). Eleutherine bulbosa (ababomvu) 
is believed to have magical and hallucinatory propeties (HUTCHINGS, SCOTT, LEWIS and 
CUNNINGHAM, 1996), and is reported to be an ingredient of a psychoactive mixture used to induce visions 
in South Africa (SOBIECKI, 2002). Diviners swallow roots of Monadenium lugardiae in the Piet Retief area 
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of South Africa to obtain clear vision before important meetings, while roots are reported to induce 
hallucinations and delirium if taken in sufficient quantities (WATT and BREYER-BRANDWIJK, 1962). 
Synaptolepis kirkii (uvuma-omhlophe) root infusions have been used as purifying ritual emetics and face and 
body washes to assist South African diviners to ‘see’ in a metaphysical sense (VAN WYK and GERICKE, 
2000). 
 
Four plants, Indigofera flaviscans, Ferraria glutinosa, Loranthus oleifolius and Plumbago zeylancia, are 
reportedly used by the !Kung (San) in the Kalahari to induce a trance-like state referred to as ‘kia’. This is 
described as an altered state of consciousness considered to be a prerequisite for healing practices (KATZ, 
1982, WINKELMAN and DOBKIN DE RIOS, 1989). Smoke from burning impepho (Helichrysum species) 
is inhaled by the Zulu diviners to induce trances in South Africa (HUTCHINGS, SCOTT, LEWIS and 
CUNNINGHAM, 1996). Turraea floribunda (umadlozana) roots are used by Zulu diviners to enter the 
‘neurotic’ state needed for divining dances (HUTCHINGS, SCOTT, LEWIS and CUNNINGHAM, 1996). 
 
Some southern African plants have been reported to possess hallucinogenic properties but these have yet to 
be investigated. Pulverized Rabiea albinota is reported to be a hallucinogenic additive to tobacco to be 
smoked or taken as snuff (VAN WYK and GERICKE, 2000). Anacampseros rhodesica is a beer additive, 
and is reported to have hallucinogenic and narcotic activity (GELFAND, MAVI, DRUMMOND and 
NDEMERA, 1985; VAN WYK and GERICKE, 2000). Leaf decoctions of Cissampelos torulosa re reported 
to be administered as enemas for hallucinations in the Transkei (HUTCHINGS, SCOTT, LEWIS and 
CUNNINGHAM, 1996). It is not clear whether this plant is used to treat or induce hallucinations.  
 
The Zulu use unspecified parts of Datura metel that are mixed with an unidentified Dioscorea species as 
hypnotic drugs against hysterical fits in girls (GERSTNER, 1941). Datura metel is also ingested and used as 
a hallucinogen or entheogen in the Tsonga girls’ initiation schools in Mozambique and the Northern Province 
of South Africa (JOHNSTON, 1972). 
 
Several plants are used by healers themselves to aid in the divination  process. For example root infusions of 
Pittosporum viridiflorum are used for accuracy in divining by the Sotho (HUTCHINGS, SCOTT, LEWIS and 
CUNNINGHAM, 1996); diviners are also reported to use the plant to induce altered states of consciousness 
for purposes of divining (SOBIECKI, 2002). Myosotis afropalustris is used in the initiation of Sotho diviners 
and to treat ‘people with the spirit’ that suggests a type of mental disturbance or spiritual calling 
(LAYDEVANT, 1932). Zulu izangoma (diviners) use root infusions of Adenopodia spicata (ibobo) as 
emetics to increase their divining power in South Africa (HUTCHINGS, SCOTT, LEWIS and 
CUNNINGHAM, 1996). The Kgatla, a Tswana group, use unspecified parts of Mundulea sericea as a 
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‘divining medicine’ (WATT and BREYER-BRANDWIJK, 1962), it is also considered to be a very powerful 
magical plant, known as mukundandou by the Vhavenda (MABOGO, 1990). MONNIG (1967) describes 
how the Pedi use Helinus integrifolius in the initiation of diviners to ‘strengthen his meory and give the 
initiate keen powers of observation’. This plant has important spiritual uses among the Zulu and Xhosa in 
Johannesburg (SOBIECKI, 2002). 
 
Stephania species are used by Sotho diviners ‘to discover’ things and are used with divining bones (Phillips, 
1917). It is not clear whether the plant is ingested. Flowers of Nymphaea nouchali are used by South African 
diviners, and tinctures of flowers are stimulant, aphrodisiac and euphoriant in low doses (VAN WYK and 
GERICKE, 2000). Flowers are sold on the muthi markets in Johannesburg for divinatory purposes 
(SOBIECKI, 2002). Adenia gummifera (impinda) is reported to have psychoactive properties that are used by 
the Zulu in divination on the east coast of South Africa (SOBIECKI, 2002). An unidentified Kaempferia 
species (now refered to as Siphonochilus perhaps S. kirkii (Hook.) B.L.Burtt) is chewed by Lobedu (a 
Northern Sotho group) traditional healers before divining (KRIGE, 1940). Euclea divinorum (magic guarri) is 
said to be used for divination in Africa, hence the name E. divinorum (SOBIECKI, 2002). Sotho diviners use 
unspecified parts Crabbea hirsuta in conjunction with divining dice in South Africa (WATT and BREYER-
BRANDWIJK, 1962). 
 
As mentioned already there are surprisingly few tradi ional African treatments for memory loss (amnesia), to 
improve cognition or treat age-related neurodegenerativ  diseases like Alzheimer’s and Parkinson’s disease. 
Four species are reported to be used in southern Nigeria by herbalists for amnesia (NWOSU, 1999). These 
include Boerhaavia diffusa (Nyctaginaceae), the roots of which are reported to contain liriodendrin (lignan) a 
Ca2+ channel blocker (POLYA, 2003). Decoctions of male inflorescences of Carica papaya (Caricaceae) with 
Zingiber officinale (Zingiberaceae) and Pauridiantha viridiflora (Rubiaceae) are also used to treat amnesia. 
C. papaya contains (S)-(-)-cotinine (pyridine pyrrolidinone), a major brain metabolite of nicotine, which is 
also an acetylcholine receptor agonist (POLYA, 2003). In southern Africa there appears to be only three 
references to plants that improve memory. Albizia adianthifolia roots are used for improving memory by the 
Venda (MABOGO, 1990). An infusion of Aptosimum decumbens or chewing the leaves is reported to 
improve the memory (RODIN, 1985). MONNIG (1967) describes how the Sotho (Pedi) use Helinus 
integrifolius in the initiation of diviners to “strengthen his meory and give the initiate keen powers of 
observation”. 
 
Several plants are associated with dealing with death of a family or community member. The Zulu regard 
Cunonia capensis (umaphethu, umhlahlane, umuthi wokuzila), Gerrardina foliosa, Nuxia floribunda nd 
Turraea floribunda (umadlozana) as a strengthening medicines that is taken after the death of a kraal (family 
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or community) member (GERSTNER, 1939). A mixture containing Schotia brachypetala (ihlusi, ihluze, 
umgxamu and uvovovo) is often taken and also washed with during purification rites after the death of a 
relative (PUJOL, 1990). As mentined death is believd to be a ‘pollutant’ (NGUBANE, 1977). The Vhavenda 
traditionally used decoctions made from root bark of Lannea schweinfurthii mixed with a fungus found 
growing on the roots to help family members to forget a recently deceased relative (MABOGO, 1990).  
 
The remainder of this Chapter consists of a Table (2.2a) listing plants that are and have been used for central 
nervous system-related purposes. This has been compiled from numerous literature sources including books, 
theses, journal articles and magazine articles. All botanical names, authorities and annotations (morphology 
and distribution) of the species are taken from GERMISHUIZEN and MEYER (2003). Table 2.2b contains 
an alphabetical list of plant species which can be us d to locate specific species in Table 2.2a. Part of this 
table has been published, in particular the plants used to treat epilepsy, convulsions, depression and age-
related mental illnesses (STAFFORD, PEDERSEN, VAN STADEN and JÄGER 2008). 
 
The following publications relate to this chapter: 
 G.I. Stafford, M.E. Pedersen, J. van Staden, A.K. Jäger. 2008. Review on plants with CNS-effects used 
in traditional South African medicine against mental diseases. Journal of Ethnopharmacology 119, 513–
537. 
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Table 2.2a. Southern African plants traditionally used for central nervous system-related purposes. Plants are 
arranged in taxonomic families alphabetically. An alph betical species reference list follows in Table 2.2b. 
FAMILY 
Species 
Colloquial name1 – meaning2 
Annotations and distribution for South 
Africa3 
 Traditional use, ethnobotanical information and known active 
constituents 
ACANTHACEAE 
Crabbea hirsuta Harv. 
Syn: C. cirsioides (Nees) Nees;  
C. robusta N.E.Br.  
letsuijana; mereko (S) 
Perennial. Herb. Ht 0.05–1.25 m. Alt 5–






In Zimbabwe, the roots are administered in porridge to treat madness 
(GELFAND et al., 1985). C. velutina S. Moore is smoked for its 




Thunbergia dregeana Ness 
isiphondo (Z) - (n) entrance at 
side of kraal 
Perennial. Herb, creeper. Ht 0.4–1 m. Alt 
5–765 m. S, KZN, 
WC, EC 
 
002 Strong infusions of root are taken by men in South Africa for diseases 
(unspecified) reputed to have been acquired from wives who have been 
the victims of sorcery (WATT and BREYER-BRANDWIJK, 1962). 
Other Thunbergia spp. are used as love charms (BATTEN and 
BOKELMANN, 1966; HUTCHINGS et al., 1996). 
ADIANTACEAE (Pteridaceae) 
Pellaea calomelanos (Swartz) 
Link 
mumvuriwedombo (Sh) 
Perennial. Herb, geophyte, lithophyte. Ht 
150–250 mm. Alt 100–2100 m. N, B, 






Taken as an infusion or smoked to treat convulsions in Zimbabwe 
(GELFAND et al., 1985). The Kwena and Kgatla administer milk 
decoctions of rhizome to frightened children at night (HUTCHINGS et 








Zulu use grated root decoctions of an unidentified species to treat high 
blood pressure and stress (HUTCHINGS et al., 1996). An exotic genus 
of which three species are found in SA; A. americana L ., A. decipiens 
Baker, A. vivipara L. 
ALLIACEAE 
Agapanthus africanus (L.) 
Hoffmanns. 
(sometime placed in Agapanthaceae) 
Syn: A. minor Lodd.,A. umbellatus L’Hér., 
Crinum africanum L., Mauhlia africana 
(L.) Dahl, Mauhlia linearis Thunb., 
Tulbaghia heisteri Fabric  
leta-la-phofu (S); ubane(-





A decoction of A. africanus and other unspecified herbs are used by 
Southern Sotho diviners to develop memory and make initiates mentally 
fit for their work (WALKER, 1996). 
 




(sometime placed in Agapanthaceae) 
Syn: A. patens F.M.Leight. 
leta-la-phofu (S); ubani (Z) 
Perennial. Herb, geophyte. Ht 0.4–1.52 m. 




Used in the initiation  of traditional healers (HUTCHINGS et al., 1996, 
CALLAWAY, 1991). Various parts are used by the Sotho o treat people 
with a type of mental illness known as ‘the spirit’ (LAYDEVANT, 
1932). The Zulu are reported to use unidentified species of Agapanthus 
for inducing visions (imibono) and dreams (SOBIECKI, 2002). Extracts 
exhibited SSRI activity (NIELSEN et al., 2003; Chapter 3). Agapanthus 
campanulatus exhibited high affinity to the serotonin re-uptake 
transporter protein in aqueous extracts from leaves nd flowers. 
 
  




Colloquial name1 – meaning2 
Annotations and distribution for South 
Africa3 
 Traditional use, ethnobotanical information and known active 
constituents 
Agapanthus praecox Willd. 
(sometime placed in Agapanthaceae) 
ubani (Z) 
 
007 Used in the initiation  of traditional healers (HUTCHINGS et al., 1996). 
Three subspecies: 
A. praecox Willd. subsp. minimus (Lindl.) F.M.Leight.  
(Syn: A. longispathus F.M.Leight., A. umbellatus L’Hér. var. minimus Lindl.),  
Perennial. Herb. Ht 0.4–0.85 m. Alt 5–600 m. WC, EC 
A. praecox Willd. subsp. orientalis (F.M.Leight.) F.M.Leight. 
(Syn: A. orientalis F.M.Leight., A. umbellatus L’Hér. var. maximus Edwards) 
Perennial. Herb. Ht up to 1.21 m. Alt 15–1435 m. KZN, EC 
A. praecox Willd. subsp. praecox 
Perennial. Herb. Ht 0.8–1 m. Alt? KZN, EC 
 
Tulbaghia alliaceae L.f. 
ishaladi lezinyoka (Z) 
Perennial. Herb, geophyte. Ht 0.26–0.45 
m. Alt 50–2250 m. WC 
 
008 Rhizome infusion administer as enemas for fits in Transkei 
(HUTCHINGS et al., 1996). The Zulu name, ishaladi lezinyoka means 
‘garlic/shallots of the snakes’, the plant parts smell of garlic and is used 
by Zulu as a snake repellent (HUTCHINGS et al., 1996). 
 
Tulbaghia leucantha Baker  
Syn: T. dieterlenii E.Phillips 
false garlic, mhondya (Sh) 
Perennial. Herb. Ht 0.1–0.25 m. Alt 30–
2325 m. N, LIM, NW, G, M, S, FS, KZN, 
L, NC, WC, EC 
 
009 Unspecified parts are eaten in porridge to treat madness in Zimbabwe 
(GELFAND et al., 1985) 
Tulbaghia violaceae Harv. 
Syn: Omentaria cepacea Salisb.,  
T. cepacea L.f. 
isihaqa (Z) 
-haqa (v) surround, encircle, 
enclose 
 
010 In Transkei the bulb is rubbed on the body as protection from evil spirits 
before ritual dancing by diviners (HUTCHINGS et al., 1996). Leaves 
are rubbed on the head of restless young children (BATTEN and 
BOKELMANN, 1966) presumably to calm them. 
 





icukudo, incukudwane, isidiya, 
umbhodiya (Z) 
-diya (isi-, izi-) (n) goat skin worn 
by women over shoulders to cover 
breasts 
 
Perennial. Geophyte. Ht ± 350 mm. Alt? 






Used to treat serious afflictions (unspecified) caused by witchcraft  
(HULME, 1954). Known to contain buphanidrine (GIBBS, 1974) which 
exhibited affinity to the serotonin transporter (SERT) protein 
(SANDAGER et al., 2005). The bulbs of Ammocharis coranica have 
yielded many alkaloids: lycorine, acetylcaranine, crinamine, 1-O-
acetyllycorine (a potent AChE inhibitor Chapter 5; ELGORASHI et al., 
2004), hippadine, 6a-hydroxypowelline, hamayne, 1-O-acetyl-9-O-
demethylpluviine, 24-methylenecycloartan-3b-ol, cycloeucalenol, 
cycloeucalenone and 24-methylenepollinastanone (KOORBANALLY et 
al., 2000). A healer from the Nongoma District of Zululand reported that 
A. coranica was used as a substitute for B ophone disticha 
(Amaryllidaceae) when the latter was unavailable, for the treatment of 
mentally ill patients (KOORBANALLY et al., 2000). 
 




Colloquial name1 – meaning2 
Annotations and distribution for South 
Africa3 
 Traditional use, ethnobotanical information and known active 
constituents 
Boophone disticha (L.f.) Herb. 
Syn: B. longepedicellata Pax 
bushman poison bulb; leshoma 
(S); incwadi (X); incotho; incwadi 
(Z) 
-ncwadi (i-, izi-) (n) book, refers 
to the leaf arrangement as the 
come out of the bulb 
 
Perennial. Geophyte. Ht 200–300 mm. Alt 
50–1800 m. N, B, LIM, G, M, S, FS, 
KZN, L, WC, EC 
 
Similar species:  
B. haemanthoides F.M.Leight. 
Syn: B. disticha (L.f.) Herb. var. ernesti-
ruschii Dinter & G.M.Schulze  
 
Perennial. Geophyte. Ht 200–300 mm. Alt 
15–800 m. N, NC, WC 
 
013 Weak decoctions of bulb scales given to sedate violent, psychotic 
patents (GORDON, 1947; VAN WYK and GERICKE, 2000). WATT 
and BREYER-BRANDWIJK (1962) report that concoctions of the bulb, 
when taken orally, cause sedation, analgesia, visual hallucinations, 
unconsciousness, irrational behaviour, talkativeness or coma. Traditional 
healers and patients in South Africa drink bulb infusions to induce 
hallucinations for divinatory purposes, and also as a medicine to treat 
mental illness (SOBIECKI, 2002). The bulb is traditionally used in 
Zimbabwe to arouse ancestral spirits (NYAZEMA, 1984; GELFAND et 
al., 1985). Among the Sotho in the Bethlehem District of Orange Free 
State (South Africa), a decoction of the bulb of B ophone disticha was 
sometimes taken as an enema for suicidal purposes (WATT and 
BREYER-BRANDWIJK, 1962).  
Alkaloids isolated from the bulb include buphanamine, buphanidrine, 
buphanine buphanisine, haemanthamine, nerbowdine, undulatine, 
lycorine, crinamidine, crinine, 3-O-acetylnerbowdine, ambelline, 
buphacetine and distchamine (RAFFAUF, 1970; VILADOMAT et al., 
1997). Other compounds that have also been isolated are a volatile oil, 
containing furfuraldehyde, acetovanillone, chelidonic acid, copper, 
laevulose, pentatriacontane, ipuranol and a mixture of free and combined 
fatty acids (Watt and Beyer-Brandwijk, 1962). Alkaloids, buphanidrine 
and buphanamine exhibited an affinity to the serotonin transporter 
(SERT) protein (SANDAGER et al., 2005).  
 
Crinum species 
umduze, umnduze (Z) 
C. bulbispermum (Burm.f.) 
Milne-Redh. & Schweick. 
lelutla, mototsw (S) 
umnduze (Z) 
C. macowanii Baker 
Syn: C. gouwsii Traub, C. macowanii 
Baker subsp. confusum I.Verd. 
C. moorei Hook.f. 
C. imbricatum Baker, C. macowanii 
Baker, C. schmidtii Regel 
 
014 Cherylline was isolated from Crinum moorei (ELGORASHI et al., 
2001a) and showed good affinity to the serotonin transporter (SERT) 
protein (ELGORASHI et al., 2004). An unidentified species is reported 
to be used in a similar manner as Boophone disticha for inducing 
hallucinations (SOBIECKI, 2002). Alkaloids have also been isolated 
from Crinum bulbispermum (ELGORASHI and VAN STADEN, 2003), 
Crinum macowanii (ELGORASHI et al., 2001b). These together with 
alkaloids from Cyrtanthus falcatus (ELGORASHI et al., 1999) have 
some weak to moderate acetylcholinesterase inhibitory activity 
(ELGORASHI et al., 2004). This prompted further quantit tive-
structure-activity relationship studies on these alkaloids (ELGORASHI 
et al., 2006). 
Pancratium tenuifolium Hochst. 
ex A.Rich 
Syn: Chapmanolirion juttae Dinter, P. 
chapmannii Harv. 
 
015 Reportedly used by San in Botswana to induce hallucinations by 
rubbing the bulb into incisions on the head (DOBKIN DE RIOS, 1986). 
 
Scadoxus multiflorus (Martyn) 
Raf.  
Syn: Haemanthus katharinae Baker, 
Haemanthus multiflorus Martyn, 
Haemanthus otaviensis Dinter, 
Haemanthus sacculus E.Phillips 
 
016 Reported to contain galanthamine (0.002%) an AChE inhibitor  
(JASPERSEN-SCHIB, 1970). According to POOLEY (2005) there are 
two subspecies which have different Zulu names: 
S. multiflorus (Martyn) Raf. subsp. katharinae (Baker) Friis & Nordal 
Syn: Haemanthus katharinae Baker 
indunjana, ubukhoswane (Z) 
Perennial. Geophyte. Ht 0.75–1.2 m. Alt? M, S, KZN, EC 
S. multiflorus (Martyn) Raf. subsp. multiflorus 
Syn: Haemanthus multiflorus Martyn, Haemanthus otaviensis Dinter, Haemanthus 
sacculus E.Phillips 
isiphompo, isiphungo (Z) 
-phungo (isi-, izi-) (n) medicine for drinking 
Perennial. Geophyte. Ht 0.5–1 m. Alt? N, B, LIM, M,S, KZN 
 




Colloquial name1 – meaning2 
Annotations and distribution for South 
Africa3 
 Traditional use, ethnobotanical information and known active 
constituents 
Scadoxus puniceus (L.) Friis & 
Nordal 
Syn: Haemanthus magnificus Herb., 
Haemanthus natalensis Pappe ex Hook., 





017 Known to cause CNS excitation or depression and visual disturbances 
(VEALE et al., 1992). 
 
Perennial. Geophyte. Ht 0.5–0.75 m. Alt 15–2100 m. B, LIM, NW, G, M, S, FS, KZN, EC 
 
ANACARDACEAE 
Harpephyllum caffrum Bernh. 
Ex Krauss 
Perennial. Tree. Ht 2–15 m. Alt 15–1400 





In Transkei, root decoctions are taken for paralysis thought to have been 
contracted from walking over an area that has been ‘polluted’ through 
sorcery (HUTCHINGS et al., 1996). 
 
Lannea discolor (Sond.) Engl. 
Syn: Odina discolor Sond.  
live-long; luvale (Lu); 
isiganganyane (Z) 
019 The Luvale of Zambia use the leaves to prevent fits (WATT and 
BREYER-BRANDWIJK, 1962).  
 
Perennial. Tree. Ht 0.75–12 m. Alt 305–1480 m. N, B, LIM, NW, G, M, S 
 




L. schweinfurthii (Engl.) Engl. var. 
stuhlmannii (Engl.) Kokwaro 
Syn: L. kirkii Burtt Davy, L. stuhlmannii 
(Engl.) Engl.  
Perennial. Tree. Ht 2–18 m. Alt 30–1370 
m. LIM, M, S 
L. schweinfurthii (Engl.) Engl. var. 
tomentosa (Dunkley) Kokwaro 
Syn: L. stuhlmannii (Engl.) Engl. var. 
tomentosa Dunkley  
Perennial. Tree. Ht 3–15 m. Alt 1050–
1200 m. N, B 
 
 
020 The Vhavenda traditionally used decoctions made from r ot bark mixed 
with a fungus found growing on the roots to help family members to 
forget a recently passed away relative (MABOGO, 1990). They are also 
used as a protection against a sleeping sickness known as vhulangwane 
and to help people forget all unpleasant events. The roots are covered 
with a dense layer of very fine root hairs, that are reportedly used as a 
sedative snuff, and the smoke of the burned roots is inhaled s a 
sedative (VAN WYK and GERICKE, 2000) 
 
Searsia chirindensis (Baker f.) 
Moffett 
Syn: Rhus chirindensis Bak. f. 
021 Bark is used to strengthen the body, stimulate circulation and for 
rheumatism (PUJOL, 1990), bark decoctions are traditionally 
administered for mental disturbances in Transkei (HUTCHINGS et al., 
1996). 
Searsia natalensis (Bernh. ex 
Krauss) F.A.Barkley 
Syn: Rhus natalensis Bernh. ex krauss 
022 Roots are used for fits in children (WATT and BREYER-BRANDWIJK, 
1962). 
Searsia pyroides (Burch.) Moffett 
Syn: Rhus pyroides Burch. 
mufokosiana (Sh) 
023 In Zimbabwe the roots are use in infusions to treat d lirium  (GELFAND 
et al., 1985). 
ANNONACEAE 
Annona senegalensis Pers. 
Syn: A. arenaria Thonn. ex Schumach., A. 
chrysophylla Bojer  
 
Perennial. Shrub or tree. Ht 1.5–8 m. Alt 





The roots are mixed with Trema orientalis to treat madness; roots are 
used to treat madness, to ward off dizziness and to induce forgetfulness 
in small children, thus facilitating weaning process  by the Zulu 
(PALMER and PITMAN, 1972). The Vhavenda use roots fr snakebites, 
venereal diseases, diarrhoea, dysentery, blood in the faeces, headaches 
and as protective charms against witchcraft (MABOGO, 1990). An 
Annona sp. is used in Ghana as an epilepsy treatment (IRVINE, 1961). 




Colloquial name1 – meaning2 
Annotations and distribution for South 
Africa3 
 Traditional use, ethnobotanical information and known active 
constituents 
Artabotrys brachypetalus Benth. 
mukosvo (Sh) 
 
Perennial. Tree, shrub or climber. Ht 0.9–4 
m. Alt 305–1400 m. B, LIM 
 
025 Root infusions are drunk to treat convulsions in Malawi (GELFAND et 
al., 1985; SOBIECKI, 2002). Artabotrys spp. Is used in Madagascar as a 
stimulant (GITHENS, 1949; SOBIECKI, 2002). 
Monanthotaxis caffra (Sond.) 
Verdc. 
Syn: Guatteria caffra Sond., Popowia 
caffra (Sond.) Benth.  
dwaba berry; umgogi 
wezinhlanya (Z) 
 
026 Root material is smoked for hysteria and administered as emetics for 
bad dreams (GERSTNER, 1941; DOKE and VILAKAZI, 1972). 
 
Perennial. Tree, shrub or climber. Ht 1–10 m. Alt 10– 190 m. M, S, KZN, EC 
Uvaria lucida Benth. 
Syn: U. gazensis Baker f., U. virens 
N.E.Br. 
umavumba (Z)  
–vumba (n) odour ,  
umazwenda –omnyama (Z) – 
darkness or ill omen of the land  
 
027 Stems are used in Zulu traditional medicine (CUNNINGHAM, 1988); 
the leaves are used for bathing patients with mental illnesses 
(SOBIECKI, 2002). In Tanzania, roots are used in decoctions to treat 
mental disease (HEDBERG et al., 1982). 
 
Perennial. Shrub or climber. Ht 1.5–10 m. Alt 0–100 m. LIM, S, KZN 
 
APIACEAE 
Alepidea amatymbica Eckl. & 
Zeyh. 
ikathazo (Z) 
-khathazo (n) a kind of herb used 






The dry rhizome and roots are smoked, or powdered and taken as a snuff 
by Zulu diviners and healers to assist in d vination  and communication 
with ancestors (HUTCHINGS et al., 1996; VAN WYK and GERICKE, 
2000). Smoking the roots reportedly results in mild se ation and vivid 
dreams (VAN WYK and GERICKE, 2000). Antihypertensive, 
antimicrobial and diuretic effects have been indicated in tests on animals 
(VAN WYK and GERICKE, 2000). Three subspecies are described: 
A. amatymbica Eckl. & Zeyh. var. amatymbica 
Perennial. Herb. Ht ± 0.1 m, when in flower up to 2.1 m. Alt 243–2620 m. LIM, G, M, S, 
FS, KZN, L, EC 
A. amatymbica Eckl. & Zeyh. var. aquatica (Kuntze) Weim. 
Perennial. Herb. Ht up to 0.1 m, when in flower up to 2.1 m. Alt 795–1220 m. EC 
A. amatymbica Eckl. & Zeyh. var. microbracteataWeim. 
Perennial. Herb. Ht up to 0.1 m, when in flower up to 2.1 m. Alt ± 800 m. KZN 
Similar species include:  
A. natalensis J.M.Wood & M.S.Evans 
Syn: A. baurii Kuntze 
Perennial. Herb. Ht up to 0.2 m, when in flower up to 0.6 m. Alt up to 2650 m. FS, KZN, 
L, EC 
 
Arctopus echinatus L.  
 
Perennial. Herb. Ht up to 0.1 m. Alt 50–
1700 m. WC, EC 
 
029 WATT (1967) mentions A. echinatus as being administered, together 
with potassium nitrate, for epilepsy. He states that in this form it may 
cause drowsiness. This plant was held in great esteem as a “comfort to 
the sick”, hence the Afrikaans vernacular name sieketroos (PAPPE, 
1847, 1857). It is thought to have been adopted from the Khoi-San by the 
Early Cape Settlers (PAPPE, 1847, 1857). Their resinous roots are 
chemically similar to those of Alepidea amatymbica Eckl. and Zeyh. 
(ikhathazo in Zulu), a well-known Zulu and Sotho medicinal plant, with 
an equally rich ethnobotanical history (VAN WYK et al., 1997; VAN 
WYK and GERICKE, 2000; MAGEE et al., 2007).  
 




Colloquial name1 – meaning2 
Annotations and distribution for South 
Africa3 
 Traditional use, ethnobotanical information and known active 
constituents 
Centella asiatica (L.) Urb.  
 
Perennial. Herb, climber. Ht up to 0.2 m. 
Alt 5–2000 m. N, 
B, LIM, NW, G, M, S, FS, KZN, L, NC, 
WC, EC 
 
030 Dried powdered leaves are used by unspecified groups as a snuff, which 
reportedly produces a calming, sedative effect (VAN WYK and 
GERICKE, 2000). Triterpenes have been demonstrated to xhibit 
tranquillising , anxiolytic activity and stress relief (VAN WYK and 
GERICKE, 2000). In parts of India it is given with milk to improve 
memory against dementia and aging (AHUJA, 1965). Constituen s in 
Centella asiatica include essential oil, triterpenoid saponins, such as 
asiaticocide, brahmoside and thankuniside, alkaloids (hydrocotyline) and 
some bitter principles (CHEVALLIER, 1996). Sedative action has been 
shown by triterpenes, such as those present in Centella asiatica 
(BRINKHAUS et al., 2000; WIJEWEERA et al., 2006). These 
triterpenes exhibit anxiolytic activity that is thought to be due to 
cholinergic mechanisms. Furthermore, an extract from C. asiatica was 
shown to exert a dose-dependent increase in GABA levels, in rat brain 
(CHATTERJEE et al., 1992). 
 
Heteromorpha trifoliata (Wendl.) 
Eckl. & Zeyh. 
Now H. arborescens (Spreng.) 
Cham. & Schltdl. var. abyssinica 
(A.Rich.) H.Wolff 
Syn: Bupleurum trifoliatum H.L.Wendl., 
H. abyssinica Hochst. ex A.Rich. var. 
abyssinica, H. abyssinica Hochst. ex 
A.Rich. var. simplicifolia A.Rich., H. 
arborescens (Spreng.) Cham. & Schltdl. 
var. trifoliata (H.L.Wendl.) Sond.  
umbangandlala (Z) 
 
Perennial. Tree, shrub. Ht up to 15 m. Alt 
up to 2800 m. B, LIM, NW, G, M, S, FS, 
KZN, L, NC, WC, EC 
 
031 Sotho use leaf decoctions that are administered for mental and nervous 
diseases (HUTCHINGS et al., 1996; WATT and BREYER-
BRANDWIJK, 1962). It is also used by Sotho to increas  the 'power' of 
the chief (JACOT GUILLARMOOD, 1971); and in the Transkei warm 
leaf infusions, sometimes with the addition of salt, re administered tree 
times a day to patients suffering mental disturbances (HUTCHINGS et 
al., 1996). In Botswana, root infusions are taken for weakness by men 
(TEICHLER, 1971; HEDBERG and STAUGARD, 1989). A plant 
known as umbangandlala (Z) is used to treat nervous debilities and 
impotency (PUJOL, 1990), the root (1 teaspoon powdered in 500 ml 




Syn: L. kolbeana Bolus, L. pyrethrifolia 
Cham. & Schltdl. 
 
Perennial. Herb. Ht 0.5–1.2 m. Alt 500–
1700 m. KZN, WC, EC 
 
032 Roots are used for narcotic drinks and powdered herbs used as nuff in 
the Cape (HUTCHINGS et al., 1996), plants are reputd to be used in 
sorcery to cause people or crops to decay or die and are used as counter 
remedies (GERSTNER, 1941) 
 
Steganotaenia araliacea Hochst. 
Perennial. Tree. Ht up to 10 m. Alt 200–
1200 m. N, B, LIM, M 
 
033 The Shona of Zimbabwe use root infusions taken in porridge to treat 
epilepsy (GELFAND et al., 1985).  
APOCYNACEAE 
Acokanthera oppositifolia (Lam.) 
Codd 
Syn: A. venenata in sense of Stapf, not of 
G.Don, misapplied name 
 
ubuhlungu-benyoka (Z) –hlungu 
(n) pain,  






Leaf infusions are administered against fit  in the Transkei but are 
reputed to be very poisonous if ‘too strong’ (quantities not specified) 
(HUTCHINGS et al., 1996). Twig decoctions are taken as battle 
‘charms’ by Thembu and large twigs are burned in huts for pr tection 
against evil spirits known as impundulu (HUTCHINGS et al., 1996). 
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Carissa edulis Vahl 
Syn: Azima pubescens Suess. 
035 In Malawi the roots are mixed with the roots of Securidaca 
longipedunculata (Polygalaceae) and used in a body wash to treat 
epilepsy (GELFAND et al., 1985). 
 
Oncinotis tenuiloba Stapf  
Syn: O. inandensis J.M.Wood & 
M.S.Evans 
 
036 Used to counteract witchcraft  as medicines made from the plant are 
believed to be powerful enough to confuse sorcerers (PALMER and 
PITMAN, 1972). 
Pleiocarpa pycnantha (K. 
Schum.) Stapf. 
Syn: P. swynnertonii S.Moore 
 
037 The roots are chewed as a timulant by an unspecified group in South 
Africa (COATES PALGRAVE, 2002). 
Rauvolfia caffra Sond. 
Syn: R. natalensis Sond. 
quinine-tree (E), kinaboom (A) 
 
Perennial. Tree. Ht 2–21 m. Alt 0–1400 m. 
LIM, NW, G, M, S, KZN, WC, EC 
 
038 Decoctions of the bark are used in South Africa as tranquilliser for 
hysteria, and for insomnia, and the dried leaves are used as a snuff for 
headaches (VAN WYK and GERICKE, 2000). In the Transkei, bark is 
used by traditional healers as a tr nquilliser  for patients believed to be 
'possessed by spirites' (BROSTER, 1981). Valley Trust healers in Natal 
reportedly use bark of umhlambamanzi (Z) to ward off 'evil spirits' 
(HUTCHINGS et al., 1996).  
 
Reserpine is used as a hypotensive agent in arterial hypertension, as a 
tranquillizer  in anxiety states and in psychoses with hallucinations and 
delirium (FATTORUSSO and RITTER, 1967). On account of their 
sedative, tranquilizing and hypotensive properties of reserpine, other 
Rauvilfia species have been investigated and numerus alkaloids isolated 
(KERHARO and ADAM, 1974). The pharmacologically important 
alkaloids reserpine and rescinnamine occur in the root but not in the 
leaves (GOODWIN and BUNNEY, 1971; HABIB and COURT, 1974, 
KHAN, 1986). Reserpine has sedative and tranquillising effects but is 
not hypnotic. It acts through the CNS and is active only in the presence 
of the hypothalamus and dienceohalon. Reserpine appars to act as an 
antimetabolite of serotonin and catecholamine and decreases the 
serotonin content of the nerve centers.  
 
Strophanthus gerrardii Stapf 
Ubuhlungubendlovu (Z) - consists 
of ubuhlungu (‘pain’) and 
bendlovu (‘of the elephant’) 
Perennial. Climber. Ht 2–12 m. Alt 20–
550 m. M, S, KZN 
039 Species known as ubuhlungu(b)endlovu are reported to be used for 
hysteria (DOKE and VILAKAZI, 1972), Fruit is also used as traditional 
medicine (CUNNINGHAM, 1988). 
Strophanthus petersianus  
Klotzch 
Syn: S. grandiflorus (N.E.Br.) Gilg 
Perennial. Shrub, climber. Ht 2–15 m. Alt 
20–975 m. LIM, KZN 
040 Unspecified parts are used by herbalists as a charm against evil (method 
of administration unknown) (WATT and BREYER-BRANDWIJK, 
1962).  
Strophanthus speciosus (Ward & 
Harv.) Reber 
Perennial. Shrub, climber. Ht 0.9–12 m. 
Alt 50–1750 m. LIM, M, KZN, EC 
041 Reported to be used by Xhoza to ‘render someone awe-inspiring 
(isitunzi)’ (SIMON and LAMLA, 1991) 
 
Wrightia natalensis Stapf 
Perennial. Tree, shrub. Ht 1.6–18 m. Alt 
20–1250 m. LIM, S, KZN 
 
042 Roots and bark are used as an aphrodisiac by the Vhavenda 
(MABOGO, 1990). 
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AQUIFOLIACEAE 
Ilex mitis (L.) Radlk. var. mitis 
Syn: I. capensis Sond. 
African/Cape holy 
Perennial. Tree or shrub. Ht 3–30 m. Alt 
10–2130 m. LIM, NW, G, M, S, FS, KZN, 






In Lesotho diviners use plants (parts and administration not specified) in 
protective rituals to protect patients from sorcery (WATT and BREYER-
BRANDWIJK, 1962). 
ARACEAE 
Acorus calamus L. 





Ground rhizomes are used for nervous disorders (PUJOL, 1990), they 
are also reported to be ground and mixed with dagga (Cannabis sativa 
L.) by dagga smokers to mask the distinctive smell (HUTCHINGS et al., 
1996), they are widely used as tonics and stimulants (HUTCHINGS et 
al., 1996), rhizomes are reported to be bitter and have eupeptic, 
antithermic, emmenagogic and tranquillizing  effects (CHIEJ, 1984), 
rhizomes and roots have s dative and analgesic properties (WATT, 
1967, LEWIS and ELVIN-LEWIS, 1977), hallucinogenic effects and 
narcotic effects on cobras are also reported (HUTCHINGS et al., 1996). 
Asarone (chemically similar to mescaline) and β-asarone (chemically 
similar to myristicin and kava alkaloids) are presumed to be active 
hallucinogenic principles (LEWIS and ELVIN-LEWIS, 1977).  
ARALIACEAE 




Unspecified groups in Malawi ingest leaf infusions, together with leaves 
of Ipomoea batatas (Convolvulaceae) and Musa species to treat 
madness (GELFAND et al., 1985). Cussonia arborea is not found in 
South Africa. 
 
Cussonia longissima Hutch. & 
Dalz.. 
046 In Ghana, unspecified parts are used to treat convulsions in children 
(IRVINE, 1961). The Sotho people use leaf decoctions together with 
other unspecified pants to treat mental disease (WATT and BREYER-
BRANDWIJK, 1962). 
 
Cussonia paniculata Eckl & 
Zeyh.. 
047 In southern Africa, theSotho use a decoction of the leaves together with 
other unspecified plants to treat early mental illness (WATT and 
BREYER-BRANDWIJK, 1962; VAN WYK and GERICKE, 2000).  
There are two sub species, C. paniculata Eckl. & Zeyh. subsp. 
paniculata (Perennial. Tree. Ht 1–4 m. Alt 300–2000 m. KZN, NC, WC, EC), C. 
paniculata Eckl. & Zeyh. subsp. sinuata (Reyneke & Kok) De Winter 
(Perennial. Tree. Ht 2–5 m. Alt 900–1980 m. B, LIM, NW, G, M, S, FS, KZN, L). 
 
Cussonia spicata Thunb. 
 
Perennial. Tree. Ht 3–17 m. Alt 5–1800 m. 
LIM, NW, G, M, S, KZN, L, WC, EC 
 
048 Root bark decoctions are administered for mental illness in Tanzania 
(CHHABRA et al., 1984). The bark is used for ‘magical’ purposes in 
South Africa (HUTCHINGS et al., 1996) and in Tzanee, South Africa 
healers use it to treat a “mind that goes bad” (SOBIECKI, 2002). 
 
Schefflera umbillifera (Sond.) 
Baill. 
Syn: Cussonia chartacea Schinz, Cussonia 
umbellifera Sond.  
Perennial. Tree. Ht 3–15 m. Alt 60–1980 
m. LIM, M, S, KZN, EC 
 
049 Leaves have been used for rheumatism, colic and to treat insanity in 
unspecified parts of southern Africa (WATT and BREYER-
BRANDWIJK, 1962). 
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ASCLEPIADACEAE 
Cynanchum obtusifolium L.f. 
Syn: C. capense R.Br., C. dregeanum 
Decne., Cynoctonum brownii Meisn. 
Perennial. Climber. Ht 2–10 m. Alt 0–250 





Root and leaf infusions are taken by Zulu as emetics for illnesses (details 




Syn: Asclepias brasiliensis (E.Fourn.) 
Schltr., Asclepias physocarpa (E.Mey.) 
Schltr., G. brasiliensis E.Fourn., G. 






051 Leaves used to ‘strengthen body’ (PUJOL, 1990), powdered leaf is used 
as sedative (VAN WYK and GERICKE, 2000). The root of Asclepias 
lineolata Schltr is used in Zambia as a narcotic to catch wild birds 
(GILGES, 1953). 
 
Annual or perennial. Herb. Ht 1–2.5 m. Alt 30–700 (–900) m. LIM, NW, M, S, KZN, WC, 
EC 
 
Pachycarpus asperifolius Meisn. 
Syn: Asclepias valida (Schltr.) Schltr., 
Gomphocarpus asperifolius (Meisn.) 
Walp., Gomphocarpus validus Schltr., P. 
inconstans N.E.Br., P. validus (Schltr.) 
N.E.Br. 
 
052 Underground parts (tubers) are dried and powdered and taken as snuff 
for headaches and to treat hysteria by the Xhosa (HUTCHINGS et al., 
1996). 
 
Perennial. Geophytic herb. Ht 0.3–1.1 m. Alt 60–1700 m. LIM, G, M, S, KZN, EC 
 
Secamone gerrardii Harv. ex 
Benth. 
053 The Zulu are report to treat ‘spinal disease’ with powdered roots of S. 
gerrardii that are mixed in a complex formula reported to contain 
Pterocelastrus rostratus Walp., Ocotea bullata (Burch.) Baill., 
Sarcophyte sanguinea Sparrm. or Hydnora sp. together with the dried 
body of a fruit bat. This mixture is rubbed into incisions made along the 
affected part (BRYANT, 1966; HUTCHINGS et al., 1996). 
 
Sisyranthus huttoniae (S. Moore) 
S. Moore 
054 Medicinal usage related to ‘ancestral’ spirits (HUTCHINGS et al., 
1996). 
 
Sisyranthus trichostomus K. 
Schum. 
055 Root and leaf infusions taken by Zulu as emetics to prevent bad dreams 
(HULME, 1954). 
 
Stapelia gigantea N.E. Br. 
Syn: S. cyclista C.A.Lückh., S. gigantea 
N.E.Br. var. pallida E.Phillips, S. 
marlothii N.E.Br., S. nobilis N.E.Br., S. 
youngii N.E.Br. 
ililo elikhulu (Z)  
-lilo  (n) lamentation,  
khulu (adj) large 
 
056 Hot stem infusions are administered by Zulu healers as emetics to treat 
hysteria (BRYANT, 1966). An unidentified plant called uzililo (Z), 
which is most likely Stapelia spp. or Huernia hystrix, is used by Zulu to 
treat mental disorders. Plants are reputed by Zulu to be used to prepare 
a medicine capable of causing death (HULME, 1954). Anthraquinones 
have been reported (WATT and BREYER-BRANDWIJK, 1962).  
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Xysmalobium undulatum (L.) 
Aiton.f. 
ishongwane (fruit, Z), ishongwe 
(X, Z), uzara, milkweed (E) 
057 Roots administered in the Transkei by Xhosa to treat hysteria 
(HUTCHINGS et al., 1996). Roots contain several glycosides, and 
extracts have exhibited weak CNS depressant and antidepressant 
activity (HUTCHINGS et al., 1996). Leaf extracts exhibited SSRI 
(antidepressant) activity (NIELSEN et al., 2003). 
 
Two Subspecies: 
X. undulatum (L.) Aiton f. var. ensifolium Burch. Ex Scott-Elliot 
Syn: X. ensifolium (Burch. ex Scott-Elliot) N.E.Br. 
Perennial. Geophytic herb. Ht ± 1 m. Alt 1000–1300 m. N, B, NW, FS, NC, EC 
X. undulatum (L.) Aiton f. var. undulatum 
Syn: Asclepias undulata L., Gomphocarpus undulatus (L.) Schltr. X. ambiguum N.E.Br., X. 
amplifolium Weim. X. dilatatum Weim., X. lapathifolium K.Schum., not of Decne., X. 
leucotrichum (Schltr.) N.E.Br., X. prismatostigma K.Schum.  
Perennial. Geophytic herb. Ht 0.5–1.8 m. Alt 80–2000 m. N, B, LIM, NW, G, M, S, FS, 





Asparagus virgatus Baker 
Syn: Protasparagus virgatus (Baker) 
Oberm. 
iphinganhloya (Z) - means what 
suppresses the ill-omen, it is used 
as a protective charm to ward off 





Roots of an unidentified species are burned, the as powdered and placed 
in incisions for febrile convulsions in Zimbabwe (CHINEMANA et al., 
1985). A. africanus Lam. (Syn: Protasparagus africanus (Lam.) Oberm.) is used 
to treat mental illness and disturbances in east Africa (KOKWARO, 
1976). The Zulu name iphinganhloya means what suppresses the ill-








The nectar is said to be narcotic and to produce weakness of the joints if 
injested in large quantities (WATT and BREYER-BRANDWIJK, 1962). 
 
Anthericum species 
Now Chlorophytum Ker Gawl. 
(Anthericaceae) see Chlorophytum 
blepharophyllum Bak.below 
inkomfe yentaba (Z) 
060 A decoction of an Anthericum species is a remedy for hysteria among 
the Southern Sotho (WALKER, 1996). 
 
Bulbine frutescens (L.) Willd. 
Syn: Anthericum frutescens L., 
Anthericum fruticosum Salisb., 
Anthericum incurvum Thunb., Anthericum 
rostratum Jacq. B. caulescens L., B. 
rostrata Willd. (B. triebneri Dinter  
Perennial. Dwarf shrub, succulent. Ht 
300–800 mm. Alt 5–2285 m. N, G, S, FS, 
KZN, L, NC, WC, EC 
 
ibhucu (Z) 
bhucu (ideo) of rotting,  
-bhucu (isi- izi-) (n) rotten matter 
 
061 Root and leaf infusions are administered by Zulu healers as emetics to 
patients thought to be going mad as a result of being bewitched 
(HULME, 1954). 
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Bulbine latifolia (L.f.) Roem. & 
Schult. 
Syn: Anthericum latifolium L.f. (B. 
brunsvigiaefolia Baker, B. ensifolia Baker, 
B. natalensis Baker, B. transvaalensis 
Baker  
Perennial. Herb, geophyte, succulent. Ht 
250–910 mm. Alt 35–1405 m. G, KZN, 
WC, EC 
ibhucu (Z) 
062 Decoctions are taken by groups of Zulu men and adolescents as emetics 
in purification rites aimed at preventing ‘anti-social behaviour’ 
(HUTCHINGS et al., 1996). Xhosa use underground organs (tubers) to 
make decoctions used to treat convulsions in children (BROSTER, 
1982; PUJOL, 1990). The root is boiled in water for a few minutes and 
the infusion taken in small doses twice daily, two teaspoons for 




063 The Shona prepare an ointment made from the root that is applied to the 
face for the treatment of madness (GELFAND et al., 1985). 
 
Gasteria croucheri (Hook.f.) 
Baker 
Syn: Aloe croucheri Hook.f., G. disticha 
(L.) Haw. var. natalensis Baker, G. 
ensifolia Haw.  
impundu (Z)  
Perennial. Herb, succulent. Ht 0.25–0.6 m. 
Alt 0–1000 m. KZN, EC 
 
064 Used to treat girls with ysteria in South Africa (HULME, 1954). 
Impundu (Z) – (n) gatepost, bulbous roots are placed between the 
gateposts at the kraal entrance to cause forgetfulnss i  evil-doers. 
ASTERACEAE 
Achyrocline stenoptera (DC.) 
Hilliard & Burtt 





Inhaled by the Zulu diviners (izangoma) to induce trances 
(HUTCHINGS et al., 1996). Used in a similar way as many Helichrysum 
species as imphepho, where the leaves and stems are burned to invoke 
the goodwill of the ancestral spirits (HUTCHINGS et al., 1996). 
 
Arctotheca calendula (L.) Levyns 066 Unspecified groups in Southern Africa use the juice from this plant as an 
antidote to strychnine (WATT, 1967). Narcotic effects have been 
observed in rabbits (VAN DER WALT and STEYN, 1940). 
 




067 Leaf juice is a Xhosa treatment for epilepsy in South Africa (WATT and 
BREYER-BRANDWIJK, 1962). 
 
Aspilia pluriseta Schweinf. 
mukushamvura (Sh) 
 
068 In Zimbabwe the root is burned and the smoke inhaled to treat delirium  
(GELFAND et al., 1985). 
 
Aster bakeranus Burtt Davy ex 
C.A. Sm. 
Syn: A. asper J.M.Wood & M.S.Evans, A. 
bakerianus Burtt Davy ex C.A.Sm. subsp. 
albiflorus Lippert, A. bakerianus Burtt 
Davy ex C.A.Sm. subsp. angustifolius 
Lippert, A. bakerianus Burtt Davy ex 
C.A.Sm. subsp. intermedius Lippert, A. 
bakerianus Burtt Davy ex C.A.Sm. subsp. 
ovalis Lippert, A. bakerianus Burtt Davy 
ex C.A.Sm. subsp. septentrionalis Lippert, 
A. grauii Lippert A. hispidus (Thunb.) 
Baker, Calendula hispida Thunb., 
Diplopappus asper Less., Diplopappus 
natalensis Sch.Bip., Felicia asper Burtt 
Davy 
 
phoa (S); noxgxekana (X); 
udlatshana, umaqhunsula, 
umhlungwana (Z) 
069 Roots of the plant known as udlutshane and reported to be A. bakeranus 
are used by Zulu people to treat psychiatric disturbances 
(HUTCHINGS et al., 1996). 
 
Perennial. Herb. Ht 0.1–0.75 m. Alt 10–2285 m. G, M, S, FS, KZN, L, EC 
 
Similar species: A. harveyanus Kuntze 
Syn: A. harveyanus Kuntze subsp. corymbosus Lippert, A. harveyanus Kuntze subsp. 
gracilis Lippert, A. harveyanus Kuntze subsp. robustus Lippert, A. harveyanus Kuntze 
subsp. xylophyllus (Klatt) Lippert, A. serrulatus Harv. var. xylophyllus Klatt, A. xylophyllus 
Klatt, Diplopappus serrulatus Harv., Felicia serrulata (Harv.) Burtt Davy 
 
Perennial. Herb. Ht 0.1–1 m. Alt 60–2075 m. LIM, NW, G, M, S, KZN, EC 
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Athrixia heterophylla (Thunb.) 
Less. 
070 Early record of root decoctions together with Anemone caffra 
(Ranunculaceae) being used in South Africa to treat mental disease 
(SMITH, 1888). 
 
Berkheya discolor (DC.) O. 
Hoffm. & Muschl. 
Syn: B. kuntzei O.Hoffm., B. 
microcephala (DC.) R.A.Dyer, B. 
polyacantha S.Moore, B. spinulosa 
N.E.Br., Stobaea acarnoides DC., Stobaea 
discolor DC., Stobaea microcephala DC. 
 
071 In Lesotho a decoction of unspecified parts, most likely leaves, is used to 
pacify nervous patients (JACOT GUILLARMOD, 1971). 
 
Perennial. Herb. Ht 0.3–0.9 m. Alt 460–2045 m. NW, FS KZN, L, EC 
 
Blumea alata (D. Don) DC. 
rutapatsikidzi (Sh) 
 
072 Leaves are used in Zimbabwe for enemas to treat convulsions 
(GELFAND et al., 1985). 
 
Brachylaena elliptica (Thunb.) 
DC. 
igqeba elimnyama/isiduli (selathi) 
(Z) 
 
073 Roots are used by Zulu healers as a substitute for the roots of Vernonia 
neocorymbosa (Asteraceae), which are used to treat hysterics 
(GERSTNER, 1939; HUTCHINGS et al., 1996). 
 
Callilepis laureola DC. 
amafuthomhlaba, ihlamvu, impila 
(Z) 
Syn: C. glabra DC., C. hispida DC., C. 
laureola DC. var. glabra (DC.) Harv., C. 
laureola DC. var. hispida (DC.) Harv. 
 
Perennial. Herb. Ht 0.3–1 m. Alt 0–2150 
m. M, S, FS, KZN, EC  
074 The Zulu use the toxic root as a protective ‘charm’ which is placed 
under the pillow to stop bad dreams (HUTCHINGS et al., 1996). Root-
stock is toxic and can be fatal if ingested even in small quantities; some 
symptoms include confusion and convulsions (VEALE, 1987). 
 
Cenia sericea DC. 
Syn:Cotula sericea L.f. 
Perennial. Suffrutex. Ht 0.05–0.3 m. Alt 
3–200 m. WC, EC 
 
075 Used in the eastern Cape region of South Africa to ssist with restful 
sleep and to break high fever (BATTEN and BOKELMANN, 1966). 
 
Chrysanthemoides monilifera 




076 In Lesotho, leafy branches are burned as a cure in the huts of mad men 
(JACOT GUILLARMOD, 1971).  
Several subspecies: 
C. monilifera (L.) Norl. subsp. canescens (DC.) Norl. 
Syn: Osteospermum pisiferum L. var. canescens DC. 
Perennial. Shrub, succulent. Ht 0.3–3.65 m. Alt 765–2210 m. M, FS, KZN, L, EC 
C. monilifera (L.) Norl. subsp. monilifera 
Syn: Lepisiphon dentatus Turcz., Osteospermum moniliferum L.
Perennial. Shrub, succulent. Ht 0.1–3 m. Alt 5–1760 m. WC, EC 
C. monilifera (L.) Norl. subsp. pisifera (L.) Norl. 
Syn: C. pisiformis Medik., Osteospermum moniliferum L. var. pisiferum (L.) Harv., 
Osteospermum pisiferum L.
Perennial. Shrub, succulent. Ht 0.3–3 m. Alt 5–1370 m. NC, WC, EC 
C. monilifera (L.) Norl. subsp. rotundata (DC.) Norl. 
Syn: Osteospermum moniliferum L. var. rotundatum (DC.) Harv., Osteospermum 
rotundatum DC. 
Perennial. Shrub, succulent. Ht 0.25–3 m. Alt 5–500 m. KZN, EC 
C. monilifera (L.) Norl. subsp. septentrionalis Norl. 
Syn: Osteospermum moniliferum L. forma foliis-subintegris Engl. 
Perennial. Shrub, succulent. Ht 0.5–3 m. Alt 1200–2400 m. LIM 
C. monilifera (L.) Norl. subsp. subcanescens (DC.) Norl. 
Syn: Osteospermum moniliferum L. var. angustifolium DC., Osteospermum subcanescens 
DC. 
Perennial. Shrub, succulent. Ht 1–3 m. Alt 15–1219 m. WC, EC 
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Cineraria aspera Thunb. 
moholu-oa-pela (S) 
Annual, occ. perennial. Herb or suffrutex. 
Ht 0.15–1.5 m. Alt 1200–2500 m. NW, G, 
M, FS, KZN, L, NC, WC, EC 
 
077 In Lesotho the leaves are smoked to treat respiratory pr blems, and are 
said to be as intoxicating as Cannabis (PHILIPS, 1917; JACOT 
GUILLARMOD, 1971). 
 
Conyza scabrida DC. 
Syn: Baccharis ivaefolia L., C. ivifolia 
(L.) Less., Pluchea scabrida DC. 
uhlabo (Z) 
Perennial. Shrub. Ht 0.38–1.2 m. Alt 5–
1920 m. N, B, LIM, NW, G, M, S, FS, 
KZN, L, NC, WC, EC 
 
078 Early records in South Africa suggest that leaf decoctions are 
administered to children suffering from convulsions (SMITH, 1895).  
 
Dicoma anomala Sond. 
Two subspecies: 
D. anomala Sond. subsp. anomala 
Perennial. Herb, prostrate. Length up to 
0.3 m. Alt 152–2200 m. LIM, NW, G, M, 
S, FS, KZN, L, EC 
D. anomala Sond. subsp. gerrardii (Harv. 
ex F.C.Wilson) S.Ortíz & Rodr.Oubiña 
Perennial. Herb. Ht 0.10.4 m. Alt up to 
2335 m. N, B, LIM, NW, G, M, S, FS, 
KZN, NC 
 
079 Unspecified parts are used for treating hysteria in South Africa 
(LAYDEVANT, 1932). In Zimabawe and South Africa, the root has a 
great reputation as a panacea (VAN WYK and GERICKE, 2000). 
 
Dicoma shinzii O. Hoffm. 
Syn: D. arenicola Muschl. ex Dinter, D. 
lanata Muschl. ex Dinter  
Perennial. Herb, prostrate. Length up to 
0.3 m. Alt 550–1900 m. N, B, LIM, NW, 
FS, NC 
 
080 Used to treat febrile convulsions (referred to as ‘arm movements’ 
possible the result of a fever) in children by the San in the Kalahari 
(VAN WYK and GERICKE, 2000). 
 
Ethulia conyzoides L. f. 081 Unspecified parts are used by Zulu to treat m dness (BRYANT, 1966; 
DOKE and VILAKAZI, 1972) 
 
Helichrysum aureonitens Sch. 
Bip. 
Syn: H. helodes Hiern 
impepho-emhlophe (Z)  
- white Helichrysum  
inkondlwane (Z) a plant used by 
the Zulu to make fires 
082 Leaves and stems are widely used as incense to invoke the goodwill of 
the ancestors and in other forms of traditional medicine (HUTCHINGS 
et al., 1996). ‘They are probably used by the izangoma (Zulu diviners) to 
induce trances’ (HUTCHINGS et al., 1996). The ‘white’ (emhlophe) in 
the Zulu name does not refer to the colour of any part of the plant itself, 
but rather to the clarity of thought brought about by using this plant in 
divination . Several species have shown other biological activities, 
MEYER, et al. (1996) has shown th.inhibition of herp s simplex virus 




NOTE: this is a large genus (± 
600 species) mainly found in 
Africa. Approx. 244 species are 
found in South Africa. 
083 Imphepho (Z) can refer to H. decorum DC., H. epapposum Bolus (Syn: 
H. flavum Burtt Davy, H. inerme Moeser excl. var. brachycladum 
Moeser), H. gymnocomum DC., H. natalitum DC., H. nudifolium (L.) 
Less., H. odoratissimum (L.) Sweet (Syn: Gnaphalium odoratissimum 
L.) or H. stenopterum DC. (Achyrocline stenoptera (DC.) Hilliard & 
B.L.Burtt). All of these are used as incense to invoke the goodwill of the 
ancestors (HUTCHINGS et al., 1996).  H. herbaceum (Andrews) 
Sweet (Syn: H. squamosum of authors, not of (Jacq.) Thunb., 
Xeranthemum herbaceum Andrews) is refered to as imphepho-
yamakhosi ‘the Helichrysum of ancestral spirits’, and is used as other 
imphepho (HUTCHINGS et al., 1996).  
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Helichrysum odoratissimum (L.) 
Sweet 
084 Leaves and stems are widely used as incense to invoke the goodwill of 
the ancestors and in other forms of traditional medicine (HUTCHINGS 
et al., 1996); The smoke is reportedly sedative, and helpful for 
insomnia. The smoke from H. foetidum (L.) Moench and H. 
stenopterum DC. are inhaled by healers in KwaZulu- Natal to induce a 
trance (VAN WYK and GERICKE, 2000). 
 
Launaea nana (Bak.) Chiov. 
Syn: Lactuca nana Baker 
Perennial. Herb. Ht up to 0.05 m. Alt 500–
800 m. LIM, M, KZN 
 
085 The Shona of Zimbabwe use the roots in a body wash as well as applying 
them to incisions made on the forehead to treat convulsions (GELFAND 
et al., 1985). This species is not found in South Africa. 
 
Lopholaena coriifolia (Sond.) 
E.Phillips & C.A.Sm. 
Syn: L. bainesii (Oliv. & Hiern) S.Moore, 
L. randii S.Moore, Othonna coriifolia 
Sond.  
 
086 The Shona of Zimbabwe apply the roots to incisions made on the 
forehead to treat convulsions (GELFAND et al., 1985). 
 
Perennial. Shrub, succulent. Ht 0.3–2 m. Alt 765–1830 m. LIM, NW, G, M, S 
 
Oncosiphon piluliferum (L.f.) 
Källersjö 
Syn: Cotula globifera Thunb., Cotula 
pilulifera L.f., Matricaria globifera 
(Thunb.) Fenzl ex Harv., Matricaria 
pilulifera (L.f.) Druce Pentzia globifera 
(Thunb.) Hutch., Pentzia pilulifera (L.f.) 
Fourc., Tanacetum obtusum Thunb.  
 
087 Reported used as part of a European remedy for treating convulsions in 
the cape of South Africa (Watt, 1967). 
 
Annual. Herb. Ht 0.1–0.6 m. Alt 8–1645 m. NW, G, M, FS, KZN, L, NC, WC, EC 
 
Oncosiphon suffruticosum (L.) 
Källersjö 
Syn: Cotula tanacetifolia L., Matricaria 
multiflora Fenzl ex Harv., Pentzia 
suffruticosa (L.) Hutch. ex Merxm., 
Pentzia tanacetifolia (L.) Hutch., 
Tanacetum suffruticosum L.  
 
088 Used by unspecified groups in South Africa to treat infantile convulsions 
(VAN WYK and GERICKE, 2000). Fresh plant material tha  is crushed 
with Exomis microphylla (Chenopodiaceae) or Ruta graveolens 
(Rutaceae, wynruit (A)) to treat infantile convulsions (VAN WYK and 
GERICKE, 2000). 
 
Annual. Herb. Ht 0.1–0.6 m. Alt 15–1500 m. N, NC, WC 
Printzia pyrifolia Less. 
Perennial. Shrub. Ht 0.9–1.6 m. Alt 600–
1700 m. FS, KZN, L, EC 
 
090 Roots are used by Zulu healers as a substitute for the roots of Vernonia 
neocorymbosa, which are used to treat hysterics (GERSTNER, 1939; 
HUTCHINGS et al., 1996) 
 
Senecio discodregeanus Hilliard 
& B.L.Burtt. 
Syn: S. dregeanus DC. var. discoideus 
DC.  
 
091 Unspecified parts are used to treat madmen in Lesotho (PHILLIPS, 
1917; JACOT GUILLARMOD, 1971). 
 
Perennial. Herb. Ht 0.4–1 m. Alt 50–2375 m. G, M, S, F , KZN, L, EC 
Solanecio angulatus (Vahl) C. 
Jeffrey 
Syn: Crassocephalum bojeri (DC.) 
Robyns, Crassocephalum subscandens 
(A.Rich.) S.Moore 
 
092 The whole plant is boiled in water and the resultant infusion is drunk to 
treat madness in Zimbabwe (GELFAND et al., 1985). 
 
Perennial. Shrub, climber, succulent. Ht up to 30 m. Alt 10–945 m. LIM, KZN 
 
*Tagetes minuta L. 
Annual. Herb. Ht up to 3 m. Alt 14–2125 
m. N, B, LIM, NW, G, M, S, FS, KZN, L, 
WC, EC 
 
094 The leaves together with Kalanchoe brachyloba (Crassulaceae) and 
Mentha aquatica (Lamiaceae) are burnt and the smoke inhaled for 
mental illness in Venda, South Africa (ARNOLD and GULUMIAN, 
1984). 
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Tarchonanthus camphoratus L. 
Syn: T. abyssinicus Sch.Bip. ex Schweinf. 
& Asch., T. camphoratus L. var. 
litakunensis (DC.) Harv., T. litakunensis 
DC., T. procerus Salisb 
Perennial. Tree or shrub. Ht 1–8 m. Alt 
750–2135 m. N, B, LIM, NW, G, M, FS, 
NC 
 
095 Dried leaves are reported to have slightly narcotic effects when smoked 
(WATT and BREYER-BRANDWIJK, 1962). Smoking the dried leaves 
in a pipe is sedative (VAN WYK and GERICKE, 2000). 
 
Vernonia adoensis Sch. Bip. ex 
Walp.  
096 The root is chewed to treat madness in Ndebele of Zimbabwe 
(GELFAND et al., 1985) 
 
Vernonia amygdalina Del. 097 Malawian women who want their beer to be ‘strong’ are said to fortify it 
by rubbing the inside of the pots used to brew the be r with leaves of V. 
amygdalina. This is reported to make the beer more intoxicating 
(WILLIAMSON, 1974). 
 
Vernonia neocorymbosa Hilliard 098 Roots are used to treat hysteria by Zulu (GERSTNER, 1939). Macerated 
leaves are used for treating epilepsy by the Swazi (WATT and 
BREYER-BRANDWIJK, 1962).  
 
BALANITACEAE 




Roots and bark are ingredients in infusions used in important protective 
rituals  against evil spirits by Zulu traditional healers (PALMER and 
PITMAN, 1972). Froth from the infusions is licked from a bowl, without 
the use of the hands, three times a day. The remainder s thrown of the 
roof or spilled at the entrance. Bark infusions are said to make a 
stimulating and exhilarating bath (HUTCHINGS et al., 1996; COATES 
PELGRAVE, 2002) 
BEGONIACEAE 




The Zulu are reported to take B. homonyma Steud. root decoctions to 
counteract idliso (poison believed to be administered in food) 
(HUTCHINGS et al., 1996). Several species including B. sutherlandii 
Hook. f. are used as protective charms and detect threats to the kraal. 
These may or may not be ingested (HUTCHINGS et al., 1996). 
BIGNONIACEAE 
Markhamia obtusifolia (Bak.) 
Sprague 
Syn: Dolichandrone obtusifolia Baker, as 
‘Dolichandra’ 
 
Perennial. Shrub or tree. Ht 0.6−15 m. Alt 





The roots are used for children with convulsions in East Africa and 
Malawi (WILLIAMSON, 1974). 
 
Tecoma capensis (Thunb.) Lindl. 
Syn: Bignonia capensis Thunb., 
Gelseminum capense (Thunb.) Kuntze, 
Tecomaria capensis (Thunb.) Spach, 
Tecomaria krebsii Klotzsch, Tecomaria 
petersii Klotzsch 
 
Perennial. Shrub, scrambler or small tree. 
Ht 0.5−7.5(–10) m. Alt 15−1645 m. LIM, 
M, S, KZN, WC?, EC 
 
102 Dried powdered bark infusions are taken for sleeplessness (ROBERTS, 
1990); reported to induce sleep (HUTCHINGS et al., 1996). 
 
Note: the sinking of Tecomaria under Tecoma is questionable and a close study of the two 
genera is needed. Recent authors vary in their use of th  two names (GERMISHUIZEN and 
MEYER, 2003). 
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BOMBACEAE 
Adansonia digitata L. 
Perennial. Tree. Ht 3–18 m. Alt 100–1060 





Bark, leaves and roots are infused with the whole plant of Myrothamnus 
flabellifolius Welw. and the preparation is ingested to treat madness by 
the Shona of Zimbabwe (GELFAND et al., 1985). 
BORAGINACEAE 
Lithospermum cinereum A.DC. 
Perennial. Herb. Ht 0.1–0.3 m. Alt 1020–





The plant is used as a sedative by the Sotho (ASHTON, 1943). Details 
of the administration were not given. 
 
Myosotis afropalustris C.H. 
Wright 
lephukhuphukhu (Z) –
phukuphuku (isi- izi-) (n) foolish 
person 
Perennial. Herb. Ht up to 0.5 m. Alt 1800–
3200 m. FS, KZN, L, EC 
 
105 Zulu make decoction from the whole plant to treat hysteria, a cupful is 
administered daily or every second day for a month (WATT and 
BREYER-BRANDWIJK, 1962). Other ingredients may include 
Agapanthus africanus, Cissus, Galium and Clematis species. Similar 
decoctions are used by the Sotho for treating hysteria and also in the 
training of healers to develop memory and make initiates (ithwasa) 
mentally fit for their work (WATT and BREYER-BRANDWIJK, 1962). 
 
Trichodesma physaloides (Fenzl) 
A.DC. 
Syn: Friedrichsthalia physaloides Fenzl, 
T. droogmansianum De Wild. & 
T.Durand, T. glabrescens Gürke, T. 
ringoetii De Wild. 
 
106 The tubers are boiled and the stem inhaled to treat madness by the 
Shona of Zimbabwe (GELFAND et al., 1985). 
 
Perennial. Herb. Ht up to 0.5 m. Alt 610–1980 m. LIM, G, M, S, KZN 
 
BUXACEAE 





Unspecified parts are used in a vapour bath to treat m ntal illness in 
southern Africa (SIMON and LAMLA, 1991). Buxamine-B and 
buxamine-C (below), isolated from Pakistan species Buxus papillosa and 
Buxus hyrcana species, have been found to inhibit AChE 
noncompetitively in a concentration dependent fashion. The IC50 values 
of buxamine-B and buxamine-C were 74 and 7.5 µM, respectively 
(ATTA-UR-RAHMAN et al., 2001; 2004; KHALID et al., 2004).  
 
Buxamine-B: R1 = H, R2 = CH3 
Buxamine-C: R1 = CH3, R
2 = H 
CAMPANULACEAE 
Wahlenbergia grandiflora V. 
Brehm. 
ushayindoda omhlope (Z) –shaya 
(v) strike or punish, -doda (n) 






Roots are chewed by Zulu boys as a protective charm to make them 
invisible when they have let the cattle stray (HULME, 1954). The 
powdered roots of W. undulata (L. f.) A. DC. which is similar in 
appearance is traditionally used by Zulu warriors as pre-battle washes 
(HULME, 1954). 
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CANNABACEAE 




Widely used in traditional medicine throughout the world. Decoctions 
are sometimes taken for hypertension, epilepsy (HUTCHINGS et al., 
1996); reported to be used as an analgesic and hypnotic i  the treatment 
of depressive mental conditions (OLIVER-BEVER, 1986); and also as a 
sedative in equine colic (MERCK, 1989); smoking or ingestion of the 
drug produces a state of euphoria followed by intellectual excitement, 
illusions, hallucinations, inco-ordination of movemnt and drowsiness 
(OLIVER-BEVER, 1986). Has been used in Europe and America to treat 
epilepsy (FORMUKONG et al. 1989). 
CANELLACEAE 
Warburgia salutaris (Bertol.f.) 
Chiov. 
Syn: W. breyeri Pott 
Perennial. Tree, shrub. Ht 2.5–10 m. Alt 




Bark is used in emetics or purgatives for febrile complaints and for 
rheumatism or the ailments known as isibhobo (-bhobo (Z) (n) sharp 
pain in chest) or amanxeba (-nxeba (Z) (n) wound), which are 
traditionally thought to be caused be sorcery (HUTCHINGS et al., 1996) 
CAPPARACEAE 
Bosica albitrunca (Burch.) Gilg 
& Ben. 
umlalampisi (Z)  
–lala (n) sleep, lie down;  





Known as fructus simulo, the unripe fruit is used to treat epilepsy in 
southern Africa (WATT, 1967; VAN WYK and GERICKE, 2000). The 
Zulu are reported to use this plant for magical purposes (POOLEY, 
1993). 
 
Cadaba natalensis Sond. 
amangwe (-emnyama) (Z)  
ngwe (n) leopard  
–nyama (n) darkness, ill omen 
 
112 Black powder from the burnt plant is used by the Zulu as an inoculation 
against ukugcucaba and ukucinda (evil spirts) (HUTCHINGS et al., 
1996). 
Capparis sepiaria L. 
usondeza (Z)  
–sondeza (v) bring close 
113 Xhosa herbalists use root decoctions administered as emetics as 
protective measures to counteract witchcraft  or render its users, such as 
soldiers and others wishing to escape detection, invisible (WATT and 
BREYER-BRANDWIJK, 1962). Traditional Zulu application for 
protection against lightning and to ward off evil (POOLEY, 1993). 
 
Capparis tomentosa Lam. 114 Unspecified parts are a Zulu application used to treat madness, as love 
charm emetics and also as charms against lightning or misfortune 
(GERSTNER, 1941), similar to C. sepiaria. Infusions of root are 
administered for a treatment of madness by the Wemba (WATT and 
BREYER-BRANDWIJK, 1962; HUTCHINGS et al., 1996). The Xhosa 
also use this plant to treat madness (PUJOL, 1990). According to 
PUJOL (1990) this is also the first plant Zulus turn to ‘in order to 
eradicate germs’ after a person has passed away. In these circumstances 
they will cook the root bark in the house and let it soak for several days 
and then the whole family will take two cups of this mixture per day. 
 
Maerua angolensis DC. 115 In South Africa the Venda use the leaves and bark which are heated over 
a fire, without water, and the resultant vapour or steam is inhaled to treat 
children with convulsions (MABOGO, 1990; VENTER, 1996). 
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CARYOPHYLLACEAE 
Dianthus crenatus Thunb. 
iningizimu (Z)  
–ningi (n) the greater number, 
many;  
–zimu (n) cannibal; zimu (ideo) of 
becoming stout 






Cold water infusions are taken as emetics by Zulu diviners to clear their 
vision and sharpen their divining faculties (HULME, 1954). The root 
infusions are also taken as love charm emetics and the face is washed in 
the froth (saponins?) that the infusion produces when whisked 
vigorously (HULME, 1954; WATT and BREYER-BRANDWIJK, 
1962). 
Silene burchellii Otth 117 Unspecified parts are used in making various important medicines by the 
Sotho (JACOT GUILLARMOD, 1971). In unspecified parts of southern 
Africa Silene burchellii s used in tonic baths taken after severe illness 
and to combat sleepness (WATT and BREYER-BRANDWIJK, 1962). 
 
Silene capensis Ott. ex DC. 
undlela ziimhlophe (X) ‘white 
paths’ 
118 In South Africa unspecified parts are used to treat d lirium  (WATT and 
BREYER-BRANDWIJK, 1962). The Xhosa diviners use thepungent 
sweet smelling root for spiritual purposes and inducing dreams (HIRST, 
1997b). The root of undlela ziimhlophe is finely ground and mixed 
vigorously with a forked stick until it produces a white froth, most like 
caused by saponins. This is consumed by novice diviners on an empty 
stomach to enhance dreaming. The objective is to full one stomach with 
the foam to a point that causes regurgitation (HIRST, 1990; 2005).   
 
CELASTRACEAE 






These trees are believed by the Zulu to have powerful magic properties 
and unspecified parts are used to blunt the effects of evil spirits 
(PALMER and PITMAN, 1972). 
 
Catha edulis (Vahl) Forssk. ex 
Endl. 
120 Leaves and twigs that are chewed or taken as a hot infusion are a Xhosa 
treatment for stimulating the CNS (HIRST, 1997a). Bark decoctions are 
taken in southern Africa as nerve tonics (PUJOL, 1990); chewed leaves 
and twigs, and also tea from the leaves are sometimes used as timulants 
in the Cape but are more extensively used in North and East Africa and 
Arabia, where young leaves are chewed to inhibit the sensations of 
hunger and fatigue and for their stimulating effects on the CNS (WATT 
and BREYER-BRANDWIJK, 1962; IWA, 1993); Leaves are reported to 
have short lasting stimulant effects, producing a marked sustaining effect 
with release from fatigue and hunger as well as euphoric effects (WATT 
and BREYER-BRANDWIJK, 1962). Chewing a twig of about ten leaves 
produces wakefulness, mental alertness and a feeling of well-being. 
Sedative effects are produced by 50 mg but 300 - 400 mg produces 
hyperexcitability, mydriasis, spinal convulsions and death from 
respiratory paralysis. Physical dependence does not apparently occur and 
deaths are rare (DUKE, 1985). 
 
Gymnosporia species 
Refer to Maytenus 
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Hartogiella schinoides (Spreng.) 
Codd 
Cassine schinoides (Spreng.) 
R.H.Archer 
Elaeodendron schinoides Spreng., 
Hartogia angustifolia Turcz., Hartogia 
capensis L., Hartogia capensis L. var. 
lanceolata Sond., Hartogia capensis L. 
var. latifolia Sond., Hartogia capensis L. 
var. multiflora (Eckl. & Zeyh.) Sond., 
Hartogia capensis L. var. riparia (Eckl. & 
Zeyh.) Sond., Hartogia schinoides 
C.A.Sm., Hartogiella schinoides (Spreng.) 
Codd, Schrebera schinoides Thunb.  
 
Perennial. Tree, shrub. Ht 2–5 m. Alt 100–
1800 m. WC, EC 
 
121 The leaves appear to have similar stimulant activity to Catha edulis 
when chewed. Reported activities include chewing the leaf to quench 
thirst  (astringent rather than quenching, therefore a possible suppressant 
and appetite suppressent. Also used to suppress fatigue (VAN WYK 
and GERICKE, 2000) 
 
Maytenus senegalensis (Lam.) 
Excell 
Syn: Gymnosporia senegalensis (Lam.) 
Loes. 
 
122 The Shona reportedly use the root which is chewed, an  the leaves which 
are rubbed on the face, to treat pilepsy (GELFAND et al., 1985). 
COATES PALGRAVE (2002) mentions the inclusion of this plant in 
beer as an aphrodisiac.  
 
Maytenus heterphylla (Eckl. & 
Zeyh.) N.K.B. Robson 
Syn: Gymnosporia heterophylla (Eckl. & 
Zeyh.) Loes. 
 
123 In various parts of East Africa, root decoctions are taken for epilepsy 
(KOKWARO, 1976).  
 
Pleurostylia capensis (Turcz.) 
Loes 
Syn: Cathastrum capense Turcz., P. 
africana Loes.  
Perennial. Tree or shrub. Ht 2–18 m. Alt 
30–1640 m. LIM, M, S, KZN, EC 
 
124 In the cape of South Africa unspecified parts are us d to encourage sleep 
and to bring good dreams (DE JAGER, 1963). 
 
Pterocelastrus rostratus Walp. 125 Bark is used as an antidote to sorcery by Zulu (DOKE and VILAKAZI, 
1972). Roots also used in a treatment to treat spinal d sease (BRYANT, 
1966) which comprises powdered roots of Secamone gerrardii, P. 
rostratus Walp., Ocotea bullata, Sarcophyte sanguinea Sparrm. or 
Hydnora sp. together with the dried body of a fruit bat. This mixture is 
rubbed into incisions made along the affected part (BRYANT, 1966; 
HUTCHINGS et al., 1996). 
CHENOPODIACEAE 
Chenopodium ambrosiodes L. 




The leaves are used in Zimbabwe by unspecified groups to treat madness 
and convulsions (GELFAND et al., 1985). South African traditional 
healers use the plant as an intoxicating snuff which assists in 
communication with the ancestors (SOBIECKI, 2002). In Madigascar 
infusions of leaves and sap are used to treat nervous complaints 
(GURIB-FAKIM et al. 1993). 
 
Exomis microphylla (Thunb.) 127 Early accounts recall that Europeans and Africans have used a milk 
decoction of the leaf in treatments of epilepsy in South Africa (SMITH, 
1888; WATT, 1967). Refer to Oncosiphon suffruticosum (Asteraceae); 
used in a treatment for infantile convulsions, togeher with Ruta 
graveolens (Rutaceae) (VAN WYK and GERICKE, 2000). 
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CHRYSOBALANACEAE 




Root infusions taken orally and to wash the body are used by the Shona 
of Zimbabwe to treat delirium (GELFAND et al., 1985). 
CLUSIACEAE 
Hypericum perforatum L. 
(sometimes placed in HYPERICACEAE) 




This plant is indigenous to Europe, where it has a long history of use, 
particularly to treat mild depression, anxiety and sleeping-disorders 
(VAN WYK and GERICKE, 2000). There are several indigenous 
Hypericum species, H. aethiopicum Thunb., H. lalandii Choisy, H. 
natalense J.M.Wood & M.S.Evans, H. oligandrum Milne-Redh., H. 
revolutum Vahl (Syn: H. lanceolatum Lam., H. leucoptychodes Steud. ex 
A.Rich.), H. roeperianum Schimp. ex A.Rich. and H. wilmsii R.Keller. 
Although many of these are used in African medicine, none are reported 
to be used for CNS-related ailments.  
 
Harungana madagascariensis 
Lam. ex Poir.  
 
130 Leaves are used as a stimulant in Madagascar (PERNET and MEYER, 
1957). 
COMBRETACEAE 
Combretum adenogonium Steud. 
ex A. Rich. 






Unspecified parts are used in Zimbabwe for the treatm nt of convulsions 
in children (GELFAND et al., 1985). Unspecified parts of Combretum 




132 Unspecified groups in Zambia use unspecified parts to reat lunacy 
(WATT and BREYER-BRANDWIJK, 1962). 
 
Combretum molle R. Br. ex G. 
Don 
133 Roots are used for convulsions and as an aphrodisiac in Zimbabwe 
(GELFAND et al., 1985). 
 
Terminalia species 134 An emetic of roots of T. phanerophlebia Engl. & Diels and T. sericea 
Burch. ex DC. are used to cause and protect against an illness called 
amanxebha (GERSTNER, 1941; WATT and BREYER-BRANDWIJK, 
1962; HUTCHINGS et al., 1996). Traditionally believed to be caused by 
witchcraft  this ailment takes the form of a pain in the chest and 
shoulders (WATT and BREYER-BRANDWIJK, 1962). Roots f T. 
stenostachya Engl. & Diels to treat epilepsy in Zimbabwe (GELFAND 
et al., 1985). 
COMMELINACEAE 




Cold infusions are used to bathe restless sleepers, especially children 
(WATT and BREYER-BRANDWIJK, 1962); root decoctions are 
administered by Xhosa orally for fits (BOLOFO and JOHNSON, 1988; 
HUTCHINGS et al., 1996). Plants are used in decoctions with Tephrosia 
capensis (Fabaceae) for heart complaints and nervous ailments in 
Lesotho (WATT and BREYER-BRANDWIJK, 1962). 
CONVOLVULACEAE 
Astripomoea malvacea 




The roots and leaves are burned and the smoke inhaled to treat madness 
by the Shona in Zimbabwe (GELFAND et al., 1985). 
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Ipomoea obscura  
usiboniseleni (Z) – (ideo) what 
has been shown to us; used in 
traditional medicine as a 
hallucinogenic (Pooley, 2005) 
 
Ipomoea ficifolia 
ikhambilesihlungu (Z) - of 
poisonous herb; used to treat 
snake-bites. 
 
Ipomoea crassipes  
Uvimbukhalo (Z) -what blocks up 
the loins; used in traditional 
medicine to treat dysentery. 
137 Unspecified groups in Zimbabwe use I. batatas (L.) Lam . with 
Cussonia arborea in the treatment of madness (GELFAND et al., 1985). 
This tropical American ornamental climber (I. tricolor  Cav.) common in 
many gardens has been reported to be hallucinogenic when 200 to 500 
seeds are chewed in South Africa (GELFAND et al., 1985). Two to four 
seeds of I. alba L . (another tropical American species) crushed in water 
and taken at night result in vivid dreams, and the seeds of an unknown 
Convolvulaceae are used to induce dreams and communicatio  with the 
ancestors (VAN WYK and GERICKE, 2000). The root of I. ommaneyi 
Rendle is used as a decoction taken orally to treat convulsions 
(GELFAND et al., 1985) and as an infusion taken orally as an 
aphrodisiac (VAN WYK and GERICKE, 2000). The active substances 
in the seeds of various species of Ipomoea and other members of the 
Convolvulaceae are alkaloids such as ergine, lysergol, and various 
clavines which are well described hallucinogens (VAN WYK and 
GERICKE, 2000). 
CRASSULACEAE 




Fresh leaf juice used by unspecified groups in the treatment of epilepsy 
in the Cape (HUTCHINGS et al., 1996), half cup doses are taken two or 
three times a day. Also used by the Sotho for various diseases 
(unspecified) and as a protective ‘charm’. 
 
Crassula alba Forssk. 
isidwe (Z) 
139 Infusions and decoctions are used as emetics to treat hysteria by the 
Zulu (GERSTNER, 1939). 
 
Crassula arborescens (Mill.) 
Willd. 
140 There are early reports of unspecified parts being used in South Africa to 
treat epilepsy (PAPPE, 1857). 
 
Kalanchoe brachyloba Welw. ex 
Britten 
141 The leaves are used together with leaves of Tagetes minuta in the 
treatment of mental illness by the Venda (ARNOLD and GULUMIAN, 
1984). K. thyrsiflora Harv. is used by the Sotho as a charm to smooth 
away difficulties and root decoctions are administered to pregnant 
women who do not feel well (WATT and BREYER-BRANDWIJK, 
1962) 
CUCURBITACEAE 
Cucumis hirsutus Sond. 
uthangazane (Z) thanga 
‘pumpkin’ + azi ‘biggish’ + ane 
‘smallish’, i.e. a plant resembling 




Roots used to treat convulsions by the Shona in Zimbabwe. Several 
cases of suspected poisoning from ingestion of the roots have been 
reported (BRYANT, 1966; GELFAND et al., 1985). Decocti ns made 
from the leaves or fruit of C. africanus L. f. are used by Xhosa healers 
as emetics for patients thought to have been bewitched (SMITH, 1895). 
Fruit if C. myriocarpus Naud. is used to make dogs ferocious in 
Zimbabwe (GELFAND et al., 1985). 
 
Momordica balsamina L 
inkaka, intshungu (Z) 
143 Decoctions or cold infusions of the runners are used to soothe 
‘squeamish stomachs’ (BRYANT, 1966). M. foetida Schumach also 
used for the same purpose. As well as in Paraguay the roots are used to 
treat epilepsy (WATT and BREYER-BRANDWIJK, 1962). 
CUNONIACEAE 
Cunonia capensis L. 






The Zulu regard this plant as a strengthening medicine that is taken 
after the death of a kraal member (GERSTNER, 1939). 
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CYATHEACEAE 





Plants known as isikhomakhoma re used by the Zulu in infusions taken 
to counteract the effects of witchcraft (HUTCHINGS et al., 1996). 
DIOSCOREACEAE 
Dioscorea diversiflora Griseb. 
udakwa (Z)  






Unspecified groups in southern Africa use tubers to treat hysterical fits 
(WATT and BREYER-BRANDWIJK, 1962). 
Dioscorea dregeana Baker 
ilabatheka (Z) – (n) for causing 
madness or excitement;  
undiyaza (Z) - be stunned, 
confused, giddy’  
udakwa (Z)-being drunk. 
147 Tuber is Zulu remedy for hysteria, convulsions and epilepsy (WATT, 
1967). In southern Africa tubers are used for hysterical fits and to cure 
insanity (GERSTNER, 1941; WATT and BREYER-BRANDWIJK, 
1962). The Zulu administer small pieces of root, boiled in water, for 
nervous spasms and cramps (PUJOL, 1990). Cold infusions are used by 
Xhosa as soporifics. Maize cobs boiled in strong tuber decoctions are 
used to inebriate monkeys so that they can be easily caught 
(HUTCHINGS et al., 1996); Two teaspoons of fresh macer te from the 
tuber are reputed to make a person drunk and intoxicated (GERSTNER, 
1939). Tubers are eaten, after being soaked in running water for several 
days, as a famine food by the Mpondo (WATT and BREYER-
BRANDWIJK, 1962). Insufficiently soaked tubers are reported to 
produce paralysis of the legs and raw tubers can produce narcosis. 
EBENACEAE 
Euclea crispa (Thunb.) Guerke 
idungamuzi (Z) male plant; 




In Zimbabwe roots of E. crispa and E. divinorum Hiern are used to treat 
epilepsy and convulsions (GELFAND et al., 1985). E. natalensis A. 
DC. root is burned and the smoke inhaled as a hypnotic (VAN WYK 
and GERICKE, 2000), and root decoctions are used by venda to treat 
epilepsy (ARNOLD and GULUMIAN, 1984). The wood of E. 
schimperi (A. DC.) Dandy is never used as firewood in South Africa as 
it is believed to lead to domestic quarrels (WATT and BREYER-
BRANDWIJK, 1962). 
 
Diospyros lyciodes Desf. 149 The Venda use root decoctions and other unspecified ingredients for 
treating epilepsy (ARNOLD and GULUMIAN, 1984). The Shona of 
Zimbabwe drink root infusions to treat epilepsy (GELFAND et al., 
1985). 
EUPHORBIACEAE 





The toxic roots (WATT and Breyer-Brandwijk, 1962) are used as 
infusion is used to treat epilepsy and are used in magic rituals in Malawi 
(WILLIAMSON, 1974). 
 
Bridelia cathartica Bertol.f.  151 Smoke from burnt roots is inhaled to treat pilepsy in Zimbabwe 
(GELFAND et al., 1985). The Zulu use unspecified parts in love charm 
treatments and for patients thought to have been bewitched 
(GERSTNER, 1941).  
 
Croton gratissimus Burch. 
ihubeshane-elikhulu 
152 The fumes from ground leaves mixed with those of other Croton species 
place on hot coals are inhaled to treat insomnia (PALMER and 
PITMAN, 1972). 
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Croton sylvaticus Hoscht. 
umzilanyoni (Z)  
–zila (um-, imi- (n) track; 
 -nyoni (n) bird, lightning (column 
of birds?) 
 
153 Bark known as umzilanyoni and reported to be C. sylvaticus is boiled 
with salt and herbs to make a tonic for listlessnes (HUTCHINGS et al., 
1996). 
Euphorbia species 
Euphorbia bupleurifolia Jacq. 
inkamasane (Z) -what squeezes 
out a little maas 
Euphorbia natalensis Bernh. 
inkamasane and inkalamasane 
(Z)-what weeps maas 
 
154 E. decussate E. Mey. ex Boiss. is reported to have been used as a 
fermenting agent in beer making in the Cape (ENGELBRECHT, 1936). 
E. helioscopia L., E. pubescens Vahl and E. tiruealli L. are reported to 
be used as a narcotic by unspecified groups in South Africa (WATT, 
1967).  
Flueggea virosa (Roxb. ex 
Willd.) Voigt. 
155 Leaf sap is reported to be used to treat epilepsy and mental illness in 
East Africa (HAERDI, 1964).  
 
Jatropha curcas L. 
inhlakuva (Z) also the Zulu name 
for castor-oil bean (Ricinus 
communis) 
156 Roots and leaf infusions of this exotic species are used for convulsions 
and fits by unspecified groupd in Africa (ADESINA, 1982). Roots are 
administered as tonics to infants in Zimbabwe (GELFAND et al., 1985). 
The leaves Ricinus communis L.  (Euphobiaceae) also and exotic is 
taken orally to treat madness in Zimabawe (GELFAND et al., 1985). 
 
Margaritaria discoidea (Baill.) 
Webster 
157 Ash from bark is an ingredient in an ointment applied to scarifications on 
the body as a stimulant and tonic (WATT and BREYER-BRANDWIJK, 
1962). 
 
Monadenium lugardiae N.E. Br. 
umhlebe (Z) 
 –hleba (v) whisper, speak of evil 
umhuwa (Z)  
158 Roots are swallowed by diviners in the Piet Retief ar a KwaZulu-Natal 
to obtain clear vision before important meetings (WATT and BREYER-
BRANDWIJK, 1962). Latex from young shoots is reported o have 
anaesthetic effects, while the roots are reported to induce hallucinations 
and delirium  if taken in sufficient (unspecified amount) quantities 
(WATT and BREYER-BRANDWIJK, 1962). 
 
Phyllanthus reticulates Poir 159 Froth (saponins) from mixtures of root bark and other ingredients, which 
have been briskly stirred in water, are licked without use of hands to give 
Zulu healers and initiates clear and penetrating v sion (HUTCHINGS et 
al., 1996). Root bark infusions are taken by Zulu as emetics or used as 
bathing ‘charms’ to conceal secrets from diviners (PALMER and 
PITMAN, 1972). 
 
Tragia meyeriana Müll. Arg. 
ubangalala (Z) 
160 Roots used by Zulu to cause xual excitement (DOKE and 
VILAKAZI, 1972). Roots of an unidentified Tragia species used as a 
stimulant and tonic in South Africa (PUJOL, 1990). 
FABACEAE 
Abrus precatorius L. 





Roots are used as sedatives and ticonvulsants in Amerindian and 
African medicine (HUTCHINGS et al., 1996). Extracts from the roots 
have moderate sedative effect (ADESINA, 1982). The leaves with palm 
oil are taken to treat convulsions in Ghana and Gabon (DALZIEL, 
1937). DESAI and RUPAWALA (1966) report on the antifertility of the 
steroidal oil derived of the seeds of Abrus precatorius L. from India.  
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Acacia amythethophylla Steud. 
ex A. Rich. 
162 Root infusions are taken to treat convulsions in Zimbabwe (GELFAND 
et al., 1985). A. nigrescens Oliv. roots are applied to the body in an 
ointment to treat convulsions in Zimbabwe (GELFAND et al., 1985). 
 
Acacia karoo Hayne 
isikhombe, umunga (Z) 
163 In Zimbabwe the roots are used for general body pains, d zziness, 
convulsions and as an aphrodiasiac (GELFAND et al., 1985).  
 
Acacia nilotica (L.) Willd. ex 
Del. 
164 Bark and root decoctions are drunk by Masai youths to aquire strength 
and courage and are reported to have an intoxicating effect 
(WILLIAMSON, 1974). Bark decoctions are also taken by the Masai as 
nerve stimulants (WATT and BREYER-BRANDWIJK, 1962). 
 
Adenopodia spicata (E. Mey.) 
Presl 
ibobo (Z), umlungumabele 
165 Root infusions are taken by Zulu diviners (iZangoma) as emetics to 
increase their diving powers (WATT and BREYER-BRANDWIJK, 
1962; HUTCHINGS et al., 1996). 
 
Albizia adianthifolia 
(Schumach.) W.F. Wight  
muvhadangoma (V) 
 
166 The Venda healers use the roots for improving memory, inducing 
dreams about medicinal plants (MABOGO, 1990) 
Argyrolobium tomentosum 
(Andr.) Druce 
umadlozana (Z) – derived from 
amadlozi (n) ancestral spirits 
umlomomnandi (Z) - pleasant 
voice 
167 Root infusions taken by Zulu diviners (angoma) to sharpen their vision 
(HULME, 1954) and communicate with ancestral spirits (amadlozi). It 
appears that grassland species with bright yellow fers that are easily 
seen, even at a distance, such as Helichrysum and Argyrolobium species 
are often burned and or taken for ‘sharpening of vision’. 
 
Bauhinia thonningii Schumach 168 Powdered root, as well as those from B. candicans Benth., are taken in 
porridge to treat convulsions by the Shona of Zimbabwe (GELFAND et 
al., 1985). 
 
Bolusanthus speciosus (H. Bol.) 
Harms 
169 Roots reported to have sleep-inducing effect by the Tsonga people 
(LIENGME, 1981). 
 
Caesalpinia bondac (L.) Roxb. 170 Unspecified groups in southern Africa use the plant to treat infantile 
convulsions (WATT, 1967). An unidentified Caesalpinia species is used 
as a Chopi remedy for convulsions (WATT and BREYER-
BRANDWIJK, 1962). 
 
Chamaecrista mimosoides (L.) 
Greene 
imbubu yotaboni (Z), umbonisela 
(Z) 
171 Cold water root infusions are taken and rubbed on the body to 
remember ‘forgotten dreams’ by Zulu (HULME, 1954). Used by 
Xhosa and Mfengu to induce sleep by being placed under pillows or 
sleeping mats (WATT and BREYER-BRANDWIJK, 1962). The Sotho 
use plant decoctions for loss of appetite in children (WATT and 
BREYER-BRANDWIJK, 1962; HUTCHINGS et al., 1996). 
 
Dalbergia obovata E. May. 
 
172 Ash from the burnt plant is used in snuff, although no narcotic effects are 
reported (WATT and BREYER-BRANDWIJK, 1962; HUTCHINGS et 
al., 1996). 
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Desmodium barbatum (L.) 
Benth. 
Syn: D. dimorphum Welw. ex Baker var. 
argyreum Welw. ex Baker, Nicolsonia 
barbata (L.) DC. var. argyrae (Welw. ex 
Baker) Schindl. 
 
173 Infused together with Faurea saligna (Proteaceae), it is taken orally once 





ugweje (Z) –(n) reddish object; 
enormous red underground 
rhizome. 
174 Zulus take root decoctions as emetics to mitigate the anger of the 
ancestors. These are taken every morning for a period of seven to ten 
days and are reported to have no side effects (HUTCHINGS et al., 
1996). Roots are also used by the Zulu as emetics for love charms 
(GERSTNER, 1939), and in Zimbabwe roots are taken as aphrodisiacs 
(GELFAND et al., 1985). 
 
Entada rheedii Spreng.  
umbhone (Z),  
intindili (Z)  
–ntindili (i-, izi-) (n) destitute 
person 
175 Tobacco smoked from pipes made from the seeds has been reported to 
cause vivid dreaming (VAN WYK and GERICKE, 2000). Powdered 
seeds are used by the Zulus for making umego medicines. These are 
taken as a protection against pollutant effects of tracks believed to be left 
by harmful animals and sorcerers (HUTCHINGS et al., 1996). 
 
Eriosema cordatum E. Mey. 
umhlabankunzi, uqontsi (Z) 
176 Hot milk infusions of roots and powdered root infusions have been 
reported on several occasions to be taken by Zulu for impotency 
(HULME, 1954; BRYANT, 1966; HUTCHINGS et al., 1996). Also used 
by the Sotho in a mixture with other unspecified plants to stimulate the 
bulls to mate in the spring (JACOT GUILLARMOD, 1971). 
 
Eriosema distinctum N.E. Br. 
ubangalala omkhulu (Z) 
177 Decoctions from pounded boiled roots are used by Zulu for urinary 
ailments and impotence (HULME, 1954). 
 
Eriosema salignum E. Mey. 
iqonsi, ubangalala (Z) 
178 Hot milk infusions of roots or cold water infusions of root bark taken in 





179 Powdered bark is administered by Zulus as snuff to treat hysteria 
(HUTCHINGS et al., 1996). Early records report the us  of the bark by 
Zulu to counteract suspected sorcery (GERSTNER, 1939), and to 
increase the potency of palm wine in unspecified parts of Africa 
(PALMER and PITMAN, 1972). Recently it has been report that the 
bark is used in South Africa for treating mental illness and the snuff of 
the bark is a mild intoxicant (SOBIECKI, 2002). 
 
Indigofera hilaris Eckl. & Zeyh. 
isikhubabende (Z) 
180 Suspected of poisoning cattle at certain seasons and is repoted to produce 
delirium  and paralysis (WATT and BREYER-BRANDWIJK, 1962). 
 
Millettia grandis (E.Mey.) Skeels 181 The Zulu use mixture of roots ground with those of Croton species with 
one part lion fat, a little ground lion bone and one portion python fat that 
is burned in homes as a tr nquilliser  and to dispel worries (PALMER 
and PITMAN, 1972). In unspecified parts of southern Africa, residues 
from evaporated ground roasted roots mixed with water re licked from 
fingers to induce sleep (PALMER and PITMAN, 1972). 
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Mimosa pudica L. 
Mimosa pigra L. 
imbune (Z)  
–buna (v) wilt, droop, become 
emaciated 
umazifisa (Z)  
 
182 Unspecified parts are used to treat children’s convulsions in Madagascar 
(JENKINS, 1987). In Mauritius, decoctions of young leaves and stems 
are given for insomnia and nervousness (GURIB-FAKEM et al., 1993). 
Leaves are also used for insomnia in Ecuador (SCHULTS and 
RAFFAUF, 1990). The Zulu name umazifisa means ‘self-desire’ and the 
plant is used as an ingredient in preparations design d to make an enemy 
impotent (HUTCHINGS et al., 1996). 
 
Newtonia hildebrandtii (Vatke) 
Torre 
udongolokamadilika (Z), 
umfomothi (Z) man medicine 
 
183 Drops of a decoction made from roasted ground bark mixed with water 
and elephant dung are licked from the hands to drive away ‘starts’ while 
sleeping (PALMER and PITMAN, 1972) 
Psoralea pinnata L. 
umhlongani (Z), umhlonishwa (Z) 
184 Cold water infusions from roots, mixed with the roots f Helinus 
integrifolius (Soap creeper, Rhamnaceae) and pounded and stirred until 
the liquid froths (saponins), are taken as emetics by healers afflicted with 
mental disturbances associated with their calling (to be a sangoma) 
(BRYANT, 1966). 
 
Rhynchosia nervosa Benth. & 
Harv. 
ubangalala (Z) 
185 Rhynchosia species are used in Zulu culture as love charm emetics 
(GERSTNER, 1941; BRYANT, 1966; PUJOL, 1990). Roots of pecies 
known as ubangalala (Z) are cooked in milk and taken in mouthfuls as 
aphrodisiacs (DOKE and VILAKAZI, 1972). Seeds of R. pyramadilis 
(Lam.) Urb . and R. longeracemosa Mart. & Gal.  have narcotic 
properties which are utilised by some South Mexican Indian tribes 
(ALLEN and ALLEN, 1981). R. pyramadilis is classed as a narcotic 
hallucinogen and is also reported to have aphrodisiac properties 
(DUKE, 1985). 
 
Schotia brachypetala Sond. 
ihlusi, ihluze, umgxamu, uvovovo 
186 Largely bark and roots used for nervous conditions (VAN WYK and 
GERICKE, 2000), smoke from leaves also inhaled (Hutchings et al., 
1996). The bark is used in a red-bark mixture known as ikhubalo to ward 
off evil or cure unspecified ailments (HUTCHINGS et al., 1996). These 
mixtures are often taken and also washed with during purification rites 
after the death of a relative. They are also used to strengthen the body 
and to steam the face (PUJOL, 1990). 
 
Senna didymobotrya (Fresenius) 
N.W. Irwin & R.C. Barneby 
Syn. Cassia didymobotrya Fresen. 
187 The roots are burned and the smoke inhaled to treat madness, while 
decoctions of the root are taken orally for c nvulsions in Zimbabwe 
(GELFAND et al., 1985). Seeds of S. occidentalis (L.) Link  are used in 
India to treat convulsions in children (LAL and GUPTA, 1973). 
 
Senna petersiana (Bolle) J.M. 
Lock 
Syn. Cassia petersiana Bolle 
 
188 A decoction of the roots together with Diospyros lycioides (Ebenaceae) 
and Euclea natalensis (Ebenaceae) are taken to treat pilepsy in Venda, 
South Africa (ARNOLD and GULUMIAN, 1984). 
Tephrosia capensis (Jacq.) Pers. 
isidamvulu, isikhwali (Z) 
189 The Sotho used cooked roots for palpitations and decoctions of the plant 
with Commelina africana (Commelinaceae) for weak hearts and 
nervousness. Reported to be toxic (WATT and BREYER-BRANDWIJK, 
1962). 
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Vigna species 190 The Zulus use several Vigna species (V. luteola (Jacq.), V. unguiculata 
(L.) Walp.  and V. vexillata (L.) A. Rich.) as emetic love charms 
(GERSTNER, 1939). V. unguiculata root is used in infusions prepared 
with porridge to treat epilepsy in Zimbabwe (GELFAND et al., 1985). 
 
FLACOURTIACEAE 
Casearia gladiiformis Mast. 
umjuluka (Z)  
–juluka (v) perspire, sweat 
 
191 
Bark is used by Zulu in traditional medicine, and the ashes of bark are 
used as a snuff (PALMER and PITMAN, 1972). The Tsonga used this 
plant to treat ‘possessed’ or mad people (JUNOD, 1962; SOBIECKI, 
2002). The Zulu use an unidentified plant referred to as umjuluka, for 
treating mental illness (MANANA, 1968). 
 
Gerrardina foliosa Oliv. 
 
192 Strengthening medicine made of unspecified parts is taken after th  
death of a kraal member (GERSTNER, 1941).  
 
FUMARIACEAE 






Unspecified parts are used to comfort and drug morning, sorrowful 
people in Lesotho (JACOT GUILLARMOD, 1971). 
GENTIANACEAE 




Used for relieving uneasiness during pregnancy by the Sotho (WATT 
and BREYER-BRANDWIJK, 1962). Preparations from C. baccifera L. 
are reported to produce sleepiness and perspiration (WATT and 
BREYER-BRANDWIJK, 1962). 
HYACINTHACEAE 
Albuca fastigiata Dryand. 





Infusions made from bulbs of A. fastigiata are used to treat idliso (Z), an 
illness believed by the Zulu to be caused by poisons administered in food 
by jealous rivals (HUTCHINGS et al., 1996), and also u ed as 
protective charms (CUNNINGHAM, 1988). Infusions made from A. 
nelsonii bulbs and the tubers of a Kniphofia species known as icacane 
are taken as emetics against sorcery (HUTCHINGS et al., 1996). 
 
Ledebouria cooperi (Hook. f.) 
Jessop 
Syn: Scilla adlamii Baker, Scilla 
cinerascens Van der Merwe, Scilla 
cooperi Hook.f., Scilla galpinii Baker, 
Scilla glaucescens Van der Merwe, Scilla 
inandensis Baker, Scilla petiolata Van der 
Merwe, Scilla pusilla Baker, Scilla 
rogersii Baker, Scilla rupestris Van der 
Merwe, Scilla saturata Baker  
icubudwana (Z) 
196 Bulbs are used to inebriate Sotho boys during circumcision rituals 
(WATT and BREYER-BRANDWIJK, 1962). This medicine is 
reportedly made with Phygelius capensis (Scrophulariaceae) and causes 
the boys to appear stunned, stupefied and to fall asleep (HUTCHINGS et 
al., 1996).  
Schizocarphus nervosus (Burch.) 
Van der Merwe 
Syn. Ornithogalum nervosum Burch., S. 
acerosus Van der Merwe, S. gerrardii 
(Baker) Van der Merwe, S. rigidifolius 
(Kunth) Van der Merwe, Scilla gerrardii 
Baker, Scilla nervosa (Burch.) Jessop, 
Scilla rigidifolia Baker, Scilla rigidifolia 
Baker var. acerosa Van der Merwe, Scilla 
rigidifolia Baker var. nervosa Baker 
ingcino, ingcolo (Z) 
 
197 Ground bulbs in milk are used as an enema to relieve nervous 
conditions in children by unspecified groups in Limpopo (northern 
Transvaal) (WATT and BREYER-BRANDWIJK, 1962).  
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HYPOXIDACEAE  





The Zulu are reported to use corm infusions for treating hysteria 
(GERSTNER, 1939). Reported to be able to cause delirium  and to treat 
it (WATT and BREYER-BRANDWIJK, 1962). Unspecified parts used 
by the Xhosa to treat insanity (SIMON and LAMLA, 1991).  
 
Hypoxis hemerocallidea Fisch. & 
C.A. Mey 
199 Corm infusions used to treat insanity in South Africa (PUJOL, 1990). 
 
IRIDACEAE 
Belamcanda chinensis (L.) DC. 




Roots are reported used by the Zulu to allay hysterical crying 
(BRYANT, 1966). The early missionary MAYR (1907) also reports on 
the use of a plant known as indawoluti as an emetic to treat hysterics. 
 
Eleutherine bulbosa (Miller.) 
Urban 
ababomvu (Z)  
–bomvu - red 
201 Tropical American species commonly grown outside Zulu homesteads as 
protective charms (HUTCHINGS et al., 1996). Also believed to have 
magical and hallucinatory  propertied by unspecified groups 
(HUTCHINGS et al., 1996). 
 
Ferraria glutinosa (Bak.) Rendle 202 Reported as having psychoactive properties and to aid novice San 
healers to enter kia or trance-like state (LEE, 1979; KATZ, 1982; 
WINKELMAN and DOBKIN DE RIOS, 1989).  
 
Gladiolus papilio Hook. f. 
ibutha, igulusha (Z) 
203 Root infusions take by the Zulu as emetics to bring good fortune 
(HULME, 1954). 
 
Moraea spathulata (L.f) Klatt 204 Preventative medicine made by the Zulu with unspecified parts which is 
believed to ’blunt’ witches deeds (GERSTNER, 1939). Toxic to live 
stock with symptoms of convulsions leading to death from respiratory 
failure (WATT and BREYER-BRANDWIJK, 1962). 
 
Sparaxis grandiflora (Delaroche) 
Ker-Gawl. 
indawoluthi emhlophe (Z) 
 
205 Used by the Zulu as an antidote against suspected sorcery (GERSTNER, 
1938). Administration method was not given. 
LAMIACEAE 
Ballota africana (L.) Benth. 
Syn: Marrubium africanum L. 
Perennial. Dwarf shrub, herb. Ht 0.3–1.2 






Infusions or brandy tinctures are used, in the Western Cape for the 
treatment of hysteria and insomnia (VAN WYK and GERICKE, 2000) 
 
Becium grandiflorum (Lam.) 
Pichi-Serm. 
Syn: B. obovatum (E.Mey. ex Benth.) 
 
207 Plants burnt as protective charms in Zimbabwe (GELFAND et al., 
1985). Unspecified parts used as cleansers against evil spirits in Kenya 
(GITHINJI and KOKWARO, 1993). 
 
Hemizygia bracteosa (Benth.) 
Briq. 
208 The leaves are smoked or chewed by the San in Botswana to give energy 
for dancing and as a stimulant (VAN WYK and GERICKE, 2000). The 
Shona of Zimbabwe are reported to used powdered leaves orally to treat 
fits (GELFAND et al., 1985). 
 
Hoslundia opposite Vahl 209 In Zimbabwe root infusions are used to treat fits and epilepsy 
(GELFAND et al., 1985). Hoslundia species are used in West Africa to 
treat epilepsy and mental illness (AYENSU, 1978). 
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Leonotis leonurus (L.) R.Br. 210 This plant is reported to be mildly narcotic (WATT and BREYER-
BRANDWIJK, 1962). Leaves are reported to have been smoked for 
partial paralysis and epilepsy (WATT and BREYER-BRANDWIJK, 
1962; HUTCHINGS et al., 1996). Aqueous extracts are reported to have 
anticonvulsant activity in animal studies (BIENVENU et al., 2002). 
 
Leucas martinicensis (Jacq.) R. 
Br. 
amandetshi (Z) 
211  In Zimbabwe, leaf infusions are used to s imulate poor appetite 
(GELFAND et al., 1985). Used by the Zulu for feverish conditions in 
children (GERSTNER, 1941). 
 
Mentha aquatica L. 212 Used as a stimulant (WILLIAMSON and EVANS, 1988) and known to 
contain flavones (BURZANSKA-HERMANN et al. 1977). Mixed with 
leafs of Tagetes minuta L. burned and the smoke inhaled for treating 
mental illness in Venda (ARNOLD and GULUMIAN, 1984). Leaf 
extracts exhibited SSRI activity (NIELSEN et al., 2003). JERKOVIC 
and MASTELIC (2001) report on the composition of free and 
glycosidically bound volatiles of Mentha aquatica L 
 
Ocimim canum Sims 213 The Ndebele of Zimbabwe use the whole plant together with the seeds of 
Ricinus communis and Chenopodium ambrosidiodes a snuff to treat 
madness (GELFAND et al., 1985). Unspecified groups in Malawi burn 
the leaves and inhale the smoke, and also wash the body of the patient 
with decoctions of the leaves, to treat convulsions (GELFAND et al., 
1985). In central Africa the leaves together with those of Cymbopogon 
densiflorus Stapf. are macerated and used as a treatment for epilepsy 
(WATT, 1967). Ocimum species are used in west Africa to treat 
delirium  (AYENSU, 1978). 
 
Pycnostachys urticifolia Hook 214 The roots are eaten in porridge, or applied to the fac and used in washes 
to treat madness and convulsions in Zimbabwe (GELFAND et al., 
1985). 
 
Salvia chamelaeagnea Berg. 215 Unspecified groups in the cape of South Africa used an infusion of the 
dried leaves as a treatment for c nvulsions (WATT and BREYER-
BRANDWIJK, 1962). 
 
Stachys thunbergii Benth. 216 Unspecified groups use the plant in combination with Valeriana capensis 
(Valerianaceae) to treat hysteria and insomnia in South Africa (VAN 
WYK and GERICKE, 2000). S. aethiopica L. is reportedly burnt in huts 
to cure feverish delirium in Lesotho (JACOT GUILLARMOD, 1971). 
 
Syncolostemon parviflorus E. 
Mey. ex Benth. 
umnandi (Z) (n) pleasant taste, 
tasty, sweetness 
 
217 Milk infusions administered by Zulu as emetics to adults to treat loss of 
appetite (GERSTNER, 1941; WATT and BREYER-BRANDWIJK, 
1962; POOLEY, 2005). 
Tinnea zambesiaca Bak. 218 The Shona of Zimbabwe use the roots and leaves as a body wash for 
convulsions (GELFAND et al., 1985). 
LAURACEAE 
Cinnamomum camphora (L.) T. 




Although not an indigenous plant it has become a popular traditional 
medicine to treat a variety of complaints, used to treat hysteria (WATT 
and BREYER-BRANDWIJK, 1962) 
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Ocotea bullata (Burch.) Baill. 
unukani (Z) 
-nuka (n) smell, strong odour 
 
220 Unspecified parts used as an emetic for emotional ad nervous 
disorders in South Africa (PUJOL, 1990). 
LOBELIACEAE 
Lobelia decurrentifolia (Kuntze) 
K. Schum. 
Syn: Dortmannia decurrentifolia Kuntze 





The Sotho are reported to believe this plant has powerful spiritual  uses 
and it is believed to have the power to stop ‘wolves’ (which is puzzling 
as they do not occur in southern Africa) and the spirit  of the ancestors 








Used together with Heteromorpha trifoliate (Wendl.) Eckl. & Zeyh. and 
Cussonia paniculata Eckl & Zeyh. by Sotho in South Africa to treat 
early nervous and mental illnesses (WATT and BREYER-
BRANDWIJK, 1927 cited in SOBIECKI, 2002). 
 
Nuxia floribunda Benth. 
Syn: Lachnopylis floribunda (Benth.) 
C.A.Sm. 
Perennial. Tree or shrub. Ht 2–17 m. Alt 
30–1980 m. LIM, M, S, KZN, WC, EC 
 
223 Bark is used in Zulu traditional medicine as a trengthening medicine 
taken after the death of a kraal member (GERSTNER, 1941). Leaves 
reported to be used for infantile convulsions and in rituals in unspecified 
parts of Africa (IWU, 1993). 
 
Strychnos species 
Strychnos decussata (Pappe) Gilg 














224 These species contains often contain strychnine and other indole 
alkaloids which are powerful CNS stimulants. The Zulu use pinches of 
scraped and ground root bark of S. decussate as snuff (PALMER and 
PITTMEN, 1972). S. henningsii is reported to be used to induce 
visionary dreams associated with ancestral spirits (SOBIECKI, 2002). 
  
LORANTHACEAE 
Loranthus oleifolius (Wendl.) 
Cham. & Schlechtd. 
Syn: Tapinanthus oleifolius (J.C.Wendl.) 
Danser, L. meyeri C.Presl, L. meyeri 
C.Presl var. inachabensis Engl., L. 
namaquensis Harv., L. namaquensis Harv. 
var. ligustrifolius Engl., L. speciosus 
F.Dietr., T. namaquensis (Harv.) Tiegh.,  
Perennial. Shrub, parasite. Ht ± 1.5 m. Alt 





Suspected as being used by the !Kung San to facilitate kia, a trance-like 
state (WINKELMAN and DOBKIN DE RIOS, 1989). An unidentified 
species is used by the Shona of Zimbabwe to treat epilepsy, madness 
and convulsions (GELFAND et al., 1985). 
 




Colloquial name1 – meaning2 
Annotations and distribution for South 
Africa3 




One species in South Africa: 
Sphedamnocarpus pruriens 
(A.Juss.) Szyszyl.  
Sphedamnocarpus pruriens ubsp. 
galphimiifolius (A.Juss.) P.D.de Villiers & 
D.J.Botha 
Perennial. Shrub, climber. Ht 0.3–5 m. Alt 
15–2000 m. B, LIM, NW, S, FS, KZN 
Sphedamnocarpus pruriens ubsp. 
pruriens 
Perennial. Shrub, climber. Ht 0.1–5 m. Alt 






Root decoctions of S. galphimiifolius (A. Juss.) Szyszyl are taken orally 
to treat mental illness by the Venda (ARNOLD and GULUMIAN, 
1984). Unspecified parts of S. pruriens (Juss.) Szyszyl are used by the 
Chopi with Securidaca longepedunculata (Polygalaceae) for people 
believed to be possessed by evil spirits (WATT and BREYER-
BRANDWIJK, 1962). Roots are used by Venda to treat mental illness 
(MABOGO, 1990). 
MALVACEAE 
Azanza garckeana (F. Hoffm.) 
Exell & Hillc. 
Syn: Shantzia garckeana (F.Hoffm.) 
Lewton, Thespesia garckeana F.Hoffm. 
Perennial. Tree, shrub. Ht 4–10 m. Alt up 





Root decoctions are taken orally to treat mental illness in Zimbabwe 
(GELFAND et al., 1985). 
 
Hibiscus pusillus Thunb. 
uguqukile (Z)  
–guqu (ideo) of changing; turning 
over; ‘having turned’ 
 
229 Emetics made from the roots are taken for bad dreams and by Zulu men 
as love charms (WATT and BREYER-BRANDWIJK, 1962). 
Malva parviflora L. 230 The Sotho reported to give root decoctions to persons who have lost near 
relatives (WATT and BREYER-BRANDWIJK, 1962). Leaf infusions 
taken by Europeans as a nerve tonic (WATT and BREYER-
BRANDWIJK, 1962). 
 
Thespesia acutiloba (Bak. f.) 
Exell & Mendonca 
231 The roots are used in baths taken to refresh the body and dispel 
troublesome spirits by the Zulu (PALMER and PITTMEN, 1972). 
 
MELIACEAE 
Ekebergia capensis Sparrm. 
umnyamathi (Z)  
– nyama (n) darkness, ill omen –





Leaves are crushed in cold water and the resulting extract is introduced 
to the nostrils to treat mental problems including madness among the 
Zulu (PUJOL, 1990). Bark of umnyamathi reported to be E. capensis is 
used to treat listlessness, undue exhaustion and to ward off evil in by the 
Zulu in KwaZulu-Natal (HUTCHINGS et al., 1996). Bark is used to 
protect chiefs against witchcraft and is also taken in love charm emetics 
(GERSTNER, 1941).  
 
Entandrophragma spicatum (C. 
DC.) Sprague 
233 The cigar shaped pods are burned and the ash mixed w th tobacco to 
make a snuff (RODIN, 1985). 
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Melia azedarach L. 234 Decoctions made from a large handful of freshly pounded leaves of this 
exotic in two litres of water are administered as emetics to epileptic 
patients after a fit  (HUTCHINGS et al., 1996). The fruit is applied 
externally to treat convulsions, spasms and nervous pain (HUTCHINGS 
et al., 1996). Reported to have CNS-suppressant activity (WATT, 1967) 
and all parts considered to be toxic (WATT and BREYER-
BRANDWIJK, 1962). Symptoms include mental confusion, stupor and 
convulsions. Root bark extracts have been shown to have sedative and 
depressant properties in animal studies in Nigeria (ADESINA, 1982). 
 
Turraea floribunda Hochst. 
umadlozana (Z)  
-dlozane (isi-, izi-) (n) nape of the 
neck, 
-dlozi (i-, ama-) (n) spirit of the 
departed, guardian spirit, ancestral 
spirit 
235 Roots are used by diviners to enter the neurotic state needed for divining 
dances (WATT and BREYER-BRANDWIJK, 1962; HUTCHINGS et 
al., 1996). Emetics made from bark are taken to prevent the fearful 
dreams thought to be symptomatic of heart weakness (BRYANT, 1966). 
Strengthening medicine made from unspecified parts are taken after the 
death of a kraal member (GERSTNER, 1941). Reported to be poisonous 
if overdoses are taken, amounts not specified (WATT and BREYER-
BRANDWIJK, 1962). 
 
Turraea nilotica Kotschy & Peyr 236 Root infusions are used to treat epilepsy, leaves are burnt and the smoke 
inhaled for treating madness in Zimbabwe (GELFAND et al., 1985). 
 
Nymania capensis (Thunb.) 
Lindb. 
237 Used by the Europeans in the Cape of South Africa to treat convulsions 
(WATT, 1967) and early accounts suggest that the Hottentots (KHOI) of 
Namaqualand also use unspecified parts to treat convulsions 
(LAIDLER, 1928). 
MELIANTHACEAE 
Bersama lucens (Hochst.) 
Szyszyl. 




The Zulu use a tincture of the bark as an emetic to calm nervous 
disorders (HUTCHINGS and VAN STADEN, 1994). Bark is also used 
by the Zulu as protective charms against evil spirits (HUTCHINGS et 
al., 1996) and to confuse one’s opponents in court (DOKE and 
VILAKAZI, 1972). 
 
Bersama tysoniana Oliv. 239 Bark is used by Xhosa to treat hysteria (WATT and BREYER-
BRANDWIJK, 1962). Bark is probably used in a similar way as B. 
lucens by the Zulu (HUTCHINGS et al., 1996). 
 
Melianthus comosus Vahl 
ibonya (Z)  
–bhonya (v) flog, beat on the 
body; (n) barren beast 
240 Roots reported to be toxic and causing human death. Root infusions act 
as violent depressants, producing emesis and also exerting marked 










C. torulosa E. Mey. ex Harv. leaf decoctions are administered as 
enemas for hallucinations in the Transkei (HUTCHINGS et al., 1996). 
Small portions of the rhizome of C. capensis L. f., which are rich in 
bisbenzylisoquinoline alkaloids, are reported to have sedative effects 
when chewed (VAN WYK and GERICKE, 2000). C mucronata A. 
Rich. are used as exual stimulants (HUTCHINGS et al., 1996). 
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Stephania species 242 Early records suggest that an unverified species is u ed by Sotho 
diviners to discover things and is used in conjunction with the divining 
bones (PHILIPS, 1917). Epistaphine from the aerial parts of Stephania 
abyssinica (Dill. & Rich.)  Walp. has significant adrenergic neurone 
blocking activity (RAY et al., 1979). 
MESEMBRYANTHEMACEAE 
Aptenia cordifolia (L. f.) 
Schwant. 
ibohlololo (Z) (ideo) of subsiding  
umjuluka (Z)  




Used by the Zulu to make love charm medicine, and is an ingredient in 
black powder (uncolozi omncane or ungcolosi) for vaccination against 
sorcery and to counteract perspiration (GERSTNER, 1941; DOKE and 
VILAKAZI, 1972). For the treatment of nervous complaints, leaf and 




244 The genus is reputed to have narcotic properties (WATT, 1967), also 
believed to have sedative properties (VAN WYK and GERICKE, 2000).  
 
Khadi acutipetala (N.E. Br.) N.E. 
Br. 
khadiwortel (A) 
245 Although the roots a largely used as a fermentation agent, possible due to 
associated fungi, it is suggested that mesembrine-typ  alkaloids in the 





-bulawo (n) body weakness as a 
result of witchcraft. 
246 Emetics made from a handful of leaves in boiling water re administered 
by the Zulu for the fearful dreams believed to be symptomatic of heart 
weakness (BRYANT, 1966), although the name suggests there is 
witchcraft  involved. 
 
Pleiospilos bolusii (Hook. f.) N.E. 
Br. 
Syn: Mesembryanthemum bolusii Hook.f.,  




247 The plant is dried and powdered and used as a snuff(VAN WYK and 
GERICKE, 2000). 
Rabiea albinota (Haw) N.E. Br. 
s'keng-keng (Griqua) 
248 The pulverised plant is reported to be a hallucinogenic additive to 
tobacco to be smoked or taken as snuff (VAN WYK and GERICKE, 
2000). 
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Sceletium species 
Sceletium emarcidum (Thunb.) 
L.Bolus ex H.Jacobsen 
Syn: Mesembryanthemum anatomicum 
Haw. var. anatomicum, 
Mesembryanthemum anatomicum Haw. 
var. emarcidum (Thunb.)DC., 
Mesembryanthemum anatomicum Haw. 
var. fragile Haw., Mesembryanthemum 
emarcidum Thunb., S. anatomicum (Haw.) 
L.Bolus, S. dejagerae L.Bolus, 
Tetracoilanthus anatomicus (Haw.) Rappa 
& Camarrone 
 
Sceletium tortuosum (L.) N.E. 
Br. 
Syn: Mesembryanthemum concavum 
Haw., Mesembryanthemum tortuosum L., 
Pentacoilanthus tortuosus (L.) Rappa & 
Camarrone, Phyllobolus tortuosus (L.) 
Bittrich, S. boreale L.Bolus, S. compactum 
L.Bolus, S. concavum (Haw.) Schwantes, 
S. framesii L.Bolus, S. gracile L.Bolus, S. 
joubertii L.Bolus, S. namaquense L.Bolus 
var. namaquense, S. namaquense L.Bolus 
var. subglobosum L.Bolus, S. ovatum 
L.Bolus, S. tugwelliae L.Bolus 
 




H Me  
mesembrine 
 
249 It has been suggested that this plant has been used by pastoralists and 
hunter-gatherers as a mood-altering substance since prehistoric-times 
(VAN WYK and GERICKE, 2000).  
 
Kougoed refers to a traditional preparation made from S. emarcidum 
(Thunb.) L.Bolus ex H.Jacobsen or S. tortuosum (L.) N.E. Br., which 
is used as a stimulant with an effect not unlike that of tobacco. To 
prepare the plant material, usually a whole plant including the roots, it is 
crushed between stones, after which it is then placed into a closed 
container for several days to ‘ferment’. On the eighth day the kougoed is 
spread out to dry in the sun. This is then chewed, smoked or powdered 
and inhaled as snuff (SMITH et al., 1996; VAN WYK and GERICKE, 
2000).  
 
Sceletium tortuosum contains mesembrine and the related alkaloids 
mesembranol and mesembranone (SMITH, et al., 1998). Mesembrine is 
known for its effects on the central nervous system. The compounds also 
act as serotonin-uptake inhibitors, and in specified doses act as anti-
depressants, minor tranquilizers and anxiolytics used in the treatment of 
mild to moderate depression, psychological and psychiatric disorders 
where anxiety is present, major depressive episodes, alcohol and drug 
dependence, bulimia nervosa, and obsessive-compulsive disorders 
(U.S.Patent 6 288 104) (GERICKE and VAN WYK, 2001). 
 
 
Trichodiadema species 250 T. intonsum (Haw.) Schwant. and T. stellatum (Mill.) Schwant. are 
used as fermentation agents, possible due to associted fungi. It is 
suggested that mesembrine-type alkaloids present in many 
Mesembryanthemaceae may contribute to the beers intoxicating 
properties (WATT and BREYER-BRANDWIJK, 1962; DOLD et al., 







Unspecified parts are administered by healers in Zimbabwe to treat 
epilepsy and madness (GELFAND et al., 1985). 
 
MYRSINACEAE 






Bark is used to make a stimulating drink by the Masai of east Africa 
(WATT and BREYER-BRANDWIJK, 1962; HUTCHINGS et al., 
1996). Healers in South Africa are reported to use this plant for spiritual 
purposes associated with ancestral spirit (amadlozi) worship 
(SOBIECKI, 2002). 
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Rapanea melanophloeos (L.) 
Mez 
253 Roots and bark are used to treat palpitations [possibly as a result of 
anxiety or stress] in various parts of the Transkei (HUTCHINGS et al., 
1996). Ground bark infusions are taken three times a day by persons who 
‘ feel like crying’ (HUTCHINGS et al., 1996). 
NYMPHACEAE 
Nymphaea nouchali Burm. f. 
izibu (Z) 
ikhubalo lechanti (Z)  






Flowers are thought to have been used in Egypt as a n rcotic to induce 
trances (EMBODEN, 1989). The fresh and dry flowers have ben used 
by diviners in South Africa. Tinctures of the flowers are used as 
stimulants, aphrodisiacs and euphoriants in low doses, but 







The powdered root is rubbed on the body to treat mental illness by the 
Vavenda (ARNOLD and GULUMIAN, 1984). 
OLEACEAE 






The bark is used in South Africa as a nerve tonic and reputed to have 
stimulating properties that induce a good feeling by the Zulu (PUJOL, 
1990). The bark is also reported to stimulate the appetite and the leaves 
are also used for their stimulating properties (PUJOL, 1990). Also in this 
family is Jasminum multipartitum Hochst. which is reported to be used 
for stress, an infusion is said to be relaxing (ASHWELL, 1994). 
ORCHIDACEAE 







Stem infusions are taken as antidotes to bad dreams and smoke from 
burning roots is inhailed for the same purposes by the Zulu 
(HUTCHINGS et al., 1996). The leaves are stems are used to make an 
infusion for treating madness in the Mpika district of Zambia 
(GELFAND et al., 1985). Used for various protective charm purposes 
and also as an aphrodisiac in Zimbabwe (GELFAND et al., 1985). 
 
Brachycorythis ovata Lindl. 
imfeyamasele yentaba (Z) 






Root decoctions of Brachycorythis ovata and Ceratandra grandiflora 
are used for the treatment of madness in the Eastern Cape (Transkei) 
(BATTEN and BOKELMANN, 1966). 
Corycium nigrescens Sond. 
umabelembuca (Z) 
260 Root infusions are taken as emetic charms to ward off evil (HULME, 
1954). 
 
Disa polygonoides Lindl. 
ihlamvu elibomvu, umklakleshe 
(Z) 
261 Tuber infusions are administered to patients who have lost the power of 
speech due to illness (HULME, 1954). 
Eulophia species  
umahayiza (Z) 




Unidentified species known as umahayiza (Z) are reported to be used as 
emetics to treat hysterical fits (GERSTNER, 1941) 
PASSIFLORACEAE 
Adenia gummifera (Harv.) 
Harms 
imfulwa (Z),  




Infusions made from root (approximately 150 mm long a d 30 mm 
thick) in three to four litres of boiling water are administered as emetic 
tonics or stimulants for seediness or depression caused by a febrile 
conditions known as umkhuhlane (common cold or fever) to the Zulu 
(BRYANT, 1966). The Shona of Zimbawe reportedly useroot infusions 
to treat madness and epilepsy (GELFAND et al., 1985). 
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PEDALIACEAE 
Sesamothamnus lugardii N.E. 




Leaves are rubbed on the face together with smoke fr m burned leaves 
which is inhaled to treat convulsions in Zimbabwe (GELFAND et al., 
1985). 
PERIPLOCACEAE 
Mondia whitei (Hook. f.) Skeels 





The Zulu chew the roots to stimulate appetite (BRYANT, 1966; 
GERSTNER, 1941). Roots are used as an aphrodisiac in Zimbabwe 
(WATT and BREYER-BRANDWIJK, 1962; GELFAND et al., 
1985).The Shambala use root infusions to treat fits in children (WATT 
and BREYER-BRANDWIJK, 1962) and by unspecified groups in South 




R. hirsuta (E. Mey.) R.A. Dyer ex 
E. Phillips 
Syn: Apoxyanthera pubescens Hochst., 
Brachystelma hirsutum E.Mey., 
Mafekingia parquetiana Baill., R. 
divaricata Harv., R. divaricata Harv. var. 
glabra N.E.Br., R. hirsuta (E.Mey.) 
R.A.Dyer ex E.Phillips var. glabra 
(N.E.Br.), R.A.Dyer, R. obovata Turcz., R. 
pubescens (Hochst.) Hochst., R. purpurea 
Harv. 
 
266 R. hirsuta is reportedly used in Lesotho to make an energizing and 
highly intoxicating beer (JACOT GUILLARMOD, 1971). Underground 
parts of various Raphionacme species are used in treatments for 
madness in Zimbabwe (GELFAND et al., 1985). 
PHYTOLACCACEAE 
Phytolacca species  
Phytolacca heptandra Retz. 
Syn: P. stricta O.Hoffm., Pircunia stricta 
Hoffm. 
Phytolacca octandra L. 




Unspecified groups use P. heptandra in emetics for delirium 
(HUTCHINGS et al., 1996). The shoots of P. octandra are used as a 
stimulant snuff in Venda (MABOGO, 1990). The roots of the exotic 
Phytolacca americana L.* are reported to have a slightly narcotic effect 
(MARTINDALE, 1967). SOBIECKI (2002) describes its pychoactive 
use in southern Africa as uncertain. 
PIPERACEAE 




Root is used by unspecified groups in southern Africa as a sexual 
stimulant, and is reported to cause leepiness (VAN WYK and 
GERICKE, 2000). P. betel L. the betel vine is used in wrapping betel nut 
(Areca catechu) which is chewed for its mild psycho-stimulating effects. 
Approximately 200 million persons chew betel regularly mainly 
throughout the western Pacific basin and south Asiabut this practice has 
spread throughout the world.  
PITTOSPORACEAE 
Pittosporum viridiflorum Sims 





Root infusions are used for accuracy in d vining  and for protecting 
patients from witchcraft  by the Sotho (WATT and BREYER-
BRANDWIJK, 1962). Root infusions are also used in Zmbabwe as 
enemas to treat dizziness (GELFAND et al., 1985). Bark decoctions are 
reported to ease pain and to produce restfulness (WATT and BREYER-
BRANDWIJK, 1962). 
PLUMBAGINACEAE 





Pounded root infusions are administered by the Zuluas emetics to dispel 
bad dreams (HULME, 1954). The powdered roots are used by the 
Xhosa as a snuff (WATT and BREYER-BRANDWIJK, 1962). Extracts 
of the roots of P. zeylancia L. had sedative activity (ADESINA, 1982). 
P. zeylancia is also suspected to have been used by San to induce tran e 
state (WINKELMAN and DOBKIN DE RIOS, 1989). 
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POACEAE 
Cymbopogon nardus (L.) Rendle 
Syn: C. afronardus Stapf, C. validus 
(Stapf) Stapf ex Burtt Davy validus 





The Zulu use the whole plant, boiled with milk and drunk twice daily 
(two small cups) to strengthen the nervous system and to stimulate the 
body (PUJOL, 1990). This grass is reported to be used to reduce the 
appetite and revitalise the nerves of moody people (HUTCHINGS et 
al., 1996). 
POLYGALACEAE 
Nylandtia spinosa (L.) Dumort. 





Unspecified parts are used to treat hysteria and sleeplessness in the 
Cape of South Africa (BATTEN and BOKELMANN, 1966) and early 




273 Unspecified parts of Sphedamnocarpus pruriens (Malpighiaceae) are 
used by the Chopi with S. longepedunculata for treating people believed 
to be possessed by evil spirits (WATT and BREYER-BRANDWIJK, 
1962). Unspecified groups in Zimbabwe used powdered root mixed in 
porridge and eaten to treat epilepsy and convulsions (GELFAND et al., 
1985). The plant is reported to contain the toxic indole alkaloid 
securinine and some ergot alkaloids (VAN WYK and GERICKE, 2000). 
A diterpene, a flavonol glycoside, and a phytosterol glycoside have been 
isolated from Securidaca longipedunculata and Entada abyssinica 
(DEBELLA et al., 2000). 
POLYGONACEAE 





Boiled leaves of this exotic weed are used to stimulate the appetite by 
the Xhosa (WATT and BREYER-BRANDWIJK, 1962). 
 
Oxygonum species 275 Roots of unspecified Oxygonum species, possibly O. dregeanum Meisn. 
are used in medicines taken to treat convulsions in Zimbabwe 
(GELFAND et al., 1985). The Kwanyama Ovambos use an infusion of 
an unidentified species as an enema to treat epileptic children (LOEB et 
al., 1956). 
PORTULACACEAE 
Avonia rhodesica (N.E.Br.) 
G.D.Rowley 




The plant is used by unspecified groups as a beer additive ‘to improve 
the kick’, and is reported to have hallucinogenic and narcotic properties 
(GELFAND et al., 1985; VAN WYK and GERICKE, 2000). 
 
Talinum species 277 Several species are edible when fresh and eaten as a green vegetable in 
may parts of southern Africa (VAN WYK and GERICKE, 2000). Root 
infusions of T. caffrum (Thunb.) Eckl. & Zeyh., or impunyu (Z) are taken 
for nervousness (GERSTNER, 1941). Tuber decoctions of T. 
crispatulum Dinter ex V. Poelln. are used by unspecified groups in 
Botswana for heart palpitations, possible caused by anxiety (HEDBERG 
and STAUGARD, 1989). 
PROTEACEAE 




Infused together with Desmodium barbatum (Fabaceae), it is taken 
orally once a day for five days to treat epilepsy in Zimbabwe 
(GELFAND et al., 1985). 
PTAEROXYLACEAE 
(Rutaceae) 
Ptaeroxylon obliquum (Thunb.) 
Radlk. 
Syn: P. utile Eckl. & Zeyh. 
 







Alcoholic extracts of the wood are used by unspecifi d groups to treat 
patients suffering from fits (HUTCHINGS et al., 1996). The Xhosa are 
reported to use the bark as a nuff for recreational purposes (WATT and 
BREYER-BRANDWIJK, 1962). 
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RANUNCULACEAE 
Anemone caffra Eckl. & Zeyh. 
Syn: Pulsatilla caffra Eckl. & Zeyh. 
 
Anemone fanninii Harv. ex Mast. 





Zulu believe the roots are used to produce hatred (DOKE and 
VILAKAZI, 1972). The burnt black roots are used ‘tomake other people 
black’ possibly indicating sorcery (GERSTNER, 1941; Hutchings et al., 
1996). In the Transkei the ground inner root is taken as snuff to treat 
dizziness (HUTCHINGS et al., 1996). A. caffra mixed with Athrixia 
heterophylla (Asteraceae) are used to treat unspecified m ntal disease 
by the Xhosa (WATT and BREYER-BRANDWIJK, 1962). Roots are 
used to make love potions and also in preparations o stimulate breast 
development in girls (BATTEN and BOKELMANN, 1966). A fanninii  
is reportedly used by the Zulu in the same way as A. caffra 
(HUTCHINGS et al., 1996). FELIX (1931) reported the use of the roots 
of an Anemone species in South Africa to treat insanity. 
 
Clematis villosa DC. subsp. 
villosa 
Syn: Clematopsis scabiosaefolia DC., 
Clematopsis scabiosifolia (DC.) Hutch. 
subsp. stanleyi Brummitt, Clematopsis 
stanleyi (Hook.) Hutch., Clematopsis 
villosa Hutch. subsp. stanleyi (Hook.) 
Kuntze  
 
281 The roots are burned and the smoke inhaled to treat madness in 





The Pondo traditionally use root infusions to wash patients suffering 
from sicknesses thought to be caused by ancestral spirits (WATT and 
BREYER-BRANDWIJK, 1962; HUTCHINGS et al., 1996). 
RHAMNACEAE 
Helinus integrifolius (Lam.) 
Kuntze. 
Syn: H. ovatus E.Mey. ex Sond., H. 
scandens (Eckl. & Zeyh.) A.Rich. 
soap creeper (E),  




Roots used in Zulu traditional medicine to treat hysteria (BRYANT, 
1966 ; POOLEY, 2005). An emetic for hysteria is made from the roots, 
pounded with the roots of Psoralea pinnata L. (Fabaceae) and stirred 
with cold water until it froths (saponins) (BRYANT, 1966). 
Rhamnus prinoides L’Herit. 
Syn: Celtis rhamnifolia C.Presl 
dogwood (Z) 
284 Unspecified groups use powdered bark that is administered as snuff to 
treat mental disorders in the Transkei (HUTCHINGS et al., 1996). The 
Chagga are reported to use the roots to inhance the narcotic effects of 
traditional beer (WATT and BREYER-BRANDWIJK, 1962). 
ROSACEAE 
Rubus ludwigii Eckl. & Zeyh. 







Roots are used to treat fits in the Transkei (HUTCHINGS et al., 1996). 
European settlers in the Cape of South Africa used roots of R. pinnatus 
Willd.  to treat convulsions (WATT and BREYER-BRANDWIJK, 
1962). 
RUBIACEAE 
Burchellia bubalina (L.f.) Sims 





Cold water infusions of pounded roots are taken as emetics against bad 
dreams (HULME, 1954). Roots are sometimes ingredients in Zulu love 
charm emetics (GERSTNER, 1941). 
 
Canthium inerme (L.f.) Kuntze 
Syn: C. ventosum (L.) Kuntze, Lycium 
inerme L.f. 
 
287 The roots are applied into incisions on the body to treat madness caused 
by chronic illness by the Shona of Zimbabwe (GELFAND et al., 1985). 
Canthium species are used in west Africa to treat m dness (AYENSU, 
1978). 
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Catunaregam species 
Syn: C. spinosa (Thunb.) Tirveng. 
thorny bone-apple 
NOTE: C. spinosa (Thunb) Tirveng. 
[Xeromphis obovata (Hochst.) Keay] 
occurs in China and is not found in Africa. 
288 Unspecified parts used as an phrodisiac in East Africa (VERDCOURT 
and TRUMP, 1969). Roots are used in drinks taken at riruals to induce 
emesis, faintness, intoxification and even death in Tete region of 
Mozambique (WATT and BREYER-BRANDWIJK, 1962). In 
Zimbabwe the roots are used to treat nausea, epilepsy and dizziness 
(GELFAND et al., 1985). 
 
Fadogia species 
F. ancylantha Hiern 
289 The powdered roots are taken in porridge to treat madness in Zimbabwe 
(GELFAND et al., 1985). 
 
Galium capense Thunb. 290 Used to treat people considered to ‘with the spirit’, a ype of mental 
disturbance or spiritual calling (LAYDEVANT, 1932; SOBIECKI, 
2002) 
 
Gardenia species 291 Roots of G. ternifolia Schumach. & Thonn. are used to treat madness 
in Malawi, while the bark is used as an ointment for treating convulsions 
in Zimbabwe (GELFAND et al., 1985). Unspecified parts of G. volkensii 
K. Schum. are taken orally in South Africa to treat epilepsy (VENTER, 
1996). 
 
Kohautia amatymbica Eckl. & 
Zeyh. 
Syn: Hedyotis amatymbica (Eckl. & 
Zeyh.) Steud; Oldenlandia amatymbica 
(Eckl. & Zeyh.) Kuntze  
umfana-ozacile (Z) - thin boy 
292 Used by unspecified groups to improve appetite of infants (POOLEY, 
2005). The Xhosa administer root infusions to babies as protective 
charms against evil (WATT and BREYER-BRANDWIJK, 1962). The 
Zulu use this plant for love charm emetics (GERSTNER, 1941). 
 
Nenax microphylla (Sond.) Salter 
Syn: Ambraria microphylla Sond. 
daggapit (A) 
293 Seeds were used by the people of the Karoo as a substitute for Cannabis 
(VAN WYK and GERICKE, 2000); presumably they have a narcotic 
effect. 
 
Pachystigma pygmaeum (Schltr) 
Robyns 
Syn: Vangueria pygmaea Schltr.;  
Vangueria setosa Conrath  
 
294 The roots are burned and the smoke inhaled to treat convulsions in 
Zimbabwe (GELFAND et al., 1985). 
Pygmaeothamnus zeyheri 
(Sond.) Robyns 
Syn: Pachystigma zeyheri Sond.;  
P. zeyheri (Sond.) Robyns var. oatesii 
Robyns; Vangueria zeyheri (Sond.) Sond.  
 
295 Root infusions are taken orally and used to wash the patients with 
delirium  in Zimbabwe (GELFAND et al., 1985). 
Vangueriopsis lanciflora (Hiern) 
Robyns  
Syn: Canthium lanciflorum Hiern;  
Vangueria lateritia Dinter  
 
296 Root infusions are dropped into the nose to treat madness by unspecified 
groups in Malawi (GELFAND et al., 1985). 
RUTACEAE 
Clausena anisata (Willd.) Hook. 




Used by Xhosa to treat mental disease and schizophrenia (PUJOL, 
1990). Pounded roots of a plant known as umnukambhiba (Z) reported to 
be C. anisata are used by the Zulu in an emetic for illness believ d to be 
inflicted by evil spirits or by the ancestors (HUTCHINGS et al., 1996). 
Aqueous extracts of the roots have shown behavioural and 
anticonvulsant activity in animal studies (MAKANJU, 1983). 
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Ruta graveolens L. 298 Herb and oil of this plant used to treat hysteria in South Africa (WATT 
and BREYER-BRANDWIJK, 1962). The plant is traditionally use in 
Europe for hysteria (VAN WYK et al., 1997) 
 
Zanthoxylum capense (Thunb.) 
Harv.  
Syn Fagara capensis Thunb. 
299 Used as an epilepsy remedy among Europeans (WATT and BREYER-
BRANDWIJK, 1962). The Zulu administer root decoctions of Z. davyi 
(Verdoorn) Waterm. as tonics to humans and animals (WATT and 
BREYER-BRANDWIJK, 1962). A species of Zanthoxylum is used to 
treat mental illness in Gabon (WALKER, 1953). 
SANTALACEAE 
Osyridicarpos schimperianus 
(Hochst. ex A. Rich.) A. DC. 
Syn: O. natalensis A.DC.  
umalala (Z) – (n) sleeping 
Perennial. Shrub. Ht 1–4 m. Alt up to 1980 





Leaves and stems are used to make babies sle p (MANANA, 1968; 
HUTCHINGS et al., 1996).  
Osyris lanceolata Hochst. & 
Steud. 
Syn: O. abyssinica Hochst. ex A.Rich. 
Perennial. Shrub. Ht 1.5–4 m. Alt up to 
3000 m. N, B, LIM, NW, G, M, S, FS, 
KZN, L, NC, EC 
 







magalismontanum (Sond.) Heine & 
J.H.Hemsl., Chrysophyllum 
magalismontanum Sond., Pouteria 






Fruit and roots used are used to treat epilepsy by the Kgatla (WATT and 
BREYER-BRANDWIJK, 1962). A strong alcoholic drink known in 
Afrikaans as mampoer is made from the fruit (WATT and BREYER-
BRANDWIJK, 1962). Unspecified groups use an infusion from roots 
and fruit to treat epilepsy in South Africa (COATES PELGRAVE, 
2002). 
 
Perennial. Tree or shrub. Ht 1–17 m. Alt 550–1830 m. B, LIM, NW, G, M, S, KZN 
 
Sideroxylon inerme L. 
amaSethole (-amhlophe) (Z) 
Perennial. Tree or shrub. Ht 1–15 m. Alt 
2–1092 m. LIM, M, S, KZN, WC, EC 
 
303 Emetics made from unspecified parts are taken to dispel bad dreams 
(WATT and BREYER-BRANDWIJK, 1962). 
Vitellariopsis marginata (N.E. 
Br.) Aubrév. 
Syn: Austromimusops marginata (N.E.Br.) 
A.Meeuse 
amaSethole (Z) 
Perennial. Tree or shrub. Ht 4–10 m. Alt 
25–700 m. M, S, KZN, EC 
 
304 The Zulus use the root of this tree which is dark red in making of 
’psychoactive medicine that cure moody people rendered neurotic by 
way of witchcraft’ (PUJOL, 1990). Root and leaf decoctions are also 
taken orally or as enemas, by Zulus as blood purifiers, strengtheners and 
sexual stimulants (HUTCHINGS et al., 1996). Root infusions are taken 
twice daily for idliso, poisoning in Zulu culture thought to be caused by 
sorcery (HUTCHINGS et al., 1996). 
SCROPHULARIACEAE 
Aptosimum decumbens Schinz 
Perennial. Dwarf shrub. Ht 0.02–0.1 m. 





An infusion of the plant or chewing leaves is reported to improve 
memory by the Kwanyama of Namibia (RODIN, 1985). 
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Harveya speciosa Bernh. ex 
Krauss 
(now in Orobanchaceae) 
Syn: Cycnium tubatum Benth., H. tubata 
(E.Mey. ex Drège) Hook. ex Steud., H. 
tubata (E.Mey. ex Drège) Reuter, 
Orobanche tubata E.Mey. ex Drège,  
Perennial. Herb, parasite. Ht 0.15−± 1 m. 
Alt 45−± 2600 m. LIM, G?, S, FS, KZN, 
L, EC 
 
306 Un specified parts used by Sotho for mental illness (WATT and 
BREYER-BRANDWIJK, 1962). 
 
Harveya huttonii Hiern. 
(now in Orobanchaceae) 
Annual? Herb, parasite. Ht 0.15−0.4 m. 
Alt 915−1415 m. EC 
 
307 Roots are chewed by unspecified groups as a sed tive for nervous 
tension in the eastern Cape region of South Africa (BATTEN and 
BOKELMANN, 1966). 
 
Phygelius capensis E. Mey. ex 
Benth. 
mafifi matso (S) 
 
Only two species in South Africa: 
P. aequalis Harv. ex Hiern 
Perennial. Shrub, dwarf shrub, herb. Ht 
0.45–2 m. Alt 915−2680 m. LIM, M, S, 
FS, KZN, L, EC 
P. capensis E.Mey. ex Benth. 
Perennial. Shrub, dwarf shrub, herb. Ht 
0.3–1.5 m. Alt 1065−2895 m. M, FS, 
KZN, L, WC, EC 
 
308 Used with the bulbs of Ledebouria cooperi (Hyacinthaceae) to inebriate 
Sotho boys during circumcision rituals (WATT and BREYER-
BRANDWIJK, 1962). This medicine reportedly causes the boys to 
appear stunned, stupefied and to fall asleep (HUTCHINGS et al., 1996). 
 
Sutera atropurpurea (Benth.) 
Hiern 
Now Jamesbrittenia atropurpurea 
(Benth.) Hilliard subsp. atropurpurea 
Syn: Chaenostoma croceum (Eckl. ex 
Benth.) Wettst. ex Diels, Lyperia 
atropurpurea Benth. in part, Lyperia 
crocea Eckl. ex Benth., Manulea 
atropurpurea (Benth.) Kuntze, Sutera 
atropurpurea (Benth.) Hiern  
 
309 The whole plant is burned and the smoke inhaled to treatmadness in 
Zimbabwe (GELFAND et al., 1985). 
 
Perennial. Dwarf shrub or shrub. Ht ± 1 m. Alt 300− 2000 m. NW, G, FS, L, NC, WC, EC 
 
SIMAROUBACEAE 
*Ailanthus altissima (Mill.) 
Swingle 





Root bark of this Chinese exotic reportedly used to treat epilepsy in 
South Africa (POTTER, 1932). 
SOLANACEAE 
*Datura ferox L. 
iloyi (Z)  
Annual. Shrub or herb. Ht 0.2–1.5 m. Alt 
5–1713 m. N, B, LIM, NW, G, M, FS, 





Leaves used to sedate hysterical and psychotic patients, also to treat 
insomnia (VAN WYK and GERICKE, 2000). 
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*Datura stramonium L. 
Syn: D. tatula L.  
iloyi (Z)  
-loya (v) bewitch, hypnotise 
 
Annual. Shrub or herb. Ht 0.35–2 m. Alt 
45–2380 m. N, B, LIM, NW, G, M, S, FS, 
KZN, L, NC, WC, EC 
 
312 Leaves used to sedate hysterical and psychotic patients, also to treat 
insomnia (VAN WYK and GERICKE, 2000). Used by Zulu as a 
hypnotic drug against hysteria and as a ‘diviner’s aid’ (POOLEY, 2005). 
 
*Nicotiana tabacum L. 
Annual, occ. perennial. Shrub or herb. Ht 
up to 1.2 m. Alt 50–1465 m. LIM, KZN, 
WC, EC 
 
313 Often taken as a snuff by southern African diviners at the start of 
divination , and is also made as an offering to ancestors (VAN WYK and 
GERICKE, 2000). 
 
Withania somnifera (L.) Dun 
Syn: Physalis somnifera L., W. 
microphysalis Suess 
 
ubuvimbha (Z)  
–vimba (v) prevent, close up, stop 
 
Perennial. Shrub or dwarf shrub, herb. Ht 
0.2–2 m. Alt 15–2300 m. N, B, LIM, NW, 
G, M, S, FS, KZN, L, NC, WC, EC 
 
314 In southern Africa infusions, decoctions and tinctures of Withania root 
are taken as an adaptogenic tonic, as well as a sedative and hypnotic 
(VAN WYK and GERICKE, 2000). In east Africa the roots are also 
reported to have narcotic and anti-epileptic effects (OLIVER-BEVER, 
1986). An unidentified plant named ubuvimba by the Zulu, reputed to be 
W. somnifera, is taken to induce clear d eams (MANANA, 1968). In 
Ayurvedic medicine (ashwaghanda) is used for many conditions, 
notabily as a brain tonic to help the elderly with learning and memory 
retention (VAN WYK and GERICKE, 2000). 
STERCULIACEAE 
Hermannia hyssopifolia L. 
Perennial. Shrub, dwarf shrub. Ht 0.3–3 m. 





Root decoctions are used among Europeans as an old Cape remedy for 
fits (WATT and BREYER-BRANDWIJK, 1962). The Plant refered to as 
umakotegoyile by the Zulu (Hermannia sandersonii Harv.) means 
‘hypnotised bride’.  
-makoti bride 
 -egoyile (v) being hypnotised 
THYMELAEACEAE 
Gnidia kraussiana Meisn. 
Syn: G. hoepfneriana Gilg, Lasiosiphon 
hoepfnerianus Vatke ex Gilg, Lasiosiphon 
kraussii Meisn. 
imfuzane (Z), umsilawengwe 
 
Perennial. Shrub, dwarf shrub. Ht 0.1–3 m. 
Alt 30–2200 m. N, B, LIM, NW, G, M, S, 





The powdered tuber is taken in porridge to treat m dness and poor 
appetite by the Shona of Zimbabwe (GELFAND et al., 1985). The Zulu 
use imfuzane, reported to be G. kraussiana to treat mental disorders 
(MANANA, 1968). The Sotho inhale smoke from burning G. 
anthylloides (L.f) Gilg  to stop bad dreams (WATT and BREYER-
BRANDWIJK, 1962). 
 
Synaptolepis kirkii Oliv. 
uvuma-omhlophe (Z) 
-vuma (v) clap hands during the 
process of divining 
-mhlophe (adv) white or clarity  
Perennial. Shrub. Ht 1.21–3.04 m. Alt 6–
155 m. LIM, S, KZN 
 
317 Root infusions have been used as purifying ritual emetics and face and 
body washes to assist South African diviners with v sions (VAN WYK 
and GERICKE, 2000). Root infusions also used to treat epilepsy by the 
Karanga (WATT and BREYER-BRANDWIJK, 1962). In eastern 
Tanzania, dried powdered inner roots are taken in tea as an aphrodisiac 
(HUTCHINGS et al., 1996). 
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TILIACEAE 
Corchorus asplenifolius Burch. 
Syn: C. serrifolius Burch. 
ubangalala (Z) 
Perennial. Herb. Ht 0.05–0.91 m. Alt 303–






The roots are taken together with Eriosema species (Fabaceae) as 








Unspecified groups use the plant in combination with Stachys 
thunbergii (Lamiaceae) to treat hysteria and insomnia in South Africa 
(VAN WYK and GERICKE, 2000).  
Varieties: 
V. capensis Thunb. var. capensis 
Perennial. Herb. Ht 0.15–1.5 m. Alt 305–3333 m. LIM, NW, G, M, S, FS, KZN, L, WC, 
EC 
V. capensis Thunb. var. lanceolata N.E.Br. 
Perennial. Herb. Ht 0.2–0.6 m. Alt 1200–3000 m. KZN, L, EC 
V. capensis Thunb. var. nana B.L.Burtt 







Weak teas of C. glabrum E. Mey. are taken at night by the Sotho 
(Tswana) to aid sleep (ROBERTS, 1990). Pounded leaves are placed in 
armpits and under neck to induce sleep and as a treatment for 
convulsion in children by the Lobedu, a Northern Sotho group (WATT 
and BREYER-BRANDWIJK, 1962). Leaf decoctions of C. myricoides 
(Hochst.) Vatke are used for bathing patients who suffer from 
convulsions in Zimbabwe (GELFAND et al., 1985). C. ternatum Schinz 
roots are taken orally in sweet beer to treat epilepsy in Zimbabwe 
(GELFAND et al., 1985). 
 
Lantana rugosa Thunb. 
Syn: L. salviifolia Jacq.  
 
Perennial. Shrub. Ht up to 1 m. Alt 30–
2160 m. N, B, LIM, NW, G, M, S, FS, 
KZN, L, NC, WC, EC 
 
321 Fruit is report to be edible but is reputed to have narcotic effects in birds 
(WATT and BREYER-BRANDWIJK, 1962). 
 
Lippia javanica (Burm. f.) Speng. 
Syn: Lantana galpiniana H.Pearson, L. 
asperifolia Rich., Verbena javanica 
Burm.f.  
 
Perennial. Shrub. Ht 0.7–5 m. Alt 5–1920 
m. B, LIM, NW, G, M, S, FS, KZN, EC 
 
322 Unspecified groups in Zimbabwe use the leaves to treat convulsions 
(GELFAND et al., 1985). The plant is used as a treatm nt for madness 
in Malawi (WILLIAMSON, 1974). 
Vitex rehmannii Gürke 
(now in Lamiaceae) 
umluthu (Z), unduly (Z) 
-luthu (ideo) of aiming true; 
-lutha (v) mislead, make a fool of.  
 
323 Unspecified parts used to treat hysteric fits by the Zulu (GERSTNER, 
1941). 
 
Perennial. Tree. Ht 2–3 m. Alt 60–1646 m. LIM, NW, G, M, S, KZN 
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Vitex wilmsii Gürke 
Now V. obovata subsp. obovata (now in 
Lamiaceae) 
Syn: V. reflexa H.Pearson, V. wilmsii 
Gürke var. reflexa (H.Pearson) W.Piep.  
Perennial. Tree. Ht 3–4 m. Alt 550–1370 
m. LIM, M, S, KZN, EC 
umluthu (Z) 
 
324 Bark infusions are taken as purifying emetics by adults when a kraal 
member is dying. Unspecified parts used to treat hys eric fits by the 
Zulu (GERSTNER, 1941).  
Subspecies: V. obovata E.Mey. subsp. wilmsii (Gürke) C.L.Bredenkamp & D.J.Botha 
Syn: V. wilmsii Gürke var. wilmsii 




indembu, iphakama (Z) 
 
V. anceps E.Mey. ex Sprague 
Syn: Aspidixia anceps E.Mey. ex Tiegh. 
Perennial. Shrub, parasite. Ht 0.5–1 m. Alt 





Unspecified parts, most likely the whole plant, of V. capense L. f.  
reported to be used by the Xhosa in the Cape to treat epilepsy (WATT 
and BREYER-BRANDWIJK, 1962). Unspecified parts of V. anceps E. 
Mey. ex Sprague is administered internally to treat hysteria in the 
Transkei. The plants are reportedly not used when in flower and 
overdosing causes drowsiness (HUTCHINGS et al., 1996). 
VITACEAE 
Rhoicissus tridentata (L.f.) Wild. 
Et R.B.Drumm 
Syn: Cissus cuneifolia Eckl. & Zeyh., R. 
cuneifolia (Eckl. & Zeyh.) Planch., R. 






Shona take a root infusion orally for the treatment of madness 
(GELFAND ET AL., 1985). 
 




(Schweinf.) B.L. Burtt 
Syn: Kaempferia aethiopica (Schweinf.) 
Benth., Kaempferia ethelae J.M.Wood, 
Kaempferia natalensis Schltr. & 
K.Schum., S. natalensis (Schltr. & 
K.Schum.) J.M.Wood & Franks  
 
indungulo (Z)  
–dungula (v) put enemy to flight, 
isiphephetho (Z)  
–phephetha (v) be blown away; 




Roots are used by Zulu to treat hysteria (GERSTNER, 1938). Over-
dosage of medicine made from S. aethiopicus reported to stupefy horses 
(WATT AND BREYER-BRANDWIJK, 1962). Unspecified groups in 
South Africa use rhizome infusions to treat pilepsy and hysteria (VAN 
WYK AND GERICKE, 2000). 
 
Perennial. Herb, geophyte. Ht 0.15–0.45 m. Alt 610–915 m. LIM, M, S, KZN, EC 
 
 
1 Ethnic groups: (A) = Arabic, (Af) = Afrikaans: SA, (E) = Europeans: SA, ( (Nd) = Ndebele: SA, (Sth) = Sotho (this 
language group includes Northern Sotho, South Sotho and Tswana), (San) = San: SA/Namibia/Angola, (Sh) = Shona: 
Zimbabwe, (Sw) = Swazi: SA, (Ts) = Tsonga: SA, (V) = Venda: SA, (X) = Xhosa: SA, (Z) = Zulu: SA. 
2 Translation of isiZulu names was achieved using NGWENYA, KOOPMAN and WILLIAMS (2003) and DENT and 
NYEMBEZI (1999).  
3 Annotations are taken from GERMISHUIZEN and MEYER (2003). 
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Table 2.2b. Alphabetical list of Southern African plants traditionally used for psychoactive purposes  
 
Species Code 
Abrus precatorius L. 
Syn: A. squamulosus E.Mey. 
161 
Acacia amythethophylla Steud. ex A. 
Rich. 
162 
Acacia karoo Hayne 163 
Acacia nilotica (L.) Willd. ex Del. 164 
Achyrocline stenoptera (DC.) 
Hilliard & Burtt 
(Syn: Helichysum stenopterum DC) 
065 
Acokanthera oppositifolia (Lam.) 
Codd 
Syn: A. venenata in sense of Stapf, not of 
G.Don. 
034 
Acorus calamus L. 044 
Adansonia digitata L. 103 
Adenia gummifera (Harv.) Harms 263 
Adenopodia spicata (E. Mey.) Presl 165 
Agapanthus africanus (L.) 
Hoffmanns. 
Syn: A. minor Lodd.,A. umbellatus L’Hér., 
Crinum africanum L., Mauhlia africana (L.) 
Dahl, Mauhlia linearis Thunb., Tulbaghia 




(Syn: A. patens F.M.Leight. 
006 
Agapanthus praecox Willd. 007 
Agave species 004 
Ailanthus altissima (Mill.) Swingle 310 
Albizia adianthifolia (Schumach.) 
W.F. Wight  
166 
Albuca fastigiata Dryand. 
Albuca nelsonii N.E. Br. 
195 
Alepidea amatymbica Eckl. & Zeyh. 028 
Aloe ferox Mill. 059 
Ammocharis coranica (Ker-Gawl.) 
Herb. 
012 
Anemone species 280 
Species Code 
Annona senegalensis Pers. 
Syn: A. arenaria Thonn. ex Schumach., A. 
chrysophylla Bojer  
024 
Ansellia africana Lindl. 257 
Anthericum species 060 
Antidesma venosum E. Mey. ex Tul. 150 
Aptenia cordifolia (L. f.) Schwant. 243 
Aptosimum decumbens Schinz 305 
Arctopus echinatus L.  029 
Arctotheca calendula (L.) Levyns 066 
Arctotis arctotoides (L. f.) O. Hoffm. 067 
Argyrolobium tomentosum (Andr.) 
Druce 
167 
Artabotrys brachypetalus Benth. 025 
Asparagus species 058 
Aspilia pluriseta Schweinf. 068 
Aster bakeranus Burtt Davy ex C.A. 
Sm. 
069 
Astripomoea malvacea (Klotzsch) A. 
Meeuse 
136 
Athrixia heterophylla (Thunb.) Less. 070 
Avonia rhodesica (N.E.Br.) 
G.D.Rowley 
Syn: Anacampseros rhodesica N.E. Br. 
276 
Azanza garckeana (F. Hoffm.) Exell 
& Hillc. 
228 
Balanites maughamii Sprague 099 
Ballota africana (L.) Benth. 206 
Bauhinia thonningii Schumach 168 
Becium grandiflorum (Lam.) Pichi-
Serm. 
207 
Begonia species  100 
Belamcanda chinensis (L.) DC. 
 
200 
Berkheya discolor (DC.) O. Hoffm. 
& Muschl. 
071 
Bersama lucens (Hochst.) Szyszyl. 238 
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Species Code 
Bersama tysoniana Oliv. 239 
Blumea alata (D. Don) DC. 072 
Bolusanthus speciosus (H. Bol.) 
Harms 
169 
Boophone disticha (L.f.) Herb. 
Syn: B. longepedicellata Pax 
013 
Bosica albitrunca (Burch.) Gilg & 
Ben. 
111 
Brachycorythis ovata Lindl. 




Brachylaena elliptica (Thunb.) DC. 073 
Brackenridgea zanguebarica Oliver. 255 
Bridelia cathartica Bertol. f.  151 
Buddleja (L.) species 222 
Bulbine frutescens (L.) Willd.  061 
Bulbine latifolia (L. f.) Roem. & 
Schult. 
062 
Burchellia bubalina (L.f.) Sims 
Syn: B. capensis R.Br., Lonicera bubalina L.f.  
286 
Buxus macowanii Oliv. 107 
Cadaba natalensis Sond. 112 
Caesalpinia bondac (L.) Roxb. 170 
Callilepis laureola DC. 074 
Cannabis sativa L. 109 
Canthium inerme (L.f.) Kuntze 
Syn: C. ventosum (L.) Kuntze, Lycium inerme 
L.f. 
287 
Capparis sepiaria L. 113 
Capparis tomentosa Lam. 114 
Carissa edulis Vahl 
Syn: Azima pubescens Suess. 
035 
Casearia gladiiformis Mast. 191 
Cassine papillosa (Hochst.) Kuntze 119 
Catha edulis (Vahl) Forssk. ex Endl. 120 
Catunaregam species 
Syn: C. spinosa (Thunb.) Tirveng. 
288 
Cenia sericea DC. 075 
Centella asiatica (L.) Urb.  030 
Species Code 
Chamaecrista mimosoides (L.) 
Greene 
171 
Chenopodium ambrosiodes L. 126 




Chrysanthemoides monilifera (L.) T. 
Norl. 
076 
Cineraria aspera Thunb. 077 
Cinnamomum camphora  (L.) T. 
Ness & C.H. Eberm. 
219 
Cissampelos pecies 241 
Clausena anisata (Willd.) Hook. f. 
ex Benth. 
297 
Clematis villosa DC. subsp. villosa 
Syn: Clematopsis scabiosaefolia DC., 
Clematopsis scabiosifolia (DC.) Hutch. subsp. 
stanleyi Brummitt, Clematopsis stanleyi 
(Hook.) Hutch., Clematopsis villosa Hutch. 
subsp. stanleyi (Hook.) Kuntze  
281 
Clerodendrum species 320 
Combretum adenogonium Steud. ex 
A. Rich. 
Syn Combretum ternifolium Engl. & Diels 
131 
Combretum microphyllum Klotzsch 132 
Combretum molle R. Br. ex G. Don 133 
Commelina africana L. 135 
Conophytum species 244 
Conyza scabrida DC. 078 
Corchorus asplenifolius Burch. 
Syn: C. serrifolius Burch. 
318 
Corycium nigrescens Sond. 260 
Cotyledon orbiculata L. 138 
Crabbea hiruta Harv. 
Syn: C. cirsioides (Nees) Nees;  
C. robusta N.E.Br.  
001 
Crassula alba Forssk. 139 
Crassula arborescens (Mill.) Willd. 140 
Crinum species 014 
Croton gratissimus Burch. 152 
Croton sylvaticus Hoscht. 153 
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Species Code 
Cucumis hirsutus Sond. 142 
Cunonia capensis L. 144 
Cussonia arborea A. Rich. 045 
Cussonia longissima Hutch. & Dalz.. 046 
Cussonia paniculata Eckl & Zeyh.. 047 
Cussonia spicata Thunb.. 048 
Cyathea dregei Kunze 145 
Cymbopogon nardus (L.) Rendle 
Syn: C. afronardus Stapf, C. validus (Stapf) 
Stapf ex Burtt Davy validus (Stapf.) Stapf. ex 
Burtt. Davy 
271 
Cynanchum obtusifolium L. f. 050 
Cysticapnos pruinosa (Bernh.) Liden 193 
Dalbergia obovata E. May. 172 
Datura ferox L. 311 
Datura stramonium L. 312 
Desmodium barbatum (L.) Benth. 
Syn: D. dimorphum Welw. ex Baker var. 
argyreum Welw. ex Baker, Nicolsonia barbata 
(L.) DC. var. argyrae (Welw. ex Baker) 
Schindl. 
173 
Dianthus crenatus Thunb. 116 
Dicoma anomala Sond. 079 
Dicoma shinzii O. Hoffm. 080 
Dioscorea diversiflora Griseb. 146 
Dioscorea dregeana Baker 147 
Diospyros lyciodes Desf. 149 
Disa polygonoides Lindl. 261 




Eleutherine bulbosa (Miller.) Urban 201 




Entada rheedii Spreng.  175 
Entandrophragma spicatum (C. 
DC.) Sprague 
233 
Eriosema cordatum E. Mey. 176 
Species Code 
Eriosema distinctum N.E. Br. 177 




Ethulia conyzoides L. f. 081 
Euclea crispa (Thunb.) Guerke 148 
Eulophia species 262 
Euphorbia species 154 
Exomis microphylla (Thunb.) 127 
Fadogia species 
F. ancylantha Hiern 
289 
Faurea saligna Harv. 278 
Ferraria glutinosa (Bak.) Rendle 202 
Flueggea virosa (Roxb. ex Willd.) 
Voigt. 
155 
Galium capense Thunb. 290 
Gardenia species 291 
Gasteria croucheri (Hook.f.) 064 
Gerrardina foliosa Oliv. 192 
Gladiolus papilio Hook. f. 203 
Gnidia kraussiana Meisn. 
Syn: G. hoepfneriana Gilg, Lasiosiphon 
hoepfnerianus Vatke ex Gilg, Lasiosiphon 
kraussii Meisn. 
316 
Gomphocarpus physocarpus E. Mey  051 
Harpephyllum caffrum Bernh. Ex 
Krauss 
018 
Hartogiella schinoides 121 
Harungana madagascariensis Lam. 
ex Poir.  
130 
Harveya huttonii Hiern. 307 
Harveya speciosa Bernh. ex Krauss 306 
Helichrysum aureonitens Sch. Bip. 082 
Helichrysum odoratissimum (L.) 
Sweet 
084 
Helichrysum species 083 
Helinus integrifolius (Lam.) Kuntze. 
Syn: H. ovatus E.Mey. ex Sond., H. scandens 
(Eckl. & Zeyh.) A.Rich. 
283 
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Species Code 
Hemizygia bracteosa (Benth.) Briq. 208 
Hermannia hyssopifolia L. 315 
Heteromorpha trifoliata (Wendl.) 
Eckl. & Zeyh. 
031 
Hibiscus pusillus Thunb. 229 
Hoslundia opposite Vahl 209 
Hypericum perforatum L. 129 
Hypoxis colchicifolia Bak. 198 
Hypoxis hemerocallidea Fisch. & 
C.A. Mey 
199 
Ilex mitis (L.) Radlk. 
Syn: I. capensis Sond. 
0430 
Indigofera hilaris Eckl. & Zeyh. 180 
Ipomoea species 137 
Jatropha curcas L. 156 
Kalanchoe brachyloba Welw. ex 
Britten 
141 
Khadi acutipetala (N.E. Br.) N.E. Br. 245 
Kohautia amatymbica Eckl. & Zeyh. 
Syn: Hedyotis amatymbica (Eckl. & Zeyh.) 
Steud; Oldenlandia amatymbica (Eckl. & 
Zeyh.) Kuntze  
292 
Lannea discolor (Sond.) Engl. 019 
Lannea schweinfurthii (Engl.) Engl. 020 
Lantana rugosa Thunb. 321 
Launaea nana (Bak.) Chiov. 085 
Ledebouria cooperi (Hook. f.) Jessop 
Syn: Scilla adlamii Baker, Scilla cinerascens 
Van der Merwe, Scilla cooperi Hook.f., Scilla 
galpinii Baker, Scilla glaucescens Van der 
Merwe, Scilla inandensis Baker, Scilla 
petiolata Van der Merwe, Scilla pusilla Baker, 
Scilla rogersii Baker, Scilla rupestris Van der 
Merwe, Scilla saturata Baker  
196 
Leonotis leonurus (L.) R.Br. 210 
Leucas martinicensis (Jacq.) R. Br. 211 
Lichtensteinia interrupta (Thunb.) 
Sond. 
Syn: L. kolbeana Bolus, L. pyrethrifolia Cham. 
& Schltdl. 
032 
Lippia javanica (Burm. f.) Speng. 322 
Species Code 
Lithospermum cinereum DC. 104 
Lobelia decurrentifolia (Kuntze) K. 
Schum. 
221 
Lopholaena coriifolia  (Sond.) Phill. 
& C.A. Sm. 
086 
Loranthus oleifolius (Wendl.) Cham. 
& Schlechtd. 
225 
Maerua angolensis DC. 115 
Maesa lanceolata Forssk. 252 
Malva parviflora L. 230 
Margaritaria discoidea (Baill.) 
Webster 
157 
Markhamia obtusifolia (Bak.) 
Sprague 
101 
Maytenus heterphylla (Eckl. & 
Zeyh.) N.K.B. Robson 
123 
Maytenus senegalensis (Lam.) 
Excell 
122 
Melia azedarach L. 234 
Melianthus comosus Vahl 240 
Mentha aquatica L. 212 
Mesembryanthemum species 246 
Millettia grandis (E.Mey.) Skeels 181 
Mimosa pudica L. 
Mimosa pigra L. 
182 
Momordica balsamina L 143 
Monadenium lugardiae N.E. Br.  158 
Monanthotaxis caffra (Sond.) Verdc. 
Syn: Guatteria caffra Sond., Popowia caffra 
(Sond.) Benth.  
026 
Mondia whitei (Hook. f.) Skeels 
Syn: Chlorocodon whitei Hook.f.  
265 
Moraea spathulata (L. f) Klatt 204 
Myosotis afropalustris C.H. Wr. 105 
Myrothamnus flabellifolius Welw. 251 
Nenax microphylla (Sond.) Salter 
Syn: Ambraria microphylla Sond. 
293 
Newtonia hildebrandtii (Vatke) 
Torre 
183 
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Species Code 
Nicotiana tabacum L. 313 
Nuxia floribunda Benth. 223 
Nylandtia spinosa (L.) Dumort. 
Syn: Mundia spinosa (L.) DC. 
272 
Nymania capensis (Thunb.) Lindb. 237 
Nymphaea nouchali Burm. f. 254 
Ocimim canum Sims 213 
Ocotea bullata (Burch.) Baill. 220 
Olea woodiana Knobl. 256 
Oncinotis tenuiloba Stapf  
Syn: O. inandensis J.M.Wood & M.S.Evans 
036 
Oncosiphon piluliferum (L. f.) 
Källersjö 
087 




(Hochst. ex A. Rich.) A. DC. 
300 
Osyris lanceolata Hochst. & Steud. 301 
Oxygonum species 275 
Pachycarpus asperifolius Meisn. 052 
Pachystigma pygmaeum (Schltr) 
Robyns 
Syn: Vangueria pygmaea Schltr.;  
Vangueria setosa Conrath  
294 
Pancratium tenuifolium Hochst. ex 
A.Rich 
Syn: Chapmanolirion juttae Dinter, P. 
chapmannii Harv. 
015 
Parinari capensis Harv 128 
Pellaea calomelanos (Swartz) Link 003 
Phygelius capensis E. Mey. ex 
Benth. 
308 
Phyllanthus reticulates Poir 159 
Phytolacca species  267 
Piper capense L. f. 268 
Pittosporum viridiflorum Sims 269 
Pleiocarpa pycnantha (K. Schum.) 
Stapf. 
Syn: P. swynnertonii S.Moore 
037 
Species Code 
Pleiospilos bolusii (Hook. f.) N.E. 
Br. 
Syn: Mesembryanthemum bolusii Hook.f.,  
P. barbarae Karrer, P. beaufortensis L.Bolus  
247 
Pleurostylia capensis (Turcz.) Loes 124 
Plumbago auriculata Lam. 270 
Printzia pyrifolia Less. 090 
Psoralea pinnata L. 184 
Ptaeroxylon obliquum (Thunb.) 
Radlk. 
Syn: P. utile Eckl. & Zeyh. 
279 
Pterocelastrus rostratus Walp. 125 
Pycnostachys urticifolia Hook 214 
Pygmaeothamnus zeyheri (Sond.) 
Robyns 
Syn: Pachystigma zeyheri Sond.;  
P. zeyheri (Sond.) Robyns var. oatesii Robyns; 
Vangueria zeyheri (Sond.) Sond.  
295 
Rabiea albinota (Haw) N.E. Br. 248 
Ranunculus species 282 
Rapanea melanophloeos (L.) Mez 253 
Raphionacme species 266 
Rauvolfia caffra Sond. 
Syn: R. natalensis Sond. 
038 
Rhamnus prinoides L’Herit. 
Syn: Celtis rhamnifolia C.Presl 
284 
Rhoicissus tridentata (L.f.) Wild. Et 
R.B.Drumm 
326 
Rhus chirindensis Bak. f. 
(= Searsia chirindensis (Baker f.) Moffett) 
021 
Rhus natalensis Bernh. Ex krauss 
(= Searsia natalensis (Bernh. ex Krauss) 
F.A.Barkley) 
022 
Rhus pyroides Burch. 
(= Searsia pyroides (Burch.) Moffett) 
023 
Rhynchosia nervosa Benth. & Harv. 185 
Rubus ludwigii Eckl. & Zeyh. 
Syn: R. rhodacantha E.Mey. 
285 
Ruta graveolens L. 298 
Salvia chamelaeagnea Berg. 215 
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Species Code 
Scadoxus multiflorus (Martyn) Raf.  
Syn: Haemanthus katharinae Baker, 
Haemanthus multiflorus Martyn, Haemanthus 
otaviensis Dinter, Haemanthus sacculus 
E.Phillips 
016 
Scadoxus puniceus (L.) Friis & 
Nordal 
Syn: Haemanthus magnificus Herb., 
Haemanthus natalensis Pappe ex Hook., 
Haemanthus puniceus L. var. puniceus 
017 
Sceletium species 249 
Schefflera umbillifera (Sond.) Baill. 049 
Schizocarphus nervosus (Burch.) 
Van der Merwe 
Syn. Ornithogalum nervosum Burch., S. 
acerosus Van der Merwe, S. gerrardii (Baker) 
Van der Merwe, S. rigidifolius (Kunth) Van 
der Merwe, Scilla gerrardii Baker, Scilla 
nervosa (Burch.) Jessop, Scilla rigidifolia 
Baker, Scilla rigidifolia Baker var. acerosa 
Van der Merwe, Scilla rigidifolia Baker var. 
nervosa Baker 
197 
Schotia brachypetala Sond. 186 




Senecio discodregeanus Hilliard & 
Burtt. 
091 
Senna didymobotrya (Fresenius) 
N.W. Irwin & R.C. Barneby 
Syn. Cassia didymobotrya Fresen. 
187 
Senna petersiana (Bolle) J.M. 
Lock 
Syn. Cassia petersiana Bolle 
188 
Sesamothamnus lugardii N.E. Br. ex 
Stapf 
264 
Sideroxylon inerme L. 303 
Silene burchellii Otth 117 
Silene capensis Ott. ex DC. 118 
Siphonochilus aethiopicus 
(Schweinf.) B.L. Burtt 
327 




Sisyranthus trichostomus K. Schum. 055 
Solanecio angulatus (Vahl) C. 
Jeffrey 
092 
Sparaxis grandiflora (Delaroche) 
Ker-Gawl. 
205 
Sphedamnocarpus pecies 227 
Stachys thunbergii Benth. 216 
Stapelia gigantea N.E. Br. 
Syn: S. cyclista C.A.Lückh., S. gigantea 
N.E.Br. var. pallida E.Phillips, S. marlothii 
N.E.Br., S. nobilis N.E.Br., S. youngii N.E.Br. 
056 
Steganotaenia araliacea Hochst. 033 
Stephania species 242 
Strophanthus gerrardii Stapf 039 
Strophanthus petersianus  
Klotzch 
Syn: S. grandiflorus (N.E.Br.) Gilg 
040 
Strophanthus speciosus (Ward & 
Harv.) Reber 
041 
Strychnos species 224 
Sutera atropurpurea (Benth.) Hiern 
Syn Lyperia atropurpureae (Benth.) 
 
309 
Synaptolepis kirkii Oliv.  317 
Syncolostemon parviflorus E. Mey. 
ex Benth 
217 
Tagetes minuta L. 094 
Talinum species 277 
Tarchonanthus camphorates L. 095 
Tecomaria capensis 102 
Tephrosia capensis (Jacq.) Pers. 189 
Terminalia species 134 
Thespesia acutiloba (Bak. f.) Exell & 
Mendonca 
231 
Thunbergia dregeana Ness 002 
Tinnea zambesiaca Bak. 218 
Tragia meyeriana Müll. Arg. 160 
Trichodesma physaloides (Fenzl) A. 
DC. 
106 
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Species Code 
Trichodiadema species 250 
Tulbaghia alliaceae L. f. 008 
Tulbaghia leucantha Bak 
Syn: T. dieterlenii E.Phillips 
009 
Tulbaghia violaceae Harv. 
Syn: Omentaria cepacea Salisb.,  
T. cepacea L.f. 
010 
Turraea floribunda Hochst. 235 
Turraea nilotica Kotschy & Peyr 236 
Uvaria lucida Benth. 
Syn: U. gazensis Baker f., U. virens N.E.Br.  
027 
Valeriana capensis Thunb. 319 
Vangueriopsis lanciflora (Hiern) 
Robyns  
Syn: Canthium lanciflorum Hiern;  
Vangueria lateritia Dinter  
296 
Vernonia adoensis Sch. Bip. ex 
Walp.  
096 
Vernonia amygdalina Del. 097 
Vernonia neocorymbosa Hilliard 098 
Vigna species 190 
Viscum species 325 
Vitellariopsis marginata (N.E. Br.) 304 
Vitex rehmannii Guerke 323 
Vitex wilmsii Guerke 324 
Wahlenbergia grandiflora V. 
Brehm. 
108 
Warbergia salutaris (bertol. F.) 
Chiov. 
110 
Withania somnifera (L.) Dun 
Syn: Physalis somnifera L., W. microphysalis 
Suess 
314 
Wrightia natalensis Stapf 042 
Xysmalobium undulatum (L.) 
Aiton.f. 
057 
Zanthoxylum capense (Thunb.) 
Harv.  










Depressive disorders, including major depression and dysthymia, are significant and disabling illnesses. It 
is estimated that one in five individuals is affected by a mood disorder in his or her lifetime. The World 
Health Organization (WHO, 1999) estimates that major depression is the fourth most important cause 
worldwide of loss in disability-adjusted life years, and will be the second most important cause by 2020 
(MURRAY and LOPEZ, 1996). Depression affects an estimated 121 million people worldwide. 
 
In South Africa in 1990, the overall suicide rate was 17.2 per 100,000, which is slightly higher than that
in the WHO report (1999). Initial estimates from the South African National Burden of Disease Study 
(2000) indicated suicide as the 10th out of 20 leading causes of mortality (BRADSHAW, 
GROENEWALD, LAUBSCHER, NANNAN, NOJILANA, NORMAN, PIETERSE, SCHNEIDER, 
2003). South Africa has a history of traumatized citizens and is a society in transition. Suicidal behavior 
among the black population in South Africa appears to be on the increase (LOURENS and NASEEMA, 
1998). South African, black youth do not only increasingly consider suicide as an option when they 
cannot cope, but act on it in certain cases as well, especially when they are under severe depression 
(MEEL, 2003). Depressive symptoms (64%) are highly prevalent immediately before suicide (HEILA, 
ISOMETSA, HENRIKSSON, HEIKKINEN, MARTTUNEN, LONNQVIST, 1997). 
 
South Africa is in a HIV/AIDS epidemic of shattering dimensions (DORRINGTON, BOURNE, 
BRADSHAW and LAUBSCHER, 2001). Depression in the HIV positive individuals is significantly 
higher. Although depressive symptoms may not be strong enough to warrant a psychiatric diagnosis, a 
careful evaluation of risks is required (FUKUNISHI, MATSUMOTO, NEGISHI, HAYASHI, HOSAKA 
and MORIYA, 1997). Depressive symptoms and suicidal eation are common amongst HIV positive 
patients, occurring at comparable or greater rates than those found in a variety of other medically il 
populations (JUDD and MIJCH, 1996). In South Africa, as is the case in most Third World countries, 
there is a serious limitation for this care as treatment for severe mental disorders is not available in most 
primary health care settings. 
 
Depression appears to have both a genetic and environmental basis. Twin studies suggest that about 25–
30% of the variance is genetic (HENN, VOLLMAYR and SARTORIUS, 2004) and that environmental 
factors account for about 75% of the variance. The most important environmental factor is stress 
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(CHARNEY and MANJI, 2004). Psychiatric treatment of depression depends on our understanding of the 
pathophysiology of the disease and of the mechanisms by which drugs relieve symptoms of depression. 
Depressive illness was initially recognized as a biochemical phenomenon in the mid-sixties of the last 
century (SCHILDKRAUT, 1965). Since then the monoamine theory of depression became widely 
accepted. It briefly states that mental depression i  due to deficiency of brain monoaminergic activity and 
that depression is treated by drugs that increase this activity (SCHILDKRAUT, 1965). Different 
mechanisms may increase the availability of brain monoamines. These include blocking the reuptake of 
the monoamine from the synapse, inhibiting the intraneuronal metabolism of the monoamine or blocking 
the presynaptic inhibitory auto- or hetero-receptors. Many recent reviews discussed the role of 
monoamines in depression (SVENSSON, 2000; HENSLER, 2002; 2003; BLIER and WARD, 2003; 
ELHWUEGI, 2004). 
 
These reviews are largely written for specialists in the field and are partly covered in Chapter 1 (page 
13). Thus a simpler explanation with an emphasis on serotonin re-uptake is given in the following 
sections, with relevant background material, to enable adequate understanding of the concepts and 
findings of this research. 
 
3.2. Monoamines and their role in depression 
 
Considerable experimental and clinical evidence support the fundamental role of NA and 5-HT in the 
etiology of depression (ELHWUEGI, 2004). There are four classes of standard antidepressants, 
monoamine oxidase (subtype-A) inhibitors (MAOIs), tricyclic antidepressants (TCAs), serotonin re-
uptake inhibitors (SSRIs) and noradrenaline (NA)–serotonin reuptake inhibitors. All these antidepressant 
drugs increase acutely the availability of these monoamines at the synapse (BALDESSARINI, 1989). 
During 2000 three out of five of the leading world wide CNS drugs were SSRI and the top  five drugs all 
involved serotonin in their mechanism of action (Table 3.2.1.). 
 
Table 3.2.1. Worldwide leading CNS products in 2000 (JONES and BLACKBURN, 2002). 
Product Generic name Mechanism of 
action 
Theraputic class 2000 sales 
(Million USD) 
Prozac Fluoxetine SSRI Antidepressant 2875 
Seroxat Paroxetine SSRI Antidepressant 2415 
Zyprexa Olanzapine DA2/5-HT2/other Antipsychotic 2391 
Zoloft Sertraline SSRI Antidepressant 2248 
Risperidal Risperidone DA2/5-HT2/other Antipsychotic 1707 
 
It is well established that neurotransmitter transporters have roles in several neurological and psychiatric 
diseases. This is directly supported by several examples of naturally occurring mutations in the 
transporter genes that cause or increase the risk of developing certain diseases. Examples include 
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mutations in the gene encoding SERT that are associated with symptoms of obsessive–compulsive 
disorder, Asperger’s syndrome, anorexia and autism (KILIC, MURPHY and RUDNICK, 2003). 
Furthermore, it is indirectly supported by the fact that the SLC6 family (SLC from solute carrier)of 
transporters, to which SERT belongs, is a target of several pharmaceutical compounds. 
 
Monoamine transporters 
The transmembrane transport of neurotransmitters is of primary importance for proper signaling between 
neurons. The transport processes are mediated by distinct classes of membrane transport protein that have 
key roles in controlling the neurotransmitter concentration in the synaptic cleft (GETHER, ANDERSEN, 
LARSSON and SCHOUSBOE, 2006). These transporters can be classed as intracellular vesicular 
transporters that are responsible for sequestering tra smitters from the cytoplasm into synaptic vesicl , 
and plasma membrane transporters that are responsible for sequestering released transmitter from the 
extracellular space (Figure 3.2.1.). There are three subclasses of intracellular transporter: the vesicular 
amine transporters SLC18 gene family), the vesicular inhibitory amino acid transporter family (SLC32) 
and the vesicular glutamate transporters (SLC17 gene family). 
 
There are two major subclasses of plasma membrane tsporter: the high-affinity glutamate transporters 
(SLC1 gene family) and the Na+/Cl--coupled transporters (SLC6 gene family). The latter subclass is the 
largest and includes transporters of dopamine, serotonin, noradrenaline, glycine and GABA (Figure 
3.2.1.; Table 3.2.2.)  
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Abbreviations: ADHD, attention deficit hyperactivity disorder; exo-THPO, 4-amino-4,5,6,7-
tetrahydrobenzo[d]isoxazol-3-ol; MDMA, 3,4-methylenedioxymethamphetamine; MPPC, 1-methyl-4-
phenylpyridinium; NPTS, N-[3-phenyl-3-(40-(4-toluoyl)phenoxy)propyl]sarcosine; OCD, obsessive–compulsive 
disorder; (R)NFPS, N-[3-(40-fluorophenyl)- 3-(40-phenylphenoxy)propyl]sarcosine; THPO, 4,5,6,7-
tetrahydroisoxazolo[4,5-c]pyridine-3-ol. 
 
As mentioned previously the monoamine transporters are of therapeutic significance as targets of 
antidepressants. Classical tricyclic antidepressant target primarily NAT and/or SERT; selective 5-HT-
reuptake inhibitors (SSRIs) are specific inhibitors f SERT, and 5-HT–noradrenaline-reuptake inhibitors 
(SNRIs) are active at both SERT and NAT (LEONARD, 1997; GOODNICK and GOLDSTEIN, 1998; 
HUMBLE, 2000; BRUNELLO, MENDLEWICZ, KASPER, LEONARD, MONTGOMERY, NELSON, 
PAYKEL, VERSIANI and RACAGNI, 2002; TORRES and CARON, 2003) (Table 3.2.2.). 
 




SLC6 gene family transporters 
Transporters: DAT, SERT, NET, GAT1–4, 
GlyT1 and GlyT2 
Ion dependence: Na+, (Cl–) (co-transport), 
SERT: K+ (countertransport) 
Structure: 12 TMs, dimers 
 
SLC18 and SLC32 gene family transporters 
Transporters: VMAT1 and VMAT2, VAChT, 
VIAAT 
Ion dependence: H+ (antiporters) 




















 Na+, K+, Ca2+, Cl– Ligand-gated ion channel 
Figure 3.2.1. Monoamine re-uptake transporters.  
In the presynaptic nerve terminals of dopamine-, 5-HT-, noradrenaline-, glycine- and GABA-containing synapses, 
vesicular transporters belonging to the SLC18 (vesicular monoamine transporter (VMAT)1 and VMAT2, and 
vesicular acetylcholine transporter (VAChT)) and SLC32 (vesicular inhibitory amino acid transporter (VIAAT)) 
gene families (black) sequester neurotransmitters into synaptic vesicles. Released neurotransmitter exrts its 
effects via ionotropic receptors (ligandgated ion channels) such as GABAA receptors, glycine receptors and 5-HT3 
receptors (grey) or via G-protein-coupled receptors (GPCRs) such as dopamine receptors, adrenoceptors, 5-HT 
receptors and metabotropic GABAB receptors (with associated G protein in gray). Theplasma membrane 
transporters responsible for removing neurotransmitter from the synaptic cleft belong to the SLC6 gene family 
(white) and are located in the membrane of the presynaptic neuron (DAT, SERT, NET, GlyT2, GAT-1 and GAT-
2) or in the membrane of glial cells (GlyT1, GAT-1, GAT-2 and GAT-3) (after GETHER, ANDERSEN, 
LARSSON and SCHOUSBOE, 2006). 
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Primarily because of the lack of trustworthy structural models, there is still limited knowledge about the 
binding sites for antidepressants at monoamine transporters (for a recent review, see TORRES, 
GAINETDINOV and CARON, 2003). The monoamine transporters are also targets of widely abused 
compounds such as cocaine and amphetamine. Naturally occurring targets of monoamine transports are 
given in Table 3.2.3. 
 
Figure 3.2.2. The serotonin transporter (SERT) resembles other 
biogenic amine transporters (i.e. noradrenaline and dopamine 
transporters). The protein’s structure is composed of twelve 
transmembrane (TM) helices with an extracellular loop between TM 
helices 3 and 4. Both polypeptide termini are located within the 
cytoplasm and six putative phosphorylation sites (potential targets for 
protein kinase A and protein kinase C) exist in the same 
compartment. The areas important for selective serotonin (5-HT) 
affinity are localized within helices 1 through 3 and helices 8 through 
12 (Adapted from LESCH, WOLOZIN, ESTLER, MURPHY, 
RIEDERER, 1993). 
 (Insert) A conceptualized structure of the molecule based on scientific findings. A transporter protein found 
in the plasma membrane of serotonergic neurons is responsible for re-uptake of the transmitter. The serotonin 
transporter is a carrier of serotonin molecules across the biological membrane. Transporters undergo 
conformational changes and move one or more molecules per "cycle", unlike channels that stay open or 
closed, thus allowing floods of molecules to move across membrane bilayers. 
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Table 3.2.3. Compounds known to interact with re-uptake of amine neurotransmitters into neurons and synaptic vesicles.  
An important way neurotransmitters are removed from the synapse (synaptic cleft) involves energy-dependent (i.e. ATP-dependant) re-uptake into the cytosol f the releasing 
neuron. A major family of 12 transmembrane α-helix transporters co-transport amine neurotransmitters with Na+ and Cl-. Uptake of amine neurotransmitters from the neuronal 
cytosol into synaptic vesicles is achieved by vesicular monoamine transporters (VMAT1 and VMAT2) that sequester dopamine, adrenaline, noradrenaline and serotonin. The 
plant derived psychoactive drug cocaine inhibits dopamine, noradrenaline and serotonin re-uptake and he ce is a stimulant. The synthetic compound fluoxetine (Prozac) inhibits 


















Dopamine transporter, noradrenaline transporter and 
serotonin transporter (topical anaesthetic, ophthalmic, 
CNS stimulant, through the elevation of synaptic 
dopamine, noradrenaline and serotonin) 
O-Desmethylibogaine (= 12-Hydroxyibogamine) 
(indole) 
Primary metabolite of ibogaine. Tabernanthe iboga, 
Voacanga thouarsii (Apocynaceae) 
Vesicular dopamine transporter ligand, serotonin 
transporter ligand at cocaine and paroxetine sites 
Ibogaine (= 12-Methoxyibogamine) 
(indole) 
Tabernanthe iboga, Voacanga thouarsii (Apocynaceae) Dopamine transporter (IC50 = 4 µM); 
Vesicular monoamine transporter; 
Serotonin transporter (IC50 = 0.6 µM) 
(elevates synaptic serotonin, currently used as anti-
addictive)  
Noribogaine (= 12-Hydroxyibogaine) 
(indole) 
Metabolic product of ibogaine. Tabernanthe iboga, 
Voacanga thouarsii (Apocynaceae) 
Dopamine transporter (IC50 = 4 µM); 
Serotonin transporter (IC50 = 40 nM) 
(elevates synaptic serotonin, anti-addictive, 
anticonvulsant, CNS stimulant, hallucinogen) 
Rscinnamine (= Reserpinine) 
(indole) 




Rauwolfia spp., Catharanthus roseus, Vinca minor 
(Apocynaceae) 
Vesicular monoamine transporter, VMAT1, VMAT2 (anti 






Hypericum perforatum (Hypericaceae) 
 
Dopamine transporter, noradrenaline transporter and 
serotonin transporter (antidepressant) 
Cannabidiol 
(phenolic) 
Cannabis sativa, Humulus lupulus (Cannabaceae) Dopamine transporter (Kd ~ 20 µM), noradrenaline 
transporter (Kd ~ 20 µM) and serotonin transporter (Kd ~ 
20 µM), GABA transporter (Kd ~ 140 µM) 
Hyperforin 
(phloroglucinol) 
Hypericum perforatum (Hypericaceae) Dopamine transporter and serotonin ransporter 
(antidepressant) 








Kavain (= Gonosan; Kawain) 
(pyrone) 
Piper methysticum (Piperaceae) Noradrenaline transporter 
(+)-Methysticin 
(pyrone) 




Cannabis sativa (Cannabaceae) Dopamine transporter (Kd = 12 µM), noradrenaline 
transporter (Kd = 12-25 µM) and serotonin transporter (Kd 




Cannabis sativa (Cannabaceae) Dopamine transporter (Kd ~ 20 µM), noradrenaline 
transporter (Kd ~ 20 µM) and serotonin transporter (Kd ~ 
20 µM), GABA transporter (Kd ~ 140 µM) 
Tyramine (=4-Hydroxyphenylalanine) 
(phenolic) 
Lophophora williamsii, Trichocereus pachanoi (Cactaceae), 
Hordeum vulgare, Lolium multiflorum (Poaceae), Citrus 
spp. (Rutaceae), Viscum album (Viscaceae) 






 Catha edulis, Maytenus krukovii (Celastraceae) 
 
Dopamine transporter and serotonin transporter (anorexic, 
CNS stimulant, euphoriant) 
Methcathinone 
(phenylpropanoid) 
 Catha edulis, Maytenus krukovii (Celastraceae) Dopamine transporter and serotonin transporter (CNS 
stimulant) 
Non-plant reference compound 
Citalopram (=Cipramil) 




Serotonin re-uptake inhibitor (antidepressant) 
Fluoxetine (= Prozac) 
(trifluorophenoxy phenyl tertiary amine) 
Synthetic Serotonin re-uptake inhibitor (antidepressant) 
Paroxetine 
(fluorophenyl isobenzofuran tertiary amine)) 
Synthetic Serotonin re-uptake inhibitor (antidepressant) 
Ritalin (= Methylphenidate)) 
(piperidine) 
Synthetic Dopamine transporter and serotonin transporter (elevates 
serotonin and dopamine, used to calm children with 
hyperactivity-attention deficit disorder) 
Zimeldine 
(aryl piridinyl amine) 
Synthetic Serotonin re-uptake inhibitor (antidepressant) 
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3.3.  Screening of southern African plants for SSRI activity 
 3.3.1.  Introduction and Summary 
Initially, seventy five extracts from 35 plant species (mostly indigenous) used in South African traditional 
medicine or taxonomically related to these were investigated for their affinity to the serotonin reuptake 
transport protein, making use of an in vitro serotonin reuptake transport protein binding assay (NIELSEN, 
SANDAGER, STAFFORD, VAN STADEN and JÄGER, 2004). Bioassay-guided fractionations of 
Boophone disticha (Amaryllidaceae) lead to the isolation and identification of two alkaloids, 
buphanadrine and buphanamine (SANDAGER, NIELSEN, STAFFORD, VAN STADEN and JÄGER, 
2005). The activity of these alkaloids inspired furthe  screening of several Amaryllidaceae alkaloids 
(ELGORASHI, STAFFORD, JÄGER and VAN STADEN, 2006) which does not form part of this thesis.  
 
 3.3.2. Materials and methods 
Plant material 
All plant material was selected on the basis of tradi ional uses described in Chapter 2. Material was 
collected from January to March 2003 in KwaZulu-Natal, South Africa (Table 3.3.2.1.). Material of 
Gethyllis ciliaris was obtained from Graham Duncan, from the Western Cape. Freshly collected plant 
parts were washed thoroughly with water and dried in an oven at 50 °C for 48-72 h. The dried material 
was ground to a fine powder and stored in plastic bottles in the dark until use. It should be noted that t is 
practice has been changed due to the detection of contaminants (most notably phthalates), most-likely 
originating from the plastic bottles. 
 
Table 3.3.2.1. Plant species, family, plant parts and voucher numbers of material collected for screening in the [3H]-
citalopram binding assay. 
Family 
Plant species 
Voucher specimen Plant parts investigated 
Agapanthaceae 
Agapanthus campanulatus F.M.Leight. 
 
Stafford 59 NU 
 
leaves, flowers and roots 
Amaryllidaceae 
Boophone disticha (L.f.) Herb 
 
Stafford 53 NU 
 
leaves, roots and bulbs 
Brunsvigia grandiflora Lindl.  Stafford 10 NU leaves and bulbs 
Gethyllis ciliaris L.f.  Stafford 76 NU bulb 
Apiaceae 
Alepidea natalensis Wood & Evans  
 
Stafford 61 NU 
 
leaves and roots 
Apocynaceae 
Acokanthera oblongifolia (Hochst.) Codd  
 
Stafford 14 NU 
 
leaves 
Stropharanthus speciosus (Ward et Harv.) Reber  Stafford 94 NU leaves 
Asclepiaceae 
Gomphocarpus fruticosa (L.) Aiton f. subsp. 
(=Asclepias fruticosa L.)  
Stafford 65 NU leaves 
Xysmalobium undulatum (L.) Aiton.f.  Stafford 95 NU aerial parts and roots 
Asphodelaceae 
Bulbine frutescens (L.) Willd.  
 
Stafford 17 NU 
 
roots 
Gasteria croucheri (Hook.f.) Baker Stafford 18 NU leaves 
Asteraceae 
Artemisia afra Jacq. ex Willd.  
 
Stafford 63 NU 
 
leaves 
Artemisia dracunculoides Pursh.  Stafford 64 NU leaves 




Voucher specimen Plant parts investigated 
Campanulaceae 
Lobelia alata Labill.  
 




Cotyledon orbiculata L.  
 




Indigofera tristis E.Mey.  
Stafford 27 NU leaves 
Indigofera woodii Bolus  Stafford 28 NU leaves 
Hyperaceae 
Hypericum lanandii Choisy  
 
Stafford 79 NU 
 
leaves 
Hypericum revolutum Vahl  Stafford 80 NU leaves 
Lamiaceae 
Hemizyga obermeyerae M.Ashby 
 
Stafford 78 NU 
 
leaves 
Leonotis leonurus R.Br. Stafford 38 NU leaves 
Mentha aquatica L.  Stafford 84 NU leaves 
Lauraceae 
Cinnamomum camphora (L.) Presl. 
 




Malva parviflora L.  
 




Olea africana (Mill) P.S. Green  
 




Mondia whitei (Hook.f.) Skeels  
 
Stafford 43 NU 
 
leaves and flowers 
Phytolaccaceae 
Phytolacca octandra  L.  
 




Piper capense L. 
 
Stafford 89 NU 
 
leaves and roots 
Rosaceae 
Rubus ludwigii Eckl. et Zeyh.  
 




Conostomium natalense (Hochst.) Bremek.  
 
Stafford 70 NU 
 
leaves and roots 
Rutaceae 
Clausena anisata (Willd.) Hook.f.  
 
Stafford 47 NU 
 
leaves and bark 
Zanthoxylum capense (Thunb.)Harv. Stafford 96 NU leaves 
Scrophulariaceae 
Diclis reptans Benth  
 




*Datura ferox L.  
 
Stafford 72 NU 
 
leaves, flowers and seeds 
*Datura stramonium L.  Stafford 73 NU leaves, seeds and seed pods 
* exotic species 
 
Preparation of plant extracts 
Two grams of dried, grounded plant material were extracted in either 20 ml demineralized (distilled and 
de-ionized) water or 70% ethanol for 60 min in an ultra sonic bath. The extracts were filtered through 
Whatman No. 1 filter paper and then evaporated to dryness using rotary evaporators for the ethanolic 
extracts and freeze-dried in the case of aqueous extracts. 
 
Bioassay-guided fractionation, isolation and identification of active constituents of Boophone disticha 
Hundred g fresh leaves of Boophone disticha were extracted with 70% ethanol (3×500 ml). This wa done 
by was done be 3x60 min periods in an ultrasound bath. The extract was fractionated on 150 g of Merck 
Silica gel 60 in a vacuum column. Five hundred milliliters of each of the following solvents were used as 
eluents: hexane; hexane:ethyl acetate 50:50; 25:75; ethyl acetate; ethyl acetate:methanol 90:10; 80:20; 
70:30; 60:40; 50:50; 40:60; 30:70; 20:80; 10:90; 2×methanol; water. Active fractions from VLC (ethyl 
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acetate:methanol 90:10 and 80:20) where dissolved in 100 ml 70% ethanol, adjusted to pH 3 with 4% 
acetic acid and partitioned against diethyl ether (3×100 ml). The pH was adjusted to 10 with NaOH and 
the aqueous phase was partitioned against diethyl et er (3×100 ml), ethyl acetate (3×100 ml) and butanol 
(4×70 ml). The active fraction (diethyl ether from basic partition) was separated on preparative TLC 
using ethyl acetate: methanol:water (90:20:10) as mobile phase. The TLC plate was detected under UV 
254/365 nm and a small part of the TLC plate was sprayed with Dragendorrf reagent to detect alkaloids. Five 
bands were scraped off the TLC plate, eluted with methanol and tested for activity. The isolated 
compounds were sent to Copenhagen where they were dissolved in CDCl3 and the structures elucidated 
by 1H-NMR and 13C-NMR (100MHz for 13C, 600MHz for 1H) using a Bruker Advance 600. 
 
Tissue preparation 
All procedures were carried out at 0-4 °C. Whole rat b ins, except cerebellum, were homogenised with 
an Ultra Turrax homogenizer in 1:10 (w/v) buffer (5 mM TRIS base, 150 mM NaCl and 20 mM EDTA, 
pH 7.5). The homogenate was centrifuged at 16,000×g for 10 min and the tissue membranes washed with 
120 ml of the same buffer. The supernatant was discarded and the pellet was suspended in buffer (5mM 
TRIS base and 5 mM EDTA, pH 7.5), left to react for 20 min and then centrifuged at 16,000×g for 10 
min. The supernatant was discarded and the pellet was washed with 120 ml buffer (50 mM TRIS base, 
120 mM NaCl and 5 mM KCl, pH 7.5) and then centrifuged at 16,000×g for 10 min. The supernatant was 
discarded and the pellet finally suspended in 120 ml buffer (50 mM TRIS base, 120 mM NaCl and 5 mM 
KCl, pH 7.5). This homogenate was kept at −70 °C until se. 
 
Validation of the serotonin re-uptake (3H-citalopram binding) assay 
In order to determine the optimum amount of [3H]-citalopram for the bioassay and establish Kd, a curve of 
[3H]-citalopram binding against ligand concentration was determined. [3H]-citalopram binding to 50 µl rat 
brain homogenate (as prepared in previous section) was measured at ten concentrations (0, 0.084, 0.167, 
0.25, 0.334, 0.501, 0.668, 0.835, 1.002, 1.169 and 1.336 mM). The various concentrations of [3H]-
citalopram (50 µl) were incubated with 50 µl rat brain tissue homogenate and 200 µl buffer (50 mM TRIS 
base, 120 mM NaCl and 5 mM KCl, pH 7.5) for 2 h at 23–26 °C and filtered through Advantec GC-50/25 
glass fibre filters under vacuum. After 24 h the radio ctivity of the filters containing protein bound [3H]-
citalopram was measured by liquid scintillation, using 5 ml Beckman Ready Value IITM scintillation fluid. 
A double determination was done. 
 
A curve of rat brain tissue homogenate volume versus [3H]-citalopram binding was used to determine the 
optimum volume of tissue homogenate in the assay.  Fifty µl 4 nM [3H]-citalopram (final concentration in 
assay 0.67 nM) was incubated with 0, 25, 50, 75, 100, 125, 150, 175, 200, 225, and 250 µl tissue 
homogenate (as prepared in previous section) and made up to 300 µl with buffer (50 mM TRIS base, 120 
mM NaCl and 5 mM KCl, pH 7.5) for 2 h at 23–26 °C. This was then filtered through Advantec GC-
50/25 glass fibre filters under vacuum. After 24 h the radioactivity of the filters containing protein bound 
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[3H]-citalopram was measured by liquid scintillation, using 5ml Beckman Ready Value IITM scintillation 
fluid. A double determination was done. 
 
The effect of extraction solvent (ethanol) on the assay was determined using five concentrations of a 
similar range that would be used when testing plant extracts (7% to 0.0007 %).  Again 50 µl 4nM [3H]-
citalopram was incubated for 2 h with 50 µl tissue homogenate and 200 µl ethanol solutions diluted with 
buffer to the above mentioned concentrations, then filt red through Advantec GC-50/25 glass fibre filters 
under vacuum. After 24 h the radioactivity of the filters containing protein bound [3H]-citalopram was 
measured by liquid scintillation, using 5 ml Beckman Ready Value IITM scintillation fluid. A double 
determination was done. 
 
[3H]-Citalopram binding assay 
The method described by PLENGE, MELLERUP and NIELSEN (1990) was used. Two hundred 
microlitre dilution of the extract (5, 1, 0.1, 0.01 and 0.001 mg/ml) in buffer (50 mM TRIS base, 120 mM
NaCl and 5 mM KCl, pH 7.5) making a final concentration in the assay of 3.3, 0.7, 0.07, 0.007, and 
0.0007 mg/ml were mixed with 50 µl 4nM [3H]-citalopram and 50 µl rat brain tissue suspension in the 
listed order. For determination of unspecific binding, 200 µl of 1.5 µM paroxetine were mixed with 50 µl
4 nM [3H]-citalopram and 50 µl tissue suspension. The total binding of [3H]-citalopram was determined 
by mixing 200 µl buffer (50 mM TRIS base, 120 mM NaCl and 5 mM KCl, pH 7.5) with 50 µl of 4 nM 
[3H]-citalopram and 50 µl tissue suspension. All samples were incubated for 2 h at 23–26 °C and filtered 
through Advantec GC-50/25 glass fibre filters under vacuum. After 24 h the radioactivity of the filters 
containing protein bound [3H]-citalopram was measured by liquid scintillation, using 5 ml Beckman 
Ready Value IITM scintillation fluid. The assay was done in triplicate. 
 
8-Hydroxy[3H]DPAT binding assay 
Two hundred microlitres of test solution were mixed with 50 µl of 8-hydroxy[3H]DPAT and 50 µl of 
tissue suspension. Buspirone (1 µM) was used to determine unspecific binding. Subsequent procedures 
were as for the [3H]-citalopram binding assay. 
 
Estimation of IC50 values and Ki values 
The IC50 values were calculated using GraFit 5 from Erithacus Software utilising a full four-parameter 
equation. The Ki values, which is independent of ligand concentration and thus more useful for inter-lab 
comparison, was calculated by Ki = IC50/(1 + [L]/Kd), where [L] is the ligand concentration (here 0.75 
nM) and Kd is 0.7 nM for citalopram. 
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 3.3.3. Results 
 
Validation of the serotonin re-uptake ([3H]-Citalopram binding) assay 
A greater concentration range (0.01 to 10 nM) of radiol belled ligand was needed to achieve a sigmoidal 
curve. By extrapolation (dotted line Figure 3.3.3.2.) it was estimated that Vmax for 50 µl rat brain tissue 
suspension was approximately 16 000 and Kd 0.6 nM. This is comparable to a Kd of (0.7 nM) reported by 
the [3H]-citalopram supplier (Amersham). 
 
The curve (Figure 3.3.3.3.) of rat brain tissue homogenate volume versus [3H]-citalopram binding 
initially shows a linear relationship as the number of SERT increases (homogenate volume) as ligand 
([3H]-citalopram) remains constant. After 50 µl rat brain tissue suspension the graph flattens 
corresponding to a deficiency in [3H]-citalopram. Thus, 0.67 nM [3H]-citalopram should bind to all SERT 
proteins in 50 µl rat brain tissue suspension. The bound [3H]-citalopram produced 5000 dpm with 50 µl 
rat brain tissue suspension. At the concentrations ested (7%-0.007%) ethanol had no observable effect on 
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Figure 3.3.2.2.  Ligand ([3H]-citalopram) concentration verses binding curve showing Vmax (±16000 
dpm) and Kd (±0.6 nM). 
Kd
CHAPTER THREE Antidepressants   132  
 
 
Screening of South African plants for SSRI activity 
Seventy five extracts from 35 plant species were sel cted for investigation in this study. Thirty seven of 
these extracts, derived from 15 plants showed some degree of affinity to the serotonin reuptake transport 
protein (Table 3.3.3.1.). Nine extracts from five plants had high affinity, characterized as high 
concentration-dependent inhibition with less than 50% [3H]citalopram binding with the three strongest 
concentrations (5, 1, and 0.1 mgml-1) and/or IC50 > 500 µgml
-1 (highlighted in bold, Table 3.3.3.1 and 







Rat brain tissue (µl) 
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Table 3.3.3.1. Screening of plant extracts for affin ty to the serotonin transporter protein 
 
Plant species Plant part Extracta Yield 
(mg) 
[3H]-citalopram binding in percentb IC50 ± SE
c 
(µg/ml) 
    5 mg/ml 1 mg/ml 0.1 mg/ml 0.01 mg/ml 0.001 mg/ml  
 





























































































Artemisia afra  leaves e 352 28 104 106 110 127 n.d. 





































































































































Bulbine frutescens roots w 135 38 17 28 7 24 n.d. 
Cinnamomum camphora  leaves w 225 83 101 102 109 110 n.d 































































Cotyledon orbiculata leaves w 732 84 86 74 75 70 n.d. 
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Plant species Plant part Extracta Yield 
(mg) 
[3H]-citalopram binding in percentb IC50 ± SE
c 
(µg/ml) 
    5 mg/ml 1 mg/ml 0.1 mg/ml 0.01 mg/ml 0.001 mg/ml  






























































































































Hemizyga obermeyerae  leaves w 362 55 105 87 88 99 n.d. 
Hypericum lanandii  leaves w 178 127 105 109 105 92 n.d. 
Hypericum revolutum  leaves w 305 139 93 110 101 114 n.d. 
Indigofera tristis  leaves e 369 125 134 117 110 124 n.d. 
Leonotis leonurus  leaves e 318 24 91 131 131 117 n.d. 
Lobelia alata  leaves w 235 75 50 23 22 11 n.d. 


















Mentha aquatica  leaves e  67 57 124 134 114 n.d. 


























































































Rubus ludwigii  roots e 128 171 161 118 104 124 n.d. 
Stropharanthus speciosus  leaves w 339 35 56 78 68 73 n.d. 
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Plant species Plant part Extracta Yield 
(mg) 
[3H]-citalopram binding in percentb IC50 ± SE
c 
(µg/ml) 
    5 mg/ml 1 mg/ml 0.1 mg/ml 0.01 mg/ml 0.001 mg/ml  






















































a solvents: w = deionized water; e = 70% ethanol 
b [3H]-citalopram binding in percent, the lower the percentage the more [3H]-citalopram has been displace by the plant extract  
c IC50 (µgml
-1) and standard error, calculated using Grafit (© Erithacus Software Limited) 
d n.d. = not detected, does not exhibit sufficient (IC50 < 500 µgml-1) dose-dependant activity
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Extracts from Agapanthus campanulatus, Boophone disticha, Datura ferox, Mondia whitei and 
Xysmalobium undulatum showed high affinity to the serotonin reuptake transport protein in the 
displacement assay utilized in this study. 
 
[A. campanulatus flowers aqueous extracts] 
(mg/mL)





















Paramet er Value St d.  Error
Y Range 102.0905 3. 5802
I C 50 0.0047 0. 0011
Slope f act or 0.3507 0. 0313
Background -2.1538 3. 2053   
[A. campanulatus roots aqueous extracts] 
(mg/mL)





















Paramet er Value St d.  Error
Y Range 90. 3116 6. 8339
I C 50 0. 2979 0. 0791
Slope f act or 1. 2407 0. 2569
Background 6. 4306 6. 0489  
 
Figure 3.3.3.1. IC50 determination of extracts of Agapanthus campanulatus which showed high affinity to the [
3H]-
citalopram binding site. 
 
Thirty eight extracts from 26 plants did not show any affinity for the serotonin transporter protein. 
Aqueous extracts of leaves, roots and flowers from Agapanthus campanulatus (Agapanthaceae) resulted 
in displacement of more than 60% transport protein bound [3H]-citalopram at the three strongest 
concentrations. Aqueous extracts of flowers and roots f Agapanthus campanulatus showed good dose-
dependent activity (Figure 3.3.3.1. above) with IC50 values of 4.7±1.1 µgml
-1 and 298±79 µgml-1 
respectively. 
 
Aqueous and ethanolic extracts of the leaves and the aqueous extract of the bulbs from Boophone disticha 
(Amaryllidaceae) resulted in displacement of more than 50% of the bound [3H]-citalopram at the three 
highest concentrations. The ethanolic extract of the leaf material (IC50 = 40±4 µgml
-1) and the aqueous 
extract of the bulb (IC50 = 23±21 µgml
-1) exhibited the best activity of the B. disticha extracts (Figure 
3.3.3.2). 
 
An aqueous extract from the seeds of exotic weed, Datura ferox displaced 80% of the bound [3H]-
citalopram at the three highest concentrations, and gave an IC50 value of 13±3 µgml
-1 (Figure 3.3.3.3). 
Xysmalobium undulatum (ethanolic leaf extract) and Mondia whitei (ethanolic leaf extract) both displaced 
bound [3H]-citalopram showing good affinity for the serotonin transporter protein (Figure 3.3.3.3), with 
IC50 values of 46±22 µgml
-1 and 39±34 µgml-1, respectively. 
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[B. disticha leaves aqueous extracts] (mg/mL)
























Parameter Value Std.  Error
Y Range 81.2867 10.7220
I C 50 0.0666 0.0294
Slope f actor 1.1782 0.6018
Background 11.1311 7.4668   
[B. disticha leaves ethanolic extracts] (mg/mL)
























Parameter Value Std.  Error
Y Range 95. 4216 4.6641
IC 50 0. 0403 0.0080
Slope f actor 0. 7758 0.1034
Background 2. 9870 3.3367  
 
[B. disticha root ethanolic extracts] (mg/mL)
























Parameter Value Std.  Error
Y Range 59. 9793 3.5953
IC 50 0. 0674 0.0134
Slope f actor 0. 9816 0.1830
Background 40. 3878 2.3645   
[B. disticha bulb aqueous extracts] (mg/mL)
























Parameter Value Std.  Error
Y Range 71. 9225 16. 7210
IC 50 0. 0233 0. 0209
Slope f actor 0. 9240 0. 6393
Background 23. 3178 11. 0915  
 
Figure 3.3.3.2. IC50 determinations of extracts of Boophone disticha which showed high affinity to the [
3H]-
citalopram binding site. 
 
[D. ferox seeds aqueous extracts] (mg/mL)























Paramet er Value Std.  Error
Y Range 81.9316 6. 3584
I C 50 0.0133 0. 0033
Slope f actor 3.9728 3. 2382
Background 18.0131 3. 2413  
[M. whitei leaves ethanolic extracts] (mg/mL)























Parameter Value Std.  Error
Y Range 118. 9299 23. 3912
I C 50 0. 3885 0. 3388
Slope fact or 0. 5319 0. 1275
Background -21. 3967 21. 6907
[X. undulatum leaves ethanolic extracts] 
(mg/mL)























Paramet er Value Std.  Error
Y Range 86.8018 8. 3063
I C 50 0.0459 0. 0220
Slope f actor 0.4932 0. 1104
Background 13.3246 7. 5143  
 
Figure 3.3.3.3. IC50 determinations of extracts of Datura ferox, Mondia whitei and Xysmalobium undulataum which 
showed high affinity to the [3H]-citalopram binding site. 
CHAPTER THREE Antidepressants   138  
 
 
Bioassy-guided fractionation, isolation and identification of active constituents of B. disticha 
NMR data for buphanamine are given in Table 3.3.3.2. below. Two compounds, buphanidrine (7.6 mg) 
and buphanamine (5.6 mg) (Figure 3.3.3.4), with activity on the SERT were isolated. Buphanidrine was 
identified by comparison with NMR data previously reported (VILADOMAT, CODINA, BASTIDA, 
SHAHEED and CAMPBELL, 1995). In the assay the IC50 values of buphanidrine (22) and buphanamine 
(23) were 274 and 1799 µM, respectively. The Ki values of the two compounds were calculated to be 132 
µM for buphanidrine and 868 µM for buphanamine. For citalopram the IC50 value was 1.3 nM, giving a 
Ki value of 0.6 nM. Both buphanidrine and buphanamine bound to the 5HT1A receptor with low affinity, 
the IC50 values were 1203 and 2975 µM, respectively. 
 















1 4.70 d (3J1,2 = 5.6) 63.6 2 2, 10, 11 
endo, 11exo 
 
2 6.05 dddd (3J2,3 = 10.0, 
3J2,1 = 5.6, 
3J2,4β = 
2.8, 3J2,4α = 1.9) 
125.4 1, 3, 4β 1, 3 1 
3 5.86 ddd (3J3,2 = 10.0, 
3J3,4α = 4.6, 
3J3,4β = 
2.9) 
127.0 2, 4α, 4β 2, 4α, 4β 1 
4 α: 2.83 dddd (2J4α,4β = 19.6, 3J4α,4a = 5.6, 
3J4α,3 
= 4.6, 4J4α,2 = 1.9) 
β: 2.21 ddt (2J4β,4α = 19.6, 
3J4β,4a = 8.2, 
3J4β,3 
= 4J4β,2 = 2.8) 
26.1 3, 4β, 4a 
 
2, 3, 4α, 4a 
3, 4β, 4a 
 
3, 4α, 11exo, 
12exo 
 
4a 3.79 t (3J4a,4α = 
3J4a,4β = 8.2) 60.3 4α, 4β 4α, 6α 1, 3, 6β 
6 α: 4.43 d (2J6α,6β = 16.7) 






6a  113.3   10 
7  140.7   β 
8  134.0   10, 13 
9  149.7   10, 13 
10 6.61 s 98.3  1, 11endo  
10a  134.8   11exo 
10b  49   1, 4α, 4β, 4a 
6α, 6β, 10 
11 endo: 1.99 dddd (2J11endo,11exo = 12.3, 
3J11endo,12endo = 8.7, 
3J11endo,12exo = 3.0, 
4J11endo,4a = 1.3) 
exo: 2.12 ddd (2J11exo,11endo = 12.3, 
3J11exo,12exo 
= 10.9, 3J11exo,12endo = 8.2) 





1, 10, 11exo, 
12 endo 
 
1, 4β, 11endo, 
12exo 
1 
12 endo: 2.99 ddd (2J12endo,12exo = 13.2, 
3J12endo,1endo = 8.7, 
3J12endo,11exo = 8.2) 
exo: 3.91m 
51.2 11exo, 11endo, 
12exo 
11exo, 11endo, 







13 5.93 AB-system (2JA,B = 1.5) 101.2    
14 4.01 59.3    
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 22 23 
 
Figure 3.3.3.4. Structures of (22) buphanidrine and (23) buphanamine isolated from Boophone. disticha. 
 
 3.3.4. Discussion and conclusions 
It is evident from Table 3.2.1. that before this study there were relatively few know  monoamine re-
uptake transporter  inhibitors of natural origin. The few that are known are far less potent than the 
currently supported synthetic compounds.  
 
Boophone disticha is used in traditional medicine for numerous purposes, e.g. hysteria in young women 
(GORDON, 1947). Sotho and Xhosa people are reported to use bulb scales as a narcotic (WATT and 
BREYER-BRANDWIJK, 1962). It is known as a toxic plant and alkaloids from the bulb are known to 
possess hallucinogenic properties (DE SMET, 1996; DU PLOOY, SWART and VAN HUYSTEEN, 
2001). Structurally, buphanamine (22) and buphanadrine (23) have the benzo-1,3-dioxole moiety in 
common with the clinically used SSRI paroxetin, which could explain their affinity to the SERT. The 
traditional use and reported hallucinogenic effects obtained after accidental or purposeful overdosing with 
Boophone disticha extracts (DE SMET, 1996; VAN WYK, VAN HEERDEN and VAN 
OUDTSHOORN, 2002) indicate that the alkaloids reach the CNS. In the SERT assay the IC50 values of 
buphanidrine and buphanamine were 274 and 1799 µM, respectively. The Ki values of the two 
compounds were calculated to be 132 µM for buphanidrine and 868 µM for buphanamine. For citalopram 
the IC50 value was 1.3 nM, giving a Ki value of 0.6 nM. Both buphanidrine and buphanamine bound to the 
5HT1A receptor with low affinity, the IC50 values were 1203 and 2975 µM, respectively. 
 
For the SSRIs, and most other types of antidepressant drugs, it takes 2-4 weeks for the therapeutic action 
to develop. A leading hypothesis of this delayed pharmacological action is desensitation of 
somatodendritic serotonin 1A autoreceptors (5HT1A) in the midbrain raphe, which act by reducing 
neuronal firing (STAHL, 1998; HOLMES, YANG, MURPHY and CRAWLEY, 2002; HENSLER, 
2002). A major goal of antidepressant development is to improve preceding drug classes with more rapid 
onset of antidepressant action and fewer unwanted side effects. Therapeutic agents acting both by 
inhibition of serotonin reuptake and by inhibiting the action of 5HT1A autoreceptors might result in a 
more rapid onset of antidepressant action. The finding that buphanidrine and buphanamine had only slight 
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affinity to 5HT1A, eliminates the possibility of a dual-action system. Although the activities of 
buphanidrine and buphanamine on the serotonin transporter were lower than the activity of the clinically 
used SSRI citalopram, the activity supports the traditional use of B. disticha as a remedy for depression 
and anxiety. 
 
Although not indigenous to South Africa Datura species are used by Zulu people as a hypnotic drug 
against hysterical fits and is also smoked for the reli f of headaches (HUTCHINGS, SCOTT, LEWIS and 
CUNNINGHAM, 1996). The Vhavenda people use Datura stramonium for insanity (MABOGO, 1990). 
Datura species are known to contain tropane alkaloids suchas hyoscyamine and hyoscine, the latter being 
a muscarinic receptor antagonist and a CNS depressant (RANG, DALE and RITTER, 1999). It is difficult 
at this stage to speculate which compounds are responsible for the observed SERT binding. 
 
Xhosa people administer powdered roots of Xysmalobium undulatum as a snuff (inhaled through nostrils) 
to treat headaches and hysteria (HUTCHINGS, SCOTT, LEWIS and CUNNINGHAM, 1996). X. 
undulatum is sold as an herbal remedy under the name ‘Uzara’ in the West, particularly Germany where it 
is used as an intestinal smooth muscle relaxant. There is significant pharmacological evidence that 5-HT3 
and 5-HT4 receptors of the submucosal sensory neurons represent promising targets for the treatment of 
functional gastro-intestinal diseases (HOUGHTON and WHORWELL, 1997; BERMAN, CHANG, 
SUYENOBU, CHANG, FITZGERALD, MANDELKERN, HAMM, VOGT and NALIBOFF, 2002), so 




Mental depression is due to deficiency of brain monoaminergic activity, in particular dopamine and 
serotonin. Different mechanisms may increase the availability of brain monoamines in order to treat 
depression. These include blocking the reuptake of the monoamine from the synapse, inhibiting the intra-
neuronal metabolism of the monoamine or blocking the presynaptic inhibitory auto- or hetero-receptors.  
 
Seventy six extracts from 35 plant species used in South African traditional medicine or taxonomically 
related species were investigated for their affinity to the serotonin reuptake transport protein. This wa  
achieved using an in vitro assay that detects plant compounds that bind to the serotonin transporter 
protein of rat brain tissue, displacing [3H]-citalopram. Aqueous and ethanolic extracts of various plant 
parts were screened and 45 extracts derived from 15 plant species showed affinity to the serotonin 
reuptake transport protein. The extracts of four plants were characterized as have high affinity for the 
SERT (more than 50% inhibition at 5, 1, and 0.5 mg/l). Plant species with high affinity to the serotonin 
reuptake transport protein included Agapanthus campanulatus, Boophone disticha, Datura ferox and 
Xysmalobium undulatum. Agapanthus campanulatus yielded high activity in aqueous extracts from leavs 
and flowers. Boophone disticha showed high activity both in aqueous and ethanolic extracts of leaves and 
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bulbs. Datura ferox showed high activity in aqueous extracts from the se d  and Xysmalobium undulatum 
showed high activity in the ethanolic extract of the whole plant.  
 
Two compounds, buphanadrine and buphanamine, were isolated by bioassay-guided fractionation from 
Boophone disticha. The IC50 values of buphanidrine and buphanamine were 274 µM (Ki = 132 µM) and 
1799 µM (Ki = 868 µM), respectively. The two alkaloids were also tested for affinity to the 5HT1A 
receptor, but only showed slight affinity. 
 
The possibility of screening plants for MAO-A inhibit on was also investigated but was abandoned due to 
low levels of MAO-A compared to MAO-B in rat liver tissue, for more details refer to Chapter 5.  
 
The following publications relate to this chapter: 
 N.D. Nielsen, M. Sandager, G.I. Stafford, J. van Staden and A.K. Jäger. 2004. Screening of 
indigenous plants from South Africa for affinity to the serotonin reuptake transport. Journal of 
Ethnopharmacology 94: 159-163. 
 M. Sandager, N.D. Nielsen, G.I. Stafford, J. Staden and A.K. Jäger. 2005. Alkaloids from Boophane 




Anti-epileptics and Anxiolytics:  
Screening for sedative-like and antiepileptic activity in the benzodiazepine-
GABAA receptor binding assay 
 
4.1.  Introduction: the GABAergic system 
 
γ-Aminobutyric acid GABA is a major inhibitory neurot ansmitter in the vertebrate central nervous 
system. Depending on the brain region, approximately 20 to 50% of all central synapses use GABA as the 
transmitter (HALASY and SOMOGYI, 1993). GABA is a small amino acid derived from glutamate by 
glutamic acid decarboxylase. GABA activates three different receptor classes: GABAA, GABAB and 
GABAC receptors (SIMMOMDS, 1983).  
 
GABAA receptors are ligand-gated chloride ion channels (BORMANN, 1988; SILVILOTTI and NISTRI, 
1991). These receptors are activated by GABA, muscimol and isoguvacine, and are inhibited by 
bicuculline, gabazine (SR95531) and (+) -β-hydrastine (WERMUTH and BIZIERE, 1986).  
 
GABAB receptors are activated by GABA, (-)-baclofen, (+)-4-amino-3-(5-chloro-2-thienyl butanoic acid 
and 3-aminopropyl-(methyl)phosphinic acid (SKF 97541), and are inhibited by phaclofen, saclofen and 2-
hydroxysaclofen (SEABROOK, HOWSON and LACEY, 1990). These receptors are known to be coupled 
to Ca2+ or K+ channels via G-proteins so as to activate the second messenger systems within the cell 
(BORMANN, 1988).  
 
GABAC receptors are derived from various isoforms of the ρ-subunit, and are directly associated with 
chloride ion channels. These receptors are activated by GABA and certain analogues of GABA such as 
cis-4-aminocrotonic acid (CACA) and trans-4-aminocrotonic acid (TACA), and are inhibited by 
imidazole-4-acetic acid and (1,2,5,6-tetrahydropyridin-4-yl)methylphosphinic acid (TPMPA) but are 
insensitive to bicuculline, barbiturates, benzodiazepines and baclofen (reviewed by MARTINEZ-
TORRES, VAZQUEZ, PANICKER, MILEDI, 1998). It has been proposed that GABAC receptors should 
be classified as a specialized set of the GABAA receptors (see BARNARD, SKOLNICK, OLSEN, 
MÖHLER, SIEGHART, BIGGIO, BRAESTRUP, BATESON and LANGER, 1998).  
 
The GABAA receptors are of great importance as they participa e in the regulation of brain excitability, 
and many important drugs such as benzodiazepines, barbiturates, neurosteroids, ethanol, and some of the 
anticonvulsants and general anaesthetics interact with these receptors so as to bring about their 
pharmacological effects (MACDONALD and TWYMAN, 1992; MACDONALD and OLSEN, 1994). 
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Table 4.1. Summary of different GABA receptors (adapted from SILVILOTTI and NISTRI, 1991). 
Receptors 
 
GABAA GABAB GABAC 
Primary 
location 
frontal cortex, cerebella 




frontal cortex and 
thalamic nuclei 
retina 






α1-6, β1-4, γ1-4, δ, ε and π R1a, R1b ρ1-3 
Agonist GABA 
Muscimol  
(hallucinogenic, spasmodic and 
toxic isolated from Amanita 










Antagonists Bicuculine  
(antiseptic, convulsant and 
haemostatic isolated from 
Adlumia fungosa, Corydalis 
incise, C. thalictrifolia and 
Hydrastis canadensis) 
Picrotoxin  
(CNS stimulant, barbiturate 
antidote, insecticide and 
nematocide isolated from 
































subunit with 4 
transmembrane domains 
 
4.2. The GABAA receptor 
As with glycine, aspartate, glutamate, acetylcholine a d 5-HT3 receptors, the GABAA receptor belongs to 
the receptor family coupled to an ionophore which is an integral part of a transmembrane hetero-
oligomeric protein. GABAA receptors are ligand-gated Cl
- channels. Its neurotransmitter GABA is a small 
amino acid derived from glutamate by glutamic acid decarboxylase. Activation of GABAA receptors by 
GABA results in an increase in neuronal membrane conductance for Cl- from the prolonged openings of 
the ion channels, this influx of Cl- causes a localized hyperpolarisition of the neuronal membrane, which 
counteracts the effects of depolarising stimuli and results in the inhibition of synaptic transmission 
(MACDONALD and TWYMAN, 1992).  
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The inhibitory action of GABA can be imitated by full agonists, such as muscimol, a natural product 
(Tables 4.1. and 4.2.) from the mushroom Amanita muscaria.  It is also competitively antagonised by 
competitive antagonists, such as bicuculline, another natural product isolated from the plant Dicentra 
cucullaria and a variety of Corydalis, Dicentra and Adlumia species, and noncompetitively antagonised 
by picrotoxin which is an equimolar mixture of picrotoxinin and picrotin isolated from Anamirta cocculus 
and related poisonous plants. 
 
Structurally different compounds interact with the GABA binding site within the GABAA receptor 
complex as agonist, partial agonist and antagonist (Table 4.1. and 4.2.)  Receptor antagonists have been 
shown to be essential tools for the characterisation of the physiological and pharmacological properties of 
receptors. The discovery of the convulsant alkaloid bicuculline as an antagonist of the inhibitory action of 
GABA in the CNS provided a vital pharmacological tool to investigate GABA-mediated inhibition. 
 
The most notable phenomenon of GABAA receptors is that they possess a variety of allosteric binding 
sites (i.e. binding sites that are different from the neurotransmitter binding sites within the receptor 
complex) for several clinically important drugs. The most widely investigated allosteric modulatory sites 
are the benzodiazepine sites (LÜDDENS, KORPI and SEEBURG, 1995). Benzodiazepines were 
launched as clinical therapeutic agents in the early 1960s before GABA was considered as a 
neurotransmitter. 
 
Benzodiazepine receptors are divided into two classes: central (receptors appeared in CNS) and peripheral 
receptors (peripheral tissues such as kidneys). Flumazenil (Ro 15-1788) only interacts with central 
receptors, while Ro 5-4868 (the 4’-chloro derivative of diazepam) is a selective ligand for peripheral 














Diazepam (Central benzodiazepine receptor agonist) Flumazenil (Ro 15-1788) 
 




Figure 4.1. Schematic illustration of the GABAA receptor. [A] The GABAA receptor, which is a Cl
- pore, has 
binding sites for barbiturates, benzodiazepines and neurosteroids. The GABA responses are blocked competitively 
by bicuculline and non-competitively by picrotoxinin. The GABA (e.g. muscimol, bicuculline and 4-PIOL) and 
benzodiazepine (e.g. diazepam and flumazenil ) recogniti n sites are known to be extracellular, whereas several 
other sites (e.g. barbiturates, neurosteroids, and alcohol) may be mostly at the transmembrane regions. Z 2+, La3+, 
picrotoxinin and TBPS most likely bind to sites in the channel proper. The vertebrate GABAA receptor is built from 
several subunits, some examples of which are listed on the right-hand side (in gray text). [B] Each subunit comprises 
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4.3. GABAA receptors and neurological disease 
 
Anticonvulsant and epilepsy treatment  
A deficiency in GABA-nergic inhibitory synaptic transmission can potentially contribute to the neuronal 
epileptic activity and the spread of focal seizure activity (OLSEN, BUREAU, HOUSER, DELGADO-
ESCUETA, RICHARDS and MOHLER, 1992). Compounds that elevate the synthesis, synaptic release, 
postsynaptic action of GABA can exhibit anticonvulsant activity. Many antiepileptic drugs exert their 
action by enhancing the brain GABA activity (e.g. benzodiazepines, barbiturates, vigabatrin) (EMILIEN 
and MALOTEAUX, 1998). The changes in GABA-nergic inhibition in human epilepsy are controversial. 
The functional GABA-nergic inhibition can be reduced, normal or slightly enhanced (MODY, 1998).  
 
The prevalence of epilepsy in developing countries is generally higher than in developed countries 
(SANDER and SHORVON, 1996). A study conducted nearly  decade ago reported an increased risk of 
dying and a greater proportion of deaths that are epil psy-related in Africa – as high as a six-fold increase 
in mortality in people with epilepsy. This is higher than the two- to three-fold increase reported in 
developed countries (CHRISTIANSON, ZWANE, MANGA, ROSEN, VENTER and KROMBERG, 
2000; DIOP, HESDORFFER, LOGROSCINO and HAUSER, 2005). The reasons for this gap between 
the developed and the developing countries are not e tirely clear but suggestions have been made that it 
might be due to social deprivation (SANDER, 2003). Interestingly, recent data suggest that people from 
socio-economically deprived backgrounds in developed countries are more likely to develop epilepsy 
(HEANEY, MACDONALD, EVERITT, STEVENSON, LEONARDI, WILKINSON and SANDER, 
2002). A study from 2000 on the prevalence of epilepsy in a large rural community situated in the 
Northern Province in South Africa showed a lifetime prevalence in children as high as 73/1000 
(CHRISTIANSON, ZWANE, MANGA, ROSEN, VENTER and KROMBERG, 2000). 
 
Some infectious diseases might be a part of the explanation. Neurocysticercosis caused by Taenia solium 
(pork tapeworm) infections may trigger epileptic outburst (DEGIORGIO, PIETSCH-ESCUETA, 
TSANG, CORRAL-LEYVA, NG, MEDINA, ASTUDILLO, PADILLA, LEYVA, MARTINEZ, NOH, 
LEVINE, VILLASENOR and SORVILLO, 2005). A study on 578 epileptic patients in Pretoria showed 
neurocysticercosis in 28% of the patients (VAN AS and JOUBERT, 1991). HIV infection of the CNS or 
opportunistic infections caused by HIV might also trigger epileptic seizures (GARG, 1999; 
VISUDTIBHAN, VISUDHIPHAN and CHIEMCHANYA, 1999). 
 
As mentioned in Chapter 2 epilepsy is one of the illnesses that is viewed with a certain degree of fear 
and ‘risk of contagious’ effect due to the cultural attitudes and beliefs in South Africa. Studies conducted 
in townships showed that the parents of epileptic ch ldren believe that the disorder is caused by various 
parameters including bewitchment, fear or evil spirits (EASTMAN, 2005). It is also viewed as a shameful 
disorder and has severe social implications in African communities as it carries a stigma, a similar 
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problem exists with HIV. Sufferers are often shunned and discriminated against with respect to education, 
employment and marriage (ANDERMANN, 1995; BASKIND and BIRBECK, 2005). 
 
This traditional African perception of epilepsy is also prominent in the treatment of the disorder where 
many people seek treatment by traditional healers and traditional medicine. There are also a large number 
of traditional treatments for epilepsy (see Chapter 2). A survey in 2000 showed, that 42.5% of epileptic 
children received traditional medicine alone or in combination with Western medicine whereas 34.6% 
received no treatment at all (CHRISTIANSON, ZWANE, MANGA, ROSEN, VENTER and 
KROMBERG, 2000). 
 
A number of southern African plants have shown in vivo anticonvulsant activity against seizures 
produced in mice by pentylenetetrazole (PTZ), picrotoxin (PIC), bicuculline (BIC) and NMDA. However, 
most of the studies have been conducted on plant extracts and the active constituents are yet to be 
identified. Recently, OJEWOLE (2008c) reported on the anticonvulsant effect of Searsia chirindensis 
(Baker f.) Moffett (syn = Rhus chirindensis Baker f.) stem-bark aqueous extract in mice. S arsia 
chirindensis stembark aqueous extract (100–800mg/kg i.p.) significantly delayed the onset of, and 
antagonized PTZ induced seizures. The extract (100–800mg/kg i.p.) also profoundly antagonized PIC 
induced seizures, but only weakly antagonized BIC induced seizures.  
 
Ojewole and his group have conducted several in vivo studies on extracts from South African medicinal 
plants including the fruit of Tetrapleura tetraptera (Schum.et Thonn.) Taub. (Fabaceae) (OJEWOLE, 
2005), avocado leaf (Persea americana Mill. (Lauraceae)), (OJEWOLE and AMABEOKU, 2006), 
Harpagophytum procumbens D.C. ex Meisn. (Pedaliaceae) roots (MAHOMED and OJEWOLE, 2006), 
Sutherlandia frutescens (L.) R.Br. (variety Incana E.Mey.) (Fabaceae) shoots (OJEWOLE, 2008a) and 
Hypoxis hemerocallidea Fisch.Mey. & Ave-Lall. (Hypoxidaceae; Syn = Hypoxis rooperii T. Moore) 
corms (misleadingly called the ‘African Potato’) (OJEWOLE, 2008b). All these studies shared the 
interesting fact that the aqueous extracts of these various plants delayed and antagonized the onset of PTZ 
and PIC induced seizures while the effect on BIC induced seizures was weaker and only present in high 
doses. 
 
Several Amaryllidaceae alkaloids isolated from Crinum and Cyrthanthus species were screened for 
potential activity in the GABAA-benzodiazepine binding assay (ELGORASHI, STAFFORD, JÄGER and 
VAN STADEN, 2006). However, none of the tested alkaloids displayed any affinity to the binding site. 
Further plant derived compounds known to interact with the GABAA-receptor are given in Table 4.2. 
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4.4. Screening of southern African plants for benzodiazepine-GABAA receptor binding 
activity 
 
4.4.1.  Introduction and Summary 
 
Initially, the aqueous and ethanol extracts of 43 tradi ional South African plants medicinal used to trea  
epilepsy and convulsions, were tested in the GABAA-benzodiazepine receptor binding assay (RISA, 
RISA, ADSERSEN, GAUGUIN, STAFFORD, VAN STADEN and JÄGER, 2004). A second screening 
of 46 ethanol extracts from 35 species, both indigenous and exotic that are traditionally used 
predominantly as sedatives or to treat various CNS-related ailments were tested in the GABAA-
benzodiazepine receptor-binding assay (STAFFORD, JÄGER and VAN STADEN, 2005). These 
investigations lead to the screening, isolation and identification of active compounds from Searsia species 
(previously Rhus) (SVENNINGSEN, DAMKJÆR MADSEN, LILJEFORS, STAFFORD, VAN 
STADEN and JÄGER, 2006) and Mentha aquatica (JÄGER, ALMQVIST, VANGSØE, STAFFORD, 
ADSERSEN and VAN STADEN, 2007).  
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Table 4.2. Compounds known to interact with ionotropic γ-aminobutyric acid (GABA) and benzodiazepine receptors.  
Benzodiazepine receptors can be divided into two classes: “central” and “peripheral” receptors, referring to the receptors appearing in CNS and peripheral tissues such as the 
kidney, respectively. Flumazenil (Ro 15-1788) only i teracts with the “central” receptors, while Ro 5-4868, the 4’-chloro derivative of diazepam, is a selective ligand for the 























Synthetic; but found in low quantities in germinatig seeds 
of Triticum aestivum (Poaceae), Solanum tuberosum 
(Solanaceae) 
Central benzodiazepine receptor agonist  
(IC50 = 18 nM ; Kd = 10 nM) 
(sedative, tranquilizer) 
Harmaline (= 3,4-Dihydroharmine; Harmidine) 
(indole) 
Banisteria caapi (Malpighiaceae), Passiflora incarnate 
(Passifloraceae), Peganum harmala (Zygophyllaceae) 
Central benzodiazepine receptor agonist (Flunitrazep m 
displacement) (IC50 ~ 100 µM) 
(ataxic, excitatory, hallucinogenic, tremorigenic) 
Harmalol  
(β-carboline, indole) 
Apocynum cannabium (Apicynaceae), Hippophae 
rhamoides (Eleagnaceae), Banisteria caapi 
(Malpighiaceae), Passiflora spp. (Passifloraceae), Peganum 
harmala (Zygophyllaceae) 
Central benzodiazepine receptor agonist 
Harman (= Aribine; Loturine; 1-Methyl-β
carboline; Passiflorin) 
(β-carboline, indole) 
Cichorium intybus (Asteraceae), Eleagnus angustifolia 
(Eleagnaceae), Passiflora incarnate (Passifloraceae), 
Sickingia (=Arariba) rubra (Rubiaceae), Symplocos 
racemosa (Symplocaceae), Peganum harmala, Tribulus 
terrestris, Zygophyllum fabago (Zygophyllaceae); smoke of 
tobacco Nicotiana tabacum (Solanaceae) 
Central benzodiazepine receptor agonist 
(co-mutagenic, convulsant, cytoxic, genotoxic, motor 
depressant, DNA intercalator, vasorelaxant, sheep 
‘Tribulus staggers’) 





Passiflora incarnata (Passifloraceae), Banisteria caapi 
(Malpighaceae), Peganum harmala, Tribulus terrestris 
(Zygophyllaceae) 




Synthetic; found in low quantities in germinating tuber of 
Solanum tuberosum (Solanaceae) 
Benzodiazepine receptor agonist 
(sedative, tranquilizer) 
                                                
1 Hallucinogen, used by Gestapo as a ‘truth drug’. 








Norharman (= β-Carboline) 
(β-Carboline, indole) 
Cichorium intybus (Asteraceae),  Tribulus terrestris, 
Zygophyllum fabago (Zygophyllaceae); smoke of tobacco 
Nicotiana tabacum (Solanaceae) 
Central benzodiazepine receptor 
Ricinine 
(dihydropyridine) 
Ricinus communis (Euphorbiaceae) Benzodiazepine receptor ligand (Flunitrazepam 
displacement) (convulsant, hypotensive, respiratory 
depressant, toxic) 
Tabernanthine (= 13-Methoxyibogamine) 
(indole) 
Tabernanthe iboga, Conopharyngia (Tabernaemontana) 
sp., Stemmadenia sp. (Apocynaceae) 
Benzodiazepine receptor agonist 
 (Flunitrazepam displacement)  
(IC50 = 150 µM) 
Temazepam 
(benzodiazepine) 
Synthetic; found in low quantities in Artemisia dracunculus 
(Asteraceae); Solanum tuberosum (Solanaceae) 
Benzodiazepine receptor agonist 
(hypnotic, sedative) 
Phenolic 
Amethoflavone (= 3’,8”-Biapigenin) 
(biflavone) 
 
Viburnum prunifolium (Caprifoliaceae), Cycas revolute 
(Cycadaceae), Searsia spp., (Anacardiaceae), Ginkgo 
biloba (Ginkgoaceae), Hypericum spp. (Hypericaeae), 
Podocarpus montanus (Podocarpaceae) 
 
Central benzodiazepine receptor partial agonist 
(IC50 = 6-15 nM) 
Apigenin (= 5,7,4’-Trihydroxyflavone) 
(flavone) 
Widespread; Lamiaceae, Asteraceae; Apiaceae; Fabacee Central benzodiazepine receptor agonist 
(IC50 =  4 µM) 
Baicalein (= 5,6,7-Trihydroxyflavone) 
(flavone) 
Scutellaria baicalensi, S. spp. (Lamiaceae), Plantago major 
(Plantaginaceae) 
Central benzodiazepine receptor ligand  
Byakangelicol 
(furanocoumarin) 
Angelica dahurica, Ferula spp. (Apiaceae), Citrus limon 
(Rutaceae) 
Central benzodiazepine receptor ligand (Diazepam 
displacement) 




Leptospermim scoparium (Myrtaceae) GABAA receptor central benzodiazepine receptor ligand 
5,7-Dimethoxyflavone 
(flavone) 
Leptospermim scoparium (Myrtaceae) Central benzodiazepine receptor ligand (Flunitrazepam 
displacement)  
(IC50 = 2 µM) 
5,7-Dimethoxy-6-methylflavone 
(flavone) 
Leptospermim scoparium (Myrtaceae) Central benzodiazepine receptor ligand (Flunitrazepm 
displacement)  
(IC50 = 45 µM) 
Dinatin (= Hispidulin; 6-Methoxy-5,7,4’-
Trihydroxyflavone; Scutellarein 6-methyl ether) 
(flavone) 
Artemisia herba alba (Asteraceae), peel of Citrus sudachii 
(Rutaceae), leaf of Digitalis orientalis and D. purpurea 
(Scrophulariaceae) 
Central benzodiazepine receptor ligand (Diazepam 
displacement)  
(IC50 = 1 nM) 








5,7-Dihydroxyflavone (= Chrysin) 
(flavone) 
Widespread; Daucus (Apiaceae), Spartium (Fabaceae), 
Scutellaria (Lamiaceae), Passiflora (Passifloraceae), Pinus 
(Pinaceae), Prunus (Rosaceae), Populus (Salicaceae), 
Escallonia (Saxifragaceae) spp. 
Central benzodiazepine receptor agonist 




Leptospermum scoparium (Myrtaceae) Central benzodiazepine receptor ligand (Flunitrazepam 
displacement)  
(IC50 = 3 µM) 
5-Hydroxy-7-methoxy-6,8-dimethylflavone 
(flavone) 
Leptospermum scoparium (Myrtaceae) Central benzodiazepine receptor ligand (Flunitrazepm 
displacement)  
(IC50 = 40 µM) 
1-Hydroxypinoresinol 
(lignan) 
Nothapodytes foetida (Icacinaceae), Valeriana officinalis 
(Valerianaceae) 
Central benzodiazepine receptor ligand 
Imperatorin 
(furanocoumarin) 
Ammi majus, Pastinaca sativa (Apiaceae), Angelica 
dahurica (Asteraceae) 
Central benzodiazepine receptor ligand (Diazepam 
displacement)  
(IC50 = 8 µM) 
Kaempferol 4’-O-methyl ether 
(flavonol) 
Pityrogramma (fern) (Adiantaceae), Baccharis 
(Asteraceae), Prunus spp. (Rosaceae), Linaria spp. 
(Scrophulariaceae),  
Benzodiazepine receptor ligand (Kd = 93 µM) 
Oroxylin A 
(flavonol) 
Scutellaria baicalensis, S. galericulata (Lamiaceae) Central benzodiazepine receptor ligand (Kd = 15 µM) 
Phellopterin 
(furanocoumarin) 
Angelica spp., A. dahurica, Ferula alliacae (Apiaceae), 
Citrus limon (Rutaceae) 
Central benzodiazepine receptor ligand (Diazepam 
displacement)  




Artemisia herba alba (Asteraceae) Central benzodiazepine receptor ligand (Diazepam 
displacement)  




Scutellaria baicalensis (Lamiaceae) Benzodiazepine receptor ligand (Kd = 0.4 µM) 
Terpene 
Cryptotanshinone  
(diterpene quinine, tanshinone) 
 
Salvia miltorrhiza (Lamiaceae)  
See Chapter 1 (pages 30-33) for additional related 
chemicals from Salvia spp. 
 
Central benzodiazepine receptor partial agonist 
(Flunitrazepam competition)  




Cyperus rotundus (Cyperaceae) Central benzodiazepine agonist 
Majonoside-R2 
(triterpene saponin) 
Panax ginsing (Araliaceae) Central benzodiazepine agonist 






















Central benzodiazepine receptor agonist 
(Kd = 4 nM) (hypnotic, tranquilizer) 
GABAA -receptor binding to sites other 








Adlumia fungosa, Corydalis incise, C. thalictrifolia, 





GABAA-receptor antagonist  
(IC50 = 20 µM) 
(antiseptic, convulsant, haemostatic) 
Chelerythrine 
(benzophenanthridine) 
Chelidonium majus, Argemone, Bocconia, Eschscholzia, 
Glaucium, Sanguinaria spp. (Papaveraceae), Zanthoxylum 
spp. (Rutaceae) 
GABAA-receptor ligand 








Colchicum autumnale, C. spp., Gloriosa superba 
(Liliaceae) 
GABAA-receptor antagonist  
(IC50 < 100 µM) 
Corymine 
(indole) 
Hunteria zeylanica (Apocynaceae)  GABAA-receptor antagonist  
(IC50 < 100 µM) 
Deformylcorymine 
(indole) 
Hunteria zeylanica (Apocynaceae) GABAA-receptor (current inhibition) 
N-Demethl-3-epi-dihydrocorymine 
(indole) 
Alstonia glaucescens (Apocynaceae) GABAA-receptor antagonist  
(IC50 < 100 µM) 
(+)-Hydrastine 
(phthalide isoquinoline) 
Berberis vulgaris, Mahonia aquifolium (Berberidaceae), 
Corydalis stricta (Papaveraceae), Hydrastis canadensis 
(Ranunculaceae) 
GABAA-receptor antagonist  
(IC50 = 2 µM) 
GABA stimulated Diazepam binding (IC50 = 0.4 µM) 




Corydalis pseudoadunca (Papaveraceae) GABAA-receptor inhibitors (blocks GABA induced 
current) 
(Kd = 1 µM) 
 
 
Laudanosine (= Laudanine methyl ether) 
(benzylisoquinoline) 
Papaver somniferum (Papaveraceae); metabolic product of 
synthetic skeletal muscle relaxant Atracurium 
GABAA-receptor antagonist  
(IC50 < 100 µM) 








Protopine (= Biflorine; Corydalis C; Corydinine; 
Fumarine; Macleyine) 
(benzylisoquinoline) 
Chelidonium majus, Argemone, Bocconia, Corydalis, 
Eschscholzia, Glaucium, Macleaya, Papaver somniferum, 
Sanguinaria spp. (Papaveraceae), Fumaria officinalis 
(Fumariaceae) 
GABAA-receptor ligand (Muscimol displacement)  
(sedative, relaxant) 
Sanguinarine (= Pseudochelerythrine) 
(benzophenanthridine) 
Chelidonium majus, Argemone, Bocconia, Corydalis, 
Eschscholzia, Glaucium, Macleaya, Papaver somniferum, 
Sanguinaria spp. (Papaveraceae), Fumaria officinalis 
(Fumariaceae), Zanthoxyllum (Rutaceae), Pteridophyllum 
spp. (Sapindaceae) 
GABAA-receptor ligand (Muscimol displacement) 
(IC50 = 39 µM) 
Securinene 
(piperidinepyrroldine) 
Phyllanthus discoides, Securinega suffraticosa 
(Euphorbiaceae), Securidaca longepedunculata (Fabaceae) 
GABAA-receptor antagonist  
 
(+)-Tubocurarine (= curare active principle) 
bisbenzylisoquinoline) 
Chondrodendron tomentosum, C. spp. (Menispermaceae) GABAA-receptor antagonist  
(skeletal muscle relaxant) 
Phenolic 
Daidzein (= 4’,7-Dihydroxyisoflavone) 
(isoflavone)  
 
Glycine max, Trifolium repens, Phaseolus, Psoralea, 
Pueraria, Sophora, Ulex, Vigna spp. (Fabaceae) 
 
(GABAA-receptor) (inactive as tyrosine kinase inhibitor 
cf. Genistein) 
Desmethoxyyangonin 
(phenolic-derived dienolide lactone, kavapyrone) 
Piper methysticum (Piperaceae) Inactive as GABAA-receptor modulatory agonist (cf. 
Yangonin and Kawain) 
(+)-Dihydrokavain (= Dihydrogonosan; 
Dihydrokawain) 
(phenolic-derived lactone, kavapyrone) 
Piper methysticum (Piperaceae) GABAA-receptor modulatory agonist; increases 




(phenolic-derived lactone, kavapyrone) 
Piper methysticum (Piperaceae) GABAA-receptor modulatory agonist; increases 
Bicuculline-binding (at IC50 = 0.1 µM); no binding to 
benzodiazepine receptor 
(anxiolytic) 
Genistein (= Genisteol; prunetol; Sophoricol; 
4’,5,7-trihydroxyisoflavone) 
(isoflavone)  
Widespread: Genista, Glycine, Phaseolus, Trifolium spp. 
(Fabaceae), Prunus spp. (Roseaceae) 
GABAA-receptor (non-competitive antagonist) 
Honokiol 
(lignan) 
Magnolia officinalis, M. obovata (Magmoliaceae) GABAA-receptor (allosteric potentiating ligand) 
(IC50 = 8 µM) 
(anxiolytic, central depressant) 
(+)-Kawain (= Gonosan; Kavain) 
(phenolic-derived lactone, kavapyrone) 
Piper methysticum (Piperaceae) GABAA-receptor agonist (allosteric potentiating ligand) 




Sassafras randaiense (Lauraceae); Magnolia officinalis, M. 
obovata (Magmoliaceae) 
GABAA-receptor (allosteric potentiating ligand) 
(IC50 = 6 µM) 
(anxiolytic, central depressant) 









(phenolic-derived lactone, kavapyrone) 
Piper methysticum (Piperaceae) GABAA-receptor modulatory agonist (at IC50 = 0.1 µM) 
no binding to benzodiazepine receptor 
(anxiolytic) 
Yangonin 
(phenolic-derived dienolide lactone, kavapyrone) 
Piper methysticum (Piperaceae) GABAA-receptor modulatory agonist (at IC50 = 1 µM) no 






Illicium anisatum (Illiciaceae) 
 
GABAA-receptor non-competitive antagonist (IC50 = 0.4-1 
µM); binds to Picrotoxinin site) 
Carnosic acid 
(diterpene) 
Salvia officinalis (Lamiaceae) GABAA-receptor chloride channel blocker; tertiary-




Rosmarinus officinalis, Salvia officinalis (Lamiaceae) GABAA-receptor chloride channel blocker; tertiary-
butylbicyclophosphorothioate (TBPS) binding (IC50 = 57 
µM) 
Coriamyrtin 
(tutinolide sesquiterpene lactone) 
Coriaria japonica, C. myrtifolia (Coriariaceae) GABAA-receptor antagonist (IC50 = 10-30 µM) 
Dihydrotutin 
(tutinolide sesquiterpene lactone) 
Picrodendron baccatum (Euphorbiaceae) GABAA-receptor non-competitive antagonist  
Ginsenosides 
(triterpene saponin) 
Panax ginseng (Araliaceae) GABAA-receptor ligand (Muscimol displacement) 
Horminone 
(diterpene) 
Salvia deserta, Plectranthus hereroensis (Lamiaceae) GABAA-receptor chloride current inhibition (IC50 = 10 
µM) 
Isohyenanchine 
(tutinolide sesquiterpene lactone) 
Picrodendron baccatum (Euphorbiaceae) GABAA-receptor non-competitive antagonist 
Picodendrins 
(tutinolide sesquiterpene lactone) 
Picrodendron baccatum (Euphorbiaceae) GABAA-receptor non-competitive antagonist (IC50 = ±1 
µM) 
Picrotin 
(tutinolide sesquiterpene lactone) 
Anamirta paniculata (= A. cocculus; Menispermum 
occulus), Tinomiscium philippinense (Menispermaceae) 
GABAA-receptor non-competitive antagonist 
(CNS-stimulant, barbiturate antidote) 
Picrotoxin (= mixture of Picrotin and Pictotoxinin) 
(tutinolide sesquiterpene lactone) 
Anamirta paniculata (= A. cocculus; Menispermum 
occulus), Tinomiscium philippinense (Menispermaceae) 
GABAA-receptor antagonist (IC50 = 0.2 µM); GABAA-
receptor chloride current inhibition (IC50 = 1 µM) 
(CNS-stimulant, barbiturate antidote) 
Picrotoxinin (= Dehydropicrotin) 
(tutinolide sesquiterpene lactone) 
Salvia deserta (Lamiaceae), Anamirta paniculata (= A. 
cocculus; Menispermum occulus), Tinomiscium 
philippinense (Menispermaceae) 
GABAA-receptor non-competitive antagonist 
(CNS-stimulant, barbiturate antidote) 
Taxodione 
(abietane diterpenoid) 
Taxodium distichum (Taxodiaceae) GABAA-receptor chloride current inhibition (IC50 = 100 
µM) 








α and β-Thujone 
(monoterpenes) 
Artemisia absinthium, Tanacetum vulgare (Asteraceae), 
Thuja occidentalis (Cupressaceae), Salvia spp. (Lamiaceae) 
GABAA-receptor antagonist/negative modulator (Cl
-
channel block) 
(convulsant, hallucinogenic, intoxicant) 
Reported neurotoxic agent of Absinthe liqueur. 
Tutin 
(tutinolide sesquiterpene lactone) 










GABAB-receptor antagonist  
(skeletal muscle relaxant) 
Isoguvacine (= Piperidine-4-carboxylic acid) 
(piperidine) 
Synthetic GABAA-receptor agonist  
 
Muscimol (= 5-Aminomethyl-3-hydroxyisoxazole) 
(isoxazole) 
Amanita muscaria (fly agaric), A. pantheria (Amanitaceae) 
Highly poisonous hallucinogenic mushrooms 
GABAA-receptor agonist  
 
Pentobarbital 
(pyrimidine trione; barbiturate) 
Synthetic GABAA-receptor agonist  
(anaesthetic, anticonvulsant) 
Phenobarbital (= 5-Ethyl-5-phenylbarbituric acid; 
phenylbarbitone) 
(pyrimidine; barbiturate) 
Synthetic GABAA-receptor agonist  
(anticonvulsant, hypnotic, sedative) 
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4.4.2. Materials and Methods 
 
Plant materials 
Plant species traditionally used to treat epilepsy and convulsions, were selected based on information in a 
database on plants used to treat mental diseases, constructed at the Research Centre for Plant Growth and 
Development, University of KwaZulu-Natal (see Table 4.4.2.1.). The information in the database mainly 
originates from published literature. Plants were colle ted in KwaZulu-Natal, mostly from the University 
of KwaZulu-Natal Botanical Garden. Voucher specimens are deposited in the University of KwaZulu-
Natal Herbarium. All plant materials were dried at 50 °C. 
 
Table 4.4.2.1. Plant species, family, plant parts and voucher numbers of material collected for screeni g in 
the [3H]-Ro 15-1788 (flumazenil) binding assays. 
Family 
Plant species 
Voucher specimen Plant parts investigated 
Agapanthaceae 
Agapanthus campanulatus F.M.Leight. 
 
Stafford 59 NU 
 
leaves, flowers and roots 
Agapanthus praecox Willd.  leaves, stems, flowers and 
roots 
Amaryllidaceae 
Brunsvigia grandiflora Lindl. 
 
Stafford 10 NU 
 
leaves and bulbs 
Scadoxus puniceus (L.) Friis & I. Nordal Stafford 206 NU leaves and roots 
Anacardaceae  
[South African Rhus recently reclassified as 
Searsia] 









Searsia dentata Thunb.  Stafford 205 NU leaves 
Searsia pyroides Burch. (syn. Searsia tridentata) Stafford 13 NU leaves 
Searsia rehmanniana Engl. Stafford 12 NU leaves 
Searsia pentheri A. Zahlbr.  Stafford 204 NU leaves 
Apiaceae 
Arctopus echinatus L. 
 




Acokanthera oblongifolia (Hochst.) Codd  
 




Cussonia paniculata Eckl. & Zeyh. 
 
Stafford 15 NU 
 
leaves 
Cussonia spicata Thunb. Stafford 16 NU leaves 
Asclepiaceae 
Gomphocarpus physocarpus E. Mey. 
 
Stafford 65 NU 
 
leaves 
Xysmalobium undulatum (L.) Aiton.f.  Stafford 95 NU aerial parts and roots 
Asphodelaceae 
Bulbine frutescens (L.) Willd.  
 
Stafford 17 NU 
 
leaves and roots 
Gasteria croucheri (Hook.f.) Baker Stafford 18 NU leaves 
Asteraceae 
Artemisia afra Jacq. ex Willd.  
 
Stafford 63 NU 
 
leaves 
Berkheya bergiana Soderb. Stafford 208 NU leaves 
Berkheya montana J.M. Wood & M.S. Evans Stafford 209 NU leaves 
Berkheya rhapontica (D.C.) Hutchinson & Burtt 
Davy 
Stafford 210 NU leaves and roots 
Helichrysum argyrolepis MacOwan Stafford 213 NU leaves 
Helichrysum hesbaceum (Andrews) Sweet Stafford 214 NU leaves 
Helichrysum nudifolium Less. Stafford 215 NU leaves 
Helichrysum ruderale Hilliard & B.L. Burtt Stafford 216 NU leaves 
Helichrysum rugulosum Less. Stafford 217 NU leaves 
Helichrysum simillimum DC. Stafford 218 NU leaves 
Helichrysum umbraculigerum Less. Stafford 219 NU leaves 




Voucher specimen Plant parts investigated 
Berkheya bergiana Soderb. Stafford 208 NU leaves 
Celastraceae 
Catha edulis (Vahl) S. Endlicher 
 




Combretum bracteosum Brandis ex Eng. 
 
Stafford 19 NU 
 
leaves and roots 
Combretum imberbe Wawra. Stafford 20 NU leaves and roots 
Crassulaceae 
Cotyledon orbiculata L.  
 




Dioscorea dregeana Baker 
 




Antidesma venosum E. Mey. Ex Tul. 
 
Stafford 21 NU 
 
roots 
Croton sylvaticus Schlecht. Stafford 122 NU bark 
Jatropha panduaeifolia Andr. Stafford 22 NU leaves and root bark 
Jatropha zeyheri Sond. Stafford 23 NU leaves 
Fabaceae 
Acacia sieberiana DC. 
 
Stafford 123 NU 
 
bark 
Acacia xanthophloea Benth. Stafford 124 NU bark 
Bauhinia galpinii N.E. Br. Stafford 24 NU leaves 
Bauhinia tomentosa L. Stafford 25 NU leaves 
Dichrostachys cinera Miq. Stafford 26 NU leaves 
Indigofera tristis E.Mey.  Stafford 27 NU leaves 
Indigofera woodii Bolus  Stafford 28 NU leaves 
Millettia grandis Skeels Stafford 125 NU leaves 
Millettia sutherlandii Harv. Stafford 126 NU leaves 
Schotia brachypetala Sond. McGaw 85 NU leaves 
Senna didymobotrya (Fresenius) N.W. Irwin & R.C. 
Barneby 
Stafford 29 NU leaves 
Senna petersiana (Bolle) J.M. Lock Stafford 30 NU leaves 




Oncoba spinosa Forssk.  
 
Stafford 31 NU 
 
leaves and roots 
Hypoxidaceae 
Hypoxis angustifolia Lam. 
 
Stafford 32 NU 
 
leaves and corm 
Hypoxis colchicifolia  Bak. Stafford 33 NU leaves and corm 
Hypoxis hemerocallidea Fisch. & C.A. Mey. Stafford 34 NU leaves, corm and roots 
Lamiaceae 
Hoslundia opposita Vahl 
 
Stafford 35 NU 
 
leaves 
Leonotis dubra E. Mey. Stafford 36 NU leaves 
Leonotis intermedia Lindl. Stafford 37 NU leaves 
Leonotis leonurus R.Br.  Stafford 38 NU leaves 
Mentha aquatica L.  Stafford 84 NU leaves 
Mentha longifolia Huds. Stafford 127 NU leaves 
Salvia chamelaeagnea Berg. Stafford 39 NU leaves 
Lauraceae 
Cinnamomum camphora (L.) Presl. 
 




Buddleja saligna Willd. 
 
Stafford 40 NU 
 
leaves 
Buddleja salviifolia Lam. Stafford 41 NU leaves 
Malvaceae 
Malva parviflora L.  
 




Ekebergia capensis Sparrm. 
 
Stafford 42 NU 
 
leaves and bark 
Periplocaceae 
Mondia whitei (Hook.f.) Skeels  
 
Stafford 43 NU 
 
leaves and bark 
Phytolaccaceae 
Phytolacca octandra  L.  
 




Piper capense L. 
 
Stafford 89 NU 
 
leaves and roots 




Voucher specimen Plant parts investigated 
Rosaceae 
Rubus ludwigii Eckl. et Zeyh.  
 
Stafford 44 NU 
 
leaves, fruit and  roots 
Rubus phoeniculacius  Maxim Stafford 45 NU leaves, roots 
Rubiaceae 
Catunaregam spinosa Thunb. 
 
Stafford 46 NU 
 
leaves and roots 
Rutaceae 
Clausena anisata (Willd.) Hook.f.  
 
Stafford 47 NU 
 
leaves and bark 
Ruta graveolens L. Stafford 48 NU leaves and stems 
Zanthoxylum capense (Thunb.)Harv. Stafford 96 NU leaves 
Solanaceae 
Datura ferox L.  
 
Stafford 72 NU 
 
leaves, flowers and seeds 
Datura stramonium L.  Stafford 73 NU leaves, seeds and seed pods 
Verbenaceae 
Clerodendrum myricoides (Hochst.) Watke 
 




Rhoicissus tomentosa (Lam.) Wild & Drum. 
 
Stafford 51 NU 
 
leaves 
Rhoicissus tridentata (L.f.) Wild & Drum. Stafford 52 NU leaves 
 
Extraction of plant materials for screening  
Two grams of material were extracted with 20 ml ethanol for 60 min on an ultrasound bath, thereafter th  
extracts were filtered. The extracts were taken to dryness under reduced pressure. The residues were 
dissolved in ethanol, respectively, at 10mg/ml. 
 
Isolation and identification of active constituents of Searsia pyroides (Rhus pyroides) 
Grounded dry plant material (100 g) was extracted three times with 1000 ml of heptane for 60 min in an 
ultrasonic bath to remove non-active lipophilic compounds. The plant material was then dried on filter 
paper. The dried plant material was extracted with 3 x 1000 ml of 96 % ethanol for 60 min in an 
ultrasonic bath. The combined extracts were filtered and evaporated to dryness. The residue was 
redissolved in 1000 ml of ethyl acetate and subsequently partitioned against 3 x 1000 ml of water. The 
organic phase was evaporated to dryness. 
 
The extracts were submitted to reversed-phase HPLC. A Phenomenex LUNA C-18 column, 5 µm, 250 x 
21 mm with a guard column (Phenomenex LUNA C-18, 5 µm, 50 x 21 mm) was employed using 
Shimadzu LC-6A pumps, a Shimadzu SPD-M6A Photodiode Array UV-VIS detector and a Shimadzu 
SCL-6A system controller. HPLC fractionation was performed using a gradient of methanol and water 
(40-100 % methanol at t = 0-20 min and 100-40 % at t = 20-30 min). Both solvents contained 0.5 % (v/v) 
phosphoric acid (85 %). The flow-rate was 8 ml/min and detection was done at 200-400 nm. The fractions 
which eluted at 22.7 min (84 % methanol) and 25.4 min (68 % methanol) inhibited the 3H-Ro 15-1788 
(flumazenil) binding assay in a competitive manner and afforded agathisflavone 1 and amentoflavone 2, 
NMR spectra were recorded on a Bruker Avance 400 MHz instrument. Apigenin - 4’,5,7-
trihydroxyflavon, ca. 95 %, was purchased from Sigma-Aldrich. 
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Isolation and identification of active constituents of Mentha aquatica 
Aerial parts (>500 g dry weight) of Mentha aquatica L. (Lamiaceae) were collected at Cedara 
Agricultural College, Hilton, KwaZulu-Natal (29°32′S 30°17′E) in February 2006. A voucher specimen 
was deposited at the University of KwaZulu-Natal Herbarium, Pietermaritzburg (Voucher number, 
Stafford 84 NU). The material was dried in an oven at 50 ºC. For initial screening one g dried, powdered 
material was extracted with 10 ml petroleum ether, ethyl acetate, ethanol or water respectively for 30 min 
in an ultrasound bath. The extracts were filtered an taken to dryness under vacuum before being re-
dissolved at 10 mg/ml in ethanol. Twenty g dried, powdered material was steam distilled with 500 ml 
distilled water for 4 h. The obtained essential oil was dissolved at 10 mg/ml in ethanol for initial 
screening.  
 
Powdered dry leaf material (250 g) was steam distilled with 2500 ml distilled water for 2 h, yielding pale 
yellow oil. The oil was applied to a 80 g Silica 60 (0.040-0.063 mm) column (65 cm long, 2 cm diameter) 
and eluted with 100 ml of each combination of toluene: thyl acetate (97.5:2.5; 95:5; 90:10; 85:15; 75:25; 
50:50). Collected fractions were combined on basis of a TLC analysis, where the plate was eluted in 
toluene:ethyl acetate 93:7. The active fraction wassubjected to GC-MS on an Agilent 6890N Network 
GC system coupled to a 5973 Network Mass Selective Detector. GC conditions: injector temperature: 
150 ºC; temperature programme: start 50 ºC, 20 ºC/min to 300 ºC; column: HP5MS. A NIST library was 
used for comparison of MS data. The active fraction was also investigated by 13C-NMR (Varian Mercury 
Plus 300 MHz; CDCl3). Optical rotation was measured on a Perkin-Elmer 241 polarimeter. 
 
For the isolation of active compound (naringenin) from M. aquatica, 15 g dried and powdered plant 
material (whole plant) was extracted with 150 ml ethanol for 30 min in an ultrasound bath. The extract 
was filtered, taken to dryness under vacuum, and then partitioned between ethyl acetate and water. The 
active ethyl acetate phase was subjected to solid-phase chromatography on a Bond Elut C2, eluted with 
water:methanol 3:1. This fraction was then applied to a prep TLC plate (Merck Silica gel 60, 0.5 mm 
thickness) and eluted in ethyl acetate:formic acid:glacial acetic acid:water (100:11:11:26). A strip at the 
side of the plate was sprayed with natural products - polyethylene glycol reagent. Bands were scraped off 
the plate and the silica eluted with ethanol. The active compound was subjected to 1H-NMR (Varian 
Mercury Plus 300 MHz; CDCl3) and optical rotation was determined on a Perkin-Elmer 241 polarimeter. 
 
Rat tissue preparation 
The tissue preparation was performed at 0–4 °C. Cerebral cortex from four rats was homogenised for 5 s 
in 20 ml of Tris–citrate (50 mM, pH 7.1) using an Ultra-Turrax. The suspension was centrifuged at 
27 000 × g for 15 min, and the pellet was washed three times with buffer. The washed pellet was 
homogenised in 20 ml of buffer and the suspension was incubated in a water bath (37 °C) for 30 min to 
remove endogenous GABA. Then the suspension was centrifuged for 10 min at 27 000 × g. The final 
pellet was resuspended in 30 ml buffer and stored in 1 ml aliquots (in Eppendorf tubes) at −20 °C. 
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[3H]-Ro 15-1788 (flumazenil) binding assay 
The assay was carried out according to KAHNBERG, LAGER, ROSENBERG, SCHOUGAARD, 
CAMET, STERNER, NIELSEN, NIELSEN and LILJEFORS (200). The membrane preparation was 
thawed and washed with 20 ml Tris–citrate (50 mM, pH 7.1, 0–4 °C). The suspension was centrifuged at 
0–4 °C for 10 min at 27 000 × g. The pellet was resuspended in Tris–citrate (50 mM, pH 7.1, 2 mg 
original tissue per ml buffer), and then used for the binding assay. Membrane suspension (500 µl) was 
added to 25 µl test solution (plant extract/standard/blank) and 25 µl of flumazenil (Ro 15-1788, purchased 
from Perkin-Elmer Life Sciences) (0.5 nM, final cone tration in assay), mixed and incubated for 40 min 
in an ice-bath (0–4 °C).  
 
Non-specific binding was determined using clonazepam (1 µM, final concentration in assay) added to 
separate samples. After incubation 5 ml of ice-cold buffer were added to the samples and the mixture 
poured directly onto Adventic glass fibre filters (GC-50) under suction, and immediately washed with 5 
ml of ice-cold buffer. The amount of radioactivity was determined by conventional liquid scintillation 
counting. Specific binding was calculated as total binding minus non-specific binding. All experiments 
were done in triplicate. 
 
4.4.3. Results and Discussion 
 
Forty three plants were initially selected for investigation as potential sources of antiepileptic comp unds. 
A total of 116 extracts were tested in the 3H-flumazenil binding assay. The binding of 3H-flumazenil 
obtained at five concentrations of all plant extracts are shown in Table 4.4.3.1 (page 163). In the second 
screening, 46 ethanolic extracts from 35 species were t sted in the 3H-flumazenil binding assay. The 
binding of 3H-flumazenil obtained at three concentrations of all plant extracts are shown in Table 4.4.3.2 
(page 167).  
 
The most active extracts were the ethanolic leaf extracts of Searsia dentata, Searsia rehmanniana, 
Hoslundia opposita and the ethanolic corm extract of Hypoxis colchicifolia, which all showed good dose-
dependent activity. 
 
Out of the 46 extracts tested in the second screening, seven showed good dose dependant activity (Table 
4.4.3.2.). These extracts were from Arctopus echinatus, Artemisia afra, Helichrysum hesbaceum, 
Helichrysum ruderale, Helichrysum simillimum, Helichrysum umbraculigerum and Mentha aquatica 
ethanolic leaf extracts. Mentha aquatica was investigated further as discussed below. Several plants 
showed moderate dose dependant activity. These plants include the ethanolic root extract of Scadoxus 
puniceus, the ethanolic leaf extracts of Helichrysum rugulosum, Millettia grandis, Mentha longifolia, 
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Malva parviflora, Phytolacca octandra and Datura ferox. The ethanolic extracts of Acacia xanthophloea 
and both leaf and tuber extracts of Piper capense exhibited moderate activity. 
 
Various flavones, including rhamnetin, eupatlitin and bonazin have been isolated from the aerial parts of 
several Artemisia species (WOLLENWEBER and JAY, 1988). The observed anticonvulsant and sedative 
activity of Artemisia dracunculus L. (Tarragon) from Iran may be linked to the presence of 
monoterpenoids in the essential oil (SAYYAH, NADJAFNIA and KAMALINEJAD, 2004). Two 
flavonoids, hispidulin and cirsilineol, from Artemisia herba-alba Asso (used traditionally in Lebanon) 
with in-vitro GABAA-benzodiazepine receptor activity were isolated by SALAH and JÄGER (2005). It is 
possible that these or similar compounds are responsible for the activity detected in Artemisia afra. 
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Table 4.4.3.1. Plant extracts initially screened for activity in the GABAA-benzodiazepine receptor assay (RISA, RISA, ADSERSEN, GAUGUIN, STAFFORD, VAN STADEN 
and JÄGER, 2004). 
 
Plant species Plant part Extract a [3H]-Ro 15-1788 (flumazenil) binding in percentb at five concentrations IC 50 ± SE
c 
(µg/ml) 
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Plant species Plant part Extract a [3H]-Ro 15-1788 (flumazenil) binding in percentb at five concentrations IC 50 ± SE
c 
(µg/ml) 
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Plant species Plant part Extract a [3H]-Ro 15-1788 (flumazenil) binding in percentb at five concentrations IC 50 ± SE
c 
(µg/ml) 
   10 mg/ml 1 mg/ml 0.1 mg/ml 0.01 mg/ml 0.001 mg/ml  
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Plant species Plant part Extract a [3H]-Ro 15-1788 (flumazenil) binding in percentb at five concentrations IC 50 ± SE
c 
(µg/ml) 




















































































































































































a solvents: w = deionized water; e = 70% ethanol 
b [3H]-Ro 15-1788 (flumazenil) binding in percent, the lower the percentage the more [3H]-Ro 15-1788 (flumazenil) has been displace by the plant extract  
c IC50 (µg/ml) and standard error, calculated using Grafit (© Erithacus Software Limited) 
d n.d. = not detected, does not exhibit sufficient (IC50 < 1000 µg/ml) dose-dependant activity
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Table 4.4.3.2. Percent binding of [3H] Ro 15-1788 (flumazenil) to the GABAA-benzodiazepine receptor in the 
presence of various concentrations of ethanolic extracts of individual plants used traditionally as sedatives or to treat 







Percentage binding (±SE) at different plant 
extract concentrations in assay 
























































































Berkheya bergiana Leaves 39.4±3.1 69.7±4.0 77.8±6.2 
Berkheya montana Leaves 40.6±2.0 81.1±5.2 78.0±7.4 








Helichrysum argyrolepis Leaves 31.6±3.6 59.8±1.4 77.0±3.8 
Helichrysum hesbaceum Leaves 12.9±0.4 44.4±2.4 67.3±3.3 
Helichrysum nudifolium Leaves 43.1±2.1 71.2±2.6 74.7±3.2 
Helichrysum ruderale Leaves 9.7±0.7 45.5±2.0 71.5±2.1 
Helichrysum rugulosum Leaves 16.1±0.4 33.8±4.4 59.2±1.1 
Helichrysum simillimum Leaves 13.3±1.8 41.0±2.0 61.3±3.3 



















































Acacia xanthophloea Bark 18.4±2.4 22.8±1.0 55.6±6.5 
Millettia grandis Leaves 18.6±0.7 52.8±2.5 66.3±3.7 
Millettia sutherlandii Leaves 30.5±3.4 53.2±2.0 64.3±5.6 
Schotia brachypetala Leaves 28.8±2.6 51.5±3.0 73.2±2.3 

















































Percentage binding (±SE) at different plant 
extract concentrations in assay 










































More than 14 species of Helichrysum are used in Zulu traditional medicine (HUTCHINGS, COTT, 
LEWIS, and CUNNINGHAM, 1996). Several species known as imphepho (zulu) are burned as ritual 
incenses at almost every traditional gathering, ritual or ceremony to invoke the goodwill of the ancestors. 
Healers burn these highly aromatic plants during consultations with patients again to invoke the goodwill 
of the ancestors and for guidance in diagnosis and treatment. The smoke is said to be helpful for insomnia 
(HUTCHINGS, SCOTT, LEWIS, and CUNNINGHAM, 1996). The smoke from imphepho is inhaled by 
healers to induce a trance. Helichrysum species contain flavonoids (VAN WYK, VAN OUDTSHOORN, 
and GERICKE, 1997), examples are helichrysetin, isolated from H. odoratissimum (L.) Less, and 
caespitin, a phloroglucinol derivative from H. caespititium (MATHEKGA, MEYER, HORN and 
DREWES, 2000). 
 
Several southern African plants have shown in vivo anticonvulsant activity against seizures produced in 
mice by pentylenetetrazole, picrotoxin, bicuculline and N-methyl-DL-aspartic acid. However, the active 
constituents are yet to be identified. The plants iclude Leonotis leonurus (Lamiaceae) (BIENVENU, 
AMABEOKU, EAGLES, SCOTT and SPRINGFIELD, 2002) whic is reported to have narcotic effects 
and is used as a substitute for Cannabis (WATT and BREYER-BRANDWIJK, 1962). The aqueous 
extracts of L. leonurus (400 mg/kg) protected against or delayed seizures induced by pentylenetetrazole, 
picrotoxin and N-methyl-dl-aspartic acid, but did not protect against bicuculline-induced seizures. In this 
study, the ethanol extracts of the three species of Le notis had weak GABAA-benzodiazepine receptor 
binding activity only at the highest concentration tested (10 mg/ml) (RISA, RISA, ADSERSEN, 
GAUGUIN, STAFFORD, VAN STADEN and JÄGER, 2004) but the aqueous extracts were not active, 
suggesting that the anticonvulsant mechanism is not via GABAA-benzodiazepine receptor.  
 
WATT (1967), one of the earliest researchers to recgnize the potential of African plants in improving 
mental health, reported the use of Cotyledon orbiculata (Crassulaceae) leaves to treat epilepsy. Again, in 
vivo studies have demonstrated both aqueous and methanol extracts of C. orbiculata have anticonvulsant 
properties (moderate protection against pentylenetetrazole, bicuculline, picrotoxin and N-methyl-dl-
aspartic induced seizures in mice) (AMABEOKU, GREEN and KABATENDE, 2007). However, in this 
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study the ethanolic extract did not show in vitro GABAA-benzodiazepine receptor binding activity 
(STAFFORD, JÄGER and VAN STADEN, 2005). 
 
Another study investigated a Northern Sotho remedy, Sehlare sa Seebana, for treatment of epilepsy. The 
recipe for this herbal remedy contains six plants, Acrotome inflata, Aptosimum indivisum, Asparagus 
suaveolens, Barleria bolusii, Commiphora marlothii and Sesamum triphyllum. Equal parts of the plants 
are placed in a red-hot clay pot and the patient inhales the smoke (JÄGER, MOHOTO, VAN HEERDEN 
and VILJOEN, 2005). Both aqueous and ethanol extracts of Aptosimum indivisum and Asparagus 
suaveolens and the aqueous extract of Commiphora marlothii showed good dose-dependent GABAA-
benzodiazepine receptor binding. Most of the plants have not been chemically investigated. Three 
metabolites: verbascoside, pinocembrinin 7-neohesperidoside and shanzhiside methyl ester were isolated 
from A. indivisum. B. bolusii contains verbascoside, which is known to inhibit the GABA receptor, but 
did not show much activity (DAELS-RAKOTOARISON, SEIDEL, GRESSIER, BRUNTE, 
TILLEQUIN, BAILLEUL, LUYCKX, DINE, CAZINI and CAZIN , 2000; JÄGER, MOHOTO, VAN 
HEERDEN and VILJOEN, 2005). 
 
Isolation and identification of active compounds from Searsia pyroides (Searsia pyroides) 
Two biflavonoids with activity in the 3H-Ro 15-1788 (flumazenil) binding assay were isolated by HPLC 
fractionation of the ethanol extract of the leaves from Searsia pyroides (SVENNINGSEN, DAMKJÆR 
MADSEN, LILJEFORS, STAFFORD, VAN STADEN and JÄGER, 2006). The structures of the two 
biflavonoids were elucidated by NMR to be agathisflavone and amentoflavone. Agathisflavone and 
amentoflavone competitively inhibited the binding of 3H-Ro 15-1788 with a Ki of 28 and 37 nM, 
respectively. Extracts of Searsia dentata and Searsia pentheri were not as active as the extract from 
Searsia pyroides; both were found to contain apigenin and agathisflavone. 
 
Apigenin, agathisflavone and amentoflavone were also subjected to a pharmacophore model for ligands at 
the benzodiazepine receptor developed by ZHANG, KOEHLER, ZHANG and COOK (1995). The model 
has previously been validated and further developed to include flavones by DEKERMENDJIAN, 
KAHNBERG, WITT, STERNER, NIELSEN and LILJEFORS (1999) and KAHNBERG, LAGER, 
ROSENBERG, SCHOUGAARD, CAMET, STERNER, NIELSEN, NIELSEN and LILJEFORS (2002). 
Conformational analyses of the compounds were performed by using the Monte Carlo Multiple Minimum 
(MCMM) method (CHANG, GUIDA and STILL, 1989) and the MMFF94 force field (HALGREN, 1996) 
as implemented in the MacroModel program version 8 (MOHAMADI, RICHARDS, GUIDA, 
LISKAMP, LIPTON, CAUFIELD, CHANG, HENDRICKSON and STILL, 1990). Each compound was 
fitted into the model in a low energy conformation according to conformational analysis. Apigenin was 
fitted into the model in the same way as previously described for other flavone derivatives (KAHNBERG, 
LAGER, ROSENBERG, SCHOUGAARD, CAMET, STERNER, NIELSEN, NIELSEN and 
LILJEFORS, 2002). The low affinity of apiginin is most probably due to its inability to fill up the L2 
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lipophilic pocket (Figure 4.2. A) which is important for high affinity binding of flavone derivatives 
(DEKERMENDJIAN, KAHNBERG, WITT, STERNER, NIELSEN and LILJEFORS, 1999).  
 
In addition, the fit reveals a steric repulsive interaction at the S4 site (Figure 4.2. A). In the fitting of 1 and 
2 it is assumed that one of the monomers in the biflavones binds to the receptor in the same way as 
apigenin (Figure 4.2. A). Thus the other monomer is regarded as a large substituent. Considering the steric 
constraints of the modelled binding site of the receptor shown in Figure 4.2. (the steric repulsive sites S1–
S5 and the hydrogen bonding sites HI, H2, A2, A3) the only reasonable way to fit 1 and 2 into the model 
is to place these large substituents in the lipophilic area L3 or in the “subunit interface” area which is 
suggested to correspond to the interface between an α d a γ subunit in the GABAA receptor 
(KAHNBERG, LAGER, ROSENBERG, SCHOUGAARD, CAMET, STERNER, NIELSEN, NIELSEN 
and LILJEFORS, 2002). Compound 1 is proposed to bind to the receptor with its substituent in the 
lipophilic pocket (L3), between the steric repulsive site (S3) and the bi-functional hydrogen bond 
donor/acceptor site (H2/A3) (Figure 4.2. B). It should be noted that the L3 area according to the model of 
ZHANG, KOEHLER, ZHANG and COOK (1995) accommodates part of diazepam in its binding to the 
receptor. Compound 2 can be fitted into the model in two different ways; with the substituent in the 
lipophilic pocket (L3), as is the case for 1, or in the “subunit interface” area. The latter offers a somewhat 
better space for larger substituents. It has previously been shown that this area in terms of the 
pharmacophore model can accommodate large substituents (KAHNBERG, LAGER, ROSENBERG, 
SCHOUGAARD, CAMET, STERNER, NIELSEN, NIELSEN and LILJEFORS, 2002). Thus, the 
binding of 2 to the receptor is proposed to take place with the substituent in the “subunit interface” area 
(Figure 4.2. C). 
 
According to the pharmacophore modelling reported above, the significantly higher affinity of the 
biflavonoids 1 and 2 compared to that of apigenin is most probably due to affinity increasing interactions 
of one of the monomers (the substituent) with amino acid residues in the “subunit interface” area or the 
L3 lipophilic area. A similar increase in affinity due to large substituents proposed to be located in a 
subunit interface of the GABAA receptor was previously reported (FRØLUND, JORGENS, 
TAGMOSE, STENSBØL, VESTERGAARD, ENGBLOM, KRISTIANSEN, SANCHEZ, 





















   1     2  
  Agathisflavone    Amentoflavone 





Figure 4.2. (A) Apigenin, (B) agathisflavone 1 and (C) amentoflavone 2 showing fit to the pharmacophore model. 
 
The binding of apigenin and amentoflavone to the flumazenil site has previously been reported 
(NIELSEN, FROKJAER and BRAESTRUP, 1988; VIOLA, WASOWSKI, LEVI DE STEIN, 
WOLFMAN, SILVERA, MEDINA and PALADINI, 1995) but apigenin showed no anticonvulsant 
properties in vivo (VIOLA, WASOWSKI, LEVI DE STEIN, WOLFMAN, SILVERA, MEDINA and 
PALADINI, 1995; AVALLONE, ZANOLI, PUIA, KLEINSCHNITZ, SCHREIER and BARALDI, 
2000). Another group reported amentoflavone to be a r l tively weak negative allosteric modulator of 
GABA action acting independently the flumazenil binding site (HANRAHAN, CHEBIB, 
DAVUCHERON, HALL and JOHNSTON, 2003). Thus, the use of these plants as anticonvulsive agents 
suggests involvement of a different neurotransmitter system. 
 
Isolation and identification of active constituents of Mentha aquatica 
In the initial screening the four solvent extracts and the essential oil were tested in the GABA-
benzodiazepine assay. The results for displacement of the radioactive ligand indicated that water (77 %),
ethanol extracts (77%) and the essential oil (64%) showed interesting displacement, whereas the 
displacement obtained with the ethyl acetate (46 %) and petroleum ether (31%) extracts were lower. This 
indicated that there were both polar and lipophilic active compounds in M. aquatica, and it was therefore 
decided to continue the isolation procedure using both the essential oil and ethanolic extracts. 
 
The sesquiterpene viridiflorol (3) (yield: 45 mg from 15 g dried material) was isolated by bioassay-guided 
fractionation from the essential oil. The GC-MS analysis of the active compound from the essential oil 
indicated that the compound was ledol, however not with a good fit. There are three naturally occurring 
isomers, ledol, viridiflorol and globulol. The optical rotation of the isolated compound was measured to 
be [α]589 = 0.9 º. (+/-)-Globulol has an optical rotation of 35-60º (WU, HUANG and CHEN, 1996), which 
eliminated the possibility that the isolated compound could be globulol. Viridiflorol and ledol both have 
an optical rotation of 2º (WU, HUANG and CHEN, 1996), so this technique could not be used to 
differentiate between these two isomers. 13C-NMR (C-1: 58.07; C-2: 25.72; C-3: 29.00; C-4: 38.38; C-5: 
CHAPTER FOUR Anti-epileptics and Anxiolytics  171  
 
39.63; C-6: 22.21; C-7: 28.48; C-8: 18.77) with comparison to data from BOMBARDA, 
RAHARIVELOMANANA, RAMANOELINA, FAURE, BIANCHINI and GAYDOU (2001), who 
synthesized the two isomers, unequivocally determined the structure to be viridiflorol (3, below). 
Viridiflorol has previously been detected in M. aquatica (UMEMOTO, ARAI, NII and FURUKAWA, 










Bioassay-guided isolation of the ethanol extract lead to the isolation of the flavanone naringenin (4). The 
1H-NMR data (H-3eq: 2.76, 1H, dd; H-3ax: 3.10, 1H, dd; H-2: 5.34, 1H, dd; H-6: 5.97, 1H, d; H-8: 5.99, 
1H, d; H-3’, H-5’: 6.9, 2H, dd; H-2’, H-6’: 6.9, 2H, dd) in comparison with previously published data 
(DU, JERZ and WINTERHALTER, 2004) determined the structure to be naringenin. An optical rotation 
[α]25589 = -20.7 (EtOH) was determined, which correspond to (S)-naringenin (4) (GIORGIO, 










The IC50 values in the GABA-benzodiazepine assay were determin d from dose-response curves (Figure 
4.3.) to be 0.19 M for viridiflorol and 0.0026 M for (S)-naringenin, giving a Ki-value of 2 mM for (S)-
naringenin. Compared to the clinically used benzodiazepine, diazepam, which had an IC50-value of 0.1 
µM, the two compounds isolated in this study were not very active. In a study on structure-activity 
relationship of flavonoids binding to the GABA-benzodiazepine site naringenin had a Ki -value of 770 
nM, about 100 times less active than diazepam with a Ki -value of 8.5 nM, but it was not stated which 
stereoisomer of naringenin was tested (DEKERMENDJIAN, KAHNBERG, WITT, STERNER, 
NIELSEN and LILJEFORS, 1999). 
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None of the isolated compounds exhibit high enough affinity to the GABA-benzodiazepine site to be 
candidates for drug development, but the displayed activity validates their use in traditional medicine. 
Those that did not exhibit activity in this investigation may act on a different mechanism related to their 
traditional use. 
 
Often plant extracts and compounds active in the flumazenil assay are not active in vivo suggesting that 
these compounds may not be able to pass the blood brain arrier (BBB). In the search for new 
antiepileptic and anticonvulsant compounds with effect on the GABAA receptor, it is essential that the 
compounds are able to pass the BBB. Therefore it is important to confirm this activity in an in vivo 
animal model or functional assay such as the cortical wedge assay. Naringenin has been shown to pass the 
BBB (YOUDIM, QAISER, BEGLEY, RICE-EVANS and ABBOTT, 2004), which means that it can 
exercise an effect on the CNS. 
 
The following publications relate to this chapter: 
 J. Risa, A. Risa, A. Adsersen, B. Gauguin, G.I. Stafford, J. van Staden and A.K. Jäger. 2004. 
Screening of plants used in southern Africa for epilepsy and convulsions in the GABAA-
benzodiazepine receptor assay. Journal of Ethnopharmacology, 93: 177-182. 
 G.I. Stafford, A.K. Jäger and J. van Staden. 2005. Activity of traditional South African sedative and 
potentially CNS-acting plants in the GABA-benzodiazepine receptor assay. Journal of 
Ethnopharmacology, 100: 210-215  
 A.B. Svenningsen, K. Damkjær Madsen, T. Liljefors, G.I. Stafford, J. van Staden and A.K. Jäger. 
2006. Biflavones from Searsia species with affinity for the GABAA/benzodiazepine. Journal of 
Ethnopharmacology, 103: 276-280. 
 A.K. Jäger, J.P. Almqvist, S.A.K. Vangsøe, G.I. Stafford, A. Adsersen, J. Van Staden. 2007. 
Mentha aquatica in the GABAA-benzodiazepine receptor assay. South African Journal of Botany, 
73: 518-521. 
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Age-related, dementia and debilitative mental disorders:  
Screening South African medicinal plants for monoamine oxidase B inhibitors 
(MAO-B) to treat Parkinson’s disease 
 
5.1.  Introduction 
 
The increasing average life expectancy is leading to major demographic changes worldwide. CNS 
disorders associated with old age, such as Alzheimer’s (AD) and Parkinson’s disease (PD), and other 
‘senile’ dementia will have dramatic societal and economic impact in the next decades (WORLD 
HEALTH REPORT, 1998). In the absence of any disease (e.g. AD, hardening of arteries in the brain) a 
person’s mental abilities will remain mostly intact throughout life. Many people maintain a mentally 
functional and active life well into their nineties. Therefore the term ‘senile dementia’ is somewhat 
misleading, since getting old in itself does not cause significant or debilitating decline. Disease impairs 
the mind, not simply aging (SPINELLA, 2005). Alzheimer’s disease is by far the most frequent cause of 
dementia, increasing in prevalence from less than 1 % below the age of 60 to more than 40 % above the 
age of 85 (LINDEBOOM and WEINSTEIN, 2004). Parkinso’s disease (PD) affects one in every 100 
persons above the age of 65 years; it is the second most common neurodegenerative (DE RIJK, 
LAUNER, BERGER, BRETELER, DARTIGUES, BALDERESCHI, FRATIGLIONI, LOBO, 
MARTINEZ-LAGE, TRENKWALDER and HOFMAN, 2000). 
 
The prevalence of AD among indigenous South African subjects is not known. Local neurologists and 
old-age psychiatrists rarely encounter the disorder (DE VILLIERS and LOUW, 1996). Cultural attitudes 
in Africa surrounding dementia may have contributed to this apparent low prevalence. One suggestion is 
that dementia sufferers may not survive for long. They may die quickly, from conditions such as 
pneumonia or diarrhoea due to the decreasing status of the olderly in the developing world (CHANDRA, 
GANGULI and RATCLIFF, 1994; LEVKOFF, MACARTHUR and BUCKNALL, 1995). Another 
explanation is that dementia, like other kinds of mental illness, remains a stigmatised condition, ands 
such may be hidden from researchers (INEICHEN, 2000). Given that rural communities still have 
difficulties in accessing tertiary health care and that memory impairment may be accepted as part of 
normal ageing, patients do not readily interface with clinicians (DE VILLIERS and LOUW, 1996). The 
demented may not even be seen as ill (DE VILLIERS and LOUW, 1996).  
 
PD occurs worldwide, but the prevalence and incidence appear to exhibit substantial geographic and 
ethnic variability, with generally lower rates reported in Africa (OKUBADEJO, BOWER, ROCCA and 
MARAGANORE, 2006). Much of the variation has been attributed to methodological differences of 
studies, but genetic and environmental diversity mabe contributory (OKUBADEJO, 2008). 
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The HIV epidemic is further complicated by the development of a subcortical dementing illness known as 
AIDS dementia complex (ADC) (GUILLEMIN and BREW, 2007). Highly active antiretroviral therapy 
(HAART) has effectively lengthened HIV infected patients’ life expectancy; indeed some are 
approaching an age where the risk of Alzheimer’s diease (AD) is starting to become significant. 
Furthermore, many such patients have hyperlipidemia, which increases the risk of AD. Consequently, it 
has been predicted, by GUILLEMIN and BREW (2007) that HIV infected patients are at an increased risk 
of AD or ADC. 
 
5.2.  Aims 
 
“Given the potential of plants which have not yet been investigated …, many different avenues need to 
be taken for the discovery of novel therapeutic agents. Action needs to be taken quickly, notably 
against diseases for which there is not yet an effectiv  remedy: AIDS, multiple sclerosis, Parkinson’s 
disease, Alzheimer disease and certain cancers” (HOSTETTMANN, MARSTON, NDJOKO and 
WOLFENDER, 2000). 
 
Despite the relatively small number of reported African herbal treatments for age-related CNS disorders 
(NEUWINGER, 2000), an attempt was made to investigate southern African plants for monoamine 
oxidase activity (subtype B) based on a lose associati n with their traditional usage and taxonomic links 
to other active species.  
 
Recently, MAO-B inhibitors have been included in the treatment of anxiety disorders, AD and PD 
(YAMADA and YASUHARA, 2004). An inexpensive peroxidase-linked photometric assay for the 
detection of MAO inhibitors was developed from earlier methods of HOLT, SHARMAN, BAKER and 
PALCIC (1997) and SCHMIDT, LI, SCHUBERT, HUANG, STOYANOVA and HAMBURGER (2003). 
This enabled the initial screening for MAO inhibitory activity of South African plants with CNS-related 
traditional usage and the isolation of some of the active compounds. 
 
Summary  
Development of the peroxidase-linked photometric assay and the subsequent determination of 
monoamine oxidase inhibitory activity by southern African medicinal plants were conducted in 
collaboration with P.D. Pedersen, from the Department of Medicinal Chemistry, The Faculty of 
Pharmaceutical Sciences, University of Copenhagen (STAFFORD, PEDERSEN, JÄGER and VAN 
STADEN, 2007). The isolation of the MAO-inhibitor naringenin from Mentha aquatica L. was achieved 
together with H.T. Olsen from the Department of Medicinal Chemistry, The Faculty of Pharmaceutical 
Sciences, University of Copenhagen (OLSEN, STAFFORD, VAN STADEN, CHRISTENSEN, JÄGER, 
2008).
Table 5.1. Compounds known to inhibit enzymes involved in neurotransmitter degradation.  
Neurotransmitters are removed by translocation into vesicles (re-uptake) or destroyed in enzyme-catalysed reactions. A variety of plant derived compounds i hibit 
acetylcholinesterase (AChE) and there is considerabl  interest in AChE inhibitors as potential therapies for cognition inhancement and for Alzheimer’s diease. 
Organophosphorous compounds alkylate an active sit, ser ne, on AChE and the AChE inhibition by this mechanism is the basis for the use of such compounds as insecticides.  



















Coelocline (Annonaceae), Berveris, Hydrastis, Mahonia, 
Nandina (Berberidaceae), Archangelica (Menispermaceae), 
Argremone, Chelidonium, Corydalis (Papaveraceae), 
Coptis, Thalictrum (Ranunculaceae), Evodia, Toddalia, 





AChE ligand  
(IC50 = 167 µM) 
BChE ligand  
(IC50 = 56 µM) 
Cassaine 
(diterpene alkaloid) 
Erythophleum guineense, E. suaveolens bark(Fabaceae) AChE ligand  
(IC50 < 550 µM) 
α-Chaconine 
(triterpene, steroidal alkaloid) 
Notholirion hyacinthinum, Veratrum stenophyllum 
(Lilaceae), Solanum tuberosum, S. choacoense, S. nigrum 
(Solanaceae) 
BChE ligand  
(at physiological postprandial (potato meal) serum levels) 
teratogen and toxic 
Coumingine 
(alkaloid) 
Erythrophleum sp. (Fabaceae) AChE ligand  
(IC50 < 550 µM) 
Dehydroevodiamine 
(indole) 
Evodia rutaecarpa (Rutaceae) AChE ligand  
(IC50 = 38 µM)  
antiamnesic 
Deoxypeganine (= deoxyvasicine) 
(quinazoline quinoline) 




Aconitum falconeri (Ranunculaceae) AChE 
Galanthamine (= Galantamine; lycoremine; 
Reminyl) 
(galanthaman Amaryllidaceae alkaloid) 
Galanthus woronii (snowdrop), Crinum, Galanthus, 
Hippeastrum, Hymenocallis, Leucojum, Lycoris, Narcissus, 
Pancratium, Ungernia spp. (Amaryllidacae) 
AChE (nACh-R allosteric modulator) 
analgesic, clinical cognitive enhancer for Alzheimer’s 




Huperzia serrata (moss), Lycopodium selago (club moss, 
Lycopodiaceae)  
AChE  
(Kd =  5 nM) 
BChE 
cholinergic – causes stomach cramps, dizziness, slurred 
speech, toxic, atropine antidote 








in vivo effects 
(-)-Huperzine B 
(carbobicyclic pyridinone) 
Huperzia serrata (moss), Lycopodium selago (club moss, 
Lycopodiaceae)  
AChE  
cholinergic – Alzheimer’s disease symptomatic treatment 
 N-(p-hydroxyphenethyl) actinidine  
(monoterpene alkaloid) 
Valeriana officinalis (Valerianaceae) AChE 
(+)-Nepapakistamine A 
(steroidal alkaloid) 
Sarcococca coriacea AChE 
Palmatine (= calystigine) 
(benzophenanthridine isoquinoline) 
Berberis, Mahonia spp. (Berberidaceae), Jateorrhiza 
palmate (Menispermaceae), Corydalis (Papaveracea), 
Coptis (Ranunculaceae) spp. 
AChE ligand  
(IC50 = 125 µM) 
BChE ligand  
(IC50 = 426 µM) 
Papaverine 
(benzylisoquinoline) 
Rauwolfia serpentine (Annonaceae), Papaver bractaetum, 
P. serpentine, P somniferum (Papaveraceae) 
AChE 
antitussive, smooth muscle relaxant, spasmolytic, 
vasodilator 
Peganine (= linarine; vasicine) 
(quinazoline quinoline) 
Adhatoda vasica, Justica adhtoda (Acanthaceae), Lunaria 
spp. (Cruciferae), Sida cordifolia (Malvaceae), Peganum 
harmala (Zygophyllaceae) 
AChE 
abortefacient, bronchodilatory, cholinergic, hypotensive, 
respiratory stimulant  
Physostigmine (= eserine; physosterine; physostol) 
(indole) 
Hippomane mancinella (Euphorbiaceae), Physostigma 
veneosum (Fabaceae) 
AChE, BChE (carbamoylates active site Serine) 
Alzheimer’s disease treatment especially amyloid plaque- 
& tangle- associated ChE over expression, 
organophosphate poison antidote, toxic 
Physovenine 
(indole) 
Physostigma veneosum (Fabaceae) AChE 
parasympathetic, toxic 
Protopine (= biflorine; corydalis C; corydinine; 
fumarine; macleyine) 
(benzylisoquinoline) 
Fumaria officinalis (Fumariaceae), Argemone mexicana, 
Corydalis ternate, Papaver somniferum (Papaveraceae) 
AChE 
(IC50 = 50 µM) 






Aconitum falconeri, A. ferox, A. spictatum (Ranunculaceae) AChE (nACh-R) 
Anticholergic, cardiac and respiratory depressant, 
hypotensive, toxic 
Sanguinarine (= pseudochelerythrine) 
(benzophenanthridine) 
Chelidonium majus, Dicentra spectabilis, D. Peregrina, 
Papaver somniferum, Sanguinaria canadensis 
(Papaveraceae), Fumaria officinalis (Fumariaceae), 
Zanthoxylum spp. (Rutaceae), Pteridophyllum spp. 
(Sapindaceae) 
AChE ligand  
(IC50 = 11 µM) 
BChE ligand  
(IC50 = 17 µM) 








in vivo effects 
 α-Solanine (= solatunine) 
(triterpene, steroidal alkaloid) 
Lycopersicon esculentum, Capsicum spp., Solanum 
tuberosum, S. nigrum (Solanaceae) 
BChE  
(at physiological postprandial (potato meal) serum levels) 
causes coma, diarrhea, hallucination, vomiting, 
insecticide, teratogen, toxic 
Ungiminorine 
(Amaryllidaceae alkaloid) 
Narcissus sp. (Amaryllidaceae) AChE 
(-)-Vaganine D 
(steroidal alkaloid) 





Triticum aestivum (Poaceae) 
 
Membrane AChE  
(IC50 = 18-90 µM) 
Terpene 
1,8-Cineole (= cajeputol; eucalyptol) 
(momoterpene) 
 
Artemisia maritima (Asteraceae), Salvia lavandulaefolia 
(Lamiaceae), Eucalyptus globulus, E. spp., Melaleuca 




(IC50 = 670 µM) 
 
α-Pinene (= 2-Pinene) 
(momoterpene) 
Juniper macropoda (Cupressaceae), Mentha, Salvia spp. 
(Lamiaceae), Eucalyptus globulus (Myrtaceae), Pinus 
palestris, P. walliciana, P. spp. (Pinaceae), Citrus spp. 
(Rutaceae) 
AChE  
(IC50 = 630 µM) 
Ursolic acid (=malol; malolic acid; micromerol; 
prunol; urson) 
(triterpene) 
Widespread AChE  
(IC50 = 6 pM) 
Other 
Solanum CPI (= potato carboxypeptase inhibitors) 
(5 kDa protein) 
 
Solanum tuberosum (potato) (Solanaceae) 
 
in vivo AChE, BChE especially AD amyloid plaque and 
tangle-associated  






AChE (carbamoylates pseudoirreversibly – forms 
carbamoyl ester with active site Serine) 
Clinical cognition enhancer for Alzheimer’s disease  
Sarin (= isopropoxy-methylphosphoryl fluoride) 
(organophosphate) 
synthetic AChE (forms phosphoryl ester with active site Serin 
Chemical warfare agent 






























Cinchona succirubra (Rubiaceae) MAO 
(IC50 = 12 µM) 
Harmaline (= 3,4-dihydroharmine; harmidine) 
(indole, carboline) 
Passiflora incarnata (Passifloraceae), Banisteria caapi, 




Harman (= aribine;loturine;1-methyl-β-carboline; 
passiflorin) 
(β-carboline, indole) 
Phaseolus vulgaris (Fabaceae), Passiflora edulis, P. 
incarnate (Passifloraceae), Singickia rubra (Rubiaceae), 
Symplocos racemosa (Symplocaceae), Peganum harmala, 
Tribulus terrestris, Zygophyllum fabago (Zygophyllaceae) 
MAO-A 
(IC50 = 0.5 µM; Kd =  5 nM) 
MAO-B 
(IC50 = 5 µM) 
antidepressant, co-mutagenic, convulsant, hypotensiv , 
motor depressant – sheep ‘tribulus stagers’ 
Harmine (=banisterine; leucoharmine;telepathine; 
yageine) 
(β-carboline, indole) 
Passiflora incarnate (Passifloraceae), Banisteria caapi 
(Malpighiaceae), Peganum harmala, Tribulus terrestris 
(Zygophyllaceae)  
MAO-A 
(IC50 = 2 nM)  
CNS stimulant, hallucinogenic 





 Palicourea marcgravii (Rubiaceae) n MAO-A 









Cichorium intybus (Asteraceae), Tribulus terrestris, 
Zygophyllum fabago (Zygophyllaceae); tobacco smoke [ex 
Nicotiana tabacum (Solanaceae)] 
MAO-A (weak) 
Benzodiazepine receptor 
‘Tribulus staggers’ in sheep 
Quinine 
(quinoline) 
Cinchona officinalis, C. succirubra, C. spp. , Remijia 
pedunculata (Rubiaceae) 
MAO-A 
(IC50 = 16 µM)  
 








in vivo effects 
Tetrahydroharmine  
(β-carboline, indole) 
Banisteria caapi (liana), Banisteriopsis caapi (ayahuasca) 
Malpighiaceae) 
MAO 
1,2,3,4-Tetrahydroisoquinoline 1-cyano adduct 
(isoquinoline) 
Tobacco smoke [ex Nicotiana tabacum (Solanaceae)] MAO-A 
(Kd ~ 30 nM) 
tobacco smoke inhibits MAO and has a protective effct 
against Parkinson’s disease 
1,2,3,4-Tetrahydroisoquinoline N-(1’-cyanoethyl), 
N-(1’-cyanopropyl) & N-(1’-cyanobutyl) adducts 
(isoquinoline) 
Tobacco smoke [ex Nicotiana tabacum (Solanaceae)] MAO-A 
(Kd ~ 30 nM) 
tobacco smoke inhibits MAO and has a protective effct 
against Parkinson’s disease 
Tryptamine (=3-(2-aminoethyl) indole) 
(indole) 
Cucumis sativus (Cucurbitaceae), Mucuna pruriens, 
Piptadenia peregrina, Prosopis juliflora (Fabaceae), 
Hordeum vulgare, Zea mays (Poaceae), Lycopersicon 
esculentum, Nicotiana tabacum, Solanum melongena, S. 
tuberosum (Solanaceae) 
Precursor of tetrahydro-β carboline which has MAO-A 
(IC50 = 5 µM) and MAO-B (IC50 ~ 50 µM) 
Phenolic 
Apigenin (= 5,7,4’- trihydroxyflavone) 
(flavone) 
 
Widespread; Lamiaceae, Asteraceae; Apiaceae; Fabacee 




(IC50 = 1; 8 µM)  
MAO-B 
Chrysin (= 5,7-dihydroxyflavone) 
(flavone) 
Daucus (Apiaceae), Pinus spp. (Pinaceae), Populus spp. 
(Salicaeae), Escallonia spp. (Saxifragaceae) 
MAO-A 
(IC50 = 2 µM)  
MAO-B 
Confluentic acid 
(depside, aryl ester) 
 
Himatanthus sucuuba (Apocynaceae) MAO-B  
(IC50 = 0.2 µM)  
Desmethoxyyangonin 
(pyrone, phenolic derivative) 
Piper methysticium (Piperaceae) MAO-B  
(IC50 = 0.3 µM) 
(+/-)-Dihydrokavain (=dihydrokawain) 
(pyrone, phenolic derivative) 
Piper methysticium (Piperaceae) MAO-B  
 
(+/-)-Dihydromethysticin  
(pyrone, phenolic derivative) 





Widespread; Aesculus californica (Hippocastanaceae), 
Pterocarpus spp. (Fabaceae), Podocarpus nagi 
(Podocarpaceae), Camellia sinensis (Theaceae) 
MAO- A 
(IC50 > 25 µM)  
 








in vivo effects 
Isopsoralen 
(furocoumarin) 
Psoralea corylifolia (Fabaceae) MAO- A 
(IC50 = 9 µM; Kd = 7 µM)  
MAO- B 
(IC50 = 13 µM; Kd = 11 µM) 
Kaempferol (=3,5,7,4’-tetrahydroxyflavone) 
(flavonol) 
Widespread as aglycone and glycosides MAO-A 
(IC50 = 0.7 µM) 
MAO-B  
(+/-)-Kavain (= gonosan; kawain) 
(pyrone, phenolic derivative) 
Piper methysticium (Piperaceae) MAO-B 
Lemuninol A 
(naphthalene dimmer) 
Diospyros sp. (Ebenaceae) MAO 
(IC50 = 12-25 µM) 
Lemuninol B 
(naphthalene dimmer) 
Diospyros sp. (Ebenaceae) MAO 
(IC50 > 62 µM) 
Lemuninol C 
(naphthalene dimmer) 
Diospyros sp. (Ebenaceae) MAO 
(IC50 > 60 µM) 
Malvidin 3-glycoside 
(anthocyanin) 
Malva sylvestris (Malvaceae), Ligustrum vulgare 
(Oleaceae), Vitis vinifera (Vitaceae) 
MAO-A 




Diospyros sp. (Ebenaceae) MAO 
(IC50 > 108 µM) 
2’-O-methylperlatolic acid 
(depside, aryl ester) 
Himatanthus sucuuba (Apocynaceae) MAO-B  
(IC50 = 81 µM)  
N-methyltyrame 
(phenolic amine) 
Palicourea marcgravii (Rubiaceae) MAO-A (competitive substrate) 
(+/-)-Methysticin  
(pyrone, phenolic derivative) 
Piper methysticium (Piperaceae) MAO-B 




Apium graveolens, Daucus carota, Levisticum scoticum, 
Pastinaca saliva, Petroselinum crispum (Apiaceae), 
Cinnamomum glanduliferum (Lauraceae), Orthodon spp. 
(Lamiaceae), Myristica fragans (Myristicaceae, nutmeg oil) 
MAO 
psychotropic 
Pelargonidin 3,5-di-O-glucoside (= pelargonin) 
Anthocyanin) 
Commiphora muhul (Burseraceae), Pelargonium zonale 
(Geraniaceae), Gladiolus sp. (Iridaceae) 
MAO-A  
(IC50 > 25 µM) red colour 
Psoralen (= ficusin) 
(furocoumarin) 
Pastinaca sativa, Petroselinium crispum (Apiaceae), 
Coronilla glauca, Psoralea corylifolia, P. spp. (Fabaceae), 
Ficus carica (Moraceae), Phebalium argenteum, 
Xanthoxylum flavum (Rutaceae) 
MAO- A 
(IC50 = 15 µM; Kd = 14 µM)  
MAO- B 
(IC50 = 62 µM; Kd = 58 µM) 








in vivo effects 
trans-Resveratrol (= 3,5,4’-trihydroxystilbene) 
(stilbene) 
Nothofagus (Fagaceae), Cassia, Intsia, Trifolium 
(Fabaceae), Veratum (Liliaceae), Eucalyptus (Myrtaceae), 
Pinus (Pinaceae), Artocarpus, Morus (Moraceae), 
Polygonium (Polygonaceae), Vitis (Vitaceae) spp. 
MAO- A 
(IC50 = 27 µM; Kd = 47 µM)  
 
Tyramine (=  4-hydroxyphenethylamine) 
(phenolic amine) 
Lophophora williamsi, Trichocereus pachanoi (Cactaceae), 
Hordeum vulgare, Lolium multiflorum (Poaceae), 
Palicourea marcgravii (Rubiaceae), Citrus spp. (Rutaceae), 
Viscum album  (Viscaceae) 
Precursor of N-methyltyramine and tetrahydro-β-carboline 




Veratrum taliense (Liliaceae) MAO- A 
(IC50 = 38 µM; Kd = 36 µM)  
Yangonin  
(pyrone, phenolic derivative) 





Nicotiana tabacum (Solanaceae) cigarette smoke 
 
MAO-A 
(Kd = 52 µM) 
MAO-B 
(Kd = 40 µM) 






Clorgyline Synthetic Irreversibly inhibits MAO-A in vivo 
Deprenyl Synthetic MAO-B clinical Alzheimer’s and Parkinson’ s disease 
treatment 
5.3. Screening of southern African plants for monoamine oxidase B (MAO-B) inhibitors  
 
5.3.1.  Introduction 
 
Monoamine oxidases (MAOs) are flavoenzymes that catalyze the oxidative deamineation of primary, 
secondary and some tertiary amines to imines, which furt er hydrolyse to the corresponding inactive 
aldehydes (BINDA, HUBÁLEK, LI, HERZIG, STERLING, EDMONDSON, MATTEVI, 2004; 
EDMONDSON, BINDA and MATTEVI, 2004). The overall oxidation reaction proceeds as follows: 
RCH2NH2 + FAD + O2 + H2O  →  RCHO + FADH2 + H202 + NH3 
Flavin adenine dinucleotide (FAD) is a redox coenzyme involved in several important reactions in 
metabolism. FAD can exist in two different redox states and its biochemical role usually involves 
changing between these two states. FAD can be reduced to FADH2, whereby it accepts two hydrogen 
atoms. 
 
Monoamine oxidase (MAO) is an enzyme present in the out r-mitochondrial membrane of neuronal and 
non-neuronal cells. Two isoforms of MAO are recognized, commonly referred to as MAO-A and MAO-
B. The enzymes have two main functions in humans; they regulate the free intra-neural concentration and 
storage of noradrenalin and serotonin; they also inact vate, by oxidative deamination, endogenous and 
ingested amines (e.g. tyramine) (RANG, DALE and RITTER, 2003). They have different substrate 
preference (Table 5.3.1), inhibitor specificity, and tissue distribution (YAMADA and YASUHARA, 
2004). MAO-A preferentially deaminates serotonin, noradrenaline, and adrenaline. In the human brain 
about 75% of MAO is of the B subtype (SAURA MARTI, KETTLER, DA PRADA and RICHARDS, 
1990). MAO-B deaminates dopamine, β-phenylethylamine (PEA), and benzylamine.  
 
Table 5.3.1. Substrate preferences for subtypes of MAO (FOLEY, GERLACH, YOUDIM and RIEDERER, 2000). 
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Inhibitors of MAO cause an increase in the amount of these amines stored and released from the nerve 
terminals, thus increasing the monoaminergic activity. Inhibition of MAO-A predominantly affects 
neurotransmitters considered to be important in depression and anxiety disorders. MAO-B inhibitors 
would increase the basal dopamine levels in the nigrostriatal dopaminergic input pathway. Selegiline is 
the only selective and irreversible MAO-B inhibitor with marketing approval in many countries 
(BODKIN and AMSTERDAM, 2002; YAMADA and YASUHARA, 2004). More recently, MAO-B 
inhibitors have been included in the treatment of anxiety disorders, Alzheimer’s disease and Parkinson’s 
disease (YAMADA and YASUHARA, 2004). MAO-B inhibition also has neuroprotective effects, since 
the oxidation step catalyzed by MAO-B yields reactive hydrogen peroxide as a by-product of amine 
turnover, the generated hydrogen peroxide and other reactive oxygen species may cause deterioration in 
neuronal function or eventually lead to neuronal deth (YAMADA and YASUHARA, 2004). 
 
The pharmaceutical potential of MAO inhibitors, in particular MAO-B inhibitors, has lead to the search 
for novel active compounds. Several MAO inhibitors from botanicals are described in Table 5.2. Apart 
from Hypericum perforatum which contains hypericin reported to show MAO inhibitory activity 
(BUTTERWECK, NAHRSTEDT, EVANS, HUFEISEN, RAUSER, SAV GE, POPADAK, 
ERNSBERGER and ROTH, 2002), several herbal remedies have been investigated. Recent discoveries of 
specific MAO-A inhibitory activity of traditionally used herbal remedies include Acorus gramineus 
(TAO, IRIE, LI and KEUNG, 2005), Rhazya stricta (ALI, BASHIR, TANIRA, MEDVEDEV, 
JARRETT, SANDLER and GLOVER, 1998), Zanthoxylum schinifolium (JO, HOUNG, BAE, LEE and 
KIM, 2002) and Kaempferia galangal (HUONG, DAT, MINH, KANG and KIM, 2002). MAO-A 
inhibitory activity has been reported in Arisaema amurense, Lilium brownie, Lycium chinense (LIN, 
HOU, YEN and LEE, 2003), Gentiana lutea (HARAGUCHI, TANAKA, KABBASH, FUJIOKA, 
ISHIZU and YAGI, 2004), Uncaria rhynchophylla (LIN, HOU, YEN and LEE, 2003; HOU, LIN, CHEN 
and LEE, 2005). 
 
Parkinson’s disease treatment with MAO-B inhibitors 
Parkinson’s disease (PD) or Paralysis Agitans was first documented in 1817 by Dr. James Parkinson as 
the “shaking palsy” that afflicted his gardener (PARKINSON, 1817, CRITCHLEY, 1955). Affecting one 
in every 100 persons above the age of 65 years, it is the second most common neurodegenerative disease 
after Alzheimer’s disease (DE RIJK, LAUNER, BERGER, BRETELER, DARTIGUES, 
BALDERESCHI, FRATIGLIONI, LOBO, MARTINEZ-LAGE, TRENKWALDER and HOFMAN, 
2000) and the most common neurologically based moveent disorder, clinically diagnosed by the 
presence of bradykinesia, postural instability, resting tremor and rigidity. 
 
PD is characterized neuropathologically by the presence of intracytoplasmic inclusions from protein 
aggregates called Lewy bodies (LBs) (BURKE, 1998) and the depletion of pigmented dopamine-
containing neurons in the region known as the substantia nigra pars compacta (FORNO, 1996). LBs 
consist of a heterogeneous mixture of proteins and lipi s. Approximately 80% of dopaminergic neurons 
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in the susbtantia nigra are already irreversibly destroyed when the first symptoms of PD become 
significantly visible. To date PD remains an incurable disease. The currently available pharmacological 
and non-pharmacological treatments are able to offer nly symptomatic relief for patients (KATZUNG, 
2001). Symptoms can be managed with several different drugs most of which either boost the levels of 
dopamine in the brain or mimic the effects of dopamine.  
 
Because dopamine is preferentially deaminated by MAO-B in the human brain, MAO-B inhibitors should 
increase the basal central dopamine levels in patients with Parkinson’s disease. The MAO-B inhibitor 
selegiline was developed for the treatment of Parkinson’s disease based on this hypothesis (KNOLL, 
2000). MAO-B inhibition also has neuroprotective effects. Since the oxidation step catalyzed by MAO-B 
yields reactive hydrogen peroxide as a by-product of amine turnover, the generated hydrogen peroxide 
and other reactive oxygen species may cause deterioration in neuronal function or eventually lead to 
neuronal death. MAO inhibitors reduce oxidant stres by limiting the formation of this reactive species 
and, hence, may contribute to the control of the aging process (BLANDINI and GREENAMYRE, 1999; 
KNOLL, 2000). The findings that selegiline prevents MPTP-induced Parkinsonism stimulated an interest 
in anti-oxidative therapy as a means of retarding the progression of Parkinson’s disease (SHOULSON, 
1998).  
 
Similarly, the use of MAO-B inhibitors in the treatment of AD has been suggested to suppress the 
neurodegenerative processes that occur, primarily by the reduced oxidant stress. The enzymatic activity of 
MAO-B increases with age, and is particularly high around senile plaques (YAMADA and YASUHARA, 
2004). 
 
The selective inhibitor of MAO-B, (R)-deprenyl (selegeline), is already in use in dopamine replacement 
therapy in PD. Currently treatment with deprenyl occurs in combination with L-DOPA, assuming that the 
MAO-B inhibitor reduces the metabolism of dopamine d laying the need for L-DOPA therapy. A 
reduction in apotic cell death due to oxidative-stre s is another positive effect reported in treatmen with 
deprenyl. A disadvantage of the treatment is that (R)-deprenyl is metabolized to (R)-ethamphetamine 
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Due to the disadvantage of the side effects associated with the traditional non-selective irreversible 
MAOIs (‘cheese effect’) coupled with the potential therapeutic value of new inhibitors that are reversible 
and selective towards either MAO-A or MAO-B, the search for new MAO inhibitors is validated (KONG, 
CHENG and TAN, 2001; 2004; VLOK, MALAN, CASTAGNOLI, BERGH, and PETZER, 2006).  
 
Detection of MAO activity 
When developing a bioassay the target must be relevant to the disease of interest. Typical targets of in 
vitro assays can be receptors as was the case in previous Chapters or enzymes and cell line models. It is 
further important that the assay gives a quantifiable response and that the assay includes a negative 
control (ensure not false positive reaction) as well as a positive control (ensure the desired reaction is 
working) (HOUGHTON, 2000).  
 
There are several different assays for detection of MAO-I described in the literature (Table 5.3.2.). They 
each have their advantages and disadvantages. Generally it is important that the assay is reproducible, 
quick, and possesses a low risk for false positive or false negative results. The sensitivity of the method is 
also important. Additionally, and most importantly in this case, would be the running cost and the 
availability of equipment required to run the assay. Radiolabelled compounds are too expensive, 
fluorometric and HPLC detection equipment was not avail ble leaving only the spectrophotometric 
option. 
 
Since hydrogen peroxide is a product formed during deamination of almost all amine oxidase substrates, 
it represents an ideal target for a quantitative amine oxidase assay, and although generally less sensitiv  
than other detection methods, spectrophotometry perha s represents that technique which is most widely 
accessible to all laboratories. 
 
Table 5.3.2. Methods for the detection of MAO activity. 




Spectrophotometric determination of 
quinoneimine dye (nm). Hydrogen peroxide 
produced during the oxidative deamination of 
monoamines in turn oxidises 4-aminoantipyrine 
in the presence of peroxidase. The oxidised 4-
aminoantipyrine condenses with vanillic acid to 
give a red quinoneimine dye. 
 
tyramine HOLT et al., 1997; 







Spectrophotometric determination of oxidative 
deamination of kynuramine by MAO.  
kynuramine WEISSBACH et 
al., 1960; 
SCHMIDT et al., 
2003 
CHAPTER FIVE Alzheimer’s and Parkinson’s disease treatments  186  
 




The fluorescence of 4-hydroxyquinoline, which 
is formed from kynuramine by MAO, is 
measured at an excitation wavelength of 315 nm 
and an emission wavelength of 380 nm, using a 
fluorescence spectrometer 
 
kynuramine KRAML, 1965; 
SATOH and 
YAMAZAKI, 







In the presence of peroxidase, the H2O2 drives 
the oxidation of Amplex Red forming 
Resorufin, the fluorescent product. The 
Resorufin fluorescence is measured using an 
excitation wavelength of 550 nm and an 
emission wavelength of 585 nm. This reaction 
has been frequently employed for measurements 














The MAO activity was determined 
radiometrically by using [3H]-5-HT creatinine 
sulfate (final radioactivity 5 mCi/mmol) and 
[14C]-PEA hydrochloride (final radioactivity 20 
mCi/mmol) as the selective substrates of MAO-
Aand MAO-B, respectively. The inhibitors used 
in this study were added right before initiation 
of the reaction by adding substrates. 











et al., 1999; KONG 
et al., 2001; KONG 





oxidase  utilizing 
HPLC 
This method utilizes high pressure liquid 
chromatography with fluorescence excitation at 
280 nm and detection at 330 nm at pH 5.0 of 
indoleacetic acid and 5-hydroxyindoleacetic 
acid, the deaminated products of two substrates 
for MAO, tryptamine, and serotonin, 
respectively. The assay allows for the complete 
separation of metabolites from either of the two 
substrates. The method has been used to 
determine MAO activity in the frontal cortex 
and caudate nucleus of rat brain using 











The end product dihydroxyphenylacetic acid 
(DOPAC) is measured by electrochemical 
detection. 
 









This assay involves the combination of human 
recombinant MAO-A, expressed as GST-fusion 
protein in yeast, with the kinetic measurement 
of the conversion kynuramine to 4-
hydroxyquinoline. 
 
kynuramine DITTMANN et al., 
2004 
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oxidase  utilizing 
HPLC 
The method is based on the separation and 
quantitation of 14C-labeled assay products by 
high-performance liquid chromatography, 
which is interfaced directly into a flow-through 
radioactivity detector. This allows on-line 
quantization of the radioactive compounds with 
picomole sensitivity. The method makes 
possible the complete separation and detection 
of the deaminated products of monoamine 
oxidase A and B substrates benzylamine and 5-
hydroxytryptamine, respectively. This assay has 
been applied to the measurement of monoamine 




NISSINEN et al., 
1984 
 
A sensitive colorimetric assay was developed by SZUTOWICZ, KOBESAND and ORSULAK (1984) to 
be used for the determination of MAO activities. However, this peroxidase-coupled method, which uses 
2,2’-azino-bis(3- ethylbenzthiazoline-6-sulfonic acid) (ABTS) as the chromogen, suffers from the 
drawback that ABTS causes substantial inhibition of MAO at concentrations present in the assay. 
Furthermore, the chromogen is insoluble and absorbs nly weakly at the relatively neutral pH conditions 
necessary for MAO activity. As a result, while this reagent is extremely useful in the discontinuous assay 
described by the authors, it is unsuitable for use in continuous measurement protocols. A peroxidase-
linked colorimetric assay, described originally by YAMADA, ISOBE, TANI and HIROMI (1979), where 
4-aminoantipyrine acts as the proton donor in the peroxidase reaction and then condenses with 2,4-
dichlorophenol to form a red quinoneimine dye was therefore considered. The absorbance, measured at 
495 nm, is directly proportional to the amount of hydrogen peroxide formed during amine metabolism. 
While this protocol has proved suitable for the assay of most, if not all enzymes classified as EC 1.4.3.6, 
HOLT, SHARMAN, BAKER and PALCIC (1997) found that no color formation was evident when 
homogenates of, or mitochondria purified from, rat liver or brain were incubated with MAO substrates. 
This was overcome by replacing 2,4-dichlorophenol with vanillic acid (HOLT, SHARMAN, BAKER and 
PALCIC, 1997), resulting in a rapid quantitative spectrophotometric assay (Figure 5.3.2). 
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Figure 5.3.2. Scheme for the continuous peroxidase-linked photome ric monoamine oxidase (MAO) inhibitor 
bioassay. (1) The inhibition of MAO isolated from rat liver tissue, which catalyze the oxidative deamination of 
monoamines (e.g. tyramine) to aldehydes. The hydrogen peroxide produced by this rate determining step oxidises 4-
aminoantipyrine (3) in the presence of peroxidase (2). The oxidised 4-aminoantipyrine condenses with vanillic acid 
(4) to give a red quinoneimine dye (5). The production of the quinoneimine dye was detected at 490 nm by a
microplate reader. 
 
The continuous peroxidase-linked photometric monoamine oxidase (MAO) inhibitor bioassay for the 
detection of MAO inhibitory activity of plant extracts was developed and validated together with P.D. 
Pedersen, Department of Medicinal Chemistry, The Faculty of Pharmaceutical Sciences, University of 
Copenhagen (PEDERSEN, 2005).  
 
Aims 
More than 120 Helichrysum species are found in KwaZulu-Natal and many are used in traditional 
remedies and cultural ceremonies (HUTCHINGS, SCOTT, LEWIS and CUNNINGHAM, 1996). The 
most frequent use is as imphepho, where the leaves and stems are burned as incense to ‘invoke the 
goodwill of ancestral spirits’ (HUTCHINGS, SCOTT, LEWIS and CUNNINGHAM, 1996). Some 
species are used by izangoma (traditional healer) to induce trances (HUTCHINGS, SCOTT, LEWIS and 
CUNNINGHAM, 1996) and dressings for infected wounds (WATT and BREYER-BRANDWIJK, 1962). 
H. nudifolium (icholocholo, in Xhoza and Zulu) a common species, is also used in infusions (teas) to treat 
colds and steam from infusions poured on hot stones is inhaled to treat bad dreams and fever (WATT and 
BREYER-BRANDWIJK, 1962). These apparent CNS-related uses prompted the investigation in the 
MAO inhibition of extracts of several Helichrysum species. The success of this screen lead to a further 
screening of other South African plants with reported CNS-related medicinal uses. Good MAO inhibitory 
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activity was detected in Mentha aquatica, which prompted the bioassay-guided fraction, isolati n and 
identifaction of an active compound. 
5.3.2. Materials and Methods 
 
Plant materials  
Seven Helichrysum species (Asteraceae) were collected in KwaZulu-Natal, South Africa from September 
2004 to January 2005 for intial screening in the peroxidase-linked photometric assay. Voucher specimens 
are deposited in the University of KwaZulu-Natal Herbarium (Table 5.3.2.1). Plant material was oven-
dried at 50 °C for two days. 
 
Table 5.3.2.1. Helichrysum species investigated, including voucher numbers and part used. 
 
Species Voucher Number  Plant part tested  
Helichrysum argyrolepis MacOwan Stafford 213 NU Leaf 
Helichrysum herbaceum (Andrews) Sweet Stafford 214 NU Whole plant 
Helichrysum nudifolium Less. Stafford 215 NU Leaf 
Helichrysum ruderale Hilliard & B.L. Burtt Stafford 216 NU Whole plant 
Helichrysum rugulosum Less. Stafford 217 NU Whole plant 
Helichrysum simillimum DC. Stafford 218 NU Whole plant 
Helichrysum umbraculigerum Less. Stafford 219 NU Whole plant 
 
Other plant species traditionally used as sedatives or to treat various CNS-related ailments, were selct d 
based on the literature relating to their use in the treatment of mental diseases. Plants were collected in 
KwaZulu-Natal, South Africa. Voucher specimens are deposited in the University of KwaZulu-Natal 
Herbarium (Table 5.3.2.2). Plant material was dried at 50 ºC for a maximum of two days. 
 
Table .5.3.2.2. Plant species, herbarium voucher numbers and plant art investigated. 
Plant name Family Voucher specimen Plant part tested 
Agapanthus campanulatus 
F.M.Leighton 
Alliaceae Stafford 59 NU Bulb and root 
Agapanthus praecox Willd. Alliaceae  Stafford 212 NU Bulb and root 
Boophane disticha (L.f.) Herb Amaryllidaceae Stafford 53 NU Leaf 
Buddleja salvifolia L. Loganiaceae Stafford 41 NU Leaf 
Cinnamomum camphora (L.)  
T.Ness & C.H.Eberm. 
Lauraceae Stafford 69 NU Leaf 
Clausena anisata (Willd.) Hook.f. Rutaceae Stafford 47 NU Leaf 
Datura ferox L. Solanaceae Stafford 72 NU Seeds 
Datura stramonium L. Solanaceae Stafford 73 NU Seeds 
Dioscorea dregeana Baker Dioscoreaceae Stafford 221 NU Leaf  
Gasteria croucheri (Hook.f.) 
Baker 
Aloaceae Stafford 18 NU Root 
Gomphocarpus physocarpus 
E.Mey 
Asclepiadaceae Stafford 207 NU Leaf 
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Plant name Family Voucher specimen Plant part tested 
Hypoxis hemerocallidea Fisch. & 
C.A. Mey 
Hypoxidaceae Stafford 34 NU Bulb 
Leonotis leonurus (L.) R.Br. Lamiaceae Stafford 38 NU Leaf 
Mentha aquatica L. Lamiaceae Stafford 84 NU Leaf 
Millettia grandis (E.Mey.) Skeels Fabaceae Stafford 125 NU Leaf 
Rhoicissus tridentata (L.f.) Wild. 
et R.B.Drumm 
Vitaceae Stafford 13 NU Leaf 
Ruta graveolens L. Rutaceae Stafford 48 NU Leaf  
Scadoxus puniceus (L.) Friis & I. 
Nordal 
Amaryllidaceae Stafford 206 NU Root 
Schotia brachypetala Sond. Fabaceae MacGaw 85 NU Bark 
Xysmalobium undulatum (L.) 
Aiton.f. 
Asclepiadaceae Stafford 95 NU Root  
 
Aerial parts of Mentha aquatica for bulk extraction and isolation of active constituent were collected at 
Cedara (29°32′S 30°17′E), KwaZulu-Natal, South Africa. A voucher specimen is deposited in the Bews 
Herbarium, University of KwaZulu-Natal, Pietermaritzburg (Stafford NU 84). 
 
Preparations of extracts for screening 
Two g of material were extracted three times with 20 ml solvent (water, 70% ethanol, ethyl acetate and 
petroleum ether) for 60 min in an ultrasound bath. The extracts were then filtered under vacuum through 
Whatman No 1 filter paper. The filtered extracts were taken to dryness under reduced pressure at 40°C. 
The residues were re-dissolved in DMSO respectively at 36 mg/ml when required, to be diluted further in 
the assay with potassium phosphate buffer (0.2M, pH 7.6) to seven final concentrations of 1, 0.5, 0.25, 
0.1, 0.01, 0.001 and 0.0001 mg/ml respectively. 
 
Isolation and structure elucidation of naringenin from M. aquatica 
Extraction: 2 g of dried, ground plant material were extracted twice either with 20 ml water, 70% ethanol, 
acetone, butanol, dichloromethane or petroleum ether in an ultrasound bath. For isolation, 500 g dried, 
ground plant material was defatted with petroleum ether. After drying, the plant material was extracted 
with 70% ethanol.  
 
Fractionation on VLC: The 70 % ethanol extract (25.71 g) was fractionated on 200 g of Merck Silica Gel 
60 in a vacuum liquid column. 400 ml of each of thefollowing solvent mixtures were used; petroleum 
ether: ethyl acetate; 100:0, 80:20, 60:40, 40:60, 20:80, 0:100 and ethyl acetate: ethanol 80:20, 60:40, 
40:60, 20:80, 0:100. The column was then washed with 400 ml methanol and 400 ml water. Active 
fractions (petroleum ether: ethyl acetate; 20:80, 0:10  and ethyl acetate: ethanol; 80:20) were combined. 
 
Preparative TLC systems: The combined active fractions were loaded on preparative TLC plates (Merck 
Silica Gel 60, 0.25 mm thickness) developed in hexan : ethyl acetate 3:2. The plates were divided into 
bands and the silica scraped off. The silica was eluted using ethyl acetate, and the eluate passed throug  a 
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Celite column to remove silica, before being assayed for MAO inhibition. An active band with Rf-value 
0.35 was loaded on a TLC plate, which was developed in hexane: ethyl acetate 1:2. The active band (80 
mg) on this plate had an Rf-value of 0.78. 
 
Stucture elucidation: 1H, 13C and 13C-DEPT NMR spectra were recorded using a Gemini Varan NMR 
instrument. Optical rotation was determined on a Perkin-Elmer 241 polarimeter. 
 
Preparation of MAO-rich rat liver homogenate 
MAO was partially purified by isolation of mitochondria from rat liver homogenates according to HOLT, 
SHARMAN, BAKER and PALCIC (1997). Briefly, male Wistar rats (280-300g), were euthanased by 
carbon monoxide and livers dissected out, washed in ice-cold potassium phosphate buffer (0.2 M, pH 
7.6), and stored at -70 °C until required. Liver tissue (5 g) was homogenized 1:40 (w/v) in 0.3 M sucrose. 
Following centrifugation at 1000 x g for 10 min the supernatant was further centrifuged at 10 000g for 30 
min to obtain a crude mitochondrial pellet. The pellet was resuspended in 4 ml of 0.3 M sucrose and was 
layered onto 40 ml of 1.2 M sucrose. A mitochondrial pellet was obtained by centrifugation at 53 000 x g 
for 2 h. Following a single wash in potassium phosphate buffer; mitochondria were suspended in 40 ml 
buffer. Total protein concentration was measured by the method of BRADFORD (1976) and adjusted 
with phosphate buffer (0.2 M; pH 7.6) to 0.2 mg protein per ml, after which aliquots of 1 ml were stored 
at -70 °C until required.  
 
Monoamineoxidase peroxidase linked assay 
The continuous peroxidase-linked photometric assay w s carried out in the 96-well microtiter format 
modified from HOLT, SHARMAN, BAKER and PALCIC (1997) and SCHMIDT, LI, SCHUBERT, 
HUANG, STOYANOVA and HAMBURGER (2003) (Figure 5.3.2). Plant extracts (water, 70% ethanol, 
ethyl acetate and petroleum ether) were re-dissolved to 36 mg/ml with DMSO. Plant extracts were ten-
fold serially diluted with potassium phosphate buffer (0.2 M, pH 7.6) and 40 µl of each dilution was 
placed in 96-well microplates to give final concentrations from 6 to 0.0006 mg/ml. Distilled water was 
use as a negative control. Each test well contained 120 µl substrate (2.5 mM tyramine in potassium 
phosphate buffer), 40 µl chromogenic solution (1 mM vanillic acid, 0.5 mM 4-aminoantipyrine, 4 U/ml 
peroxidase in potassium phosphate buffer), 40 µl enzyme (rat liver homogenate) and 40 µl of sample. 
Background wells contained potassium phosphate buffer (0.2 M, pH 7.6) in place of enzyme (rat liver 
homogenate). To test for specific MAO-B activity the rat liver homogenate was pre-incubated (37 °C; 30 
min) with 50 µM clorgyline (selective MAO-A-I) to to al block MAO-A activity. Reactions were 
followed at 490 nm using a microplate-reader. Absorancy readings were taken every 5 min over a period 
of 40 min. Plates were incubated between readings at 37 °C. Percent inhibition was calculated from the
slope of the absorbancy/time plot (test well reading minus background reading), relative to negative 
controls (distilled water) serving for measurement of 0% inhibition plots. IC50 concentrations were 
calculated using Grafit 5© (Erithacus Software Limited). Assays were done in triplicate. For 
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determination of MAO-A/B selectivity, pure enzymes (Sigma) were used at 8 U/ml in place of rat liver 
homogenate. Clorgyline and deprenyl were used as selective inhibitors. 
 
5.5.3. Results and Discussion 
 
MAO-I activity of aqueous and ethanolic extract of seven Helichrysum species using a peroxidase-linked 
photometric assay are shown in Table 5.3.3.1 and Figure 5.3.3.1. Clorgyline and Selegiline (L-deprenyl) 
are irreversible inactivators of MAO which have been used extensively because of their selectivity for 
MAO-A and MAO-B respectively. They were included in the assays as positive controls. Although 
MAO-A and MAO-B are expressed in most mammalian tissues, marked species differences in both tissue 
distribution and substrate specificities have been d scribed. In the rat liver it is thought that MAO-B is 
predominant (INOUE, CASTAGNOLI, MABIC, IGARASHI and CASTAGNOLI, 1999). Seven species 
were assayed for MAO inhibitory activity using a peroxidase-linked photometric assay. H agyrolepis 
(water extract IC50 = 0.1 µg/ml; ethanol extract 0.8 µg/ml), H. umbraculigerum (water extract IC50 = 2.4 
µg/ml; ethanol extract 3.1 µg/ml) were the most active species, although all species tested exhibited 
varying degrees of MAO inhibitory activity. These active species showed good dose-dependant activity 
(Figure 5.3.3.1.). It is possible that the active compound(s) has been extracted by both water and 70% 
ethanol; in both plants the aqueous extract was more active. This validates the use of these plants in 
infusions as it is traditionally administered, but f rther research is required to determine if the smoke 
derived from these plants has any biological activity. 
 
Table 5.3.3.1. Determination of MAO-I activity of aqueous and ethanolic extracts of seven Helichrysum species 
using a peroxidase-linked photometric assay (IC50 values expressed in µg/ml). Values are the mean of results 
obtained from three assays. 
 
Plant extract IC 50  (µg/ml) 
b 
H.agyrolepis, water 0.1±0.009 
H.agyrolepis, ethanol 0.8±0.3 
H.herbaceum, water 57.3±84.1 
H.herbaceum, ethanol 108.5±126 
H.nudifolium, water n.d.  
H.nudifolium, ethanol 7.3±4.8 
H.ruderale, water 22.9±82 
H.ruderale, ethanol 3.3±5 
H.rugulosum, water 155.2±335 
H.rugulosum, ethanol 17.2±34 
H.simillimum, water 23.0±14 
H.simillimum, ethanol n.d.  
H.umbraculigerum, water 2.4±1.8 
H.umbraculigerum, ethanol 3.1±0.1 
Clorgyline (selective MAO-A inhibitor) 31±10 nM 
Selegiline  (selective MAO-B inhibitor) 111±68 nM 
Clorgyline + Selegiline (1:1) 39±2 nM 
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a IC50 and standard error calculated using Grafit 5 (© Erithacus Software Limited). Extract concentration in (µg/ml) 
and standard reference drugs in nM. 
 
MAO-I activity has not be shown in Helichrysum species, but two active compounds have been isolated 
from other Asteraceae. Norharman (=β-carboline) an indole alkaloid from Cichorium intybus is a week 
MAO-A inhibitor (POLYA, 2003). Apigenin, a flavone which occurs in Erigeron annuus and Matricaria 
chamomilla amongst other non-Asteraceae species, especially the Apiaceae, is a MAO-A inhibitor (IC50 = 
8 µM) (POLYA, 2003). In the previous Chapter it was demonstrated that H. hesbaceum, H. ruderale, H. 
simillimum and H. umbraculigerum (ethanolic leaf extracts) possessed good dose depenant i  vitro 
GABAA-benzodiazepine receptor binding activity (STAFFORD, JÄGER and VAN STADEN, 2005). 
 
[H.agyrolepis water extract] (mgml-1)














Parameter Value Std. Error
Y Range 71.2184 8.8891
IC 50 0.0001 9.34502e-005
Slope factor 0.4414 0.2540
Background 28.9063 6.4943
[H.agyrolepis ethanol] (mgml-1)















Parameter Value Std. Error
Y Range 81.3296 8.4279
IC 50 0.0008 0.0003
Slope factor 3.9736 5.5410
Background 24.9206 5.2686  
 
[H.umbraculigerum water extract] (mgml-1)









Parameter Value Std. Error
Y Range 75.7282 10.5309
IC 50 0.0024 0.0018
Slope factor 0.5138 0.1832
Background 23.2340 7.3084
[H.umbraculigerum ethanol extract] (mgml-1)














Parameter Value Std. Error
Y Range 79.8087 0.6181
IC 50 0.0031 0.0001
Slope factor 1.8290 0.0484
Background 24.8540 0.5025  
 
Figure 5.3.3.1. IC50 determinations of H. argyrolepis (upper) water extracts, ethanol extracts and H. 
umbraculigerum (lower) water extracts, ethanol extracts. 
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Table 5.3.3.2 shows the IC50 values for MAO inhibitory activity of South African medicinal plants. IC50 
concentrations and standard error were calculated using Grafit 5© (Erithacus Software Limited). The 
standard error (SE) calculated is related to closene s of fit of the activity at each concentration of extract 
to the sigmoidal IC50 graph. Therefore a high SE is an indication of poor d se-dependant activity. The 
non-polar extracts of Ruta graveolens leaf material exhibited the best MAO inhibitory activity (ethyl 
acetate extract = IC50 5±1 µg/ml; petroleum ether extract = 3±1 µg/ml) and specific MAO-B inhibition 
(ethyl acetate extract = IC50 7.±6 µg/ml; petroleum ether extract = 3±1 µg/ml) (Figure 5.3.3.2). Schotia 
brachypetala, Mentha aquatica and Gasteria croucheri also exhibited good MAO-B inhibition activity. 
 
Table 5.3.3.2. MAO inhibitory activity of South African medicinal plants. 
FAMILY 
Species 















































































































































































































































(selective MAO-A inhibitor) 
Selegiline (R-deprenyl) 
(selective MAO-B inhibitor) 
Clorgyline + Selegiline (1:1) 









a IC50 and standard error calculated using Grafit 5 (© Erithacus Software Limited). Extract concentration in (µg/ml) 
and standard reference drugs in nM. b activity not detected – nd, extract not tested – nt  
 
[R. graveolens, ethyl acetate extract] (mgml-1)















[R. graveolens, ethyl acetate extract] (mgml-1)

















[R. graveolens, petroleum ether extract] 
(mgml-1)















[R. graveolens, petroleum ether extract] 
(mgml-1)

















Figure 5.3.3.2. IC50 determinations of Ruta graveolens MAO activity (left) ethyl acetate (upper; IC50 = 5±1 mg/ml) 
and petroleum ether extracts (lower; IC50 = 3±1 mg/ml), and MAO-B activity (right) ethyl acetate (upper; IC50 = 7±6 
mg/ml) and petroleum ether extracts (lower; IC50 = 3±1 mg/ml). 
 
Since ancient times, R. graveolens (garden rue) has been an important plant in the European 
pharmacopoeia (SAN MIGUEL, 2003). Its medicinal value is due to the numerous secondary metabolites 
it contains like furocoumarins, furoquinolines and acridone alkaloids. Recently, the methanol, petroleum 
ether, ethyl acetate and water–methanol extracts of R. graveolens were found to possess antimicrobial and 
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cytotoxic activities (IVANOVA, MIKHOVAA, NAJDENSKIB, TSVETKOVAB and KOSTOVA, 2005). 
Amongst furocoumarins, bergapten has been used for ecades for the treatment of various skin diseases 
such as vitiligo and psoriasis (SONG and TAPLEY, 1979). Further studies are required to determine the 
chemical(s) involved in the MAO inhibition. Mentha aquatica is known to contain flavones and 
flavanone derivatives (BURZANSKA-HERMANN, RZADKOWSKA-BODALSKA and 
OLECHNOWICZ-STEPIEN, 1977) which may be responsible for the observed activity. 
 
Tyramine is a substrate for both MAO-A and MAO-B. An important characteristic of traditional MAOIs, 
such as tranylcypromine and phenelzine, is their lack of selectivity for MAO isoenzymes. By inhibiting 
both these compounds the metabolism of ingested exogenous tyramine often results in the accumulation 
of tyramine. This has the potential to precipitate  dangerous hypertensive crisis, known as the ‘cheese 
effect’ (YAMADA and YASUHARA, 2004). There are very few known specific MAO-B inhibitors and 
it is hoped that such novel compounds can be isolated nd identified from the active plants highlighted in 
this investigation. 
 
Isolation and structure elucidation of naringenin from M. aquatica 
The 70 % ethanol extract of M. aquatica was the most active in the MAO-inhibitory bioassay (IC50 = 40 
µg/ml). Naringenin was isolated from a 70 % ethanol extract by bioassay-guided isolation utilizing VLC 










The 70 % ethanol extract was the most active in the MAO-inhibitory bioassay. Naringenin was isolated 
from a 70 % ethanol extract by bioassay-guided isolation utilizing VLC and TLC and identified on basis 
of 1H, 13C and 13C-DEPT NMR, by comparison with data reported previously (DU, JERZ, and 
WINTERHALTER, 2004). Values from 1H-analysis: 2,70 δ(H-3eq), 3,10 δ (H-3ax), 3,31 δ (Me-d), 5,34 δ 
(H-2), 5,88 δ (H-6) 5,90 δ (H-8) 6,82 δ (H-3`,H-5`), 7,31 δ (H-2`-H-6`). Values from 13C analysis: 
43,8(C-3), 48,99( MeOH-d4), 80,2(C-2), 96,0(C-8), 96,8(C-6) 103,1(C-10) 116,1(C-3`-C-5`) 128,9(C-2`-
C-6`) 130,8(C-1`), 158,7(C-4`) 164,6(C-9), 165,2(C-5), 168,0(C-7), 197,5(C-4). An optical rotation 
[ ]25589α = -20.7 (ethanol) was determined, which correspond to (S)-naringenin (GIORGIO, 
PARRINELLO, CACCAMESE and ROSINI, 2004). 
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The IC50 values for MAO inhibition by naringenin were 342±33 µM for the rat liver mitochondrial 
fraction, 955±129 µM for MAO-A and 288±18 µM for MAO-B. This reflects that the rat liver 
mitochondrial fraction mainly contains MAO-B, and the bioassay-guided isolation therefore must be 
viewed as an isolation for MAO-B inhibitors  The IC50 values for clorgyline (MAO-A inhibitor) and 
deprenyl (MAO-B inhibitor) were found to be 0.3±0.05 nM and 105±10 nM respectively. 
 
A number of flavonoids have previously been shown to have MAO inhibitory activity. Four flavonoids, 
quercitrin, isoquercitrin, rutin and quercetin isolated from Melastoma candicum exhibited MAO-B 
inhibition with IC50-values of 19.06, 11.64, 3.89, 10.89 µM, respectively, in an assay where deprenyl had 
an IC50-value of 19.06 µM (LEE, LIN, SHEN, YANG, YEN and HOU, 2001). However, it has also been 
reported that quercetin is a selective MAO-A inhibitor with an IC50-value of 0.01µM for MAO-A and 20 
Bulk extraction 
500 g M. aquatica extracted with 70 % 
EtOH after de-fatting with Pet. Ether 
(25.71 g; IC50 = 0.04 mg/ml) 
A B C D E F G H I J K L M 
VLC 
Active fractions - 
petroleum ether: ethyl 
acetate; 20:80, 0:100 and 
ethyl acetate: ethanol; 
80:20 fraction 71 (400 mg; IC50 = 0.04 mg/ml) 
A B C D E F G H I J K L 
A B C D 
A B C D 
A B C D 
Preparative TLC - hexane:ethyl acetate (3:2) 
Preparative TLC - both hexane:ethyl acetate (1:2) 
Preparative TLC - hexane:ethyl 
acetate:water (5:20:1) 
fraction 71DC (7.3 mg; IC50 = 0.01 mg/ml) 
fraction 71C (197.5 mg; IC50 = 
0.03 mg/ml) 
fraction 71D (100.3 mg; IC50 = 0.03 mg/ml) 
fraction 71CB (84.4 mg; IC50 = 0.01 mg/ml) 
fraction 71DCC (1.9 mg; IC50 = 0.14 mg/ml) 
NMR: Naringenin 
(IC50 = 342±33 µM for the rat liver 
homogenate, 955±129 µM for MAO-
A and 288±18 µM for MAO-B) 
Figure 5.3.3.3. Flow chart showing bioassay-guided fractionation and isolation of naringenin from  
M. aquatica. 
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µM for MAO-B (CHIMENTI, COTTIGLIA, BONSIGNORE, CASU, CASU, FLORIS, SECCI, 
BOLASCO, CHIMENTI, GRANESE, BEFANI, TURINI, ALCARO, ORTUSO, TROMBETTA, 
LOIZZO and CUARINO, 2006). (+)-Catechin and (-)-epicatecin have been shown to inhibit MAO-B with 
IC50–values of 088.6 µM and 58.9 µM in an assay where deprenyl had an IC50-value of 0.31 µM (HOU, 
LIN, CHEN and LEE, 2005). Two flavonoids isolated from Sophora flavescens, formononetin with IC50-
values of 21.2 µM for MAO-A and 11 µM for MAO-B and kushenol F with IC50-values of 103.7 µM for 
MAO-A and 63.1 µM for MAO-B, had a slight selectivity for MAO-B (HWANG, LEE, HONG, LEE, 
LEE, HWANG and RO, 2005). 5-Hydroxyflavanone isolated from Sinofranchetia chinensis also 
exhibited better inhibitory activity towards MAO-B with IC50-values of 39.6 µM for MAO-A and 3.8 µM 
for MAO-B (HARAGUCHI, TANAKA, KABBASH, FUJIOKA, ISHIZU and YAGI, 2004). It is 
difficult to compare the IC50-values obtained for the flavonoids, as assay conditi s vary between studies, 
and not all studies give values for standard compounds.  
 
It is been considered doubtful whether plant constituents, especially flavonoids, are able to reach the 
brain. Naringenin has been shown to pass the blood-brain barrier (YOUDIM, QAISER, BEGLEY, RICE-
EVANS and ABBOTT, 2004), which means that it can exercise an effect on the CNS. Naringenin has 
been shown to have many effects outside the CNS, such as being a cancer chemopreventive agent, a 
mutagenic inhibitor, a genotoxicology inhibitor, and having antioxidant, hypocholesterolic, antibacterial, 
antiviral, antiallergic, antiangionetic, apopotic and cytostatic activity (HODEK, TREFIL and 




The quantitative spectrophotometric assay has proven to be an inexpensive method for the detection of 
potential MAO inhibitory activity. It has also lead to the bioassay-guided fractionation and isolation of an 
active compound. The selectivity of the compound was successfully determined using pure MAO-A and 
MAO-B. Further research is required to determine the active constituents of Helichrysum agyrolepis, H. 
umbraculigerum, Ruta graveolens, Schotia brachypetala, Mentha aquatica and Gasteria croucheri. The 
success of traditional medicines is often attributed to the ‘placebo effect’ (WEISS, 1988), rather than 
through active principles producing predictable physiological responses, some of these findings support 
the latter and may lead to the discovery of novel MAO inhibitors. 
 
Galanthamine, also referred to as Galantamine (Reminyl® - Johnson & Johnson), is approved in many 
European countries for the treatment of Alzheimer’s disease (SRAMEK, FRACKIEWICS and CUTLER, 
2000). This alkaloid was first isolated from the European snowdrop (Galanthus spp., most notably G. 
woronowii), but is also obtained from Narcissus spp., Leucojum spp. (esp. L. aestivium) and many other 
Amaryllidaceae spp. as well as synthetically (HEINRCH and TEOH, 2004). The long acting, selective, 
reversible, and competitive acetylcholinesterase inhib tory properties of galanthamine have inspired the
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search for other AChE inhibitors from the family Amaryllidaceae (RISA, RISA, ADSERSEN, 
STAFFORD, VAN STADEN and JÄGER, 2004).  
 
Aqueous and ethanol extracts of five plants used in southern Africa to treat memory loss; Malva 
parviflora L. (leaves), Boophone disticha (L.f.) Herb. (leaves and bulbs), Albizia adianthifolia 
(Schumach.) W. Wright (stem bark), Albizia suluensis Gerstner (root bark) and Crinum moorei Hook.f. 
(bulbs) were investigated for AChE inhibitory activity (RISA, RISA, ADSERSEN, STAFFORD, VAN 
STADEN and JÄGER, 2004) using an assay on thin layer chromatography (TLC) based on Ellman’s 
reaction (ELLMAN, COURTNEY, ANDRES and FEATHERSTONE, 1961).  
 
Promising resultswere obtained with Amaryllidaceae bulbs of Boophone disticha and Crinum moorei. 
Aqueous and ethanol extracts of Crinum moorei and Boophone disticha lso showed AChE inhibiting 
activity in the TLC assay. KwaZulu-Natal grasslands are particularly rich in Amaryllidaceae, with over 
20 species from nine genera used in Zulu medicine (HUTCHINGS, SCOTT, LEWIS and 
CUNNINGHAM, 1996). Several alkaloids, isolated and identified by Dr E.E. Elgorashi from South 
African Amaryllidaceae, including Crinum moorei Hook.f., Crinum macowanii Baker, Crinum 
bulbispermum (Burm.f.) Milne-Redh. & Schweick. and Cyrtanthus falcatus R.A.Dyer, were recently 
screening to determine their AChE inhibitory activity (ELGORASHI, STAFFORD and VAN STADEN, 
2004; ELGORASHI, MALAN, STAFFORD and VAN STADEN, 2006). Differences in AChE inhibitory 
activity could be related to structural differences, in particular different ring types. Lycorine-type 
alkaloids were the most active against AChE with 1-O-acetyllycorine (IC50 = 0.96µM) exhibiting 
inhibitory activity comparable to that of galanthamine. The inhibitory activity of the alkaloids lycorine 
and 1,2 di-O-acetyllycorine was 100-times less potent than thatof 1-O-acetyllycorine (ELGORASHI, 
STAFFORD and VAN STADEN, 2004). 
 
These findings support earlier reports claiming the inhibitory activity of AChE by lycorine-type alkaloids 
(LÓPEZ, BASTIDA, VILADOMAT and CODINA, 2002). LÓPEZ, BASTIDA, VILADOMAT and 
CODINA (2002) suggested that the aromatic ring C that gives a certain planarity to those molecules could 
explain the higher activity of assoanine and oxoassnine compared to other lycorine-type alkaloids. 
Crinum glaucum and Crinum jagus (Amaryllidaceae) have been used in Nigeria by tradiional healers for 
memory loss and other CNS-related ailments associated with aging. HOUGHTON, AGBEDAHUNSI and 
ADEGBULUGBE (2004) isolated alkaloids from the plants and tested their AChE inhibitory properties. 
Several reviews have been published on plants used through the World to treat age-related dementia 
(HOWESand HOUGHTON, 2003; HOWES, PERRY and HOUGHTON, 2003; HOUGHTON, 2005 
BARBOSA FILHO, MEDEIROS, DINIZ, BATISTA, ATHAYDE-FILHO, SILVA et al., 2006; 
HOUGHTON, REN and HOWES, 2006; HOSTETTMANN, BORLOZ, URBAIN and MARSTON, 
2006; ADAMS, GMÜNDER and HAMBURGER, 2007; MUKHERJEE, KUMAR, MAL and 
HOUGHTON, 2007). Some of the know ACHE inhibitors isolated from plants are given in Table 5.2. 
 
CHAPTER FIVE Alzheimer’s and Parkinson’s disease treatments  200  
 
AChE is also the target of drugs designed to combat neuromuscular disorders, such as myasthenia gravis 
and glaucoma (TAYLOR, 2001). 
 
The following publications relate to this chapter: 
 A. Risa, J. Risa, A. Adsersen, G.I. Stafford, J. van Staden and A.K. Jäger. Acetylcholinesterase 
inhibitory activity of plants used as memory-enhancers in traditional. South African Journal of 
Botany 70, 664-666. 
 G.I. Stafford, P.D. Pedersen, A.K. Jäger and J. van Staden. Monoami e oxidase inhibition by 
southern African traditional medicinal plants. South African Journal of Botany 73, 384-390 
 H.T. Olsen, G.I. Stafford, J. van Staden, S.B. Christensen, A.K. Jäger. Isolation of the MAO-
inhibitor naringenin from Mentha aquatica L. Journal of Ethnopharmacology 117, 500-502. 
 G.I. Stafford, P.D. Pedersen, J.C. Chukwujekwu, A.K. Jäger and J. van Staden. Helichrysums: 
antibacterial and monoamine oxidase inhibitory activity of South African summer-rainfall species. In 
preparation.  
 
CHAPTER SIX  
 
Summary and Conclusions:  
Implications and future research areas 
 
6.1. Summary of main findings 
 
This thesis has two main objectives: firstly, to bring together a comprehensive and detailed record of 
psychotropic plants used in southern Africa by indigenous peoples for medicinal or cultural purposes; and 
secondly, this research attempts to determine the validity and rationale of the use of these plants by 
screening them in various biological assays for psychotropic activity. The first object was achieved with 
an annotated list that was compiled from available ethnobotanical literature of plants traditionally used for 
central nervous system-related purposes. It contains more than 330 species, from 94 families, which are 
currently used or have been used for cultural, medicinal and recreational purposes related to the central 
nervous system.  
 
The second aim was partially achieved with 320 extracts from nearly 100 species being screened in one or 
more of four bioassays. The assays were selected to detect potentially useful neurological activity for the 
treatment of mental illness. The plant extracts to be screened were selected based on their traditional use. 
Twenty-three Amaryllidaceae alkaloids were screened for inhibition of the serotonin reuptake transporter 
protein (SERT); GABAA-benzodiazepine receptor binding and inhibition of acetylcholinesterase. Three 
flavonoids and a sesquiterpene with affinity to thebenzodiazepine site were isolated using bioassay-
guided fractionation. This study is the first comprehensive investigation of the CNS activity of South 
African plants. 
 
6.1.1. Southern African plants with CNS-related activity 
 
When an attempt is made to classify plants used in African traditional medicine according to their use in 
treating ailments that are defined by western concepts difficulties inevitably arise. An important causal 
factor considered in African traditional medicine is the status of relations existing between the ‘unwell’ 
individual and other human beings, both the living, and the deceased. Thus, philosophy, religion, 
psychiatry, physiology and biology, are all essential elements within the practice of African traditional 
medicine. It is therefore difficult to tease apart the biomedically important plants from those that are
culturally important or are used for religious purposes, for example those plants used to counteract, or 
protect patients from ‘witchcraft’ or ‘sorcery’. Several factors need to be considered when working with
such plants. Firstly, almost all of the literature available on African medicinal plants has been documented 
by people who do not belong to the cultural or even language group that they are reporting on. One needs 
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to be aware that it is possible that in the translation and interpretation of the plant use, biases dictated by 
the recorders own world-view and beliefs may have occurred.  Where possible the method of preparation 
and mode of administration should also be considered. It is import to determine if the plant material is 
likely to have an effect on the user’s physiology. If the plant material is not ingested, inhaled, taken as an 
enema, applied topically or applied to scarification r cuts in the skin then it is unlikely to have a 
biomedical mode of action.  
 
An annotated list compiled from available ethnobotanic l literature of plants traditionally used for central 
nervous system-related purposes is provided (Table 2.2., page 68). It contains more than 330 species, 
from 94 families, which are currently used or have been used for cultural, medicinal and recreational 
purposes related to the central nervous system (CNS). Where available, information pertaining to local 
names and their meaning, plant part used, preparation method, dosage, route of administration, known 
and potentially active constituents are included. The Zulu botanical names were looked at in some detail 
and a strong correlation between the traditional use and the name was observed. 
 
A large proportion of the plants are used to treat mental disorders such as madness, nervous disorders and 
various types of hysteria. Often the specific details (i.e. symptoms) of these ailments are not given and
therefore they can not be classified further. Nearly 150 plant species from 63 families are used to treat 
sympyoms of epilepsy and convulsions, possibly reflecting the severity of this problem in the population. 
The families most often represented are Fabaceae (15 species), Asteraceae (13 species) and Lamiaceae (9 
species). Over 40 plant species from 26 families ar used for ailments that could be described as being 
similar to depression. The number of plants used for dementia and age-related mental problems is lower, 
with only 15 species from 7 families recorded (STAFFORD, PEDERSEN, VAN STADEN and JÄGER, 
2008). This could be due to a previous demographic situation, where traditional healers less frequently 
encountered very old patients.  
 
What follows are brief summaries of the main findings of the research contained in this thesis. This is 
concluded with a summary table (Table 6.1) of the screening results of all four assays employed in this 
thesis. 
 
6.1.2. Southern African plants with antidepressant activity 
 
Seventy five extracts from 34 indigenous plant species used in South African traditional medicine or 
taxonomically related to these were investigated for their affinity to the serotonin reuptake transport 
protein, making use of an in vitro [3H]-citalopram serotonin reuptake transport protein bi ding assay 
(NIELSEN, SANDAGER, STAFFORD, VAN STADEN and JÄGER, 2004). Aqueous and 70% 
ethanolic extracts of various plant parts were screened and 45 extracts derived from 15 plant species 
showed affinity. The affinity of 12 extracts from four plants was characterized as high (more than 50% 
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inhibition at 5, 1, and 0.5 mg/ml). Plant species with high affinity to the serotonin reuptake transport 
protein included Agapanthus campanulatus, Boophone disticha, Datura ferox and Xysmalobium 
undulatum. Agapanthus campanulatus yielded high activity in aqueous extracts from leaves and flowers. 
B. disticha showed high activity both in aqueous and ethanolic extracts of leaves and bulbs. D ferox 
showed high activity in aqueous extracts from the se d  and X. undulatum showed high activity in the 
ethanolic extract of the whole plant.  
 
Two compounds, buphanadrine and buphanamine, were isolated by bioassay-guided fractionation on 
vacuum-liquid-chromatography and preparative thin-layer-chromatography from B. disticha 
(SANDAGER, NIELSEN, STAFFORD, VAN STADEN. and JÄGER, 2005). The structures of the 
compounds were determined by 1H and 13C NMR. Fractions were tested for affinity to the serotonin 
transporter in a binding assay. The IC50 values of buphanidrine and buphanamine were 274 µM 
(Ki = 132 µM) and 1799 µM (Ki = 868 µM), respectively. These two alkaloids were also tested for affinity 
to the 5HT1A receptor, but only showed slight affinity. The affinity of these two alkaloids to the serotonin 
transporter prompted the screening of a further 20 alkaloids isolated from other South African 
Amaryllidaceae, Crinum moorei, C. bulbispermum, C. macowanii, and Cyrtanthus falcatus 
(ELGORASHI, STAFFORD, JÄGER and VAN STADEN, 2006). The majority of the Amaryllidaceae 
alkaloids assayed that showed affinity to the serotonin transporter were crinine-type alkaloids. However, 
the most active was cherylline, a cherylline-type alkaloid (IC50 = 3.4 µM, Ki = 1.6) (ELGORASHI, 
STAFFORD, JÄGER and VAN STADEN, 2006). 
 
Further studies have been performed by a collegue on the ethanolic extracts from Agapanthus 
campanulatus, Boophone disticha, Mondia whitei and Xysmalobium undulatum for functional inhibition 
(semi-in vivo assay) of SERT, noradrenalin uptake (NAT) and dopamine uptake (DAT) using COS-7 cells 
expressing hSERT, hNAT or hDAT (PEDERSEN, SZEWCZYK, STACHOWICZ, WIERONSKA, 
ANDERSEN, STAFFORD, VAN STADEN, PILC JÄGER, 2008). Extracts from Agapanthus 
campanulatus, Boophone disticha and Mondia whitei showed an effect in the functional assays. Ethanolic 
extracts from Agapanthus campanulatus, Boophone disticha, Mondia whitei and Xysmalobium 
undulatum, were investigated for in vivo antidepressant-like effects in three animal models for depression 
(PEDERSEN, SZEWCZYK, STACHOWICZ, WIERONSKA, ANDERSEN, STAFFORD, VAN 
STADEN, PILC JÄGER, 2008). The assays employed were forced swim test in both mice and rats and 
the tail suspension test in mice. All four extracts exhibited antidepressant-like effects in the animal 
models in various degrees. 
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6.1.3. Southern African plants with antiepileptic and anxiolytic activity 
 
Aqueous and ethanol extracts of 43 plants that are traditionally used to treat against epilepsy and 
convulsions were initially tested in the GABAA-benzodiazepine receptor binding assay, where the binding 
of 3H-Ro 15-1788 (flumazenil) to the benzodiazepine sitis measured. Out of the 118 extracts tested, one 
aqueous and 18 ethanol extracts showed activity (RISA, RISA, ADSERSEN, GAUGUIN, STAFFORD, 
VAN STADEN and JÄGER, 2004). The most active extracts in this initial screening were the ethanolic 
leaf extracts of Searsia pyroides, Searsia rehmanniana, Hoslundia opposita and the ethanolic corm 
extract of Hypoxis colchicifolia. All of these showed good dose-dependent activity. A further forty-six 
ethanol extracts from another 35 species, both indigenous and exotic that are traditionally used 
predominantly as sedatives or to treat various CNS-related ailments were tested in the GABAA-
benzodiazepine receptor-binding assay (STAFFORD, JÄGER and VAN STADEN, 2005). Out of the 46 
extracts tested, seven have shown good activity and 10 with moderate activity. The most active extracts 
were the ethanolic leaf extracts of Arctopus echinatus, Artemisa afra, four Helichrysum species and 
Mentha aquatica. Again all these extracts exhibited good dose-dependent activity. 
 
Two biflavonoids with activity in the 3H-Ro 15-1788 (flumazenil) binding assay were isolated by high 
pressure liquid chromatography fractionation of the ethanol extract of the leaves from Searsia pyroides. 
The structures of the two biflavonoids were elucidate  by nuclear magnetic resonance spectroscopy to be
agathisflavone and amentoflavone (SVENNINGSEN, MADSEN, LILJEFORS, STAFFORD, VAN 
STADEN and JÄGER, 2006). Agathisflavone and amentoflav ne competitively inhibited the binding of 
3H-Ro 15-1788 with a Ki of 28 and 37 nM, respectively. Extracts of Searsia dentata and Searsia pentheri 
were not as active as the extract from Searsia pyroides; both were found to contain apigenin and 
agathisflavone. The monomer apigenin, agathisflavone and amentoflavone were fitted into a 
pharmacophore model for ligands binding to the GABAA receptor benzodiazepine site. This reflected the 
affinities of the compounds in the [3H]-flumazenil binding assay. 
 
Further functional characterization of the S arsia extracts showed inhibitory effects on spontaneous 
epileptiform discharges in mouse cortical slices (PEDERSEN, VESTERGAARD, STAFFORD, VAN 
STADEN and JÄGER, 2008). Interestingly, the effect was not caused by the previous isolated flavonoids. 
The extracts contained N-methyl-d-aspartic acid (NMDA) receptor antagonists, which might explain the 
effect of the plants reported by the traditional healers. However, these findings need be confirmed by in 
vivo anticonvulsive studies before any conclusions can be made. 
 
Mentha aquatica, a mint that is found in Europe and Africa, is used in Zulu traditional medicine for 
spiritual purposes. The ethanolic leaf extract exhibited a strong affinity to the GABA-benzodiazepine 
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receptor. Viridiflorol from the essential oil and (S)-naringenin from an ethanolic extract were isolated by 
bioassay-guided fractionation using binding to the GABA-benzodiazepine site. Viridiflorol had an IC50 of 
0.19 M and (S)-naringenin of 0.0026 M (JÄGER, ALMQVIST, VANGSØE, STAFFORD, ADSERSEN 
and VAN STADEN, 2007). 
 
6.1.4. Southern African plants useful in the treatment of Alzheimer’s and Parkinson’s diseases 
 
Twenty plants used in Zulu traditional medicine forseveral CNS-related ailments were screened for 
MAO inhibition and specific MAO-B inhibition activity (STAFFORD, PEDERSEN, JÄGER and VAN 
STADEN, 2007). MAO-B inhibitors are currently employed in the treatment of neurodegenerative related 
illnesses such as Parkinson's and Alzheimer's disease . A photometric peroxidase linked assay was used
to determine the inhibition of the oxidative deaminat on of tyramine by MAO isolated from rat liver. Ruta 
graveolens exhibited the best MAO inhibitory activity (ethyl acetate leaf extract = IC50 5 ± 1 µg/ml, 
petroleum ether extract = 3 ± 1 µg/ml) and specific MAO-B inhibition (ethyl acetate l af extract = IC50 
7 ± 6 µg/ml petroleum ether extract = 3 ± 1 µg/ml). Schotia brachypetala, Mentha aquatica and Gasteria 
croucheri also exhibited good MAO-B inhibition activity.  
 
Six extracts of varying polarity of Mentha aquatica were tested in a photometric peroxidase linked MAO 
bioassay (OLSEN, STAFFORD, VAN STADEN, CHRISTENSEN and JÄGER, 2008). The 70% ethanol 
extract had highest inhibitory activity. (S)-Naringenin was isolated from the extract by bioassay guided 
fractionation on VLC and preparative TLC. The strucure of the compound was determined by 1H, 13C 
and 13C-DEPT NMR and optical rotation. The IC50 values for MAO inhibition by naringenin were 
342 ± 33 µM for the rat liver mitochondrial fraction, 955 ± 129 µM for MAO-A and 288 ± 18 µM for 
MAO-B respectively.  
 
Further studies on twenty-three Amaryllidaceae alkaloids having several different ring types were 
evaluated for their acetylcholinesterase enzyme inhibitory activity. The alkaloid 1-O-acetyllycorine 
(IC50 = 0.96 ± 0.04) showed significant AChE inhibitory activity (ELGORASHI, STAFFORD and VAN 
STADEN, 2004).  
 
6.2. General conclusions 
 
A total of 96 species from 35 families were investiga ed for biological activity in this study. From seven 
of these species, 25 pure compounds were screened. Th  main findings of this study are summarised in 
Table 6.1. Interesting activity (both SSRI and AChEI activity) was observed from members of the 
Amaryllidaceae, in particular the Amaryllidaceae alkaloids. These findings together with several studies 
conducted throughout the world suggest that this family has the potential to provide more useful and 
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novel biologically active compounds. These results also illustrate that using ethnobotanical knowledge as 
a guide in deciding which southern African plants to screen for the treatment of age-related CNS ailments 
is perhaps not necessarily the best option, due to the relatively small number of such traditional 
treatments. Taxonomic based decisions, such as screening southern African Amaryllidaceae for AChE 
inhibitors, on the knowledge that European genera have given promising candidates, may be more 
successful. This study provided one alkaloid, 1-O-acetyllycorine from Crinum moorei, which has shown 
activity comparable to that exhibited by galanthamine. Perhaps further studies on other Amaryllidaceae 
genera, such as Apodolirion, Brunsvigia, Cyrtanthus, Gethyllis, Haemanthus and Strumaria may yield 
novel alkaloids with promising activity. 
 
Steroidal alkaloids of members of the Buxaceae, specifically Sarcococca and Buxus species, have shown 
anti-cholinesterase activities (CHOUDHARY, SALMA, SHEHNAZ, ASAAD, ABDUL, ATTA-UR-
RAHMAN, MASOOD, 2003; CHOUDHARY, PRASAD, AHMAD, ROSA, ATTA-UR-RAHMAN, 
2005). There are only two representatives of Buxaceae in South Africa, namely Buxus macowanii, which 
is used to treat madness, and B. natalensis. Niether of these species have been investigated for 
cholinesterase inhibitory activity. 
 
Two genera from the Anacardiaceae, S arsia (Syn = Rhus) and Lannea have been reported to have 
anticonvulsant activity. The active constituents, notably flavonoids, of several Searsia species have been 
demonstrated. The leaves of Lannea discolor are used by the Luvale people of Zambia to treat fits 
(WATT and BREYER-BRANDWIJK, 1962). The Zulu people use root infusions (isiganganyane) as a 
wash for convulsions in South Africa. Lannea schweinfurthii roots are used by unspecified ethnic groups 
in South Africa as a sedative snuff (VAN WYK and GERICKE, 2000). The powdered root is sprinkled on 
food and used as a sedative in Venda people (ARNOLD and GULUMIAN, 1984). These species, and 
perhaps other members of the Anacardiaceae, should be investigated further for their ability to suppress 
the CNS through the GABA system. 
 
Figure 1.5.1. (page 40) shows the important elements of neuronal signal transduction and the potential 
targets of compounds that have an effect on the CNS. Three targets are employed in this thesis: (1) the 
inhibition of the serotonin reuptake transporter protein (SERT); (2) GABAA- benzodiazepine receptor 
binding; and (3) inhibition of catabolic enzymes (e.g. acetylcholinesterase and monoamine oxidase). 
There are, however, many other targets within the central nervous system that were not investigated in 
this study. For example, the effect of plant extracts and isolated compounds were tested on one 
monoamine re-uptake system, namely the serotonin re-uptake system. This system is indeed important in 
the treatment of depression although other aspects su h as the noradrenaline transporter (NET) remain to 
be investigated. The NET is another important cellular binding site for clinically used antidepressant, 
and in particular dual serotonin-noradrenaline re-uptake inhibitors (SNRI). Thus, although some plants 
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did not exhibit any activity in the bioassays employed in this study, they may exert their effect on the
CNS through other biological pathways.  
 
When used by the traditional healers, the medicinal plants are often combined in complex mixtures. Thus 
the potential number of neuroactive compounds in the pool of ingredients is increased, which makes the 
identification of active components very difficult. This also raises the question of the potential for 
synergistic relationships between the numerous compounds present in such mixtures. Much of the 
ethnobotanical literature on the southern African plants is several decades or more old. African traditional 
medicinal knowledge is not static, and is constantly being added to, while some practices are being lost.
Field studies comprising interviews with traditional healers are needed to gain a better understanding of 
which plants are currently valued and to update the body of knowledge that has been accumulated so far. 
 
This research has highlighted some the difficulties of studying medicinal plants in assays for CNS 
activity. Although this project has made a substantial contribution to our understanding of South African 
traditional medicine’s effect on some systems within the CNS, still very few compounds have been 
isolated and characterized. Most CNS studies on African plants are conducted on crude extracts and in 
animal systems where the mechanism of action might involve several different neurotransmitter systems. 
The lack of selectivity, the need for functional ass ys (i.e. not as specific as in vitro assays but more 
informative than in vivo assays) and the mismatch between in vitro and in vivo findings makes it a 
challenging task to examine plants for potential new drugs. 
 
Overall, the findings reported in these and subsequent studies yield creditability to some of the practices 
used in South African traditional medicine in the tr atment of mental illness. They support the idea that 
there are several culturally and medicinally important psychoactive plants in southern Africa similar to 
the numbers observed in the New World. Knowledge of the biological activities and active constituents of 
plants utilised in traditional medicine opens up a ossibility for development of standardized products, 
which would help secure more reliable medication for patients.  
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Table 6.1. Summary of the biological activity of plant extracts and isolated compounds screened in the four 
bioassays for CNS activity (+++ good activity; ++ moderate activity, + mild activity detected; - no activity 
detected). Data take from research documented in this thesis, as well as ELGORASHI, STAFFORDand VAN 
STADEN (2004); ELGORASHI, STAFFORD, JÄGER and VAN STADEN (2006) and STAFFORD, 






SSRI GABAA AChE MAO 
Agapanthaceae 









Agapanthus praecox   -  + 
Amaryllidaceae 

















































































































Gethyllis ciliaris -    
Scadoxus puniceus   -  - 
Anacardaceae 
[Southern African Rhus was reclassified as Searsia] 










Searsia dentata   +   









Searsia rehmanniana   +   
Searsia pentheri   +   














Arctopus echinatus  ++   
Apocynaceae 






Stropharanthus speciosus  -    
Araliacea 




Cussonia spicata   -   
Asclepiaceae 







Xysmalobium undulatum  + -  - 
Asphodelaceae 






Gasteria croucheri - -  + 
Asteraceae 






Artemisia dracunculoides  -    
Berkheya bergiana   -   
Berkheya montana   -   
Berkheya rhapontica   -   
Helichrysum argyrolepis   -  + 
Helichrysum hesbaceum   +  - 
Helichrysum nudifolium   -  + 
Helichrysum ruderale   +  + 
Helichrysum rugulosum   -  + 
Helichrysum simillimum   +  - 
Helichrysum umbraculigerum   +  + 
Campanulaceae 
Lobelia alata  
 
- 
   
Celastraceae 











Combretum imberbe   -   
Crassulaceae 



















Croton sylvaticus   -   
Jatropha panduaeifolia   -   
Jatropha zeyheri   -   
Fabaceae 






Acacia xanthophloea   +   
Bauhinia galpinii   -   
Bauhinia tomentosa   -   
Dichrostachys cinera.  -   
Indigofera tristis  - -   
Indigofera woodii    -   
Millettia grandis   -   






SSRI GABAA AChE MAO 
Millettia sutherlandii   -   
Schotia brachypetala   -  + 
Senna didymobotrya   -   
Senna petersiana   -   
Sutherlandia frutescens   -   
Flacoutiaceae 





Hypericum lanandii  
 
- 
   
Hypericum revolutum  -    
Hypoxidaceae 




Hypoxis colchicifolia    -   





   
Hoslandia opposita   +   
Leonotis dubra   -   
Leonotis intermedia   -   
Leonotis leonurus   - -  + 






Mentha longifolia   -   
Salvia chamelaeagnea   -   
Lauraceae 













Buddleja salviifolia   -  + 
Malvaceae 












Olea africana  
 
- 
   
Periplocaceae 



























Rubus phoeniculacius    -   
Rubiaceae 






Conostomium natalense  -    
Rutaceae 







Ruta graveolens  -  + 
Zanthoxylum capense  - -   
Scrophulariaceae 
Diclis reptans   
 
- 
   






SSRI GABAA AChE MAO 
Solanaceae 







Datura stramonium - -  - 
Verbenaceae 









Rhoicissus tridentata   -  - 
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